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Abstract 
Background 
Sarcopenia and age-related cognitive decline (ARCD) are important age-related conditions 
which significantly impact upon the quality of life of older adults. ARCD is a well-
established research area, whereas sarcopenia is a relatively new field. Research into the 
inter-relationships between them and possible common underlying mechanistic processes is 
lacking. 
Methods 
Several research techniques were used: a large systematic review; the development of an 
image analysis technique to measure neck muscle size on volumetric MR brain scans; the 
subsequent use of the technique in elderly cohort studies; statistical modelling to investigate 
the role of glucocorticoids in sarcopenia; and an invasive clinical study to develop a novel 
technique to measure the activity of 11beta-hydroxysteroid dehydrogenase (11βHSD1) in the 
human brain in vivo. 
Results 
I consistently found a relationship between: some measures of brain structure and muscle 
size; markers of brain structure and muscle function, mostly grip strength and gait speed; and 
cognition and muscle function. However, I found no relationship between current cognition 
and muscle size in any of the above studies. Cortisol was identified as a possible explanatory 
factor in the relationship between both cognition and brain volume with gait speed. I found an 
association between markers of immunosenescence and sarcopenia (neck muscle CSA and 
grip strength) and an association between expression of the cortisol amplifying enzyme 
11βHSD1 and quadriceps strength.  
I developed a technique to measure 11βHSD1 activity across the human brain, which found 
that the amount of cortisol produced within the brain was not detectable and highlighted the 
asymmetries within the cerebrovascular venous system. 
Conclusions 
Further longitudinal studies looking at the association between sarcopenia and ARCD are 
now required to investigate these important relationships further and hopefully this will lead 
to improved therapeutic options.  
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Chapter 1 Sarcopenia and age-related cognitive 
decline: diagnosis, structural change 
and underlying mechanistic processes 
1.1 Introduction 
As the population of the world ages there is mounting scientific interest in not just the 
pathologies which have a higher incidence with older age but in those conditions which are a 
direct and universal consequence of ageing itself (Medical Research Council, 2009, The 
Academy of Medical Scientists, 2009, United Nations Programme on Ageing and The 
International Association of Gerontology and Geriatrics, 2007). With increasing age there are 
declines in physiological function throughout the human body, however the biological 
processes underlying these changes are not fully understood.  
Several hundred theories of ageing exist (Vina et al., 2007, Medvedev, 1990). Attempts to 
group these theories together have led to classifications such as: cellular versus organismal 
senescence, which groups theories together as to whether they exert a mainly cellular or 
tissue level effect; or damage-based (aka stochastic) and programmed theories of aging, 
where damage-based implies accrued injury secondary to cellular processes (eg metabolism) 
and programmed suggests predetermined genetic pathways occurring on a fixed time 
schedule. However it is being increasingly recognised that these classifications are not 
mutually exclusive and it is unlikely that the complex process of ageing will be underpinned 
by one theory. Therefore many of the identified theories are likely to play a role. 
The common cause hypothesis is not an ageing theory per se but a construct to investigate 
organismal senescence. It postulates that the biological processes leading to ageing are the 
same in each organ and therefore each person will have an intrinsic rate of ageing affecting 
all their organs whilst extrinsic factors may modify that rate in specific organs (eg UV 
radiation and skin) (Baltes and Lindenberger, 1997, Lindenberger and Baltes, 1994, 
Christensen et al., 2001, Anstey and Smith, 1999, Anstey et al., 1997). Therefore if extrinsic 
factors played less of a role in determining the rate of senescence than intrinsic factors, then 
where the intrinsic rate of ageing was slow a subject’s composite organs would be 
biologically “younger” (ie they may have less evidence of both brain and muscle ageing) than 
a subject who had an intrinsically faster rate of senescence of the same chronological age. If 
the common cause hypothesis was found to be correct, potential therapies to slow the 
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underlying processes could have wide therapeutic benefits by affecting multiple different 
organs or tissue types at once. However if extrinsic factors are more found to be more 
important in determining rate of senescence it may be that different organs and tissues age at 
very different rates depending on their relative exposures to the relevant factors (eg alcohol 
may be more ageing to the brain than to muscle), or if the rate of intrinsic ageing was variable 
between different organs (ie free radicals may cause more damage to neurons than myocytes). 
Both sarcopenia and cognitive ageing are major causes of morbidity in the elderly population 
and research has found significant relationships between cognitive and physical ageing 
(Christensen et al., 2000, Deary et al., 2011). This introduction highlights current evidence 
for the structural changes found in sarcopenia and cognitive ageing and the mechanistic 
pathways underlying them, leading on to the research aims of this thesis. 
1.2 Sarcopenia 
1.2.1 Definition of sarcopenia 
It has been shown that both muscle mass and function decline with age (Janssen et al., 2000, 
Martin et al., 2000, Overend et al., 1992a): this is termed sarcopenia. Sarcopenia is a common 
cause of morbidity and mortality in older persons (Cruz-Jentoft et al., 2010). However, the 
exact diagnostic definition for sarcopenia is still under debate with differences between all 
the main published criteria, and it is not yet included in the International Classification of 
Diseases (Cruz-Jentoft et al., 2010, Fielding et al., 2011, Muscaritoli et al., 2010). Several 
papers have suggested definitions based on the clinical picture or diagnostic criteria. 
Most working definitions of sarcopenia state that is it is a syndrome in which there is loss of 
both muscle mass and function (strength and/or power) during the course of normal ageing 
(Roubenoff, 2001, Cruz-Jentoft et al., 2010, Muscaritoli et al., 2010). The reason that both 
muscle mass and function must be taken into account is that the relationship between the two 
variables is non-linear (ie mass cannot predict strength and vice versa) and ageing muscle 
shows features of both decreasing mass and function (Goodpaster et al., 2006). 
Several operational diagnostic criteria have been put forward. Initially these were based on 
DEXA measurements of appendicular muscle mass. Baumgartner et al. defined sarcopenia as 





two standard deviations below the mean of a young reference group (Baumgartner et al., 
1998). This ratio is now referred to as the skeletal muscle mass index (SMI). Since then 
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others have attempted to modify this to account for fat infiltration of muscle with age. For 
example, Newman et al used a residual method to correct for fat mass and height and found it 
correlated with functional status better than Baumgartner’s method (Newman et al., 2003). 
Other diagnostic criteria have used bioimpedance analysis (BIA) as the measure of muscle 
mass. Janssen et al. used the ratio of total muscle mass (measured using BIA) against total 
weight instead of height in their analysis of the NHANES III data (Janssen et al., 2002). 
Others have used the Baumgartner SMI equation but used the BIA measured value for 
skeletal muscle mass. Chien et al showed no statistical difference between MRI measured 
skeletal muscle mass and BIA estimated muscle mass, so were able to calculate a prevalence 
of sarcopenia using the SMI with either the MRI or BIA measurement (Chien et al., 2008). 
Most studies agree that the measurement should be compared to that of a young healthy 
population matched for gender and ethnicity, however establishing these reference datasets 
for both sexes and all ethnicities is not complete, with one consensus group recommending at 
least 100 subjects per group (Morley et al., 2011).  
Many of the original studies did not take into account that the diagnosis of sarcopenia can 
only be made when there is loss of both muscle mass and function. There are therefore now 
an increasing number of papers showing measurement techniques and cut-off values for 
functional measures also. These centre on handgrip strength and gait speed (Fried et al., 2001, 
Cesari et al., 2009, Lauretani et al., 2003), however exact cut offs are not widely agreed upon. 
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Table 1-1: Proposed diagnostic criteria for sarcopenia from different consensus groups 
Group Year Structural cut off Functional cut off 
European Working 
Group on Sarcopenia 
in Older People 
(EWGSOP) 
(Cruz-Jentoft et al., 
2010) 
2010 Low muscle mass, using CT, 
MRI, DEXA or BIA 
(definition or cut off not 
given) 
Gait speed ≤0.8m/s or low 
grip strength (definition or 





Diseases and Nutrition 
in Geriatrics” 
(Muscaritoli et al., 
2010) 
2010 Muscle mass ≥2SD below the 
mean measured in young 
adults of the same sex and 
ethnic background 
Gait speed <0.8m/s in 4 metre 
walk test or any other well 
established functional test 




Group on Sarcopenia 
(Fielding et al., 2011) 
2011 Lean mass (measured by 
DEXA) <20
th
 percentile of 
values of healthy young 










Gait speed <1m/s in 4 metre 
walk test 
Society of Sarcopenia, 
Cachexia and Wasting 
Disorders 
(Morley et al., 2011) 
2011 Appendicular lean 
mass/height
2
 > 2SD below 
that of healthy people aged 
between 20-30years old of 
the same ethnicity 
Gait speed <1m/s in 4 metre 
walk test or a distance of 
<400metres covered during 6 
minute walk test 
 
Securing a widely accepted operational diagnosis for sarcopenia is clearly a research priority 
so that clinicians can make an accurate diagnosis and researchers have a standardised method 
with which to base future studies.  
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1.2.2 Structural changes associated with sarcopenia 
1.2.2.1 Decreased muscle mass and cross-sectional area 
Studies have shown that loss of muscle mass starts between 30 and 40 years of age and 
appears to accelerate with age (Roubenoff, 2000, Janssen et al., 2000). The rate of loss of 
muscle mass has been found to be between 0.5-2% per year (Frontera et al., 2000, 
Goodpaster et al., 2006, Mitchell et al., 2012). This widely quoted range is predominantly 
based on studies comparing young and old subjects however a large study looking at muscle 
mass within a longitudinal study found comparable figures. It followed 2300 70-79 year old 
men and women for 7 years and found DEXA calculated leg lean mass decreased by 0.8% 
per year for men and 0.7% per year for women (Koster et al., 2011). There appears to be 
more muscle mass lost from the lower compared to the upper limbs (Janssen et al., 2000). 
Even within a limb, some muscles appear to decrease in size more than others; a study 
looking at elderly and young women found that the soleus muscle changed the least with age, 
whilst the psoas major showed the most decline (Ikezoe et al., 2011). Two studies (each with 
n>250) have shown that men lose proportionately more muscle mass than women (Janssen et 
al., 2000, Gallagher et al., 1997). 
Cross-sectional area is correspondingly seen to reduce, with studies finding a 25-35% 
reduction in cross-sectional area between younger (18-30s) and older (70+) subjects in the 
quadriceps (Young et al., 1984, Young et al., 1985, Overend et al., 1992b), the psoas major 
and sacrospinalis muscles (Imamura et al., 1983) and the plantar flexors (Rice et al., 1989). 
Cross-sectional area is important when considering muscle function as muscle strength 
depends on the number of sarcomeres in parallel. The number of sarcomeres in series dictates 
the maximum shortening velocity (ie the fibre length) which is important for muscle power. 
1.2.2.2 Decreased strength and muscle quality 
Although decreased muscle mass appears to be the major factor in age-related loss of muscle 
function (strength and power), there also appears to be an impairment of muscle fibre quality 
which contributes to this loss to a lesser extent, which is particularly important in the very old 
(Welle, 2002). As mentioned briefly above, it has been shown that muscle function and mass 
do not decline in a parallel manner (Young et al., 1985, Skelton et al., 1994). A longitudinal 
study of 1880 subjects in their seventies found that strength declined at 2-4% per year 
whereas mass declined at about 1% per year (Goodpaster et al., 2006). Therefore there is a 
loss of force per cross-sectional area with age. There is also a decrease in peak power per unit 
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volume with age, as power (work done per unit time) and strength (maximal force) also 
decline with age at different rates (Cruz-Jentoft et al., 2010). In a study of 100 healthy men 
and women between 65 and 89, power was found to decline at 3-4% per year whilst strength 
was found to decline at 1-2% per year (Skelton et al., 1994). 
A cross-sectional study looking at 500 Finnish men found decreases in strength between 35 
and 47% between the ages of 33 and 73 for muscle groups as disparate as the truncal 
extensors and flexors, knee extensors, hand grip and elbow flexors (Viitasalo et al., 1985). 
Another cross-sectional study of 654 subjects found decreases in isometric, concentric and 
eccentric peak torque for knee extensors and noted that strength appears to start later and 
decline slower in women compared to men (Lindle et al., 1997). 
Loss of strength from proximal and distal muscles may be similar and unlike muscle mass 
losses between the sexes also appears to be similar, on a proportional basis (Doherty, 2003). 
These findings are replicated in the longitudinal studies in this area (Aniansson et al., 1986, 
Aniansson et al., 1992, Aniansson et al., 1983, Clement, 1974). 
1.2.2.3 Infiltration of fat and connective tissue 
Studies have found increased amounts of interstitial fat and other non-muscle tissue in cross-
sectional imaging of elderly subjects compared to younger subjects (Rice et al., 1989, 
Forsberg et al., 1991). One study showed a two-to-three fold difference in non-contractile 
muscle mass seen on cross-sectional imaging between older (>65y) and younger (<45y) men 
and women. This was an increase from 6% in the young group to 15% in the older group 
(Kent-Braun et al., 2000, Forsberg et al., 1991). Therefore the reduction in muscle cross-
sectional area actually accounts for an even greater loss of contractile mass than is accounted 
for using the CSA of the muscle alone. Fat infiltration of muscle can itself lead to worsening 
sarcopenia, mediated through macrophage released inflammatory cytokines (eg TNFα, IL1 
and IL-6) (Goodpaster et al., 2003, Goodpaster et al., 2000). 
1.2.2.4 Decrease in fibre size, with type 2 fibres showing more atrophy than 
type 1 fibres 
The majority of studies have shown a much greater reduction in size of type 2 fibres 
compared to type 1 fibres. Evidence has shown that the area occupied by type 2 fibres has 
decreased by roughly 20-50% by old age and type 1 by 1-25% (Larsson, 1978, Andersen, 
2003, Doherty, 2003). Whereas two other studies showed no decrease in type 1 fibre area and 
a decrease of 26-29% in type 2 surface area between ~20y and 70-80 years of age (Lexell et 
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al., 1988, Nilwik et al., 2013). However as one third of fibres are neither type 1 or 2 by old 
age (due to co-expression of myosin heavy chain 1 and 2) the differentiation between muscle 
fibre type is probably less important in old age (Andersen, 2003, Klitgaard et al., 1990a, 
Klitgaard et al., 1990b). 
1.2.2.5 Decrease in both type 1 & 2 fibre number 
Several studies have shown a reduction in fibre number with age. Lexell et al. examined 
cross-sections of the quadriceps muscle taken at autopsy from males aged from 20 to 80 years 
of age and found a decrease in fibre number of 39% with age which started around 30 years 
old (Lexell et al., 1988). This sets sarcopenia apart from disuse atrophy where there is only a 
decrease in fibre size, not in number (Narici and Maffulli, 2010). The main process thought to 
account for fibre loss is denervation. Type 1 and 2 fibres are affected to the same extent 
thereby maintaining the proportions of fibre types (Sato et al., 1984, Mitchell et al., 2012). 
1.2.2.6 Cytoskeleton changes with age 
One paper which compared muscle biopsies from young volunteers (23-37 years) with older 
volunteers (66-77 years) found several morphological abnormalities. These comprised: an 
accumulation of internal nuclei (myonuclei are usually found at the periphery of the cell), 
ring fibres (where myofibrils encircle the long axis of the muscle fibres), ragged red fibres, 
lipofuscin and nemaline rod structures and a disarrangement of myofilaments and Z-lines 
(Jakobsson et al., 1990). 
Evidence investigating the efflux of calcium through the sarcoplasmic reticulum as triggered 
by the motor neuron, which causes the muscle contraction, shows mixed results. There are 
studies showing both an impairment of the process in older muscle and no change with age 
(Delbono et al., 1995). 
Rate of relaxation following contraction is longer in older muscle, which may be because of 
the action of Ca
2+
-ATPase. This enzyme promotes the uptake of calcium back into the 
sarcoplasmic reticulum from the sarcoplasm and it has been shown that there is reduced Ca
2+
-
ATPase activity in older muscle. However one study has shown that if older muscle is trained 
using resistance exercises the effect of age on the enzyme is reduced but with no consequent 
shortening of relaxation time (Hunter et al., 1999). 
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1.2.2.7 Neuromuscular junction 
The role of the neuromuscular junction (NMJ) in the development of sarcopenia is not well 
understood. The NMJ has a “high safety factor” which means that the chance of an action 
potential arriving at the NMJ and not causing an action potential in the muscle is very low 
(Luff, 1998). Studies have indicated that there may be a progressive decline in the NMJ with 
age, evidenced by increased remodelling and fragmentation (Oda, 1984, Robbins and Fahim, 
1985).  
One study looking at NMJs in mice found that 85% of NMJs in young mice could be 
considered normal, whereas only 40% of the NMJs in older mice could be. It is interesting 
that the lesions they found were not specific to the ageing process, but were just found more 
frequently (Ludatscher et al., 1985). However in view of the high safety factor associated 
with NMJs it appears that they can tolerate quite a degree of dysfunction before they cease to 
work.  
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Table 1-2: Table summarizing studies on structural changes seen in ageing muscle 
Structural change 
seen in sarcopenia 
Authors Number Study findings 
Decreased muscle 
mass/CSA & strength 
(Aniansson et al., 1983) 
(Aniansson et al., 1986) 
(Aniansson et al., 1992) 
9 In 9 men followed up after 3, 7 & 11 years, 
more strength was lost from the lower than 
upper limbs 
2.3-3.2% decrease in knee extensor strength 
per annum 
 (Clement, 1974) 2000+ Strength declines more rapidly than muscle 
mass with age 
 (Frontera et al., 2000) 12 Thigh muscle CSA decreases by 1.4%/year 
in 60+year old men  
 (Gallagher et al., 1997)  284 Men lose more muscle mass than women in 
absolute terms 
 (Goodpaster et al., 2006) 1880 Skeletal mass decreases by approximately 
1% per year in people aged 70+ years 
Knee extensor strength decreases by 2.6 to 
4.1% per year according to sex and 
ethnicity  
 (Janssen et al., 2000) 468 Skeletal muscle lost from age 45y 
Men lose proportionately more than women 
Lower limbs lose more than upper limbs 
 (Skelton et al., 1994) 100 In men and women age 65-89 years power 
decreases more quickly than strength 
Strength decreases at 1-2% per annum and 
power decreases at 3.5% per annum 
 (Koster et al., 2011) 2300 Leg lean mass decreases by 0.8%/year in 
men and 0.7%/year for women aged 70-79 
 (Young et al., 1984) 50 35% reduction in CSA of quads & 35% 
reduction in strength in women between 
20y and 70y  
 (Young et al., 1985) 24 25% reduction in CSA of quads & 39% 
reduction in strength in men between 20y 
and 70y 
Infiltration of fat and 
connective tissue 
(Forsberg et al., 1991) 50 Women have more muscle fat content than 
men 
People over 60y have more muscle fat 
content than people under 60y 
 (Kent-Braun et al., 2000) 44 Two-fold increase in non-contractile 
content of locomotor muscles in elderly 
compared to young subjects on MRI 
 (Rice et al., 1989) 20 Elderly subjects had significantly more 
non-muscle tissue within muscle than 
young subjects 
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Decrease in muscle 
fibre size and number 
(Andersen, 2003) 12 Type 1 25% decrease and type 2 57% 
decrease in fibre size between young (25y) 
and old (88y) subjects 
Greater percentage of fibres co-expressing 
MHC 1 & 2 in older subjects 
 (Klitgaard et al., 1990b) 17 Type 2 fibres have a greater decrease in 
size with age than type 1 fibres 
 (Lexell et al., 1988) 43 Muscle fibre loss starts at 25y and 
continues throughout adult life 
Type 2 fibres show a bigger reduction in 
size than type 1 fibres 
 (Sato et al., 1984) 200 Type 1 fibres decreased in number and 
increased in size after 60y 
Type 2 fibres decreased in size after 40y 




(Delbono et al., 1995) 20 Decreased excitation-calcium release-
contraction coupling in older skeletal 
muscle compared to younger 
 (Hunter et al., 1999) 28 The older group had slower relaxation rates 
and times, decreased sarcoplasmic 
reticulum calcium uptake and Ca2+-
ATPase activity and a larger relative type I 
fibre area than the younger group 
 (Jakobsson et al., 1990) 28 Type 1 fibres were the same size in young 
and old subjects, but type 2 fibres were 
smaller in the elderly group 
Increased frequency of cytoskeleton micro-





(Oda, 1984) 12 Pre and post-synaptic changes seen with 
increasing frequency with age (eg peri-
junctional acetyl-choline receptors) 
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1.2.3 Mechanistic processes causing sarcopenia 
1.2.3.1 Inflammation 
1.2.3.1.1 Inflammatory Cytokines 
Increasing age is associated with chronic low grade inflammation; there are mildly elevated 
levels of interleukin-6 (IL-6), tissue necrosis factor-alpha (TNFα) and C-reactive protein 
(CRP) (Bruunsgaard et al., 2001). 
IL-6, interleukin-1 beta (IL-1β) and TNFα are pro-inflammatory cytokines which are thought 
to be involved in the muscle catabolism seen with sepsis, trauma and cancer. It is less clear 
what their roles are in the pathogenesis of sarcopenia. Raised IL-6 and TNFα levels have 
been associated with reduced muscle mass and strength in both cross-sectional and 
longitudinal studies (Visser et al., 2002, Beyer et al., 2012). However, it remains unclear if 
the elevated cytokines are a causal pathway in the development of sarcopenia or a marker of 
incident comorbidity which in itself is a risk factor for sarcopenia. 
Both TNFα and IL-6 are known to upregulate the proteolytic ubiquitin proteasome pathway 
(UPP) pathway which could be an explanatory mechanism (Skipworth et al., 2006). Another 
hypothesis is that during inflammation there is an increased rate of hepatic acute phase 
response proteins which may use amino acids that would otherwise have been used in muscle 
protein synthesis. However, it seems unlikely that this is a main pathway in sarcopenia as 
there are not large increases of acute phase response proteins with normal ageing. Another 
theory is that cytokines can induce muscle apoptosis by DNA fragmentation. This has been 
demonstrated in animal models but not humans (Skipworth et al., 2006).  
1.2.3.1.2 Tissue Necrosis Factor α 
TNFα is the classical activator of the nuclear factor-kappa B (NF-kB) signalling pathway. 
There are 5 known NF-kB transcription factors, all of which are expressed in skeletal muscle. 
Their functions include roles in apoptosis, inflammation and tissue differentiation. NF-kB can 
upregulate proteolytic pathways and inhibit muscle differentiation and function through 
suppression of MyoD mRNA and protein. Tissue expression of IL-1β and TNFα is induced 
by NF-kB activation and therefore this cycle is self-perpetuating and may explain the chronic 
progressive atrophy seen in sarcopenia. Interestingly NF-kB has also been shown to be 
activated via non-classical pathways (eg in disuse atrophy) therefore TNFα would not have to 
be raised for NF-kB to be contributing to sarcopenia (Skipworth et al., 2006). 
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TNFα seems to play a role in cancer cachexia by inducing catabolic genes including the E3 
ubiquitin ligases; atrogin-1 and MuRF-1. It had been postulated that this could be mirrored in 
ageing muscle, however human data has shown the mRNA levels for these two genes are 
unchanged in ageing muscle (Leger et al., 2008). 
1.2.3.1.3 Interleukin-6 
Higher IL-6 and CRP levels have been found to be associated with loss of muscle strength in 
a large longitudinal study (Schaap et al., 2006), and muscle mass in the Health ABC study 
(Visser et al., 2002). Levels of IL-6 appear to increase with age, particularly following the 
menopause in women (Hager et al., 1994, Ershler and Keller, 2000). IL-6 is known to be 
suppressed by dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate 
(DHEAS) therefore it could be that the lower levels of DHEA and DHEAS seen with 
increasing age contribute to raised IL-6 levels (Straub et al., 1998).  
There are several other hypotheses as to how raised IL-6 levels may contribute to sarcopenia. 
Plasma IL-6 levels are known to increase proteolysis within muscle however it is not known 
if the degree of increase seen with ageing is enough to cause atrophy and it is thought that 
proteolysis is not a major factor in normal ageing muscle (Tsujinaka et al., 1996). However 
IL-6 may exert its effect through less direct routes. It is known that raised IL-6 causes 
anorexia, which would lead to decreased protein substrate. Also, IL-6 can both activate 
cortisol secretion and induce 11beta- hydroxysteroid dehydrogenase (11HSD1) expression, 
so it may exert its effect via a glucocorticoid pathway (Weber et al., 1997, Tomlinson et al., 
2001). IL-6 is known to stimulate the release of corticotrophin-releasing factor from the 
hypothalamus which will lead to increased levels of circulating corticosteroids, however 
glucocorticoids are also know to inhibit IL-6 production from a variety of tissues (Ershler and 
Keller, 2000). Therefore a negative feedback loop may exist. 
We do not know how local cytokine production within muscle is affected by age. Research to 
date has used circulating values of IL-6 therefore this area merits further study. 
1.2.3.2 Cellular senescence 
1.2.3.2.1 Mitochondrial ageing 
Older muscle shows reduced activity of mitochondrial enzymes, reduced mitochondrial 
volume and an increased proportion of abnormal mitochondria (Trounce et al., 1989, Conley 
et al., 2000, Rifai et al., 1995, Marzetti et al., 2013). As mentioned above, it has been shown 
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that the number of ragged red fibres increases with normal ageing. These are clumps of 
diseased mitochondria which accumulate in the subsarcolemmal region of the muscle fibre 
and may reflect an age-related decline in muscle mitochondrial oxidative metabolism (Rifai 
et al., 1995). However it is unclear if the degree of mitochondrial dysfunction found in 
normal ageing muscle is sufficient to cause the corresponding decrease in muscle function 
(Welle, 2002). 
1.2.3.2.2 Oxidative damage 
Markers of damage caused by oxidative stress are found to accumulate with age. Both 
lipofuscin, which is thought to result from the oxidative polymerization of lipids, and the 
antioxidant enzyme glutathione are found in higher levels in old rats (Weindruch, 1995).  
There are several possible hypotheses as to how oxidative damage may contribute to 
sarcopenia. Cellular metabolism generates free radical particles which include reactive 
oxygen and nitrogen particles and reactive aldehydes. These particles can cause damage to 
proteins, DNA and lipids. Mechanisms to repair the damage caused by these particles are not 
perfect therefore over time damage is accrued. Damage to both somatic and mitochondrial 
DNA occurs, although it is difficult to categorise exactly what the functional outcome of this 
damage is. Despite the accruing damage to mitochondrial DNA most copies are in fact 
normal (Welle, 2002). 
Interleukins 4, 10, 13 and 15 are anti-inflammatory cytokines. IL-15 in particular has shown 
direct inhibition of proteolysis and lipid oxidation in skeletal muscle (Magee et al., 2008), 
and there is evidence that IL-15 decreases with age in rats (Marzetti et al., 2009). 
A study investigating transgenic mice that lacked the enzyme superoxide dismutase showed 
increased mitochondrial dysfunction leading to neuromuscular junction dysfunction and 
accelerated sarcopenia (Jang et al., 2010). This supports the theory that impairment in dealing 
with oxidative stress contributes to sarcopenia. 
1.2.3.2.3 Satellite cells 
Satellite cells are myogenic precursor cells, which are found between the sarcolemma 
(muscle cell wall) and the basal lamina of muscle fibres. They are activated following muscle 
injury whereupon they proliferate and differentiate into myoblasts. These myoblasts then fuse 
with other myoblasts to form myotubes which can then form a new muscle fibre or fuse with 
an existing fibre as a repair mechanism. However the muscle fibre loss which occurs with 
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ageing does not appear to trigger these cells (Welle, 2002). It appears that the trans-
membrane receptor notch is responsible for activating the satellite cells and that activation of 
notch appears to decline with age (Carlson et al., 2009). Insulin-like growth factor 1 (IGF-1) 
can trigger activation of satellite cell division also, and this can be triggered by exercise 
(Adams and Haddad, 1996, Adams and McCue, 1998). This represents a pathway through 
which the decreased levels of IGF-1 seen with age can contribute to the sarcopenic process. 
Satellite cells are crucial for maintaining muscle mass, but their role in the pathogenesis of 
sarcopenia is still unclear; however satellite cell activation upon exercise is a potentially 
effective countermeasure for sarcopenia (Thornell, 2011). 
1.2.3.2.4 Denervation  
Multiple studies have shown a significant loss of motor units with age which appears to occur 
predominantly after the age of 60 years old (Lexell et al., 1983, Campbell et al., 1973). A 
motor unit consists of a motor neuron and the muscle fibres it innervates. Therefore, if there 
is a reduction in the number of motor neurons there will be a reduction in the number of 
motor units. There is a 70% reduction in the number of motor neurones in the spinal cord by 
the age of 90 compared to young, healthy controls (Vandervoort, 2002). Electrophysiological 
tests have shown there is a greater decrease in motor unit number in distal rather than 
proximal muscles (Galea, 1996). Number of motor units recruited and firing frequency of 
motor nerves have both been found to be reduced with increasing age (Kamen et al., 1995). 
As motor neurons are lost with age the remaining motor fibres are reinnervated by 
neighbouring motor neurons through axonal sprouting and it has been found that the size of 
motor units increases with age, ie the number of fibres innervated by each motor neuron. 
These findings have been replicated in areas as diverse as the lumbosacral spinal cord to the 
biceps brachii to the extensor digitorum brevis in the leg (Tomlinson and Irving, 1977, 
Campbell et al., 1973, Brown et al., 1988). Fibre type is dependent in part on innervation and 
this period of change in innervation may account for the changes in fibre types seen with age 
(Welle, 2002). It has been shown that larger motor units can show more fatigability and this 
may contribute to the declining strength seen with age (Welle, 2002). 
It is interesting to note that diseases of alpha motor neurons (αmn) in which there are rapid 
neuronal loss do not show similar signs to sarcopenia (ie decreased fibre number, size) until 
there has been a loss of 80-90% of the number of αmns. An explanation may be that there is 
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impairment in reinnervation of the fibres seen with age which would lead to muscle fibre 
loss, although there is evidence which both refutes and supports this hypothesis (Carlson and 
Faulkner, 1996, Carlson and Faulkner, 1998, Kanda and Hashizume, 1991). 
One possible factor contributing to the denervation seen with age is the damage that free 
radicals may cause to motor neuron DNA. As this damage is cumulative and as each motor 
neuron has only one nucleus, unlike myocytes, damage to a few key genes could lead to 
significant malfunction of the cell or even cell death.  
1.2.3.2.5 Protein Turnover 
The proteins within muscle are in constant turnover, being synthesised and broken down at an 
average rate of 1-2% per day (Fearon et al., 1988). Protein turnover is in equilibrium when 
protein synthesis is equal to protein half-life, a proxy for protein breakdown.  
The rate of muscle protein and mitochondrial protein synthesis has been shown to be slightly 
slower in older adults in samples of vastus lateralis (Yarasheski et al., 1993). This appears to 
be due to reduced translational efficiency, as total RNA and mRNA concentrations are stable 
between young and old subjects (Welle et al., 2000). Another study found that the rate of 
myosin heavy chain synthesis declines with age and that the rate was correlated with IGF1, 
DHEA and free testosterone in men (Volpi et al., 2001). However, these decreases in muscle 
synthesis rate are small. Older muscle does not appear able to increase rates of muscle protein 
synthesis following anabolic stimuli (eg amino acid feed or acute exercise) as successfully as 
young muscle can (Cuthbertson et al., 2006). 
Results from studies looking at rates of muscle proteolysis are conflicting but overall it seems 
that an increased rate of proteolysis is not a main pathway of sarcopenia. It appears that 
proteolysis is either unaffected or only very slightly increased with age (Volpi et al., 2001, 
Volpi and Rasmussen, 2000, Welle, 1995, Balagopal et al., 1997). 
1.2.3.2.6 Gene expression 
There have been multiple studies looking at differences in gene expression between young 
and old muscle, with many of the studies using mice. However, it appears that mice are 
unlikely to be a good model for the effect of ageing on gene expression in human muscle. 
Most of the genes found to be over or under-expressed in older human muscle were not so in 
mice and genes that were found to be over-expressed in aged mice were not so in human 
tissue (Welle et al., 2001). 
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Of the articles looking at human muscle, one review article surmised that fewer than 2% of 
genes expressed in muscle are consistently over- or under-expressed in old compared to 
young muscle (Welle, 2002). Welle et al found that older muscle has reduced levels of 
several mRNAs which encode: proteins involved in mitochondrial electron transport and 
ATP synthesis; and enzymes involved in glucose and glycogen metabolism (Welle et al., 
2000). However, Coggan et al. found no change in the level of enzymes involved in the 
glycolytic pathway (Coggan et al., 1993). Roth et al identified around 50 genes as 
differentially expressed in relation to age from a microarray representing around 4000 human 
genes and using a cut-off of >1.7-fold; these represented structural, metabolic, and regulatory 
gene classes (Roth et al., 2002). With new and improved techniques developing in the field of 
molecular biology, hopefully future studies will deliver more reproducible findings. 
1.2.3.3 Hormones and Growth Factors 
1.2.3.3.1 Testosterone and DHEA 
Testosterone is associated with muscle strength and testosterone levels are known to decrease 
with age. Several studies have looked at testosterone supplementation and muscle mass and 
strength. The results have been mixed with some studies documenting improvements in lean 
mass and muscle strength and a decline in fat mass, whilst others showed no change (Kim, 
1999, Wang et al., 2000, Maggio et al., 2013). It may be that the degree of hypogonadism of 
the subjects prior to commencing therapy affects the outcome. There are frequent side effects 
with supplementation also including a raised haematocrit and raised PSA. 
DHEA is a precursor of testosterone secreted mainly from the adrenal glands which 
contributes significantly to testosterone production in women. However, DHEA levels have 
been found to be correlated with lean body mass in men but not women (Abbasi et al., 1998). 
A study of DHEA replacement therapy in women resulted in no increase in muscle mass or 
strength and in men only slightly improved strength with no increase in mass (Morales et al., 
1998). Therefore it appears that DHEA will not be a useful treatment in sarcopenia.  
Testosterone and IGF1 levels have been associated with muscle strength and this generates a 
hypothesis for how lowered levels of testosterone could lead to sarcopenia (Ashton et al., 
1995). Raised levels of testosterone increase levels of IGF1 and its binding protein, therefore 
it would follow that lowered levels could cause the converse. 
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1.2.3.3.2 Oestrogen and Progesterone 
It is not clear what role oestrogen and progesterone have to play in the aetiology of 
sarcopenia. Most studies looking at HRT and sarcopenia have found no improvement in 
muscle strength or mass with HRT (Haarbo et al., 1991, Baumgartner et al., 1999). However 
matters are complicated by the fact that oral oestrogens decrease both IGF1 levels and the 
free fraction of testosterone (by increasing sex hormone biding globulin levels). One study on 
HRT did however find an increase in lean body mass and a decrease in total fat mass; 
however it only included 16 subjects (Sorensen et al., 2001). 
1.2.3.3.3 IGF1 and Growth Hormone (GH) 
IGF1 has several anabolic effects on muscle, including; increased protein synthesis, enhanced 
satellite cell proliferation and improved reinnervation of muscle fibres following denervation 
(Barton-Davis et al., 1999). 
Growth hormone levels fall with increasing age and this leads to decreased circulating levels 
of IGF1. Patients with GH deficiency have been shown to have more adipose tissue and less 
lean tissue than age-matched controls (Binnerts et al., 1992). The decline in GH and IGF-1 
levels seen with aging is attributed to changes in the effect of the hypothalamic factors 
(somatostatin (SRIF) and growth hormone–releasing hormone (GHRH)) on the pituitary 
gland. As people age there is a reduction in the response to GH to GHRH and a simultaneous 
increase in the inhibitory SRIF tone (Kamel, 2003). Low protein diet in rats has been found to 
decrease levels of IGF1, suggesting another possible mechanism for the levels seen in older 
humans (Miura et al., 1992). 
Trials of treatment with growth hormone, to increase IGF1 levels, have shown increased 
muscle mass but no improvement in strength (Welle et al., 1996, Papadakis et al., 1996). 
There also appears to be a high incidence of side effects which would largely prohibit any 
long-term use of GH as a treatment for sarcopenia (eg glucose intolerance, raised blood 
pressure). Therefore, alternative treatments which would increase levels of IGF1/GH without 
incurring the side-effects have been investigated. One potential method is intravenous or 
subcutaneous GHRH which appears to raise levels of IGF1 and GH whilst maintaining the 
major counter regulatory mechanisms which attenuate the adverse effects of overtreatment; 
however, this approach requires further human studies (Iovino et al., 1989, Corpas et al., 
1992). Interestingly a study investigating a GHRH antagonist in mice showed some anti-
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ageing effects including improved longevity but no improvement in muscle strength (Banks 
et al., 2010). 
GH may affect muscle mass through the glucocorticoid system. GH replacement therapy has 
been shown to decrease the conversion of cortisone to cortisol, possibly through decreased 
activity of 11βHSD1 (Sigurjonsdottir et al., 2009). In human hypopituitary patients (Weaver 
et al., 1994) and in rats, treatment with either GH or IGF1 or both has been shown to prevent 
steroid induced myopathy (Matsushita et al., 1996). 
IGF1 and insulin are known to activate the anabolic phosphatidylinositol 3-kinase pathway 
(PI3K) which leads to an activation of the Akt pathway which subsequently activates the 
mammalian target of rapamycin (mTOR) kinase which leads to increased protein synthesis. It 
is known that this pathway is deactivated in muscle wasting (Sacheck et al., 2004). This 
pathway (ie IGF1/PI3K/Akt) inhibits the forkhead box class O (FOXO) transcription factors. 
The FOXO transcription factors regulate expression of parts of the proteolytic ubiquitin-
proteosome pathway (UPP), therefore if the IGF1/PI3K/Akt pathway is deactivated, the 
FOXO pathway is not inhibited and the UPP pathway is upregulated causing proteolysis (Stitt 
et al., 2004). However, a review by Murton et al has highlighted that the pathway seems to 
only be upregulated in inflammatory muscle wasting (eg cancer cachexia, COPD) (Murton et 
al., 2008). Also, as proteolysis has been shown not to be a major factor in sarcopenia, it 
seems unlikely that the UPP pathway plays a major role. 
Increased inflammatory cytokines may also contribute to growth factor inhibition with age. 
There are 6 IGF binding proteins and each can either positively or negatively affect the 
bioavailability of IGF1 and both GH and TNFα appear to modulate the levels of the IGF 
binding proteins (Skipworth et al., 2006, Lang et al., 2006). TNFα, IL-1β and other 
inflammatory cytokines all cause growth factor inhibition, mainly IGF1 (Broussard et al., 
2004).  
1.2.3.3.4 Insulin 
Insulin is an anabolic hormone which promotes muscle protein production. Insulin resistance 
is increasingly prevalent with increasing age and therefore may present a possible pathway 
for the development of sarcopenia, either through decreased anabolism or increased glycation 
which, is thought to impair muscle strength (Hook et al., 2001, Haus et al., 2007). This 
process seems self-perpetuating as it is known that sarcopenia causes insulin resistance, 
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secondary to increasing fat deposition within muscles and other metabolic pathways, which 
leads to decreased anabolism which will worsen sarcopenia (Janssen and Ross, 2005). 
1.2.3.3.5 Ghrelin 
Ghrelin is a peptide which appears to have opposing effects to leptin. It stimulates GH 
secretion and increases appetite. No human studies have been performed as yet looking at 
ghrelin as a treatment for sarcopenia, although one study has found a negative association 
between age and both ghrelin and IGF1 (Akamizu and Kangawa, 2007).  
1.2.3.3.6 Glucocorticoids 
It is well known that glucocorticoids at pharmacological levels or within the context of 
pathology (eg Cushing’s disease) can cause muscle atrophy (Schakman et al., 2013). 
However, the role of glucocorticoids (GC) in the context of normal ageing and their effect on 
musculature is much less well understood. It is thought that the relatively small increases 
seen with normal ageing are not enough to contribute in any significant way to the process of 
sarcopenia (Welle, 2002). However, two hypotheses could explain how glucocorticoids 
contribute to sarcopenia at normal circulating levels.  
Firstly it may be that 11βHSD1 is upregulated in muscle in old age. 11βHSD1 is an intra-
cellular enzyme found in muscle and other tissues which plays a pivotal role in increasing the 
amount of intra-cellularly active glucocorticoid (Cooper et al., 2002). There is some evidence 
that 11βHSD1 expression increases with age in bone but it is not known if this is also the 
case in muscle (Cooper et al., 2002).  
Secondly, muscle’s ability to repair and renew itself following bouts of acute illness lessens 
with increasing age (eg satellite cells are less active with increasing age). Therefore recurrent 
bouts of ill-health across the lifecourse with subsequent acute rises in cortisol could have an 
additive effect on muscle mass and structure even if basal levels of cortisol were not elevated. 
There are several potential pathways by which glucocorticoids may contribute to sarcopenia. 
Firstly, they upregulate protein degradation pathways and secondly they cause an increase in 
glutamine synthetase activity (to increase gluconeogenesis rates) which decreases the amount 
of amino acids available for muscle protein synthesis. As noted below they also upregulate 
myostatin in a dose dependent manner (Ma et al., 2003). 
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It is interesting to note that hypercortisolaemia as seen in Cushing’s disease and medical 
treatment, causes muscle atrophy of the proximal limb muscles (a different distribution from 
sarcopenia), and causes preferential wasting of the fast-twitch (type 2) fibres (the same as 
sarcopenia) (Schakman et al., 2013, Gupta and Gupta, 2013). 
1.2.3.3.7 Myostatin 
Myostatin inhibits muscle differentiation and growth. It has a major role in maintaining 
satellite cells in their quiescent state and it also inhibits MyoD, a protein which promotes 
myogenesis (Doherty, 2003). It has been found that glucocorticoids upregulate myostatin 
expression (Ma et al., 2003). Serum myostatin levels negatively correlate with fat free mass 
and muscle mass, and therefore are found to increase with age (Yarasheski et al., 2002). One 
potential issue with suppressing myostatin as a sarcopenia treatment strategy is that it may 
lead to depletion of muscle stem cells. 
1.2.3.3.8 Angiotensin II 
Angiotensin II upregulates the UPP pathway, inhibits protein synthesis and modulates the 
IGF1 pathway (Skipworth et al., 2006). Plasma angiotensinogen levels are increased by 
corticosteroids, indicating another potential mechanism for the effect raised GC levels can 
have on muscle. The use of ACE-inhibitors as a potential therapeutic treatment has therefore 
been explored. However, studies have found conflicting results on whether they provide a 
functional benefit (Witham et al., 2008, Witham et al., 2014, Sumukadas et al., 2014). 
1.2.3.3.9 Ciliary neurotrophic factor 
Another growth factor called ciliary neurotrophic factor (CNTF) has been shown to promote 
motor neuron survival in rodents and increase muscle mass, but its expression in human 
muscle has not been investigated (Ma et al., 2003, Morley, 2012). 
1.2.3.4 Inherited factors 
Between 30 and 85% of adult muscular strength and 45–90% of adult muscle mass is 
hereditary (Rolland et al., 2008, Tan et al., 2012). Low birth weight has been associated with 
sarcopenia in older men and women when corrected for weight and height (Aihie-Sayer et al., 
2004, Yliharsila et al., 2007). This indicates that early life-exposures and epigenetics play an 
important role in the development of sarcopenia. 
The number of studies investigating potential candidate genes for individual differences in 
muscle strength and mass has rapidly expanded over the past few years. Candidate genes 
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have been tested and variants in the following have been associated with sarcopenia: PI3-
K/Akt/mTOR pathway, serum response factor, peroxisome proliferator-activated receptor-
gamma coactivator (PGC)-1α, ubiquitin-proteasome system, autophagy-dependent signalling, 
myostatin, TNF-α and NF-κB and IGF-I signalling (Tan et al., 2012, Sakuma et al., 2014). 
Genetic linkage analysis of the myostatin pathway found polymorphic markers which were 
linked to lower extremity muscle strength around both the myostatin and IGF1 gene 
(Huygens et al., 2004, Huygens et al., 2005). An IGF2 variant has also been associated with 
arm and leg strength (Schrager et al., 2004). Mutations in the ciliary neurotrophic factor A 
allele have been found to be associated with lower quadriceps strength (Roth et al., 2001). 
Polymorphisms of the angiotensin converting enzyme gene have been shown to influence 
peak knee extensor power in response to resistance training (Giaccaglia et al., 2008). 
Polymorphisms in the vitamin D receptor have been associated with muscle mass and 
strength in elderly men and women (Roth et al., 2004, Geusens et al., 1997). Also, variants in 
the thyrotrophin-releasing hormone receptor (TRHR) have been found to be associated with 
clinically relevant differences in muscle mass in older women (Lunardi et al., 2013).Clearly 
further research in this important area is required, with particular emphasis on the possible 
location of a potential drug target for improving muscle mass or more importantly muscle 
strength in older aged adults.  
1.2.3.5 Lifestyle 
1.2.3.5.1 Physical Activity  
Reduced levels of physical activity appear to be a universal phenomenon of ageing, found in 
animals ranging from fruit flies to mice to humans (Sallis, 2000). Inactivity at any age leads 
to muscle atrophy and even amongst the physically active elderly, rates of physical activity 
are roughly 20% lower than they were in younger age groups (Morse et al., 2004).  
What is less clear is whether this is cause or effect, ie whether people have lower levels of 
physical activity because they have a greater degree of sarcopenia or whether lower levels of 
activity cause sarcopenia. Although increased physical activity can delay the disability caused 
by sarcopenia it cannot halt the underlying process and there will continue to be a relative 
decline in mass and function (Liu and Latham, 2009). Studies looking at athletes have found 
that whilst exercise does slow down losses in muscle mass and strength, there is still a 
continued decline (Faulkner et al., 2007). Therefore it is hypothesised that whilst exercise can 
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hypertrophy the remaining fibres it cannot prevent the neuropathic processes which 
contribute to muscle apoptosis. 
Two things have been found to predict muscle bulk in older age; the peak muscle bulk 
achieved in young adulthood and the rate of decline thereafter (Roubenoff and Hughes, 
2000). This would support the lifecourse approach study of ageing, where not only factors 
which affect rate of decline are investigated but also factors which promote achieving a good 
peak muscle mass, which would include physical activity in young and mid-adulthood. 
Resistance exercise has been shown to increase muscle mass and muscle strength even in the 
very elderly (Fiatarone et al., 1990, Fiatarone et al., 1994, Liu and Latham, 2009). One 
possible mechanisms is that resistance exercise has been shown to decrease skeletal muscle 
TNFα expression even in the very elderly (80y+) and TNFα has been shown to be inversely 
correlated with skeletal muscle protein synthesis (Greiwe et al., 2001). Resistance and 
endurance exercise have also been shown to increase circulating IGF1 levels in the young, 
however these findings were not replicated in the older population. One study has shown 
increased IGF1 immunoreactivity in older muscle following resistance exercise, showing that 
IGF1 may play an important autocrine/paracrine role in older human muscle rather than as a 
circulating hormone (Singh et al., 1999). 
Physical activity does not solely affect the muscle fibre changes seen within sarcopenia. 
Doubling the rate of physical activity can also half the amount of non-contractile tissue 
(Kent-Braun et al., 2000). 
1.2.3.5.2 Nutrition 
There are many reasons for the decreased food intake seen with older age. These include: 
poor dentition, decreased sensations of taste and smell, psychological factors (eg depression), 
early satiety secondary to decreased relaxation of the fundus and increased CCK and leptin 
levels (Morley et al., 2001). It is postulated that decreased nutritional intake contributes to the 
aetiology of sarcopenia, by both a subsequent weight loss, including muscle mass, unless 
energy expenditure is concurrently reduced, and failure to meet nutritional requirements 
within a smaller diet (eg inadequate protein intake). 
Evidence for whether nutritional supplements or high-protein diets increased muscle mass, 
strength or protein synthesis have found contradictory evidence, with some studies finding a 
positive effect and others not (Fiatarone et al., 1994, Campbell, 1995, Welle and Thornton, 
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1998, Borsheim et al., 2008). One study suggests this may be because the supplements 
contained carbohydrate which appears to impair the anabolic response to ingested protein and 
that unless energy expenditure also increased the subjects decreased their nutritional intake to 
match previous levels; therefore their overall nutritional intake remained the same. They also 
found that supplementation with only essential amino acids improved muscle protein 
synthesis in elderly subjects (Volpi et al., 1998). A study looking at the effects of nutritional 
supplementation and exercise on muscle strength and mass found no additional benefits of 
taking the supplements in either those exercising or not (Fiatarone et al., 1994). Conflicting 
results in these studies may partially be representative of how protein deficient the subjects’ 
diets were prior to the intervention.  
Other possible nutritional effects have been found. Eicosapentaenoic acid is an omega-3 fatty 
acid which may have anti-inflammatory effects which could attenuate sarcopenia (Magee et 
al., 2008). Both low vitamin D levels and high parathyroid hormone levels have been found 
to increase the risk of muscle wasting in old age (Visser et al., 2003). The effect of improved 
nutrition on sarcopenia requires further research. 
1.2.3.5.3 Smoking and alcohol 
Perhaps surprisingly, smoking and alcohol were found to have no strong association with 
muscle mass in a large cross-sectional study of older British men (Atkins et al., 2014) or in a 
cohort of in-patients, where sarcopenia was diagnosed as the combination of decreased 
muscle mass and function (Gariballa and Alessa, 2013). In a community study in Brazil, 
where sarcopenia was again defined using the EWGSOP criteria (requiring decreased muscle 
size and function) smoking status was found to be associated with sarcopenia. Alcohol 
consumption was not associated with sarcopenia status in women, or in men at moderate 
levels, but high daily intake of alcohol was associated with an increased odds ratio of having 
sarcopenia in men (Alexandre Tda et al., 2014). It may be that smoking and alcohol intake do 
not have a linear relationship with sarcopenia, where low or moderate intake has no negative 
effect, but that excessive consumption has deleterious consequences. 
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Figure 1-1: Pathways influencing sarcopenia 
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Figure 1-2: Diagram showing the interaction between mediators which contribute to sarcopenia 
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1.3 Age-related Cognitive Decline 
1.3.1 Definition of age-related cognitive decline (ARCD) 
In 1962 Kral suggested a distinction between benign and malignant senescent forgetfulness 
(Kral, 1962). He described the benign form as following a relatively static course, whereas 
the malignant form frequently progressed to dementia and consequently early death. This 
early paper documenting distinct patterns of cognitive decline has led to much scientific 
investigation (Petersen et al., 2009). Although scientific understanding of the cognitive 
impairments seen with ageing is continuing to evolve, there are some central tenets which are 
widely agreed upon.  
There are deteriorations in some parts of cognition seen with age. This is now termed “age-
related cognitive decline” and is in the ICD-10 (code R 41) as such. Other commonly used 
terms include: age-associated cognitive decline (AACD), normal cognitive ageing, 
cognitively impaired not demented (CIND) and age-associated memory impairment. 
Unfortunately their use has not been consistent, being used for various populations within the 
normal/pathological cognitive ageing spectrum in different articles, which has led to some 
confusion in the literature.  
Not all cognitive processes decline with age. When describing which areas of cognition 
appear to be affected by the ageing process it is typical to divide cognitive processes into 
fluid and crystallised abilities. It has been shown that whilst crystallised abilities remain 
largely resistant to changes with age, fluid abilities do show evidence of decline. Crystallised 
abilities include: autobiographical memory, semantic knowledge, emotional processing and 
some language skills. Fluid abilities include: speed of processing, working memory, 
inhibitory function and long-term memory (Hedden and Gabrieli, 2004, Park and Reuter-
Lorenz, 2009). Studies have shown that the decline seen in these processes begins in early 
adulthood, with some deterioration seen by the early 20s (Salthouse, 2009).  
It is also apparent that the rate of decline varies greatly between individuals. Although some 
people show sharp cognitive decline, others can have a more benign picture whilst others can 
even show improvement in some cognitive domains with age (Wilson et al., 2004). However, 
the underlying mechanisms which account for these differences are not fully understood. This 
is further complicated by the fact that the neuropathology found in Alzheimer’s disease 
(amyloid plaques and neurofibrillary tangles) can also be found in ARCD (Keller, 2006). 
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A further entity exists where subjects have a degree of cognitive decline which is considered 
pathological, but which is not severe enough to be termed dementia. The term now used for 
this entity is mild cognitive impairment (MCI) and it is under the umbrella of mild 
neurocognitive disorder in DSM-5. MCI has a variety of definitions but typically is described 
as non-normative cognitive ageing with no effect on social functioning (eg ability to perform 
activities of daily living), whereas a diagnosis of dementia must include an effect on social 
functioning. However diagnostic cut offs or criteria for MCI are less well agreed upon and 
clinical judgement appears to remain paramount. In fact in several large studies investigating 
MCI, a team of specialists were required to distinguish between ARCD, MCI and dementia 
(Manly et al., 2008, Fischer et al., 2007), which is indicative of the degree of overlap between 
them.  
However, whilst ARCD, MCI and dementia do show a degree of overlap, it is unlikely that 
they all lie on the same pathological continuum for two reasons. Firstly, the pattern of which 
cognitive areas are affected by dementia and normal cognitive ageing are different and 
secondly, there are behavioural and psychological symptoms which accompany dementia 
which are not seen to any degree with normal cognitive ageing (Petersen, 2004).  
It is widely quoted that the rate of conversion from MCI to dementia is around 10-15% per 
year (Petersen et al., 1999). However, these figures come from studies looking at selective 
populations (eg referrals to a memory clinic). Prospective studies show lower rates, between 
6-10%. Both these figures are much higher than the conversion rate from ARCD to dementia 
which is 1-2% per year (Petersen et al., 1999).  
The prevalence of MCI varies around the world and according to diagnostic criteria but most 
studies show the prevalence to be around 14-18% in people over 70 y (Petersen et al., 2009). 
The prevalence of dementia in the UK is around 7% of people over 65 y. 
1.3.2 Cognitive ageing - a natural ageing process or a disease? 
A fundamental question when considering the changes seen in cognition with age is whether 
they are due to intrinsic ageing processes, as sarcopenia appears to be, or whether there are 
pathological processes involved. Conditions which appear as part of the natural ageing 
process should be universal, should not be reliant on specific risk factors and can vary widely 
in rate of progress and timing of incidence between individuals. Studies have shown evidence 
for both sides of this argument with regard to cognitive ageing.  
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Small argues that if cognitive decline was an inevitable part of normal ageing then the mean 
scores for relevant memory tests should simply move to the left and retain a similar variance, 
however animal and human studies have demonstrated that the variance increases with age 
and some studies have found bimodal distributions (Small, 2001, Rapp and Amaral, 1992). 
However, the human studies did look solely at cross-sectional studies and no longitudinal 
studies were examined. Another paper which looked at the relation between incident disease 
and decreases in MMSE found that in healthy subjects who were not diagnosed with any 
disease process within a set time period, MMSE only decreased by 0.1 points per year. They 
concluded that significant cognitive change cannot be attributed to age alone. However the 
MMSE is not a particularly sensitive test therefore a further study is required to repeat this 
process using more sensitive cognitive tests (Starr et al., 1997). Another large study (n=1360) 
found that co-morbidities only explained a small part of the individual differences seen in 
normal cognitive ageing: additional variance added for each specific disease ranged from 
1.5% to 3.5% (van Boxtel et al., 1998). 
Furthermore, variances in childhood IQ have been associated with disease states in later life 
including psychiatric illness, hypertension, lung cancer and ischaemic heart disease, and 
childhood IQ is known to predict later life IQ (Zammit et al., 2004, Starr et al., 2004, Hart et 
al., 2003, Deary et al., 2004b). Therefore it may be that low childhood IQ contributes to the 
risk of developing the diseases which increases risk of cognitive decline, so that childhood IQ 
is acting as a confounding factor.  
It is therefore extremely complicated to pick apart what is due to the intrinsic ageing process 
and what is due to pathological processes. Some of the risk factors for developing cognitive 
decline (eg level of physical fitness) increase with age but it is difficult to fully appreciate if 
this is due to the natural ageing process or to accumulating pathology (eg osteoarthritis). 
Many diseases increase in prevalence and incidence with age further complicating the 
picture. 
Currently there is evidence for both sides of the argument. Therefore until we have a large 
enough study with sensitive enough tests of fluid ability, we will have to accept that cognitive 
decline with age could indeed represent part of the normal ageing process but may be due to 
age accumulated pathology, the extent of which has not yet been fully delineated.  
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1.3.3 Structural changes associated with ARCD 
1.3.3.1 Brain size 
The human brain shrinks with age but not in a uniform pattern. Certain areas shrink 
throughout adult life (the tertiary association cortices, the neostriatum, and the cerebellum); 
some stay relatively stable in size (sensory cortices and the pons); and some show accelerated 
decline in older age (subcortical white matter and the hippocampus, which is accelerated by 
hypertension) (Raz and Rodrigue, 2006). Changes in cortical thickness and subcortical 
volume can be mapped using MRI, with annual reductions of between 0.5% and 1.0% seen in 
most brain areas (Fjell and Walhovd, 2010). As the brain shrinks there is a corresponding 
increase in the size of the ventricles and the volume of CSF. Most studies so far have not 
demonstrated any strong association between structural brain differences and cognitive ability 
in old age (Deary et al., 2009). This is perhaps surprising, but may be because as functional 
areas of the brain atrophy, the brain recruits other areas to perform its tasks. One review did 
find that neuroanatomical change accounted for a substantial degree of the reductions in 
specific cognitive abilities. They found that between 25% and 100% of the differences seen 
in selected cognitive functions with age could be explained by differences in structural brain 
characteristics (Fjell and Walhovd, 2010). Large longitudinal studies with careful covariate 
selection are required in this area. 
1.3.3.2 Neuronal and white matter structural changes 
Although there is evidence of limited neuronal loss from the hippocampus with age, loss of 
neurons with age is otherwise not a major feature contributing to the volume loss seen in the 
ageing brain (Keller, 2006). Shrinkage of individual neuron size, reduction of synaptic spines 
and a lower numbers of synapses probably accounts for the reduction in grey matter volume 
(Fjell and Walhovd, 2010).  
White matter structural change is also an important feature of normative brain ageing; studies 
demonstrate that the presence of white matter hyperintensities (evidenced by both T2-
weighted and diffusion tensor imaging (DTI)) is linked to cognition in older age (Bendlin et 
al., 2010, Shenkin et al., 2005), and that the length of myelinated axons is reduced by up to 
50% in healthy ageing (Fjell and Walhovd, 2010). 
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1.3.4 Mechanistic processes causing ARCD 
1.3.4.1 Inherited factors 
1.3.4.1.1 Genetics 
Heritability studies have estimated that roughly 50% of general cognitive ability is inherited 
and this proportion appears to be lowest in childhood and increases throughout life to old age, 
perhaps dropping again in the very old (Haworth et al., 2010, Deary et al., 2006b). Measures 
of cognition with age reflect peak cognitive ability and subsequent rate of decline. Therefore 
genetic influences will affect both these factors in different individuals to different extents.  
The most studied gene with regard to cognitive ageing is apolipoprotein E (APOE). The 
APOE gene has three common alleles: epsilon 2, 3 and 4. In a caucasian population the E3 
allele is the most prevalent with an occurrence rate of 79% and there is no increased or 
decreased risk of cognitive decline with this allele. The E4 allele has been associated with 
increased risk of developing Alzheimer’s disease (AD) (occurrence rate 14%, 2-3 times 
increased risk of AD) and the E2 allele with increased longevity and survival and it is thought 
to be protective against Alzheimer’s disease (occurrence rate 8%) (Wisdom et al., 2011). A 
large meta-analysis of the effects of the APOE alleles on cognitive functioning in a healthy 
elderly population found that carriers of the E4 allele performed significantly worse on tests 
of episodic memory, executive functioning, and overall global cognitive ability. Carriers of 
the E2 allele had higher scores on episodic memory (Wisdom et al., 2011). However the 
effect sizes are small, probably only accounting for 1-2% of the variance seen in cognitive 
decline (Deary et al., 2009). 
Other candidate gene studies have been more successful. A polymorphism in brain-derived 
neurotrophic factor (BDNF) has been found to be associated with individual differences in 
memory function and variation in DISC1 genotype has been associated with cognition in old 
age (Egan et al., 2003, Thomson et al., 2005). Variations in the KLOTHO gene (which is 
known to play a part in oxidative stress) have been shown to affect cognition in childhood 
and may also play a role in cognitive ageing, but further studies are needed in this area 
(Deary et al., 2005). A polymorphism in the prion protein gene (PRNP), part of the 
antioxidant defence genes, has been found to be associated with improved cognition age 79 y 
(Kachiwala et al., 2005). However associations do not necessarily imply underlying 
mechanism. Also, gene-gene and gene-environment effects are thought to play a role in the 
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differences seen with cognitive ageing but further investigation is needed to map out these 
interactions further. 
Several other candidate genes have been investigated and found to have no relation to 
individual differences in cognitive ageing. These include polymorphisms in the angiotensin-1 
converting enzyme (which plays a role in regulation of blood pressure) and 
methylenetetrahydrofolate reductase (MTHR) (which affects homocysteine levels) both of 
which failed to show any association (Visscher et al., 2003). 
Unfortunately studies of candidate gene in this field so far have lacked consensus (Payton, 
2009). This might be because they have missed the large to moderate effect polymorphisms 
or that small effect sizes and interactions will prove to be more important. They have largely 
been under-powered considering the small effect size the genes appear to have and they have 
looked at differing populations and age-ranges when it is likely that different genes may be 
important in different populations and age groups. They are also reliant on selection by 
researchers from within previously decided candidate areas therefore genome wide 
association studies (GWAS) may bypass some of these issues. 
GWAS has identified SNPs in the APOE region and the TOMM40 region (translocase of the 
outer mitochondrial membrane 40 homolog) as having genome wide significance in their 
association with ARCD (Davies et al., 2014). Further replicative GWAS studies in this area 
would now be useful. 
1.3.4.1.2 Lifecourse influences 
The association between childhood IQ and cognitive decline has already been discussed, but 
there are other pieces of evidence which support a lifecourse approach to studying the 
aetiology of cognitive ageing. A large cohort study has found that birthweight and postnatal 
growth are independently associated with cognition (Richards et al., 2002) and a cross-
sectional study has found that parental socioeconomic status and cognitive ability in late 
adulthood are associated even after adjustment for education (Turrell et al., 2002). 
Furthermore placental weight and birth weight have been found to be associated with markers 
of white matter disease in elderly subjects (Shenkin et al., 2009). As all age related decline 
represents the combination of peak function and subsequent decline, determinants of peak 
function will always prove important when trying to find ways to modify the ageing process. 
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1.3.4.2 Hormones and neurotransmitters 
1.3.4.2.1 GH/IGF1/Insulin 
The effect on the brain of the falling levels of growth hormone and IGF-1 seen with age is a 
controversial topic at present. There are observational studies showing both correlations of 
IGF-1 levels with cognitive function and no correlation (Sonntag et al., 2005). However, 
most of these studies are quite small in size. Animal studies looking at treatment with GHRH 
and IGF-1 show improved cognition, however human studies have shown mixed results 
(Sonntag et al., 2005). One study of elderly women treated with IGF-1 for 1 year showed 
IGF-1 levels comparable to younger women but no benefit to cognition and a study of elderly 
men treated with GH for 6 months showed no overall improvement in cognition (Friedlander 
et al., 2001, Papadakis et al., 1996). Whereas a randomised controlled trial of growth 
hormone-releasing hormone was found to improve cognition in both healthy older adults and 
those with MCI (Baker et al., 2012). 
1.3.4.2.2 Glucocorticoids 
Chronically elevated cortisol has been shown to impair memory and cognition, whereas 
acutely elevated cortisol may enhance memory in the short term (Het et al., 2005). There is 
evidence that chronically elevated glucocorticoids (GC) contribute to ARCD (Meaney et al., 
1995). High levels of glucocorticoids (eg during chronic stress) have been shown to decrease 
neuronal survival following hypoxic ischaemia and to inhibit neurogenesis (Sapolsky and 
Pulsinelli, 1985) and GCs regulate pathways involved in inflammation, the immune response, 
cellular proliferation, cell death, mood and memory (Chapman and Seckl, 2008). Therefore 
potential pathways which would explain their negative effects are numerous. 
Another potential pathway is via the intracellular enzyme, 11βHSD1. 11βHSD1-deficient 
mice show increased learning ability in old age than wild type mice and treatment with an 
11βHSD1 inhibitor has shown an improvement in cognition within 10 days in wild type mice 
(Sooy et al., 2010). Human studies in elderly men and diabetic subjects also found 11βHSD1 
inhibition to improve cognition even in a short time frame (Sandeep et al., 2004). 
Interestingly, a study investigating polymorphisms affecting the 11βHSD1 gene found no 
association with variances in cognitive ageing (Deary et al., 2006a). 
1.3.4.2.3 Testosterone, DHEA and Oestrogen 
Testosterone levels are associated with cognitive function in old age (ie hypogonadal men 
have poorer cognitive function) but whether testosterone replacement improves cognition is 
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less clear with some studies showing a minor benefit and some no benefit (Sih et al., 1997, 
Kenny et al., 2002). DHEA and DHEAS have been shown to decrease markedly with age and 
correlations have been found between levels and degree of cognitive function, however 
studies looking at the benefit of replacement on cognition have been disappointing (Sorwell 
and Urbanski, 2010). There is evidence that oestrogen replacement is beneficial for cognitive 
ageing and memory but it must be started straight after the menopause as replacement 
commenced later than this does not confer the same benefit (Sherwin, 2006). 
1.3.4.2.4 Neurotransmitters 
Dopamine is a catecholamine neurotransmitter which has many functions, including being 
involved in cognition and memory, and cerebral dopamine receptor density decreases with 
age starting in the 40s (Volkow et al., 1996). A polymorphism of the COMT gene, which 
plays a role in dopamine metabolism, has been associated with verbal declarative memory 
age 79, which may highlight a role for this pathway in normal cognitive ageing (Harris et al., 
2005). 
Levels of serotonin have also been found to decrease with age and a polymorphism within the 
serotonin transporter gene has been found to be associated with increased rates of cognitive 
decline in a non-demented population (Payton et al., 2005). 
1.3.4.3 Inflammation 
Current studies investigating markers of inflammation and cognitive function and decline 
have thus far found some conflicting results. However, even when positive these studies 
typically show a small effect size.  
Evidence that inflammation has a role in the development of ARCD is plentiful. 
Homocysteine was found to be negatively associated with cognitive function and cognitive 
decline and this association is stronger in those with high IL-6 or CRP (van den Kommer et 
al., 2010). Increased circulating levels of CRP, fibrinogen, and elevated plasma viscosity 
predicted poorer subsequent cognitive ability and were associated with age-related cognitive 
decline in several domains, including general ability (Marioni et al., 2009). One study with a 
31 year follow up period demonstrated an association between CRP and degree of cognitive 
decline (Laurin et al., 2009) and a follow up study of elderly women showed that high serum 
CRP predicts poorer memory 12 years later (Komulainen et al., 2007). Another study 
demonstrated that raised levels of IL-6 and CRP in midlife are moderately associated with 
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lower cognitive status, but there was only a small association with cognitive decline over 
roughly 10 years (Gimeno et al., 2008). Genetic variation in the interleukin-1 beta-converting 
enzyme gene is associated with better cognitive function and lower IL-1B production levels 
(Trompet et al., 2008). Schram et al found systemic markers of inflammation to be only 
moderately associated with cognitive function and decline, but they found stronger 
associations in carriers of the APOE epsilon4 allele (Schram et al., 2007). 
In a study of 500 healthy middle aged adults an inverse relationship between circulating 
levels of IL-6 and performance was found on clusters of tests assessing auditory recognition 
memory, attention/working memory and executive function, in contrast there was no 
association between IL-6 and performance on tests of general memory (Marsland et al., 
2006). It may be that inflammation mediates the negative effect that the metabolic syndrome 
plays on cognition. A large longitudinal study (n=2600) showed an increased relative risk of 
cognitive decline when comparing those with metabolic syndrome and those without. 
However, this risk was completely attenuated after stratifying for inflammation. Relative risk 
for cognitive impairment in the high inflammation group was 1.66 (1.19-2.32) and in the low 
risk group was 1.08 (0.89-1.30) (Yaffe et al., 2004).  
IL-6 and CRP were found to be prospectively associated with cognitive decline in well-
functioning elders but TNFα was not in the Health, Aging, and Body Composition Study 
(Yaffe et al., 2003). The MacArthur Study of Successful Aging found an association between 
IL-6 levels and subsequent cognitive decline in 70-79 year olds (Weaver et al., 2002). 
However, there is also strong evidence which shows no association between inflammation 
and cognitive ageing. A population-based study (n=1200) showed that markers of 
inflammation (CRP, IL-6, and albumin) are not associated with cognitive decline in older 
persons (Dik et al., 2005). Also, the Women's Health Study (n=4200) found no association 
between level of CRP and poorer cognitive performance (Weuve et al., 2006). 
One further point is that age 11 IQ scores have predicted age 70 CRP levels, therefore the 
argument of reverse causation again comes to the fore, whereby lower IQ in childhood leads 
to greater levels of inflammation in later life (Luciano et al., 2009). This may be because low 
childhood IQ is a marker of “system integrity” (ie how well the body as a whole is put 
together) or because it is associated with cardiovascular risk factors in later life. 
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1.3.4.4 Lifestyle 
1.3.4.4.1 Diet 
Low levels of B vitamins (mainly B6, folate (B9) and B12) have been shown to be associated 
with high homocysteine levels and predict cognitive decline (Tucker et al., 2005). 
Supplementation with folic acid has been shown to improve cognition and decrease plasma 
homocysteine levels whether the subjects are deficient in folate or not (Durga et al., 2007). 
Studies looking at dietary antioxidant intake and cognitive decline have had mixed results, 
with some showing a degree of benefit and others showing no benefit at all (Dai et al., 2006, 
Engelhart et al., 2002, Morris et al., 2002, Morris et al., 2005). A clinical trial investigating 
antioxidant supplements (vitamin C and E) has shown improved cognitive function when 
both are taken but no improvement when taken separately (Grodstein et al., 2003). 
Polyphenols have been found to improve longevity, decrease tauopathy and improve memory 
in animal studies (Cellerino, 2009, Pfleger et al., 2010, Richetti et al., 2011). They have 
antioxidant properties and are thought to improve the cellular senescence of neurons. Direct 
evidence in humans is lacking. 
Omega-3 fatty acids have been found to decrease risk of cognitive decline possibly by 
upregulating genes that are important for maintaining synaptic function and plasticity 
(McCann and Ames, 2005). They have been shown to be anti-inflammatory and anti-oxidant 
(Deary et al., 2009). Interestingly one study found that only those who were not carriers of 
the APOE E4 allele benefitted from the positive effects of omega-3 fatty acids (Whalley et 
al., 2008). Saturated fats have been found to reduce molecular substrates that support 
cognitive processing and therefore increase the risk of neurological dysfunction (Greenwood 
and Winocur, 2005). 
An important addendum to the above evidence is that it appears that it is not the exact intake 
of the nutrients themselves that mediates the beneficial effect on cognition but the diet as a 
whole. Therefore whilst each nutrient may play a role, some of the effect may be due to a 
combination of micronutrients being ingested together. Dietary patterns are influenced by 
wealth, geography, culture and multiple other factors and perhaps investigating successful 
dietary patters rather than specific nutrients may be more fruitful. 
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1.3.4.4.2 Smoking and alcohol 
Drinking moderate amounts of alcohol, particularly red wine, may be beneficial for cognition 
in old age (Truelsen et al., 2002, Stampfer et al., 2005). The skin of red grapes contains a 
polyphenol which may be a mechanistic explanation. However prior intelligence and 
socioeconomic status may mediate this relationship as these have both been found to be 
associated with amount of alcohol and type consumed (Corley et al., 2011). 
Smoking is a major risk factor for cognitive decline and dementia (Anstey et al., 2007b). This 
may be due to increased risk of atherosclerosis or increased inflammation. 
1.3.4.4.3 Physical activity 
Several large studies have shown a decreased risk in cognitive decline with increased levels 
of physical activity (Rovio et al., 2005, Yaffe et al., 2001) and a Cochrane review found that 
physical exercise interventions improved some domains of cognitive function (Angevaren et 
al., 2008). One study has shown that this effect may be stronger in those carrying the APOE 
E4 allele (Rovio et al., 2005). This effect could be mediated via decreased risk of the 
metabolic syndrome or atherosclerotic disease and cardiovascular fitness. 
1.3.4.4.4 Mental activity 
Studies appear to have determined a “use it or lose it” effect. That is that people who remain 
mentally engaged appear to show less cognitive decline. The effects need to be corrected for 
prior cognitive ability or else they may just be demonstrating that people with higher 
cognitive ability stay more mentally engaged and are already known to have lower rates of 
cognitive impairment. That would be an example of the cognitive reserve hypothesis in 
action, which is that people with higher cognitive abilities have to experience more cognitive 
decline before any impairment becomes apparent. However evidence in this area is not 
consistent and further studies are required (Salthouse, 2006). 
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Figure 1-3: Pathways influencing ARCD 
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1.4 Conclusions 
This literature review summarises the evidence that there is deterioration in muscle structure 
and function, and brain structure and function seen as part of normal ageing within humans. 
Whilst there is evidence for relationships (although non-linear) between muscle size and 
function, and brain size and cognition, the interrelationships between brain and muscle 
structure and function are less well understood. It will be important to investigate whether 
those who are subject to steeper declines in cognitive function with normal ageing also have a 
steeper decline in muscle mass and, more importantly, muscle function with age. If this is 
found to be true, it would support the theory that there are common mechanisms underlying 
both brain and muscle ageing, which if addressed could simultaneously improve deterioration 
in both.  
This review also highlights that many of the potential processes underlying the development 
of these age-related conditions may be shared and therefore that future treatments to slow the 
progress of one may have positive effects on the other. Possible common underlying factors 
include: glucocorticoids, immunosenescence and inflammation, genetics, and environmental 
and lifestyle factors. 
Pathologically raised levels of glucocorticoids are known to affect both muscle and brain, 
however much less is understood about why the small elevation seen with ageing is 
associated with such profound effects. Potential hypotheses which might explain this include; 
the effect of recurrent elevations of glucocorticoids (eg with acute illness) as opposed to 
mean levels, or raised 11βHSD1 activity in muscle and brain with age.  
Immunosenescence and inflammation appear to play a role in the development of sarcopenia 
and ARCD. However the mechanisms underlying the relationships are not clear and current 
evidence remains contradictory. 
The role of genetics in the rate of development of age-related conditions such as sarcopenia 
and ARCD is still not clear with candidate gene studies thus far showing conflicting results. 
APOE E4 is known to have a role in several ageing conditions including cognitive ageing but 
it is not known whether it is associated with sarcopenia. 
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The role of environmental factors (eg maternal nutrition, socioeconomic status) and lifestyle 
choices (eg smoking, levels of physical activity) also require further study as possible 
common aetiological factors.  
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1.5 The research aims of this thesis 
1. To undertake a systematic review of the literature linking brain and muscle structure 
and/or function 
2. To develop a novel method for measuring neck muscle cross-sectional area on 
magnetic resonance (MR) brain scans to be used as a measure of muscle size within 
healthy ageing studies 
3. To examine the relationship between muscle size and function with brain volume and 
cognition in healthy ageing studies and to examine the role of potential covariates in 
these relationships 
4. To examine the role of immunosenescence in sarcopenia and explore the role of 
important covariates within a healthy ageing study 
5. To investigate the relationship between glucocorticoids and muscle structure and 
function in younger and older healthy adults 
6. To develop a novel method to quantify 11βHSD1 activity in the human brain in vivo 
7. To assess methodological aspects of human brain cerebrovascular studies which may 
impact on future studies using these techniques 
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Chapter 2 A systematic review of the evidence that 
brain structure is related to muscle 
structure and their relationship to brain 
and muscle function in humans over the 
lifecourse 
2.1 Introduction 
Maintaining good levels of brain and muscle function across the lifespan is crucial to 
achieving a good quality of life (Salthouse, 2012, Johansson et al., 2012, Sayer et al., 2006). 
There is substantial evidence showing an association between cognition and muscle function 
(Abellan van Kan et al., 2009, Atkinson et al., 2007, Scherder et al., 2007, Drago et al., 2011, 
Moran et al., 2013), however the role of muscle and brain structure within this association is 
less well understood. A greater understanding of this role will help to improve current 
knowledge of the mechanisms linking brain and muscle function over the lifecourse. 
Several theories have been proposed as to why relationships between brain and muscle 
structure and function may exist. The common cause hypothesis postulates that there are core 
common underlying processes which drive ageing throughout the human body. The construct 
was originally described in a paper by Lindenberger and Baltes in 1994 who noted that 
measures of visual and auditory acuity accounted for variance in intelligence in old age 
(Lindenberger and Baltes, 1994). Since then experiments in caloric restriction have 
demonstrated that the ageing process can be slowed down in multiple systems throughout the 
body by one intervention (Speakman and Mitchell, 2011, Park and Prolla, 2005). However, 
environmental factors also impact on how tissues change across the lifecourse and another 
theory by Mitnitski et al proposes that the number of environmental stressors experienced (eg 
disease, smoking) and the ability to recover from them, vary the level of deficit accumulation 
experienced in multiple organ systems, and hence how tissues like brain and muscle change 
with age (Mitnitski et al., 2013).  
Potential underlying mechanisms include: pro-inflammatory cytokines (eg TNF-alpha and 
IL-6); the role of glucocorticoids and their intracellular amplifier 11beta-hydroxysteroid 
dehydrogenase type 1 (Meaney et al., 1995, Cooper et al., 2002, Het et al., 2005); the role of 
vitamin D (Roth et al., 2004, Geusens et al., 1997); exercise as a way to improve 
cardiovascular fitness in addition to its beneficial effect through hormones and cytokines 
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(Adams and Haddad, 1996, Adams and McCue, 1998, Davis et al., 2011); and cellular 
senescence (eg through oxidative stress) (Deary et al., 2005, Jang et al., 2010).  
In view of these theories, there should be a correlation between the structure and function of 
brain and muscle throughout our lifetime in the absence of significant pathology. This 
systematic review will search for studies that test the hypotheses that brain structure is related 
to muscle structure and/or function and that muscle structure is related to brain function in 
healthy children and adults. Previous studies and reviews have looked at evidence relating 
brain function (eg MMSE score) to muscle function (eg walking speed) therefore  this 
separate but closely related field of literature will not be included in this review (Duff et al., 
2008, Atkinson et al., 2007, Alfaro-Acha et al., 2006, Angevaren et al., 2008). 
2.2 Methods 
The study protocol was published online in December 2011 at: 
http://www.ccace.ed.ac.uk/sites/default/files/Kilgouretal.pdf. 
2.2.1 Inclusion criteria 
2.2.1.1 Population 
All human subjects regardless of age were included in the study; from newborn babies to the 
oldest old, including post-mortem studies. This study is examining the relationship between 
brain and muscle in health, not within the effects of pathology therefore studies looking at 
how a disease affects brain or muscle were excluded. However studies which included a 
healthy control group, where the data from these subjects can be or was analysed separately 
were included. As morbidity increases in frequency with age it would be very restrictive to 
include solely those studies which include only participants who are free from any disease, 
therefore studies will be included provided the subjects have been recruited in a way that did 
not predispose to morbidity being more prevalent than in the general population (eg from a 
diabetes clinic). 
It was planned that subgroup analysis would be undertaken where possible and would include 
data being extracted to investigate the effects of gender, age, socioeconomic status and 
ethnicity. 
2.2.1.2 Interventions/Comparators 
Not applicable as the study is investigating normal physiology. 
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2.2.1.3 Outcomes 
Brain structure 
 Whole brain volume (WBV) or total brain volume (TBV) 
 Volume or cross sectional area of regions within the brain (eg hippocampus, frontal 
lobes) 
 White matter integrity (eg White matter hyperintensities (WMH) or white matter signal 
abnormalities (WMSA) 
 Histological findings about brain structure on autopsy 
Brain function 
 Any recognised measure of cognitive function including: memory, attention, executive 
function, language and processing speed 
 Reaction time will not be used as this is dependent on aspects of brain and muscle 
structure and function 
Muscle structure 
 Muscle cross sectional area on CT, MRI or USS 
 Muscle volume (using CT or MRI) 
 Whole body lean tissue mass using DEXA, giving: total lean mass (TLM) or 
appendicular lean mass (ALM) 
 Bioimpedance analysis (BIA) 
 Histological findings on muscle biopsy or on autopsy 
Muscle function 
 Any recognised test of muscle strength, including isometric, isotonic, isokinetic tests 
 Any recognised test of muscle power 
 Functional tests of muscle function (eg usual or maximum gait speed) 
2.2.1.4 Study Design 
As this review is studying a physiological relationship, intervention studies were not 
included, unless they contained either a control arm with extractable data with no placebo 
treatment or baseline data prior to the intervention. Observational studies including cohort 
studies and cross sectional studies were included and the control arm of case control studies. 
Case reports were excluded as these would not contain evidence of normal physiological 
relationships out with pathology. The only other limiter used was “human” in Medline, 
Embase and PsycINFO but not Cinahl as it appears to screen out human studies erroneously. 
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2.2.2 Search strategy 
Database searches of Medline, Embase, CINAHL and PsycINFO were undertaken. All 
languages were included in the search. The Medline search strategy can be found in 
Appendix 1. The searches were all performed on 6
th
 March 2014. A grey literature search was 
performed using Google and Google Scholar. Hand searching through citations and 
references of relevant articles was also undertaken. 
2.2.3 Study selection 
The search was undertaken by two independent researchers. Titles +/- abstracts found using 
our search strategy were independently screened for relevance. The full text of the selected 
studies was reviewed against the inclusion criteria, and reasons for exclusion at this stage 
were recorded. At this point the two researchers met to discuss shortlists and discuss any 
articles which only one researcher had selected to decide if they should be included or not. 
Disagreements were resolved by consensus or adjudication by a third party (a Professor in 
Geriatric Medicine). 
2.2.4 Contacting authors 
Of the 84 studies found through our search, I wrote to 79 to request data or associations 
which were not given in the text. Five of the studies had given all the associations for the 
variables listed in the text. A letter was sent by email to either the corresponding author (after 
checking they were still working at the study location) or the last author (after the same 
checking process). Only one author was written to from each study (eg all articles arising 
from the Kansas Brain Aging Project, were grouped together when requesting extra 
data/associations). After the initial email a further email was sent around 2 weeks later to act 
as a reminder. Studies were given a minimum of around 1 month to reply.  
Out of the 79 studies I wrote to: 25 studies (32%) sent either the requested data or 
associations; 22 (28%) replied stating they would try and send the data or associations to us 
but then never did; 12 studies (15%) replied stating they either no longer had access to the 
data or did not want to send either the requested data or associations to us; and 20 (25%) 
never replied to either of the emails. 
2.2.5 Quality assessment and risk of bias 
All papers included in the study had their inclusion and exclusion criteria reviewed to check 
for possible bias in the study selection. The topic of the review is not looking at an 
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intervention, therefore the risk of reporting bias for an individual paper is small. Also, in most 
of the papers, the relationship between muscle and brain was not the primary topic of the 
paper, further decreasing the risk of reporting bias. However when contacting the authors, 
asking for either the data or the associations, it was considered that the studies which replied 
may show some bias. The authors may look at their data and only reply if an association was 
found, or if they found a strong relationship they may not want this to be initially reported 
within a systematic review, but rather in a paper in its own right. All summary measures were 
included (eg odds ratio, beta). 
We were unable to choose a single quality assessment tool to use for our systematic review as 
we had decided to include any type of study which contained the required data, and the major 
quality assessment tools are usually focussed on one type of study design (eg interventional 
or observational). I therefore reviewed the most well-known of the quality assessment tools, 
identified using the EQUATOR website and relevant internet searches, and used these to 
compile the data extraction sheet (eg STROBE and PRISMA guidelines) which was used to 
assess methodological quality and bias. Furthermore as we were using control group data 
from several of the studies we were unable to find any pre-existing quality assessment tool 
which specifically dealt with this scenario. 
2.2.6 Data extraction 
I performed the data extraction using a data extraction sheet which I had written, which had 
been approved by the two co-authors (OT, JS) (appendix 1). 
2.2.7 Data analysis 
A narrative synthesis was completed. It was thought unlikely that the data would be 
comparable enough to allow meta-analysis (ie different measures of cognition, different 
muscle groups studied using different machines) and this proved correct. It was hoped that 
sub-group analysis would be undertaken, either in the form of a meta-analysis or more likely 
as a narrative synthesis for the reasons mentioned in the above paragraph.  
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2.3 Results 
The search results are presented in the PRISMA flow diagram in figure 2.1. Reasons for 
exclusion of articles after reviewing the full text are reported in table 2.1. After applying the 
inclusion and exclusion criteria 84 articles were identified; 53 articles either reported the 
appropriate associations or sent us the data or associations requested (table 2.2, 2.3 & 2.4), 
and 31 articles contained the required data but did not report the association between them 
and did not supply either the data or associations requested (table 2.5). Out of the 53 articles 
which could be included in the review; 6 contained data on brain structure and muscle 
structure (table 2.2); 33 contained data on brain structure and muscle function (table 2.3); and 
14 contained data on brain function and muscle structure (table 2.4). 
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Figure 2-1: PRISMA flow diagram showing study selection 
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Table 2-1: Full-text articles excluded, with reasons 
Reason Number 
Selected subjects (eg all had hip fracture, all had dementia 
etc) 
73 
No measure brain or muscle structure 57 
Review article, no relevant references 56 
No measure muscle structure or function 47 
Abstract, no published results within timeframe or irrelevant 34 
No measure brain structure or function 19 
Protocol paper, no published results within timeframe 12 
Anthropometry only measure of structure 10 
Letter or editorial, no results 7 
Technique or theory paper 5 
Case Report 2 
No full text available 1 
Total 323 
 
2.3.1 Association of brain structure and muscle structure 
Of the six articles which looked at the relationship between brain structure and muscle 
structure, three were from the Kansas Brain Aging Project (Honea et al., 2009, Burns et al., 
2010, Wetmore et al., 2011), and the others were from Germany, UK and USA, Phoenix 
(Heymsfield et al., 2012, Kilgour et al., 2013, Weise et al., 2013) (table 2.2). There were no 
longitudinal data available for this section as the studies identified were either cross-sectional 
in nature or only supplied data from a single wave of a longitudinal study. 
The Kansas Brain Aging Project was set up to determine the effects of exercise and 
cardiorespiratory fitness on age-related brain changes. Only one of the papers from this 
project reported the relationship between brain and muscle structure (Burns et al., 2010): 
Burns et al reported a positive relationship between WBV and TLM (beta 0.20, p<0.001) 
when control and subjects with Alzheimer’s disease (AD) were grouped together, adjusting 
for age sex and intracranial volume (ICV), and they note that this was driven by WM volume 
(Burns et al., 2010). They state that this relationship persists in just the control group but do 
not give any statistics for this relationship. A General Linear Model (GLM) was performed 
on the data from the non-demented group supplied to us by the study authors from the Kansas 
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Brain Aging Project (Honea et al., 2009, Burns et al., 2010, Wetmore et al., 2011). WBV, 
grey matter (GM) volume and hippocampal volume were not predicted by TLM adjusting for 
age, sex and ICV +/- education. White matter (WM) volume was predicted by TLM (t 3.12, 
p=0.003, partial eta squared 14%) adjusting for age, sex and ICV. Adjusting for total years of 
formal education only slightly attenuated the results (t 2.99, p=0.004, partial eta squared 
13%). The Kansas Brain Aging Project states that it recruited its subjects using media 
advertising; however, this may lead to a skewed sample as it may be that the controls 
identified were more likely to have a relative with dementia and therefore be interested in the 
topic. Also the exclusion criteria included diseases very common in older age (eg diabetes 
mellitus, any cardiovascular disease in previous 2 years etc) meaning that the “normal” 
controls are likely to be healthier than a random sample of subjects within this age group. 
This means that the associations we are looking at may be present to a lesser or greater extent 
in this population than the population as a whole.  
Kilgour et al also looked at older subjects however they used neck muscle CSA as a measure 
of muscle bulk (Kilgour et al., 2013). They found that total neck muscle CSA predicted 17% 
of the variance in whole brain volume (p=0.01), but they found no significant association 
between total neck muscle CSA and ventricular, hippocampal or cerebellar volumes 
(p > 0.05), adjusting for age, sex, ICV and NART (a measure of childhood intelligence). This 
study only looked at older men and again the exclusion criteria may mean the sample 
represented a “supra-normal” population in terms of health in this age group. 
The other two studies looked at younger subjects. Heymsfield et al specifically set out to 
investigate the relationship between brain mass and body composition (Heymsfield et al., 
2012). They performed multiple linear regression and found that after adjusting for age and 
fat mass, FFM predicted brain mass in men (beta 0.023, R2 5%, p=0.01) and women (beta 
0.003, R2 6%, p=<0.0001). Fat mass or bone mineral content did not significantly predict 
brain mass in either sex. So they conclude that it is FFM that drives the relationship between 
body size and brain size not bone or fat mass. This study only included non-smokers and 
recruited its subjects from very specific sites (eg university students and staff and local 
businesses) which will affect the generalisability of the results. 
Weise et al investigated the associations between regional grey matter volume and fat free 
mass index (FFMI = FFM/height
2
) (Weise et al., 2013). They found several areas of grey 
matter volume that were significantly associated with FFMI (p<0.01, see table 2.2), however 
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after adjusting for percentage body fat or fat mass only two areas remained significant (the 
right temporal pole and bilateral ventromedial prefrontal cortex). No regression coefficients 
were shown in the paper, meaning that although the results were significant the effect size 
was not known. Again this study excluded all smokers and anyone with a “significant” 
medical history affecting the generalisability of the results. 
 
 
Chapter 2  51 
























43.1 Structure: Brain volume 
transformed into mass 
using 1.036g/cm3 
Function: not measured 
DEXA for 
FFM 
Study: Linear regression models found 
that after adjusting for age and fat 
mass, FFM predicted brain mass in 
men (beta 0.023, R
2
 5%, p=0.01) and 




















100 Structure: Whole brain, 
hippocampal, ventricular, 
cerebellar volumes and 
ICV 
Function: 9 tests of 
cognitive function 
reduced to 2 factors 
(cognitive processing 







Study: Total neck muscle CSA was 
found to predict 17% of the variance in 
whole brain volume (t = 2.86, p = 0.01). 
However, total neck muscle CSA did 
not significantly predict the variance in 
ventricular, hippocampal or cerebellar 
volumes (p > 0.05). Total neck muscle 
CSA did not significantly predict 
variance in either the memory factor or 
the cognitive processing factor 
(p > 0.05), however, it did predict 10% 
of the variance in the NART score 
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appropriate. 
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42.9 Structure: MRI for WM, 
GM, CSF, WBV and 
ICV 
Function: Logical 
Memory I & II, Free & 
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naming test, Verbal 
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Study: Positive relationship between 
WBV and TLM when control and AD 
subjects grouped together (beta=0.20, 
p<0.001), adjusting for ICV, age and 
sex. This appears to be driven by WM 
(beta 0.19, p<0.001) rather than GM 
(beta 0.06, p=0.27) States this persists 
in just the control group but doesn’t 
give any statistics for this. Positive 
relationship between MMSE and 
global cognitive score (composite of 
the cognitive tests) and lean mass when 
grouping AD and control subjects 
together. States that controlling for 
dementia status attenuates these results, 
but no specific statistics given. 
Calculated: See Wetmore et al (2011) 
for Kansas Brain Aging Project data 
analysis. 





















41.1 Structure: MRI for GM, 









Calculated: See Wetmore et al (2011) 
for Kansas Brain Aging Project data 
analysis. 








31.6 Structure: MRI brain 




Study: Fat-free mass index (FFMI) was 
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bilateral temporal lobes, ventromedial 
 















study CSF, regional GMV) 
Function: not measured 
ht
2
) prefrontal cortex (vmPFC) (mainly 
subgenual portion of the ACC) and 
caudolateral orbitofrontal cortex and 
unilaterally with the left insular cortex 
(all p<0.01). After adjusting for 
percentage body fat and fat mass, 
negative associations of FFM with 
GMV of the right temporal pole and 
bilateral vmPFC remained. All models 
adjusted for age, sex and handedness. 
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2.3.2 Association of brain structure and muscle function 
Thirty three studies which included measures of brain structure and muscle function were 
identified (table 2.3). The muscle function variables most commonly studied were grip 
strength and gait speed. Only one study was identified which used a different measure of 
muscle function and that was maximal isometric knee extension strength (IKES) (Rosano et 
al., 2010). The brain structure variables include: corpus callosum area, and volumes for total 
and regional GM and WM, cerebrospinal fluid (CSF), cerebellum, hippocampus, basal 
ganglia and whole brain volume and measures of prevalence of WMH, either volume or 
scoring systems (eg Fazekas). 
2.3.2.1 Brain structure and grip strength 
The PATH through life project (Anstey et al., 2007a, Sachdev et al., 2005, Sachdev et al., 
2006, Sachdev et al., 2009), the Cardiovascular Health Study (Barnes et al., 2009, Rosano et 
al., 2005, Rosano et al., 2006, Rosano et al., 2008, Rosano et al., 2011, Longstreth et al., 
1996), the Lothian Birth Cohort 1936 study (Aribisala et al., 2013), a study from japan (Doi 
et al., 2012) and a study from Philadelphia (Hardan et al., 2003) all looked at the relationship 
between grip strength and brain structure. All the identified papers looked at the relationship 
in cross-sectional analyses except for the Lothian Birth Cohort 1936 study which looked at 
the longitudinal relationship. 
There are four papers identified by our search strategy from the PATH through life project, 
which was set up to track and define the lifespan course of depression, anxiety, substance use 
and cognitive ability. In one paper from this project, Anstey et al (2007) studied the 
relationship between the area of the corpus callosum (CC) (measured in three sections: 
anterior, midbody and posterior; and total area) and grip strength (Anstey et al., 2007a). They 
used the grip strength from the hand the subject wrote with and adjusted for age, sex and 
ICV. They found no significant relationship between total, anterior or posterior CC area and 
grip strength however they found a positive relationship between midbody CC area and grip 
strength (beta -0.09, p<0.05). They conclude that this is due to the association between 
midbody CC and the motor cortices. Another paper from the PATH through life project 
studied the association between grip strength and the percentage of WM occupied by WMH 
in different brain areas (Sachdev et al., 2005). They found that a larger percentage of WMH 
per WM volume is associated with decreased grip strength for both the total brain and several 
brain areas (frontal, temporal, parietal, anterior horn and periventricular body (all p<0.01)). 
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However, the amount of WMH in the occipital lobe, the cerebellum and the posterior horn 
was not associated with grip strength. The 2009 paper from this study further investigated the 
relationship between WMH and grip strength (Sachdev et al., 2009). This time they looked at 
the relationship in men and women separately. They found that larger amounts of WMH was 
associated with reduced grip strength, adjusting for age, depression severity and brain atrophy 
index, in men (p<0.05) but not in women (n/s). However they comment that they feel that the 
relationship between WMH volume and motor function is likely to be the same in both sexes 
and that their finding may be due to the difference in WMH amount between men and women 
in their study population. Sachdev’s 2006 paper from this study did not look at the 
relationship between motor function and brain structure and the authors did not respond to 
our data request (Sachdev et al., 2006). The recruitment method appears sound in this study 
using electoral rolls and a good response rate of 58.3% response rate, however only 18.6% of 
the subjects had a MRI brain and the studies are not clear as to how they selected who had a 
scan and who didn’t. 
The Cardiovascular Health Study (CHS) is a large, longitudinal, observational study of risk 
factors for cardiovascular disease in adults 65 years or older, which commenced in 1989. The 
CHS measured grip strength and gait speed and WMSA, however only one paper from this 
study looked at the relationship between grip strength and WMSA (Longstreth et al., 1996). 
In this paper Longstreth et al (1996) performed a partial correlation which found no 
significant association between grade of WMSA (graded on a scale of 0-9) and grip strength 
in either the dominant or non-dominant hand (p>0.05) after adjusting for age, sex and 
presence of clinically silent stroke on MRI. Since this study was performed, measurement of 
WMH has improved greatly and now most studies would use WMH volume and mention site 
of lesions as opposed to the 10 point scale used in this study. Recruitment was performed 
through medicare lists, meaning only certain sections of society would be included (ie not 
those who have never paid into the scheme or those fully covered by private health 
insurance). 
The paper by Doi et al used multiple linear regression to show that grip strength is not related 
to brain atrophy (beta -0.082 (SE 0.005) p=0.54) (Doi et al., 2012). They measured brain 
atrophy by mapping the MR brain scans from their subjects to those from healthy controls. 
Most studies used an index to intracranial volume to calculate degree of brain atrophy. No 
associations with the other measured brain volumes were included in the paper. The MLR 
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included adjustment for age, gender, BMI, education, MMSE, Tokyo Metropolitan Institute 
of Gerontology Index of Competence, geriatric depression scale and change in walking speed 
whilst dual tasking, which may represent over adjustment considering the size of the study 
(n=110).  
The paper by Hardan et al looked at the association between caudate volume and grip 
strength in both hands in children and young adults (Hardan et al., 2003). They found non-
significant statistical trends using Pearson’s correlation between total caudate volume and 
mean grip strength in the right (r=-0.303, p=0.05) and left (r=-0.28, p=0.07) hands. The 
relationships are negative, therefore there is a trend that those with larger caudate nuclei were 
found to have lower grip strength in both hands. The study does not state the gender of the 
subjects and the correlation was not adjusted for age, which considering the rapid changes in 
body size that occur throughout this age period (mean age 18.6y (sd 8.6)) seems a major flaw. 
The Lothian Birth Cohort 1936 study measured grip strength at baseline and 3 years later at 
which point brain volumes were also measured (Aribisala et al., 2013). It is the only study to 
look at longitudinal changes in muscle strength and brain structure. Grip strength at wave 1 
predicted ventricular volume at wave 2 (standardized beta -0.10), however there was no 
significant association with other brain volumes, and grip strength at wave 2 predicted 
ventricular volume (-0.11) and NAWM (0.08). Therefore, stronger grip strength was 
associated with less brain atrophy in this wave. However, decreased grip strength (ie change 
in grip strength) over 3 years was not significantly associated with any brain volume 
measure. Therefore longitudinal change in grip strength in this study was not associated with 
brain structure. This may be because the actual change in grip strength between the two 
waves in this cohort is very small and a longer follow up period may be required to 
demonstrate longitudinal changes. 
2.3.2.2 Brain structure and gait speed 
The Sydney Older Person’s Study (Piguet et al., 2006), the TASCOG study (Callisaya et al., 
2013, Srikanth et al., 2010, Srikanth et al., 2009), the Three-City Study (Elbaz et al., 2013, 
Dumurgier et al., 2012, Dumurgier et al., 2010, Soumare et al., 2009), the AGES-Reykjavik 
study (Rosano et al., 2010), ABC1921 study (Starr et al., 2003), WML and mobility study 
(Wolfson et al., 2005, Guttmann et al., 2000), further studies from Boston (Manor et al., 
2012, Hajjar et al., 2010, Novak et al., 2009, Moscufo et al., 2012, Moscufo et al., 2011), the 
Cardiovascular Health Study (Rosano et al., 2012, Barnes et al., 2009, Rosano et al., 2006, 
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Rosano et al., 2005, Rosano et al., 2011, Rosano et al., 2008, Longstreth et al., 1996), the 
Oregon Brain Aging Study (Silbert et al., 2008, Marquis et al., 2002), the LBC 1936 study 
(Aribisala et al., 2013) all looked at the relationship between structural brain measures and 
gait speed. There were 27 papers, comprising 12 studies, identified to include in this section, 
making it the most researched association in our review. Six of the studies only looked at 
cross-sectional analyses and the other six studies also included longitudinal analyses. Cross-
sectional and longitudinal analyses will be reported separately below. The measurement of 
gait speed varied considerably, with studies variously using maximum speed or usual pace, 
and some studies requiring a turn halfway through the measurement and others not. The 
distance used for the measurement also varied from 2.5 to 75 metres, however the most 
commonly used measure was usual pace over 6 metres. 
2.3.2.2.1 Cross-sectional analysis of the relationship between brain structure and 
gait speed 
The following studies either only looked at the relationship between brain structure and gait 
speed in cross-sectional analyses or looked at cross-sectional and longitudinal analyses. Here 
the cross-sectional results are discussed. The Sydney Older Person’s Study was set up to 
investigate the environmental, biological and social determinants of healthy ageing. Within it 
Piguet et al looked at the relationship between timed walk over 5 meters, adjusted for lower 
limb arthritis, and cerebellar vermis area (broken down into V1, V2 , V3 and total), and total 
cerebellar volume. None of the measures of cerebellar size/volume significantly predicted the 
timed walk (Piguet et al., 2006). Around 50% of the subjects in this study were war veterans 
and war widows selected from a specific register which may cause issues with the 
generalisability of results. Also, the analyses were not adjusted for gender which is unusual as 
both brain structure and gait speed are frequently found to be predicted by gender, however 
as detailed above the results were not significant anyway. 
The Three-City study is a longitudinal study of the relation between vascular diseases and 
dementia in persons aged 65 years and older in France, which includes measures of WM 
volume and maximum walking speed over 6 metres and a repeat walking speed test at the 
fourth follow up assessment (ie roughly 7 years after the first). This was a well-designed 
study with a large n, random sampling from the electoral rolls and minimal exclusion criteria. 
There were four papers identified from this study which contained reference to these 
variables.  
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Soumare et al looked at the association between WMH volume and baseline walking speed 
(Soumare et al., 2009). They adjusted for age, gender, education and brain white matter 
volume. They found a significantly lower mean walking speed in those with a total WMH 
volume above the 75
th
 percentile compare to those below the 25
th
. They found similar 
relationships for both deep WMH and periventricular hyperintensities (PVH), however 
further analyses revealed that PVH may have more of an effect on walking speed than deep 
WMH. Elbaz et looked at this association further and found that large WMH volumes were 
not associated with slow walking speed among highly educated participants (OR = 0.72), but 
were associated with a 2-fold-increased risk of slow walking speed among those with low 
education (OR = 3.19/1.61 = 1.99) (p interaction=0.026) (Elbaz et al., 2013). Results 
remained unchanged after adjustment for height, BMI, and MMSE score.  
Dumurgier et al looked at GM volumes and gait speed in the same cohort and found that only 
basal ganglia volume (beta 0.075 (SE 0.025) p=0.003) was significantly associated with 
walking speed; driven by caudate nucleus volume (beta 0.114 (SE 0.024) p<0.001) 
(Dumurgier et al., 2012). All other regional GM volumes were not significantly associated 
with walking speed. 
The authors from the Three-City study provided further associations between the variables of 
interest on written request (Callisaya et al., 2013, Srikanth et al., 2010, Srikanth et al., 2009). 
They looked at the relationship between WM volume and maximal walking speed at baseline 
using a multiple linear regression (MLR) and found no significant association.  
The AGES-Reykjavik study includes an MRI brain and usual walking pace over 6 metres 
(Rosano et al., 2010). There was good study design for an observational cohort study, with no 
exclusion criteria on the grounds of health and a large randomly sampled population. The MR 
brain imaging included a magnetization transfer imaging sequence, which can be used to 
calculate the magnetisation transfer ratio (MTR), which can detect normal and diseased brain 
tissue by looking at the homogeneity of the brain tissue being studied. They found that in 
men usual walking speed was predicted by WMH volume (beta 0.13, p=0.02) but not by 
degree of brain atrophy or peak MTR height (both p>0.05) (adjusted for age and brain size) 
(Rosano et al., 2010). However in women slower walking speed was associated with: lower 
MTR height (ie indicating abnormal brain tissue) (beta -0.14 (p=0.01); increased WMH (beta 
0.12, p=0.003); and greater brain atrophy (beta 0.15, p=0.01) (Rosano et al., 2010). 
Additionally they comment that isometric knee extension strength was found to positively 
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correlate with peak height MTR (p<0.005) however they do not give the strength of the 
correlation or say what it was adjusted for.  
The Aberdeen Birth Cohort 1921 study is a longitudinal study which includes a measure of 
gait speed (self-paced walk time over 6 metres) and a MR brain scan, which was assessed for 
WMH. Lower gait speed was significantly associated with increased WMH in the brainstem 
(p=0.009, partial eta squared 7%), but not in the cerebral white matter or with PVHs (Starr et 
al., 2003). It is not clear when looking at the analyses in this paper what they were adjusted 
for. 
Seven papers were identified which met the inclusion criteria from the Boston area in the 
United States. These include two papers from the WML and mobility observational follow up 
study (Wolfson et al., 2005, Guttmann et al., 2000), two papers looking at mobility, brain 
changes and cardiovascular risk factors at baseline (Moscufo et al., 2011) and follow up at 2 
years (Moscufo et al., 2012), two papers conducted at the Beth Israel Deaconess Medical 
Centre, where it seems there may be overlap between the study volunteers (Hajjar et al., 
2010, Novak et al., 2009) and a case-control study about diabetic peripheral neuropathy 
(Manor et al., 2012). The baseline paper from the WML and mobility study comments that 
gait velocity was not significantly predicted by WMSA corrected for ICV, however does not 
give any specific figure for this analysis (Guttmann et al., 2000).  
Moscufo et al recruited 99 subjects to a longitudinal study about mobility, brain changes and 
cardiovascular risk factors (Moscufo et al., 2011, Moscufo et al., 2012). Here, the baseline 
associations are discussed. Gait speed was measured using time to walk 2.5 metres as part of 
the Short Physical Performance Battery (SPPB). This is a considerably shorter distance than 
most other measures of gait speed used. The authors supplied Spearman partial correlations 
between the brain volumetric variables and gait speed, which were not described in the paper. 
Greater WMH burden (rho=-0.365, p=0.0002) and CSF volumes (rho=-0.284, p=0.004) are 
associated with slower gait speed. White matter was not found to significantly predict gait 
speed, however larger GM volume did predict faster gait speed (rho=0.232, p=0.020) 
(Moscufo et al., 2011).  
An analysis was made in the baseline paper, to investigate whether location of WMH affected 
gait speed (Moscufo et al., 2011) . They selected 10 regions of interest (ROI), which were 
neural pathways involved in sensory input or motor response and performed a Spearman’s 
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correlation with a corrected significance threshold of ≤0.005 (calculated using the Bonferroni 
method to adjust for multiple comparisons). All 10 ROI were found to significantly correlate 
with the walking speed score at p<0.005 (rho values between 0.279 and 0.426), except in the 
superior longitudinal fasciculus (p=0.035) (Moscufo et al., 2011). This study included a large 
list of exclusion criteria which may affect the generalisability of the results. Also, it was not 
clear what was adjusted for in the analyses in the paper however the author responded to this 
query and showed that adjustment for age and gender did not affect their results. 
Two papers carried out their studies at the Beth Israel Deaconess Medical Centre. One paper 
looked at healthy volunteers (Novak et al., 2009) and the other looked at stroke patients in 
comparison to healthy volunteers (Hajjar et al., 2010). It does not explicitly state the healthy 
volunteers are the same for each study, but the exclusion criteria, time period and author list 
would indicate this. The first study measured gait speed over 12 minutes at normal walking 
speed. MR brain images were analysed for WMH burden and brain volumes corrected for 
ICV. They found that gait speed was correlated to frontal WM volume (r 0.4, p=0.003) and 
frontal grey matter volume (r 0.3, p=0.01) (Novak et al., 2009). However total WMH burden 
was not associated with gait speed. It is not exactly clear why they looked at frontal brain 
volumes and gait speed and no other regions of the brain or total brain volume. The second 
paper also measured gait speed over 12 minutes and used MR brain images. In the non-stroke 
group, white matter volume was found to predict gait speed (B 1.30, p=0.03) but not grey 
matter (p>0.05). They comment that greater brain atrophy is associated with slower gait 
speed, but this is for the whole group, so includes stroke patients. The volunteers were 
recruited from a health centre patient list, but it doesn’t say why they were attending the 
health centre or whether this is where they receive their primary care, more details would 
have been useful to assess how generalisable the results are.  
The final study from Boston was by Manor et al and quoted results from the control group 
(Manor et al., 2012). They found no association between total GM volume or regional GM 
volumes and walking speed over 75 metres (p>0.005, Bonferroni adjusted). They were being 
compared to subjects with diabetic peripheral neuropathy in this study. No results for WM or 
CSF were reported in the study. As this study used 75 metres for their gait speed it may be 
that this represents a test of cardiorespiratory function more than shorter distances and 
therefore this measure may be less reliant on muscle function. 
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Seven studies from the Cardiovascular Health Study (CHS) met our criteria for inclusion. 
However three of the studies did not contain any associations between the variables of 
interest and the study authors did not supply the raw data or correlations (Barnes et al., 2009, 
Rosano et al., 2008, Rosano et al., 2011). As above, the participants were all selected from 
Medicare Lists possibly affecting the generalisability of results, and the papers used a 10 
point scale for WMH grade and ventricular enlargement, whereas now this would usually be 
measured in exact volumetric terms which may improve errors secondary to subjective 
judgement. The first study used gait speed measured over 15 feet, and MR brain images 
which were used to measure ventricular enlargement (VE) and WMH both of which were 
recorded on a 10 point scale (0-9). Both greater ventricular enlargement (p<0.001) and 
greater WMH burden (p=0.003) were associated with slower baseline gait speed (Rosano et 
al., 2005). The model included adjustment for age, sex, race and education.  
The next study looked at a subset of the CHS who had undergone two MR brain scans, 
separated by roughly 5 years, and a MMSE and had undergone assessment on the GaitMat, a 
4 metre long instrumented walking surface (Rosano et al., 2006). THE MR brain scans were 
classified as above, but given binary cut-offs for the analysis of WMH grade ≥3 or <3 and VE 
>4 or <4 for some of the analyses. Gait speed was correlated with WMH grade (r=-0.18, 
p<0.0001) and with WMH in the brainstem (r=-0.18, p<0.01). Logistic regression was used 
to analyse the relationship further and gait speed was separated into quartiles. This showed 
that those in the lowest two quartiles of gait speed (ie<1.02m/s) had double the likelihood of 
having WMH graded 3 or above (p=0.03). VE graded >4 was not found to be significantly 









 quartile) (Rosano et al., 2006).  
Longstreth et al is mentioned in the above section on grip strength and brain structure, as this 
was also studied in this paper (Longstreth et al., 1996). Gait speed was again measured over 
15 feet and WMH burden was scored 0-9 on MR brains scans. Time to walk 15 feet was 
found to correlate with WMH grade (partial correlation coefficient 0.153, p<0.001, adjusting 
for age, sex and presence of clinical silent stroke on MR brain). The population in this study 
and the study by Rosano et al (Rosano et al., 2005) overlap considerably and only appear to 
differ in the time they were still in the study and the particular inclusion and exclusion criteria 
for that part of the study.  
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In a separate paper, Rosano et al found that prefrontal area volume significantly predicted 
time to walk in a stepwise forward model (beta -0.15, p=0.02) (Rosano et al., 2012). This 
relationship was attenuated when adjustment was made for DSST score, which is a measure 
of processing speed. They conclude that smaller prefrontal area volume may contribute to 
slower gait speed through slower information processing. 
The final two studies identified are both from the Oregon Brain Aging Study (OBAS) 
(Marquis et al., 2002, Silbert et al., 2008). OBAS I is a prospective study commenced in 1989 
of healthy older adults age 65 years or older at the initial assessment, a second arm was added 
in 2004, OBAS II, with subjects 85y or older at the start of the study. The exclusion criteria 
were extensive, with no known comorbidities being allowed at the time of recruitment to the 
study. In a population of 65 year olds, this will lead to results not really applicable to the 
general population. Marquis et al (2002), looked at the correlation of timed walk, measured at 
self-selected pace over 9 metres, against brain volumes. Hippocampal volume was found to 
negatively correlate with timed walk (partial r=-0.12), however no significance value was 
given and it did not explicitly state what was adjusted for in the correlation (Marquis et al., 
2002). The correlation between TBV and timed walk was <0.1.  
Further data from the study was requested, which was kindly provided. Baseline data from all 
subjects from OBAS I and II who had had a MRI brain scan and a timed walk at baseline was 
used to perform our analysis (n=176). GLMs were performed to investigate the relationship 
between brain structures and gait speed, calculated in metres per second for the analysis. In 
an unadjusted model, gait speed was predicted by TBV, hippocampal volume and WMH 
volume, all p<0.001. Upon adjusting for age, sex, ICV and height, TBV (t 3.61, p=0.004, 
partial eta squared 4.3%) and WMH (t -2.80, p=0.006, partial eta squared 4.4%) significantly 
predicted gait speed, but hippocampal volume did not (p>0.05).  
2.3.2.2.2 Longitudinal analysis of the relationship between brain structure and gait 
speed 
The following studies reported longitudinal relationships between brain structure and gait 
speed. The Tasmanian Study of Cognition and Gait was set up to examine the role of age-
related brain changes in causing problems with walking, balance and cognitive abilities in the 
general community. It measured brain volumes and usual walking speed over 4.6 metres at 
baseline and 31 months (Callisaya et al., 2013). They found that a greater decline in gait 
speed over this period was associated with more WM atrophy and hippocampal atrophy and 
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greater accumulation of WML (p<0.05). There was a non-significant trend with GM atrophy 
and decline in gait speed (p=0.06). Subjects recruited to the TASCOG study were selected 
from electoral rolls and only minimal exclusion criteria were applied. The response rate was 
also good (56%). 
The following papers looked at the longitudinal relationship within the three-city study as 
described above. Soumare et al looked at the association between WMH volume at baseline 
and decline in walking speed over the 7 year follow up period (Soumare et al., 2009). They 
found that having a WMH volume greater than the 90
th
 percentile, more than doubled the risk 
of decline in walking speed compared with subjects with lower volumes of WMH. This 
finding was replicated when looking at PVH but not for deep WMH volume. 
The authors from the Three-City study provided further associations between the variables of 
interest on written request (Callisaya et al., 2013, Srikanth et al., 2010, Srikanth et al., 2009). 
They looked at the relationship between WM and walking speed decline over 31 months 
using a multiple linear regression (MLR) and found no significant association. Finally they 
performed a logistic regression between a one standard deviation increase in WM volume and 
the risk of having the highest walking speed decline, which was again not significant. 
Although the walking speed was measured longitudinally, the brain structure measurements 
were only recorded at baseline in the study. 
The second paper from the WML and mobility study recorded variables after a period of 
follow up (19-22 months) (Wolfson et al., 2005), the baseline data is described above in the 
cross-sectional analysis section (Guttmann et al., 2000). The follow up paper found a change 
in gait speed between visit 1 and 2 did not predict WMSA volume at follow up (p=0.07). 
They also state they found a significant negative relationship between change in gait speed 
between visits and CSF volume at follow up (r=0.733, p<0.005) and a positive relationship 
between change in gait speed and WM volume at follow up (r=0.558, p<0.05) (Wolfson et 
al., 2005). However both the quoted correlations are positive. In this study gait speed was 
measured at both visits, but the brain structure measurements were only performed at the 
second visit. 
The follow up paper from the Moscufo study was performed after 2 years and found that 
change in WMH burden, either total or in any of the 7 regional areas, over 2 years was not 
associated with a decline in usual walking speed (p>0.1) (Moscufo et al., 2012). However 
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decline in walking speed was entered as a binary variable for this analysis (ie decline or no 
decline in walking speed over 2 years), which may have missed a relationship between 
greater WMH burden and greater declines in walking speed. 
The CHS papers included some longitudinal analyses. Rosano et al found that both greater 
ventricular enlargement (VE) (p<0.001) and greater WMH burden (p=0.003) were associated 
with greater decline in gait speed over the 4 year follow up period (Rosano et al., 2005). 
Indeed, after adjusting for baseline performance, those with severe VE were found to have 
2.5x the decline in gait speed compared to those with minimal VE at baseline. The model 
included adjustment for age, sex, race and education. Again, in this study gait speed was 
measured longitudinally whereas the brain structure measurements were only performed at 
the initial time point. 
Silbert et al (2008) used longitudinal data from the OBAS study and found that a higher 
baseline total WMH volume was associated with a greater increase in timed walk over follow 
up (R
2
=0.08, p=0.0052), the average follow up was 9.1 years (Silbert et al., 2008). They then 
looked at whether location of WMH mattered and found that whilst periventricular (PV) 
WMH volume was associated with a greater change in timed walk over follow up (R
2
=0.12, 
p=0.0039), a higher subcortical WMH volume was not. These analyses were adjusted for age 
and ICV. They next looked at change in WMH volume with time and found that a higher rate 
of accumulation of PV WMH was associated with a greater increase in timed walk (R
2
=0.15, 
p=0.0453). However there was no relationship described between subcortical or total WMH 
accrual and change in timed walk, and it is not clear if these analyses were not performed or 
possibly more likely, that there was no significant association found. This is probably an 
example of reporting bias for negative findings. 
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Brain structure and grip strength 
1. (Sachde














52.8 Volumes of 
GM, WM and 
CSF, ICV and 









Study: Total brain WMH volume predicted grip 
strength in men (beta -0.140, delta R
2 
0.019, p<0.05) 

























Study: Grip strength adjusted for sex and ICV was 
found to correlate with CC midbody area (r=0.103, 
p<0.05), however CC total area and anterior and 
posterior CC areas did not significantly correlate with 
grip strength (p>0.05). 
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Study: None, see other articles from the PATH 
through life project for analysis using this dataset. 
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Study: Total brain WMH significantly predicted grip 
strength (beta -0.09, p=0.002) adjusted for age, sex 
and depression. Correcting for comorbidity, cognition 
and brain atrophy did not attenuate the results (beta -
0.13, p =0.001). 














Study: A MLR model found that grip strength is not 
related to brain atrophy (beta -0.082 (SE 0.005) 
p=0.54). Adjusting for age, gender, BMI, education, 
MMSE, Tokyo Metropolitan Institute of Gerontology 
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volunteers) Index of Competence, geriatric depression scale and 
























Study: Non-significant trends showed a negative 
correlation between right grip strength and total 
caudate volume (r=-0.303, p=0.05) and left grip 
strength (r=-0.28, p=0.07) in the control group. Not 
corrected for age or sex. No relationships given for 
other measures. 





































Study: None of the brain size measures (cerebellar 
vermis area, cerebellar volume or cerebral volume) 
significantly predicted timed walk (p>0.05) after 
adjustment for age (but not sex, as was not deemed to 
be a significant contributor after univariate analyses). 
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Study: MLR were performed to investigate the 
relationship of longitudinal change in brain volumes 
and gait speed. They found that white matter atrophy 
(beta 0.25 (CI 0.09-0.40) p=0.001), greater WML 
progression (beta -0.89 (CI -1.75- -0.02) p=0.045), 
grey matter atrophy (beta 0.25 (CI 0.00-0.19) p=0.06) 
and hippocampal atrophy (beta 0.01 (CI 0.00-0.02) 
p=0.006) were all associated with a greater decline in 
gait speed. 
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Study: none, see Callisaya et al (2013) for analysis 
using the TASCOG dataset. 
10. (Srikant









55.4 WMLV, TBV Gait speed 
using 4.2m 
GAITRite 
Study: none, see Callisaya et al (2013) for analysis 
using the TASCOG dataset. 
 
















Study: Logistic regression stratified by education 
found that high WML volumes were not associated 
with slow walking speed among highly educated 
participants (OR = 0.72), but were associated with a 
2-fold-increased risk of slow walking speed among 
those with low education (OR = 3.19/1.61 = 1.99) (p 
interaction=0.026), adjusted for sex, age and total 
WM volume. Results remained unchanged after 
adjustment for height, BMI, and MMSE score. 
Given: WM volume did not predict walking speed at 
baseline, adjusted for age, gender and ICV in a MLR 
(p>0.05, n=1510), or decline in walking speed over 7 
years, adjusted for age, gender, ICV and baseline 
walking speed, (p>0.05, n=928). A logistic regression 
found that WM volume was not significantly 
associated with an increased risk of being in the 


































Study: A linear regression found that only basal 
ganglia volume (beta 0.075 (SE 0.025) p=0.003) was 
significantly associated with walking speed; driven by 
caudate nucleus volume (beta 0.114 (SE 0.024) 
p<0.001). All other regional GM volumes were not 
significantly associated with walking speed. A semi-
bayes model found again only the basal ganglia 
volume (beta 0.061 (SE 0.028) p=0.03) was 
significantly associated with walking speed; driven by 
caudate nucleus volume (beta 0.050 (se 0.019) 
p=0.007). There was found to be a linear relationship 
between quartiles of caudate nucleus volume and 
faster walking speed (p for linear trend (0.001). These 
relationships were attenuated slightly for total basal 
ganglia volume by adjusting for MMSE and 
comorbidity plus smoking but not for caudate nucleus 
volume. All models adjusted for; age, sex, BMI, 
education level, ICV, volume of WMLs and silent 
 
Chapter 2  68 
WMLs infarcts. 






































Given: See Elbaz et al (2013) for Three-City Study 
data analysis. 
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Study: A significantly lower mean walking speed 
was found in those with a total WMH volume above 
the 75th percentile compared to those below the 25
th
 
(Beta -0.026, p=0.0003). A similar relationship was 
found for both deep WMH and PVH. A WMH 
volume greater than the 90th percentile more than 
doubled the risk of decline in walking speed 
compared with subjects with lower volumes of 
WMH (OR 2.6 (1.5-4.5), p=0.001). This finding was 
replicated when looking at PVH but not for deep 
WMH volume. 
Given: See Elbaz et al (2013) for Three-City Study 
data analysis. 














59.8 WMH in 
deep/subcortical







Study: A slower 6metre walk test was associated with 
increased brain stem lesions (F 7.11, p=0.009, partial 
eta2 0.070), but not with WMH (deep) (F 3.33, 
p=0.071) or PVH (F 2.47, p=0.12). Doesn’t state if 
age and sex are adjusted for in these models. If HADS 
score and Raven’s score are adjusted for, brainstem 

















walk test at 
preferred 
Study: Within linear regression models, global GM 
volume and all of the regional GM volumes were not 
associated with walking speed in the control group 
 
Chapter 2  69 







pace (p>0.005, Bonferroni adjusted). Adjusted for age, sex 




























Study: Gait speed was not significantly associated 
with GM volume (p=0.85), but was significantly 
associated with WM volume (B=1.30, p=0.03) 














47.4 GM, WM, CSF, 











Study: Gait speed was significantly associated with 
frontal WM normalized for brain tissue volume 
(R=0.4, p=.003). Gait speed was significantly 
associated with frontal GM normalized for brain 
tissue volume (R=0.3, p=.01). Adjusted for age and 
BMI (but not gender). Doesn’t say about other 
regional brain volumes, ie temporal etc. WMH 
volumes and PVH and punctuate scores were not 
associated with gait speed (p>0.05). 
19. (Moscuf










84 (3.9) 40 WMH volume 
as % of ICV 
and regional 
WMH burden 
expressed as % 
of ROI volume. 











and 2y f/u. 
Study: Total WMH burden was significantly 
associated with usual walking speed at baseline but 
not at follow-up, and maximum walking speed was 
not associated with total WMH at baseline or follow 
up. At baseline, regional WMH burden in the 
splenium of corpus callosum and anterior and superior 
corona radiata, was significantly associated with both 
walking measures (p<0.05) and in addition the body 
of the corpus callosum was also associated with usual 
walking speed (p<0.05). At follow-up, WMH burden 
in the splenium was significantly associated with both 
walking measures (p<0.05) and in the body with 
maximum walking speed. Change in WMH burden, 
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either total or in any of the 7 regional areas, over 2 
years was not associated with a decline in usual 
walking speed (p>0.1). 
Given: WMH burden is significantly associated with 
lower gait speed after adjustment for age, sex and 
BMI (rho=-0.327, p=0.0008). WM/ICV is not 
significantly associated with gait speed with or 
without adjustment (p>0.05). GM/ICV is significantly 
associated with gait speed with adjustment for age, 
gender and BMI (rho=0.232, p<0.05). CSF/ICV is 
significantly associated with gait speed with 
adjustment for age, sex, BMI (rho=-0.285, p=0.004). 
20. (Moscuf










nal study  
83(4) 42.4 WM, GM, 







expressed as % 







Study: Total WMH burden (ie % of ICV) correlates 
with gait speed (rho=-0.288, p=0.004). Also all 9x 
regional burden measurements correlate with gait 
speed score too except sup. longitudinal fasciculus. 
No adjustment. 
Given: See Moscufo et al (2012) for analysis using 
this dataset. 
21. (Wolfso
































Study: Slower baseline gait velocity predicted more 
WMSA at visit 1 (p<0.05), but not change in WMSA 
volume between visit 1 and 2 (p<0.07). Significant 
negative relationship of between-visit change in gait 
velocity to CSF volume (r=0.733, p<0.005) and a 
positive relationship of between-visit change in gait 
velocity to WM volume (r=0.558, p<0.05). Betas not 
given. Brain volumes normalized for ICCV according 
to image processing section. 
22. (Guttma




























Study: Gait velocity was not significantly predicted 
by age nor WMSA volume (no figures given or p 
value) adjusted with and without MMSE score. 
 



























Study: Prefrontal area volume significantly predicted 



























over 15ft  
Study: none, see Rosano (2012), Rosano (2006), 
Rosano (2005) and Longstreth (1996) for analysis 





























Study: Gait speed was significantly correlated to total 
WMAs (r=-.18, p<0.0001) and white matter lesions in 
the brainstem (r=-.18, p=0.01). After adjusting for 
age, slower gait speed was still significantly 
associated with white matter grade (p=0.02). Logistic 
regression found that those in the lowest two quartiles 
of gait speed (ie<1.02m/s) had double the likelihood 
of having WMH graded 3 or above (p=0.03), after 
adjustment for age, race, gender, and prevalent 
clinical CVD. VE graded >4 was not found to be 
significantly predicted by gait speed, however VE 
graded>5 was, independent of age, gender, race and 
presence of CVD (OR=2.91 for 1st vs. 4th quartile, 
OR 3.82 for 2nd vs 4th quartile) 
 































Study: Grade of ventricular enlargement was 
associated with baseline gait speed and mean change 
in gait speed/year. Gait speed decline was 2.5x that 
for those with severe VE than minimal VE. (p<0.001). 
Grade of WMH was associated with baseline gait 
speed and mean change in gait speed/year (p=0.003). 
In both analyses adjustment had been made for age, 
sex, race and education and CV risk factors (BMI, 
systolic BP, antihypertensive meds, internal carotid 
















38.5 PV WMH and 











Study: Adjusted for age and ICV, higher baseline total 
WMH vol. was associated with increased rate of 
change in timed walking in seconds (r
2
=0.08, 
p=0.0052). This relationship became non-significant 
after adjustment for multiple comparisons to threshold 
p value. PVH volume is associated with increased rate 
of change in timed walk in seconds (r
2
=0.12, 
p=.0039). However, baseline subcortical WMH vol. 
was not related to change in gait performance over 
time. Higher rate of PVH accumulation is associated 
with increased rate of change of time to walk 9m 
(r
2
=0.15, p=.0453). Adjusted for age, ICV and 
baseline WMH volume: 
Calculated: In an unadjusted GLM, gait speed was 
predicted by total brain, WMH and hippocampal 
volume (p<0.001). The relationship remained 
significant after adjusting for sex, age, ICV and 
height, for total brain volume (t=3.61, p=.004, partial 
eta squared 4.3%) and WMH (t=-2.80, p=0.006, 
partial eta squared 4.4%) but not for hippocampal 
volume.  
28. (Marqui



















Study: Negative correlation between hippocampal 
volume and time to walk 30ft (r=-.12). No p value 
given.  
Calculated: See Silbert et al (2008) for Oregon Brain 
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Study data) pace. Aging Study data analysis. 


























WMH and PVH 
and total WMH 
volume, brain 










Study: In men: Time to walk 6metres predicted by 
WMH volume (beta 0.13, p=0.02) but not brain 
atrophy or peak height MTR (adjusted for age and 
brain size as includes measure of brain atrophy). In 
women: Usual walking speed predicted by lower 
MTR height (ie indicating abnormal brain tissue) 
(beta -0.14 (p=0.01), increased WMH (beta 0.12, 
p=0.003) and greater brain atrophy (beta 0.15, 
p=0.01) (adjusted for age and brain size). Lower 
muscle strength associated with peak height MTR 
(p<0.005, beta not given). 
30. (Aribisa
la et al., 
2013) 
UK, LBC 






















wave 1 and 
2 
Study: Grip strength at wave 1 significantly predicts 
ventricular volume at wave 2 (standardized beta -
0.10), however there was no significant association 
with other brain volumes. 6metre walk at wave 1 
predicted TBV (-0.07), ventricular volume (0.09), 
NAWM (-0.07) and WML (0.11) all p<0.05. Grip 
strength at wave 2 was associated with ventricular 
volume (-0.11) and NAWM (0.08). 6MW at wave 2 
was associated with TBV (-0.07), NAWM (-0.09) and 
WML (0.11) all p<0.05. Change in physical function 
between wave 1 and 2 (ie decrease in grip strength or 
increase in 6MW) was not significantly associated 
with any brain volume measure. GM volume did not 
significantly associate with any of the physical 
function variables at wave 1 or 2. All analyses were 
adjusted for age, ICV, age 11 IQ, years of education, 
social class, comorbidity and smoking status. 



























Study: none, see Rosano (2012), Rosano (2006), 
Rosano (2005) and Longstreth (1996) for analysis 
using the Cardiovascular Health study dataset. 
 




































Study: none, see Rosano (2012), Rosano (2006), 
Rosano (2005) and Longstreth (1996) for analysis 





























Study: Time to walk 15ft correlated with white matter 
grade (0-9) (r=0.153, p<0.001), with adjustment for 
age, sex and presence of clinically silent stroke on 
MRI. Same model showed no significant associated 
between grip strength in dom hand or non-dom hand 
and white matter grade (p>0.05).  
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2.3.3 Association of brain function and muscle structure 
Fifteen papers were identified which looked at brain function and muscle structure: DEXA 
was used in eleven of the studies; BIA in two; and CT for thigh muscle CSA and MRI for 
neck muscle CSA in the final two papers (table 2.4). Measures of brain function were the 
MMSE, the Community Screening Instrument of Dementia (CSI-D), Trail Making Test 
(TMT) A and B, digit span and a measure of global cognitive performance (using z scores 
from multiple cognitive tests). The studies included the Kansas Brain Aging Project (Honea 
et al., 2009, Burns et al., 2010, Wetmore et al., 2011) and the MHEM study (Kilgour et al., 
2013), both mentioned in the above section, and studies from Canada (Berryman et al., 2013), 
Chile (Bunout et al., 2005), the Chinese University of Hong Kong (Auyeung et al., 2011, 
Auyeung et al., 2008), Denmark (Pedersen et al., 2012), Italy (Magri et al., 2006), Lithuania 
(Lasaite and Krasauskiene, 2009), Taiwan (the I-Lan Longitudinal Aging Study, ILAS) (Liu 
et al., 2014), and from the USA, the Baltimore Longitudinal Study of Aging (Moore et al., 
2014) and the FITKids Study (Kamijo et al., 2014, Kamijo et al., 2012). All the papers 
included in this section used cross-sectional data except the four papers from the Chinese 
University of Hong Kong which contain longitudinal data on cognitive test scores and lean 
mass; the results from these studies have been grouped together at the end of this section. 
From the Kansas Brain Aging Project, Burns et al (2010) found a relationship between both 
MMSE (beta 0.11, p=0.009) and global cognitive performance (beta 0.12, p=0.007) and 
TLM, again grouping AD and control subjects together (Burns et al., 2010). They state that in 
this relationship if the AD subjects are removed from the analysis the results are attenuated, 
but do not show any results for this. A GLM was performed on the data from the non-
demented group supplied to us by the study authors, and I found that neither the global 
cognitive performance score nor MMSE was predicted by TLM adjusting for age and sex. 
Adjusting for height and education did not affect this.  
The MHEM study used 9 different cognitive tests, which they reduced to two factors using 
principal components analysis (Kilgour et al., 2013). Total neck muscle CSA did not 
significantly predict variance in either the memory factor or the cognitive processing factor 
(p > 0.05), however, it did predict 10% of the variance in the NART score (t = −2.12, 
p < 0.05). The NART score is a measure of childhood intelligence and the authors comment 
that the finding is the opposite of what they hypothesized, as they found that lower childhood 
intelligence is associated with larger neck muscle size in old age.  
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Berryman et al supplied the baseline data from their physical training intervention trial. 
Subjects had performed a MMSE and modified Stroop test and underwent a DEXA scan at 
baseline (Berryman et al., 2013). A GLM was performed which showed no association 
between LBM and MMSE or the Stroop naming, reading or inhibition tasks. However there 
was an association between the Stroop flexibility task and LBM (t 2.126, p=0.039, partial eta 
squared 9.3%), however after adjusting for education and height the effect was attenuated 
(p>0.05). This effect was in the opposite direction than might be expected, ie bigger muscle 
mass is associated with a worse score (the Stroop test is measured in seconds to perform the 
task). No details are given in the paper as to how the subjects were recruited, therefore it is 
unknown if this was a potential source of bias, and there was also quite an extensive 
exclusion criteria list another source of bias in the results as the subjects are likely to be 
healthier than the average population in this age group (60-85y). 
The two papers from Chile are a study by Bunout et al which includes baseline data for a 
randomized controlled trial (RCT) investigating an exercise intervention in the elderly 
(Bunout et al., 2005) and a paper by Bites et al which used baseline trial data from several 
studies, including the study by Bunout et al, held on their University database (Bites et al., 
2013). The paper by Bunout et al was a retrospective analysis of data held from previous 
studies performed by their University. Recruitment details for the subjects from all the 
individual studies were lacking and therefore there are several sources of bias attributable to 
the methodology used in this paper. The authors sent one data sheet for both studies as there 
is a large amount of overlap between the studies (overlap n=203). A GLM was performed 
which showed total LM (t 2.38, p=0.018, partial eta squared 1.4%) and leg LM (t 3.53, 
p<0.001, partial eta squared 3.1%) were both associated with MMSE score but arm LM is 
not. After adjusting for height the relationship between TLM and MMSE became non-
significant and between leg LM and MMSE is attenuated (t 2.09, p=0.038, partial eta squared 
1.1%). Therefore it seems that leg LM is driving the relationship between total LM and 
MMSE. 
Pedersen et al investigated cognition and physical fitness in normal controls, subjects with 
impaired glucose tolerance and type 2 diabetes (Pedersen et al., 2012). They supplied the raw 
data for their control group to be analysed. Subjects underwent DEXA for FFM and six 
cognitive tests (a cognitive z score was computed as a marker of general cognition). FFM did 
not predict the cognitive z score with or without adjusting for BMI and childhood intelligence 
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(Danish Adult Reading Test, DART). The six individual cognitive tests were then analysed. 
There was no association between FFM and most of the individual cognitive tests. Also, 
unadjusted there was no significant association between the letter fluency test (using “s”) and 
FFM (P>0.05), however after adjustment for BMI and DART, letter fluency was significantly 
associated with FFM (t 2.34, p=0.02, partial eta squared 7.7%). Letter fluency is a test of 
executive function and this may indicate that change in this type of cognition with age is 
associated with FFM in older age. TMT-A test did significantly predict FFM (t 3.08, 
p=0.003, partial eta squared 12.3%), but after adjusting for BMI and DART the relationship 
became non-significant. The TMT-A test is a measure of processing speed. The subjects were 
recruited using newspaper adverts, a possible source of bias, and the control group was 
significantly smaller than the case group. As with all the case-control studies in this review 
no relevant power calculations were undertaken as the association in the control group was 
not an outcome measure for this study. 
Magri et al (2006) performed a cross-sectional study looking at postmenopausal women and 
HRT, however their study also contained a control group of young healthy women which 
were used for our analyses after the study authors kindly supplied their data (Magri et al., 
2006). A GLM was performed with MMSE as the outcome/dependent variable and FFM as 
the predictor/independent variable as measured by BIA. FFM did not significantly predict 
MMSE after adjustment for age (p>0.05) (Magri et al., 2006). Adjustments for BMI and 
educational level did not further affect these results. There are a couple of methodological 
issues with this study which could affect the generalisability of these results. Firstly, all the 
control subjects were recruited from the place of work of the study authors, and secondly the 
exclusion criteria were extensive including any recent acute or chronic illness, smoking 
history, no medication and 2 or less caffeinated drinks per day. 
Lasaite et al performed an observational case-control study which looked at women with 
osteoporosis and healthy controls (Lasaite and Krasauskiene, 2009). The study data for the 
healthy controls was supplied to us on request. The cognitive measures were the TMT-A and 
B and a digit span test. FFM was measured using BIA. A GLM was performed on the 
available data. FFM did not predict TMT-A or B adjusting for age +/- height (p>0.05). There 
was a non-significant trend with FFM predicting digit span adjusting for age (t 1.96, p=0.06, 
partial eta squared 13%), however when adjusted for height too, the relationship was 
attenuated (p=0.37). The controls in this study were also all older women, but the way they 
 
Chapter 2  78 
were recruited and the exclusion criteria were not documented in the study, therefore 
represent possible sources of bias. 
The I-Lan Longitudinal Aging Study is an ageing cohort study in Taiwan, in the paper 
identified only baseline data was used (Liu et al., 2014). Within the study they performed a t 
test comparing mean MMSE in those with a normal relative appendicular skeletal mass 
(RASM=ASM/height
2
) with those in the lowest 20% for RASM, and they found a significant 
difference in both men and women. They also supplied the results of a linear regression on 
our request for further data, which showed that RASM did not predict MMSE after adjusting 
for age and sex (beta -0.003, p=0.940). This may mean there is a non-linear relationship 
between cognition and muscle mass. This is a large population based study with random 
sampling of the population register to recruit subjects and minimal exclusion criteria. It was 
not clear why they chose to use the lowest 20% of RASM, as guidelines on sarcopenia vary 
on which cut off to use and, as we now know, when analysed as a continuous variable there 
was no significant association. It would therefore be interesting to see a scatter plot of this 
data to look for a non-linear relationship 
The Baltimore Longitudinal Aging Study is a large longitudinal cohort study, in which the 
subjects underwent four cognitive tests and had a mid-femur CT for thigh CSA (Moore et al., 
2014). No associations between the cognitive tests and thigh CSA were included in the study, 
but the authors sent the results of a MLR they had performed on cross-sectional data. They 
found that none of the cognitive tests predicted thigh CSA, adjusting for age and gender. 
After adjusting for age, gender and height, the digit-span backward test became significantly 
negatively associated with thigh CSA (beta -1.55, p=0.024), meaning those with bigger thigh 
muscles perform better on the test (a higher score is better in the digit span tests). As the 
association between digit-span backward and thigh CSA was only significant after adjusting 
for height in addition to age and gender, this may represent residual confounding rather than a 
true association. It doesn’t say in this paper how the volunteers in this study were recruited 
which may indicate a source of bias. 
The next study to look at cognition and muscle structure is the FITKids study based in 
Illinois, USA (Kamijo et al., 2014, Kamijo et al., 2012) which looked at 7-9 year olds. Two 
papers from this study were identified; however there were no relevant associations in the 
papers and the study authors kindly provided us with the raw data on which to perform an 
analysis. As the subjects were all from the same study the authors provided us with one 
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dataset for the study. I performed a GLM which found that TLM did not predict the Kaufman 
Brief Intelligence Test, used to assess IQ. The subjects were the control group in a study 
looking at childhood obesity and as such all had a normal BMI. It doesn’t state in the paper 
how they were recruited which may be a source of bias. 
The only longitudinal data identified in this section came from four papers from the Chinese 
University of Hong Kong which used data from a large prospective longitudinal study 
looking at bone mineral density in older Chinese adults to assess the relationship between 
physical and cognitive function (Auyeung et al., 2011, Auyeung et al., 2008, Lee et al., 2011, 
Auyeung et al., 2013). They used two measures of cognitive function; the MMSE and the 
cognitive score from the Community Screening Instrument for Dementia (CS-CSID). Only 
one of the papers included the associations between the cognitive tests and muscle mass 
(Auyeung et al., 2011). They found that in men, but not in women, lower appendicular 
skeletal mass (SM) at baseline predicted lower MMSE at follow up (for a 2.54kg increase in 
appendicular SM, there would a 0.246 change improvement in MMSE, p<0.001). However 
after adjustment for age, years of education and baseline MMSE, the relationship became 
non-significant (P>0.05) (Auyeung et al., 2011). The authors from this study kindly supplied 
further analyses of their data upon our request. 
They performed Spearman’s partial correlations, adjusting for age and sex. There was no 
significant relationship between baseline CS-CSID and total LM or appendicular LM at 
baseline or 4 years. However baseline MMSE predicted both baseline total LM (partial rho 
0.058, p=0.002) and appendicular LM (partial rho 0.061, p=0.001) and 4 years follow up total 
LM (partial rho 0.058, p=0.002) and appendicular LM (partial rho 0.054, p=0.005). However, 
the effect size is small. They also looked at the whether those with lower MMSE at follow up 
had lower muscle mass at baseline or follow up but found no significant associations 
(p>0.05) (Auyeung et al., 2011). Unfortunately the study authors did not supply data for the 
relationship between change in cognition and change in muscle mass over the four year 
follow up which would be very interesting in such a large study population. Also, the method 
of recruitment may have been a source of bias as the subjects were recruited through talks at 
community centres and housing estates, which may have only accessed a particular sub-
population of older people.  
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Calculated: A GLM showed no association 
between LBM and MMSE, Stroop naming, 
reading or inhibition tasks, adjusted for sex 
and age. However there was an association 
between the Stroop flexibility task and LBM (t 
2.126, p=0.039, partial eta squared 9.3%), 
however after adjusting for education and 
height the effect was attenuated (p>0.05).  
2. (Bites et 
al., 2013) 











Calculated: Authors sent one data sheet for 
this study and Bunout et al, as there is a large 
amount of overlap between the studies. 
N=401, mean age 75.3 (sd 4.8), males 28.7%. 
GLM performed adjusting for sex and gender. 
Total LM (t 2.38, p=0.018, partial eta squared 
1.4%) and Leg LM (t 3.53, p<0.001, partial 
eta squared 3.1%) were both associated with 
MMSE score but Arm LM is not. After 
adjusting for height the relationship between 
total LM and MMSE is non-significant and 
between leg LM and MMSE is attenuated (t 
2.09, p=0.038, partial eta squared 1.1%). 
3. (Bunout et 
al., 2005) 









Calculated: See Bites et al 2013 for analysis 






















Given: CS-CSID did not predict TLM or ASM 
at baseline or at 4 years (all p>0.05). However 
baseline MMSE was associated with baseline 
 














TLM (rho=0.058, p=0.002) and ASM 
(rho=0.061, p=0.001) and at follow-up (TLM 
rho=0.058, p=0.002, ASM rho=0.054, 
p=0.005). MMSE at follow up was not 




















Study: In men, low baseline ASM predicted 
lower MMSE score after 4 years (B = 0.246, 
p<0.01) however after adjustment for age, 
years of education and baseline MMSE it no 
longer did (p>0.05). In women, ASM did not 
significantly predict MMSE after 4 years, 
either before adjustment or after (p>0.05).  
Given: see Auyeung et al (2013) for analysis 
using this dataset 



















Given: see Auyeung et al (2013) for analysis 




















Given: see Auyeung et al (2013) for analysis 




























Calculated: FFM did not predict the cognitive 
z score with or without adjusting for BMI and 
childhood intelligence (Danish Adult Reading 
Test, DART). The six individual cognitive 
tests were then analysed: FFM did not predict 
RAVLT, SDMT, category fluency (using 
animals) or TMT-b test, with or without 
adjusting for BMI and childhood intelligence 
(DART). Unadjusted, there was no significant 
 






















association between the letter fluency test 
(using “s”) and FFM (P>0.05), however after 
adjustment for BMI and DART, letter fluency 
was significantly associated with FFM (t 2.34, 
p=0.02, partial eta squared 7.7%). TMT-a test 
did significantly predict FFM (t 3.08, p=0.003, 
partial eta squared 12.3%). After adjusting for 
BMI and DART the relationship became non-
significant. 











0 MMSE FFM 
(BIA) 
Study: none 
Calculated: FFM did not significantly predict 
MMSE (p>0.05), adjusting for age. 
Adjustments for BMI and educational level 













66.2(6.3) 0 TMT-A 





Calculated: FFM does not significantly predict 
TMT-A or B adjusting for age +/- height 
(p>0.05). Trend with FFM predicting digit 
span (t 1.96, p=0.06, partial eta squared 13%) 
but attenuated when adjusted for height in 
addition to age (p=0.37). 


















Study: A t test comparing mean MMSE in 
those with normal RASM and those within the 
lowest 20% of RASM found a significant 
difference in men and women of all ages 
(p<0.05). 
Given: In a MLR, RASM did not predict 
MMSE after adjusting for age and sex (beta -
0.003, p=0.940). Adjusting for education in 
addition did not affect the results. 

















Given: In a linear regression, none of the 
 




















A & B 
(CT) cognitive tests predicted thigh CSA, adjusting 
for age and gender. After adjusting for age, 
gender and height, the digit-span backward 
test became significantly associated with thigh 
CSA (beta -1.55, p=0.024).  

























Calculated: Authors sent one data sheet for the 
FITKids study as there is considerable overlap 
in subjects between the two Kamijo et al 
papers (Kamijo et al., 2014, Kamijo et al., 
2012), (n= 139, mean age 8.8 (sd 0.6), male 
51.1%). A GLM found that TLM did not 
predict K-BIT after adjustment for age and 
gender (p>0.05). Adjusting for BMI in 
addition did not alter the results. 
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n Study design Mean age 
(sd) 
Male (%) Brain structure or 
function 
Muscle structure or 
function 
Studies with brain structure and muscle structure (re: table 2.2) 
1. (Chowdhu
ry et al., 
1994) 
Sweden 8 Methodology 
paper 
35 (8) 100 Brain volume (CT) Calculated skeletal 
muscle volume (CT) 










over 52 weeks 
69.6 (2.9) 0 Whole brain volume 
(MRI) 
Gait speed, quads 















75 (9) 40 Score on Age-Related 
White Matter Change 
Scale (MRI) 









45.2 (13.9) 100 Caudate, putamen, 
nucleus accumbens and 
medial septal / diagonal 
band volumes and ICV 
(MRI) 
Bilateral grip strength 













Median 50 0 Episodic verbal memory 
















study (AD vs 
MCI vs 
normal) 
70.0 (7.0) 43 CVLT-II, Logical 
memory, RCFT, digit 
span, digit symbol 
coding, D-KEFS verbal 
fluency, BNT, clock, 
WTAR, Stroop. 
Body composition 
(DEXA) in subgroup in 
Perth 








69.4 (2.9) 0 Stroop test, MMSE Sub-total lean mass 
(DEXA) 
 





n Study design Mean age 
(sd) 
Male (%) Brain structure or 
function 









M 14.9 (1.8), 
F 15.1 (1.9) 
48.8 Executive function and 
Memory  
FFM (BIA) 

















80.51(3.9) 0 SPMSQ Lean mass and ALM 
(DEXA) 
11. (Nourhash









































46.8 MMSE FFM (BIA) 
14. (Malaguar
nera et al., 
2007) 

















0 15 words test and Trails 
B test 
BIA and DEXA 
16. (Genton et 
al., 2011) 















MMSE FFM (BIA), ASMM 
(DEXA) and BCM (total 
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2011) 
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Age 70-79 at 
baseline 
48.5 3MS Total bone-free lean 
mass, trunk lean mass, 
appendicular lean mass 
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40 3MS (annual), WAIS R 
digit span, Fuld object 
memory evaluation, 
Color Trails 1 and 2, 
clock drawing (all less 
than annual) 
Annual skeletal tissue 
mass (DEXA) 
30. (Haren et 
al., 2008) 







56.1(4.4) 100 MMSE, TMT A&B TLM and ASM (DEXA) 
31. (Dvorak & 
Poehlman, 
1998) 
USA, Vermont 30 Case-control 
study 
73(7) 43.3 MMSE ASM and FFM (DEXA) 
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2.4 Discussion 
This systematic review looked at the evidence for whether: a) brain structure is related to 
muscle structure, b) brain structure is related to muscle function and c) brain function is 
related to muscle structure in healthy humans over the life course.  
2.4.1 Brain volumes and muscle mass 
The relationship between brain structure and muscle structure was first reviewed (summary in 
table 2.6). Three studies tested for an association between whole brain volume and muscle 
mass; the three papers from the Kansas Brain Aging Project are treated as one study 
(Heymsfield et al., 2012, Kilgour et al., 2013, Honea et al., 2009, Burns et al., 2010, Wetmore 
et al., 2011). Two studies found a positive association between WBV and muscle mass 
(Heymsfield et al., 2012, Kilgour et al., 2013) and one study found no significant association 
(Honea et al., 2009, Burns et al., 2010, Wetmore et al., 2011). However, this study found a 
significant positive association between WM volume and FFM but no association between 
GM volume and FFM (Honea et al., 2009, Burns et al., 2010, Wetmore et al., 2011). A 
different study looked at regional GM volume and found four areas negatively associated 
with FFM but found most areas to have no association with FFM (Weise et al., 2013). Two 
studies found no association between hippocampal volume and muscle mass (Honea et al., 
2009, Burns et al., 2010, Wetmore et al., 2011, Kilgour et al., 2013). One study looked at 
ventricular volume and cerebellar volume and muscle size and found no association either 
(Kilgour et al., 2013). Four of the studies were of older adults and two were of younger 
adults, and it may be that the relationship between brain and muscle structure varies over the 
life course. Furthermore if there is a relationship between whole brain volume and muscle 
size it looks like it may be regional brain volume that drives this relationship rather than total 
volume. The studies are all cross-sectional and a large longitudinal study is needed to explore 
these relationships further. 
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Table 2-6: Number of studies
# 












Whole brain size and muscle size - 1 (70) 2 (311) (Honea et al., 2009, 
Burns et al., 2010, 
Wetmore et al., 2011, 
Heymsfield et al., 2012, 
Kilgour et al., 2013) 
White matter volume and muscle 
size 
- - 1 (70) (Burns et al., 2010, 
Weise et al., 2013, 
Honea et al., 2009, 
Wetmore et al., 2011) 
Grey matter volume and muscle size 1 (76)* 2 (146)* - (Burns et al., 2010, 
Honea et al., 2009, 
Wetmore et al., 2011, 
Weise et al., 2013) 
Hippocampal volume and muscle 
size 
- 2 (121) - (Burns et al., 2010, 
Kilgour et al., 2013, 
Honea et al., 2009, 
Wetmore et al., 2011) 
Cerebellar volume and muscle size - 1 (51) - (Kilgour et al., 2013) 
Ventricular volume and muscle size - 1 (51) - (Kilgour et al., 2013) 
*this study found negative associations between some areas of grey matter volume (the right temporal pole and bilateral 
vmPFC) and muscle size but found the majority of GM areas had no association 
#Number of studies reflects the result found for each study not each paper (ie for whole brain size and muscle size all the 
papers from the Kansas Brain Aging Project (Honea et al., 2009, Burns et al., 2010, Wetmore et al., 2011) have been 
grouped as one study as they all use the same data). This was to prevent the repetition of results from a single study that may 
occur if several papers from the same study repeated analyses. 
2.4.2 Brain structure and muscle function 
Next evidence for an association between muscle function and brain structure was reviewed 
(summary in table 2.7 & 2.8). Muscle function was either grip strength (5 studies) or gait 
speed (13 studies) apart from in one paper where isometric knee extensor strength (IKES) 
was used (Rosano et al., 2010). 
2.4.2.1 Brain structure and grip strength 
Only one study looked at the relationship between whole brain, GM or WM volume and grip 
strength (Aribisala et al., 2013). There were no significant associations except for a positive 
relationship between WM volume and grip strength at wave 2 (age 73) (Aribisala et al., 
2013). This could mean that the relationship between WM volume and grip strength only 
becomes important with age, once a volumetric threshold is passed. Another study found no 
association between caudate volume and grip strength (Hardan et al., 2003). However the 
basal ganglia may be expected to play less of a role in grip strength than in gait speed. Two 
studies found a negative association with markers of brain atrophy and grip strength (Doi et 
al., 2012, Aribisala et al., 2013), however one of these studies also looked at change in grip 
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strength over 3 years and found no association with ventricular volume (a marker of brain 
atrophy) (Aribisala et al., 2013). This means that whilst cerebral atrophy and grip strength 
appear to be associated, decline in grip strength does not predict cerebral atrophy. A 
longitudinal study including both measures would help explain this relationship further. 
One study found an association between WMH and grip strength (Sachdev et al., 2005). They 
found that location of the WMH is important, with some brain areas correlating with grip 
strength and others not (Sachdev et al., 2005). On looking at the data separated by sex, this 
relationship persisted in men, but not women, but the study authors think this is due to a sex 
difference present in their study population, with the men having higher volumes of WMH 
(Sachdev et al., 2009). Two larger studies found no association between WMH and grip 
strength, however one of these studies used a visual rating scale from 0-9 to measure WMH, 
which may lead to differing results than using WMH volumes (Aribisala et al., 2013, 
Longstreth et al., 1996). The other study also looked at change in grip strength over 3 years 
and WMH volume at follow up and found no association (Aribisala et al., 2013). WMH are 
known to predict dementia and cerebrovascular disease but their relationship to physical 
function is less well understood (Debette and Markus, 2010). 











Grip strength and whole brain 
volume  
- 1 (694) - (Aribisala et al., 2013) 




 (Aribisala et al., 2013) 
Grip strength and GM volume - 1 (694) - (Aribisala et al., 2013) 
Grip strength and caudate volume - 1 (41) - (Hardan et al., 2003) 
Grip strength and ventricular 
volume/brain atrophy 
2 (804) - - (Doi et al., 2012, 
Aribisala et al., 2013) 
Grip strength and WMH 1 (478) 2 (4352) - (Sachdev et al., 2005, 
Aribisala et al., 2013, 
Longstreth et al., 
1996) 
Change in grip strength over f/u and 
whole brain volume 
- 1 (694) - (Aribisala et al., 2013) 
Change in grip strength over f/u and 
WM volume 
- 1 (694) - (Aribisala et al., 2013) 
Change in grip strength over f/u and 
GM volume 
- 1 (694) - (Aribisala et al., 2013) 
Change in grip strength over f/u and 
ventricular volume 
- 1 (694) - (Aribisala et al., 2013) 
Change in grip strength over f/u and 
WMH volume 
- 1 (694) - (Aribisala et al., 2013) 
a. at wave 1 in this study there was no association and at wave 2 there was a positive association (Aribisala et al., 2013) 
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2.4.2.2 Brain structure and gait speed 
Two studies found a positive association between WBV and gait speed (Silbert et al., 2008, 
Marquis et al., 2002, Aribisala et al., 2013), whereas studies investigating the relationship 
between WM and GM volume and gait speed found less unanimous results. Three studies 
found a positive association between WM volume and gait speed (Hajjar et al., 2010, Novak 
et al., 2009, Aribisala et al., 2013) and two studies found no association (Elbaz et al., 2013, 
Moscufo et al., 2012). Four studies found no association between GM volume and gait speed 
(Dumurgier et al., 2012, Manor et al., 2012, Hajjar et al., 2010, Aribisala et al., 2013) but 
three studies found a positive relationship (Novak et al., 2009, Moscufo et al., 2012, Rosano 
et al., 2012). There was no evidence that hippocampal volume or cerebellar volume were 
associated with gait speed (Silbert et al., 2008, Marquis et al., 2002, Piguet et al., 2006). It 
may be that specific sub-regions of the white and grey matter are associated with gait speed, 
for example one paper found an association between basal ganglia volume and gait speed but 
no association with total GM and gait speed. Further studies looking at regional brain areas 
will help to clarify these relationships. Five studies looked at markers of brain atrophy and 
gait speed; two found a negative association (ie more atrophy associated with a slower gait 
speed) (Moscufo et al., 2012, Rosano et al., 2006, Rosano et al., 2005) and one found no 
association (Rosano et al., 2010), with one finding an association at wave 1 but not at wave 2 
(Aribisala et al., 2013).  
No association was found between change in gait speed over follow up and whole brain, WM 
and GM volume (mean length of follow up in each study, 3 and 7 years) (Elbaz et al., 2013, 
Aribisala et al., 2013).However one large study did find an association between ventricular 
volume and change in gait speed over follow up (mean 4 years) (Rosano et al., 2005) but 
another study found no association (mean follow up 3 years) (Aribisala et al., 2013). Only 
one study looked at the relationship between change in gait speed and change in brain 
structure over time (mean follow up 30.6 months) (Callisaya et al., 2013). They found a 
positive association between change in gait speed and WM and hippocampal atrophy but no 
association with GM atrophy. The well-established relationship between cognitive decline 
and gait speed and cognitive decline and brain atrophy could underpin the possible 
relationship between brain atrophy and gait speed (Abellan van Kan et al., 2009, Atkinson et 
al., 2007, Scherder et al., 2007, Drago et al., 2011, Moran et al., 2013). It is interesting that 
the only study to look at both variables in a longitudinal study found significant associations 
between brain structure and gait speed and further studies like this are needed.  
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Eleven studies were found which looked at gait speed and WMH, making it the most studied 
relationship in our review. Seven of these studies found that greater levels of WMH were 
associate with slower gait speed (Soumare et al., 2009, Moscufo et al., 2012, Wolfson et al., 
2005, Rosano et al., 2006, Rosano et al., 2005, Silbert et al., 2008, Marquis et al., 2002, 
Aribisala et al., 2013, Rosano et al., 2010, Longstreth et al., 1996), but four other smaller 
studies found no association (Starr et al., 2003, Novak et al., 2009, Moscufo et al., 2012, 
Guttmann et al., 2000). Two of these studies found that this is primarily due to the volume of 
PVH and not subcortical WMH lesions (Soumare et al., 2009, Silbert et al., 2008) and two 
papers found that volume of brainstem WMH was associated with gait speed (Starr et al., 
2003, Rosano et al., 2006). One small study (n=14) found no association between gait speed 
and WMH progression over follow up (19-22 months) (Wolfson et al., 2005). However, 
change in gait speed was found to be associated with WMH volume in two large studies 
(Soumare et al., 2009, Rosano et al., 2005) with another study showing no association 
(Aribisala et al., 2013). Two studies looked at change in both variables; one found that 
greater decline in gait speed was associated with greater WMH progression (Callisaya et al., 
2013), whereas the other found no association (Moscufo et al., 2012). Further studies looking 
not just at total WMH volume but their rate of accumulation and location within the brain, 
and their association with gait speed should help clarify this area. 











Gait speed and whole brain volume - - 2 (885) (Silbert et al., 2008, 
Marquis et al., 2002, 
Aribisala et al., 2013) 
Gait speed and WM volume - 2 (1587) 3 (813)
b
 (Elbaz et al., 2013, 
Hajjar et al., 2010, 
Novak et al., 2009, 
Moscufo et al., 2012, 
Aribisala et al., 2013) 




 (Dumurgier et al., 2012, 
Manor et al., 2012, 
Hajjar et al., 2010, 
Novak et al., 2009, 
Moscufo et al., 2012, 
Rosano et al., 2012, 
Aribisala et al., 2013) 
Gait speed and hippocampal volume - 1 (191) - (Silbert et al., 2008, 
Marquis et al., 2002) 
Gait speed and cerebellar volume - 1 (111) - (Piguet et al., 2006) 




 - (Soumare et al., 2009, 
Starr et al., 2003, 
Novak et al., 2009, 
Moscufo et al., 2012, 
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Wolfson et al., 2005, 
Guttmann et al., 2000, 
Rosano et al., 2006, 
Rosano et al., 2005, 
Silbert et al., 2008, 
Marquis et al., 2002, 
Aribisala et al., 2013, 
Rosano et al., 2010, 
Longstreth et al., 1996) 







 - (Moscufo et al., 2012, 
Rosano et al., 2006, 
Rosano et al., 2005, 
Aribisala et al., 2013, 
Rosano et al., 2010) 
Gait speed and WMH progression 
over f/u 
- 1 (14) - (Wolfson et al., 2005) 
Change in gait speed over f/u and 
whole brain volume 
- 1 (694) - (Aribisala et al., 2013) 
Change in gait speed over f/u and 
WM volume 
- 2 (1622) - (Elbaz et al., 2013, 
Aribisala et al., 2013) 
Change in gait speed over f/u and 
GM volume 
- 1 (694) - (Aribisala et al., 2013) 
Change in gait speed over f/u and 
CSF/ventricular volume 
- 1 (694) 1 (2450) (Rosano et al., 2005, 
Aribisala et al., 2013) 
Change in gait speed over f/u and 
WMH volume 
- 1 (694) 2 (4152) (Soumare et al., 2009, 
Rosano et al., 2005, 
Aribisala et al., 2013) 
Change in gait speed over f/u and 
WM atrophy 
- - 1 (225) (Callisaya et al., 2013) 
Change in gait speed over f/u and 
GM atrophy 
- 1 (225) - (Callisaya et al., 2013) 
Change in gait speed over f/u and 
hippocampal atrophy 
- - 1 (225) (Callisaya et al., 2013) 
Change in gait speed over f/u and 
WMH progression 
- 1 (77) 1 (225) (Callisaya et al., 2013, 
Moscufo et al., 2012) 
b. one study only looked at frontal WM/GM volume not total WM volume (Novak et al., 2009) 
c. basal ganglia volume was positively associated with gait speed in this study (Dumurgier et al., 2012) 
d. one study only looked at prefrontal area volume within GM (Rosano et al., 2012) 
e. this study found usual walking speed was negatively associated with WMH but that maximum walking speed was not 
(Moscufo et al., 2012) 
f. except brainstem WMH which were negatively associated with gait speed in this study (Starr et al., 2003) 
g. at wave 1 there was a negative association and at wave 2 there was no association in this study (Aribisala et al., 2013) 
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2.4.3 Cognitive function and muscle mass 
Nine studies were found which looked at cognitive function and muscle structure (table 2.9). 
Three studies looked at a measure of global cognitive performance (a composite score of 
several tests used in their study) and muscle size and all 3 found no association (Kilgour et 
al., 2013, Wetmore et al., 2011, Pedersen et al., 2012). The Kaufman Brief Intelligence Test 
can also be used as a marker of general cognition and it too found no association with muscle 
size (Kamijo et al., 2014, Kamijo et al., 2012). Seven studies looked at muscle size and 
MMSE score, which is a useful screening tool for dementia but is not a robust test of 
cognitive function. Four of the studies found no association between MMSE and muscle mass 
(Wetmore et al., 2011, Berryman et al., 2013, Magri et al., 2006, Liu et al., 2014) and one 
found an association but with a very small effect size (Auyeung et al., 2013). However in one 
study which showed no association between MMSE and FFM, when comparing subjects with 
normal RASM and those within the lowest 20% of RASM this study found a significant 
difference in mean MMSE (Liu et al., 2014). Several of the included studies did not include 
those with cognitive impairment and it may be that an association does exist between MMSE 
and muscle size but in a non-linear relation, affecting the frailer older adult more, but that it 
was not picked up in these studies due to the method of analysis in a linear regression. 
Overall though in healthy individuals it seems that no such association exists. The final study 
found an association between leg LM and MMSE but not between total or arm LM (Bites et 
al., 2013). Sarcopenia is known to affect leg and arm muscles differently which perhaps 
explains this effect (Janssen et al., 2000). Another screening tool for dementia, the cogscore 
part of the CSI-D, also found no association with muscle mass (Auyeung et al., 2013). It is 
well established that gait speed and cognition are associated in older age and these results 
appear to show that muscle size is not a driving force behind this relationship (Abellan van 
Kan et al., 2009, Atkinson et al., 2007, Scherder et al., 2007). 
With regard to the individual cognitive tests (which measure processing speed and executive 
function), there were no significant associations (Lasaite and Krasauskiene, 2009, Moore et 
al., 2014, Berryman et al., 2013, Pedersen et al., 2012), except for the NART (a measure of 
childhood IQ, which showed a negative association with neck muscle CSA (Kilgour et al., 
2013). The authors comment that perhaps subjects with higher cognition are more likely to 
have sedentary jobs and therefore more likely to lose their muscle mass over time. None of 
the studies looking at cognition and muscle size contained longitudinal associations therefore 
whilst these results appear to support no association between muscle mass and cognition; it 
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may be that longitudinal data would show an association, whereby those that lose more 
muscle with age have a sharper slope of decline in their cognition also. Longitudinal studies 
will help to elucidate these complex relationships further. 











Muscle size and global cognitive 
score 
- 3 (193) - (Kilgour et al., 2013, 
Wetmore et al., 2011, 
Pedersen et al., 2012) 




 (Wetmore et al., 2011, 
Berryman et al., 2013, 
Bites et al., 2013, 
Auyeung et al., 2013, 
Magri et al., 2006, Liu 
et al., 2014) 
Muscle size and California 
Verbal Learning Test 
- 1 (786) - (Moore et al., 2014) 
Muscle size and CSI-D - 1 (3153) - (Auyeung et al., 2013) 
Muscle size and digit span - 2 (815)
j
 - (Lasaite and 
Krasauskiene, 2009, 
Moore et al., 2014) 
Muscle size and Kaufman Brief 
Intelligence Test 
- 1 (139) - (Kamijo et al., 2014, 
Kamijo et al., 2012) 
Muscle size and modified Stroop 
test 
- 1 (48) - (Berryman et al., 
2013) 
Muscle size and NART 1 (51) - - (Kilgour et al., 2013) 
Muscle size and TMT-a - 3 (887) - (Pedersen et al., 2012, 
Lasaite and 
Krasauskiene, 2009, 
Moore et al., 2014) 
Muscle size and TMT-b - 3 (887) - (Pedersen et al., 2012, 
Lasaite and 
Krasauskiene, 2009, 
Moore et al., 2014) 
h. Leg LM was associated with muscle size but not total LM or arm LM in this study (Bites et al., 2013) 
i. In an MLR there was no association between MMSE and FFM but when comparing subjects with normal RASM and 
those within the lowest 20% of RASM this study found a significant difference (Liu et al., 2014) 
j. Digit span forwards unadjusted and adjusted was not associated with thigh muscle CSA, but adjusted backwards digit 
span was negatively associated with thigh muscle CSA in this study (Moore et al., 2014) 
2.4.4 Limitations 
In the review protocol the decision was made to write to study authors for relevant 
associations or data that were not given in the study but could be calculated using the 
recorded variables. This expanded the number of articles included in the review and the scope 
that they covered, however this may have led to some bias in which articles responded to the 
request and therefore what was reported, as study authors who found an association may have 
been more likely to reply. Of the 79 articles written to 59 replied therefore 25% did not 
respond. However the studies that did respond included both those which showed a 
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significant association and those that did not. The associations which were sent to us and the 
associations performed by us have not undergone peer review (eg for variable selection when 
adjusting the models), however I have included this information in our review and the 
statistical technique used to remain as transparent as possible. 
The studies included in the review used a wide variety of techniques to record the variables of 
interest which means it is difficult to compare them (eg in a meta-analysis). For example, gait 
speed was recorded over multiple lengths, using automated and manual techniques and 
different levels of speed (ie maximum or usual pace). The large differences in how gait speed 
was measured combined with the fact that over longer distances it can become a test of 
cardiovascular fitness etc more than a test of muscle function, makes it difficult to compare 
the results of these studies directly. Another example would be the relationship between brain 
size and muscle size where we found three studies investigating this relationship. One study 
used brain mass (MRI) and lean mass (DEXA), one used brain volume (MRI) and neck 
muscle CSA (MRI) and one used brain volume (MRI) and lean mass (DEXA). Therefore 
none of the studies were directly comparable and hence meta-analysis could not be 
performed. These issues of variation in measurement technique persisted across the other 
relationships also; therefore meta-analysis was not possible. Hopefully more standardized 
testing will come about in the wake of resources like the NIH toolbox which may allow meta-
analysis of studies in this area in the future (NIH, 2014). 
When looking at the relationship between brain size and muscle size or function it is 
important to make sure that the size of the individual being studied is not acting as a 
confounding factor (ie that large people have large brains and large muscles). This meant that 
it was important to ensure that some measure of body size had been adjusted for in each 
association (eg ICV, height, BMI). In most of the studies I looked at this occurred but in 
some it did not and this may lead to a false relationship being reported. 
A relatively wide range of ethnicities are represented in the study, however Caucasian 
subjects were by far the most commonly studied and there were no studies including those of 
Arabic or Indian ethnicity. Also most of the studies used subjects in their sixties, seventies or 
eighties, meaning the validity of our findings for other age groups, particularly children and 
adolescents is limited. 
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Finally, while a few of the studies included longitudinal data, it would be very useful to have 
more studies looking at the relationships over time as these may be able to highlight potential 
modifiable factors. 
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2.5 Conclusions 
An increasing body of research has now linked brain function (cognition) and muscle 
function (eg gait speed) (Abellan van Kan et al., 2009, Atkinson et al., 2007, Scherder et al., 
2007, Drago et al., 2011, Moran et al., 2013), however less well studied is the role of muscle 
and brain structure in this relationship. This systematic review looks at the evidence for 
whether: brain structure is related to muscle structure; brain structure is related to muscle 
function; and brain function is related to muscle structure in healthy humans across the 
lifecourse.  
The review found evidence of a positive association between whole brain volume and total 
white matter volume with muscle size, and evidence that some areas of regional grey matter 
volume (right temporal pole and bilateral vmPFC) are negatively associated with muscle size 
(Honea et al., 2009, Burns et al., 2010, Wetmore et al., 2011, Heymsfield et al., 2012, Kilgour 
et al., 2013, Weise et al., 2013).  
The review found no evidence of a relationship between grip strength and whole brain 
volume, however there was some evidence of a positive association between grip strength 
and WM volume. Markers of brain ageing, that is brain atrophy and greater WMH 
accumulation, were associated with grip strength (Doi et al., 2012, Aribisala et al., 2013, 
Sachdev et al., 2005). Unlike grip strength, there is evidence that gait speed is positively 
associated with whole brain volume; this relationship may be driven by total WM volume or 
regional GM volumes, specifically the hippocampus (Silbert et al., 2008, Marquis et al., 
2002, Aribisala et al., 2013). Like grip strength, gait speed is also associated with markers of 
brain ageing; WMH accumulation, brain atrophy and WM atrophy all show evidence of 
either a temporal association with gait speed or change in gait speed with time, with PVH and 
brainstem WMHs playing a particularly important role, but not subcortical WMH (Rosano et 
al., 2005, Soumare et al., 2009). 
The evidence overwhelmingly points to no association between cognition and muscle size, 
except in the case of MMSE where it is mixed, but MMSE is more a screening tool for 
dementia than a true marker of cognitive function (Kilgour et al., 2013, Wetmore et al., 2011, 
Pedersen et al., 2012, Berryman et al., 2013, Bites et al., 2013, Auyeung et al., 2013, Magri et 
al., 2006, Liu et al., 2014).  
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I have identified some evidence which supports the common cause hypothesis, in so far as 
associations were identified between brain structure and muscle size, and physical function 
and some measures of brain structure. However most of the data is from cross-sectional 
studies therefore there may be contributing factors other than ageing per se which have 
caused these associations. Also, some relationships showed no evidence of a convincing 
association (eg cognition and muscle size) implying that ageing processes are affecting these 
tissues differently and the common cause hypothesis may not play a large role. This may be 
because structure and function do not decline in parallel and differing extrinsic and intrinsic 
factors may be more important for structure or function leading to these discordant results. 
Interestingly whilst there was no evidence of an association between grip strength and whole 
brain volume there was an association between grip strength and markers of brain ageing (eg 
brain atrophy). For any measure such as grip strength or whole brain volume, there are two 
factors which will affect their magnitude in older adults: their peak in young adulthood and 
their trajectory of decline with ageing. Therefore as most of the studies that were identified in 
the review were cross-sectional both of these factors will affect the relationships we looked 
at, whereas longitudinal studies will allow correction for baseline measures and a better 
assessment of whether the trajectories are in parallel or not. Large longitudinal studies should 
ultimately be able to prove or disprove the common cause hypothesis and these studies are 
therefore needed to explore these relationships over time, which will allow a better 
understanding of the potential causal relationships. 
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Chapter 3 Methods for the Lothian Birth Cohort 
1936 study 
3.1 Introduction 
The Lothian Birth Cohort 1936 study is an example of a longitudinal ageing cohort study. It 
has a particular focus on cognitive ageing but also includes data on a large number of 
potential covariates. By developing the technique described in chapter 4 to measure neck 
muscle cross-sectional area on the brain scans performed as part of LBC 1936, I was able to 
use data already collected as part of the study and investigate its relationship with this 
measure of muscle size. The LBC 1936 study was therefore an extremely important resource 
for my thesis. In this chapter the premise of the LBC 1936 study and its structure are 
described, along with the methods used to measure the main brain and muscle variables and 
important covariates used in this thesis. 
3.2 Background and sample 
On 4
th
 June 1947 nearly all children attending school in Scotland sat a general mental ability 
test, called the Moray House Test number 12 (MHT), this was called the Scottish Mental 
Survey 1947 (Education, 1949). It was intended to repeat, and for its results to be compared 
with, the Scottish Mental Survey 1932, which again was a population wide measure of 11 
year olds in Scotland using the same test but in 1932. There was concern that the mean 
intelligence level of the population might be decreasing, however they found the opposite, 
with children in the 1947 study scoring slightly better than children in the 1932 study. There 
were 70,805 children tested out of a possible 75,211 born in 1936 in the total population. This 
information is highly valuable as Scotland is the only country to have ever performed a 
population wide intelligence test.  
In 2004 a cohort study was set up to follow up around 1000 of these participants who were 
currently resident in the Lothian area of Scotland (Deary et al., 2007b). The primary aim of 
the study was to test for genetic, medical, physiological, demographic and other determinants 
of individual differences in non-pathological cognitive ageing over the lifecourse, from age 
11 to age 70. Potential participants were contacted and after consenting to take part 
underwent a series of cognitive, physical and biochemical tests, at the Wellcome Trust 
Clinical Research Facility (WTCRF) at the Western General Hospital, Edinburgh (Wave 1 
2004-2007, n=1091), and returned for further testing at age 73 (Wave 2 2007-2010, n=866). 
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All participants were Caucasian, all born in 1936 and almost all lived independently in the 
Lothian region (Edinburgh city and surrounding area) of Scotland. The participants have 
recently completed wave 3 of testing (2011-2013, n=697) and wave 4 of testing is due to 
commence at the end of 2014. 
The following list represents a summary of the variables recorded within waves 1 and 2 of the 
LBC 1936 study: 
 Social and demographic data 
 Physical and medical measures 
 Blood and urine analysis 
 Inflammatory and immunological markers 
 Cognitive test scores 
 Volumetric MR brain imaging, quantitative and qualitative measures of white matter 
hyperintensities and diffusion-tensor-MR derived variables of long-range tracts (eg 
fractional anisotropy) 
 Doppler ultrasound of the carotid arteries 
 Retinal and facial photography 
 Personality tests 
 Genetic analysis (including GWAS, telomere length and methylation analysis) 
 Other (including questionnaire on social environment in childhood and adulthood, 
smoking and alcohol history, food frequency questionnaire) 
3.3 Ethics 
Ethics permission for the LBC 1936 study protocol was obtained from the Multi-Centre 
Research Ethics Committee for Scotland (MREC/01/0/56) and from the Lothian Research 
Ethics Committee (LREC/2003/2/29) and covered the sub-studies in this thesis because the 
ethics approval included the use of the data for future research purposes. The research was 
carried out in compliance with the Helsinki Declaration. All participants gave written, 
informed consent.  
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3.4 Brain variables 
3.4.1 Cognitive testing 
3.4.1.1 Moray House Test No. 12 
This was taken at about age 11 on June 4
th
 1947 and was re-administered when participants 
were seen again at about age 70 (Education, 1949). It contained the following items: 
following directions (14 items), same-opposites (11), word classification (10), analogies (8), 
practical items (6), reasoning (5), proverbs (4), arithmetic (4), spatial items (4), mixed 
sentences (3), cypher decoding (2), and other items (4). The maximum score was 76 and 
scores were used to construct age 11 and age 70 IQ. 
3.4.1.2 Mini-Mental State Examination 
The MMSE was originally designed as a bedside test to screen for cognitive impairment, but 
is now widely used as a screening tool for dementia (Folstein et al., 1975). It comprises items 
on attention and orientation (10 points), verbal registration (3 points), working memory (5 
points), short-term verbal memory (3 points), naming (2 points), verbal repetition (1 point), 
verbal comprehension (3 points), writing (1 point), reading a sentence (1 point) and 
constructional praxis (1 point). A score of less than 24 out of 30 is used to indicate possible 
dementia, however it should be noted that greater age, pre-morbid IQ and number of years of 
formal education are all known to be associated with lower MMSE scores and therefore a 
score of 24 may well be considered normal for a 90 year old with little formal education, but 
abnormal for a 65 year old architect. 
3.4.1.3 National Adult Reading (NART) and the Wechsler Test of Adult Reading 
(WTAR) 
These tests are used to estimate prior cognitive ability. The participant pronounces 50 
irregular words from a sheet; these words use the discordance between graphemes (the 
smallest semantically distinguishable unit in a written language) and phonemes (significant 
sounds) which occur within the English, and other, languages (eg the b in subtle is not 
pronounced) (Holdnack, 2001, Nelson and Willison, 1991). The NART test has been 
validated against true pre-morbid IQ using data from the 1932 Scottish Mental Survey, giving 
it a retrospective validity covering a 66 year interval (Crawford et al., 2001). 
3.4.1.4 Logical Memory I and II 
These two tests from the Wechsler Memory Scale-IIIUK (WMS-IIIUK) are designed to test 
immediate and delayed verbal declarative memory (Wechsler, 1998b). Participants are read 
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two short stories each containing 25 elements, and are asked to recall information about the 
stories immediately after they have listened to them and again later. These tests are two of 5 
subtests used from the Wechsler Memory Scale within the LBC 1936 study. The Wechsler 
Memory Scale was first designed in 1945 and was revised in 1987 and 1997; the UK version 
was used for the LBC 1936 study. The Wechsler Memory Scale was designed to test five 
types of memory function: auditory memory, visual memory, visual working memory, 
immediate memory, and delayed memory, when all seven subtests are administered.  
3.4.1.5 Backward digit span 
The backward digit span tests working memory and is also from the WMS-IIIUK (Wechsler, 
1998b). The participant needs to repeat backwards increasingly long strings of numerical 
digits. 
3.4.1.6 Verbal paired associates  
These are used to test verbal learning and memory and are also from the WMS-IIIUK 
(Wechsler, 1998b). The participant has to remember a list of pairs which include words 
having no obvious connection. 
3.4.1.7 Spatial span 
This is used to test non-verbal, spatial learning & memory and are also from the WMS-IIIUK 
(Wechsler, 1998b). The participant has to repeat a sequence of touching the top of a number 
of blocks in a pattern, first in the same order and then in reverse order. 
3.4.1.8 Digit symbol coding 
This is used to test speed of information processing and is from the Wechsler Adult 
Intelligence Scale-IIIUK (WAIS-IIIUK) (Wechsler, 1998a). The participant must fill in as 
many the associated symbols as possible in two minutes. The Wechsler Adult Intelligence 
Scale was originally published in 1955 and third revision was published in 1997. It uses 10 
subtests to create index scores representing four major components of intelligence: verbal 
comprehension, perceptual reasoning, working memory and processing speed. The UK 
version was used in LBC 1936. 
3.4.1.9 Block design 
The block design tests constructional ability and is from the WAIS-IIIUK (Wechsler, 1998a). 
The participants are given two minutes to use blocks to copy specific designs. 
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3.4.1.10 Symbol search 
This tests speed of information processing and is also from the WAIS-IIIUK (Wechsler, 
1998a). The participant checks a row of symbols to see if it contains one of a pair of target 
symbols, completing as many as possible within an allocated time. 
3.4.1.11 Letter-number sequencing 
This tests working memory and is also from the WAIS-IIIUK (Wechsler, 1998a). The 
participant listens to increasingly long, strings of numbers and letters. They then repeat them, 
with the numbers first, in numerical order, and then the letters in alphabetical order. 
3.4.1.12 Matrix reasoning 
This tests non-verbal reasoning and is also from the WAIS-IIIUK (Wechsler, 1998a). The 
participant has to complete a pattern displayed as a matrix with one piece missing. 
3.4.1.13 Verbal fluency 
Verbal fluency is used to assess executive function (Lezak, 2004). The participant is asked to 
name as many words as possible in one minute beginning with a given letter (C, F and L were 
used in LBC 1936). 
3.4.1.14 Simple and four-choice reaction time 
These tasks were used to assess speed and variability of simple information processing 
(Deary et al., 2001). The tasks were administered using a box with an LCD screen and five 
response keys (1, 2, 0, 3, 4). In the simple task only the 0 key is used and the other four keys 
are used in the four-choice task.  
3.4.1.15 Inspection time 
This was used to test speed of elementary visual processing. The participant indicated, with 
no pressure on response time, which of two parallel, vertical lines of markedly different 
lengths was longer after increasingly short lengths of exposure (Deary et al., 2004a).  
3.4.2 G cognition, G processing speed and G memory 
For a previous study three composite cognitive scores were derived using principal-
components analyses (PCA) to represent three distinct cognitive domains (Corley et al., 
2011). Regression scores were calculated for the first unrotated principal component of the 
tests in each domain. In each case, the scree slopes and eigenvalues suggested that a single 
component could be extracted. 
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3.4.2.1 G Cognition 
A cognition factor score, representing general cognitive ability, was derived from a PCA of 
scores on six tests; Letter–Number Sequencing, Matrix Reasoning, Block Design, Digit 
Symbol, Digit Span Backwards, and Symbol Search. The first unrotated principal component 
explained 53% of the variance, and all subtests had high loadings. 
3.4.2.2 G Processing speed factor 
A processing speed factor was derived from a PCA of scores on a set of speed of processing 
measures, namely, Symbol Search, Digit Symbol, inspection time and simple and choice 
reaction time. The first unrotated principal component for the speed factor explained 51% of 
the variance, and all tests had high loadings. 
3.4.2.3 Memory factor 
A memory factor was derived from a PCA of scores on a set of memory measures; Logical 
Memory I and II, Spatial Span, and Verbal Paired Associates I and II. The first unrotated 
principal component explained 43% of the variance, and all tests had high loadings. 
3.4.3 Imaging Protocol 
The volumetric MR brain scans from LBC 1936 used in this thesis had already been 
performed, as a primary outcome for that study was brain volume measurement (Wardlaw et 
al., 2011). The MR imaging was performed with participants in the supine position on a 1.5 
tesla MR imaging unit (Signa HDxt, GE Healthcare, Milwaukee, USA) at the Brain Research 
Imaging Centre (www.bric.ed.ac.uk). A phased array eight channel head coil was used and 
inversion recovery prepared volumetric T1 weighted images were acquired on a coronal 
plane for each patient. For this set of images, the alignment was perpendicular to the long 
axis of the hippocampus determined from a preliminary T2 weighted sagittal sequence. The 
flip angle was 8°, bandwidth 15.63 KHz, echo time (TE) 4ms minimum to 13ms maximum, 
repetition time (TR) 9.6ms and inversion or preparation time (TI) 500ms. The field of view 
(FOV), fixed superiorly at the cranial vertex, was 25.6cm x 25.6 cm, slice thickness 1.3mm 
with no slice gap leading to 160 slices, displayed on a 192 x 192 matrix. These images took 
8.13 minutes to acquire per patient.  
3.4.4 Brain volume and WMHs 
The intracranial volume (ICV) was chosen to include the contents within the inner skull table. 
The inferior limit was the axial slice just superior to the tip of the odontoid peg at the foramen 
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magnum and superior to the inferior limits of the cerebellar tonsils. It was obtained semi-
automatically using the T2*W sequence. All brain volume images were corrected for ICV in 
final models. This is to ensure that the associations I found between brain volumes and 
muscle size and function were not just due to body size (eg people with bigger skulls might 
be expected to have larger neck muscle CSA). 
The CSF, white matter lesions (WML) and normal-appearing white matter (NAWM) 
volumes were calculated from binary masks generated by an in-house developed software 
tool written in MATLAB that applies a technique named MCMxxxVI, which stands for 
Multispectral Colouring Modulation and Variance Identification and also represents the 
number “1936”, reflecting the Lothian Birth Cohort 1936 for which it was developed 
(Hernandez et al., 2010). The brain tissue volume was estimated by subtracting the volume of 
the ‘CSF+veins+meninges’ from the ICV.  
Ventricular volume was obtained by thresholding the T1W images. The optimum threshold to 
delineate the boundaries of the ventricles was calculated as the mean intensity value from 
four sample regions: two inside the lateral ventricles and two in the superior temporal cortex. 
In those subjects with a stroke lesion the total hyperintense WML volume was manually 
edited to exclude stroke by thresholding on the FLAIR volumes. I used only the “True 
WML” variable in our analyses which did not include stroke lesion volumes. 
WMLs were also scored on the FLAIR and T2W images using the Fazekas scale, which 
codes separately for deep and periventricular lesions (Fazekas et al., 1987). The left and right 
hemispheres were scored separately and combined to give an overall value indicating the 
highest WML score. 
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3.5 Muscle variables 
3.5.1 Neck muscle CSA 
See chapter 4 for the development of the tool for measuring neck muscle CSA on volumetric 
MR brain scans. 
3.5.2 Physical function measures 
3.5.2.1 Grip strength 
Grip strength is a commonly used measure of physical function in large cohort studies. This 
is because: the equipment used to test it is easily transportable and inexpensive; it correlates 
well with more other more complicated to measure measures of muscle strength (eg lower 
extremity muscle power and isometric knee extension strength) (Lauretani et al., 2003); and it 
has been found to correlate with disability associated with activities of daily living (ADLs) 
(Al Snih et al., 2004, Rantanen et al., 1999). 
Grip strength was measured using a North Coast Hydraulic Hand Dynamometer (JAMAR). 
Each measurement was taken three times and the highest reading was recorded for both 
hands. 
3.5.2.2 6 metre walk test (6MWT) 
Gait speed is another commonly recorded variable of muscle function within large cohort 
studies. Again this is because it is inexpensive and easy to record and is associated with a 
range of adverse health outcomes, including: severe mobility limitation, hospitalisation 
events and mortality (Cesari et al., 2009). 
The 6MWT was measured by hand using a stopwatch. Subjects were asked to start from 
standing still and walk 6 metres down a corridor as quickly as possible. Subjects were 
allowed to use any usual walking aid if they wished to. 
 
Chapter 3  108 
3.6 Covariates from LBC 1936 used in the thesis 
3.6.1 Age and sex 
Sex at birth was recorded at wave 1 of the study as Male =1 and Female =2. Age used for all 
analyses in the thesis pertaining to LBC 1936 was age in days at time of MR brain scan at 
wave 2.  
3.6.2 Height and weight 
Height (in centimetres) was measured with a SECA stadiometer, after shoes had been 
removed, and weight (in kilograms) was measured using electronic SECA scales with a 
digital readout, without outer clothing or shoes.  
3.6.3 Social factors 
Participants gave details of their social history at the initial interview at wave 1 of LBC 1936. 
A trained psychologist collected details of: number of years of full-time formal education 
completed; occupational history or for women their husband's occupational class if it was 
higher than their own (allowing categorisation within HMSO social class, categorised from I, 
professional, to V, unskilled); details of overcrowding at age 11 (ie the number of rooms in 
the participant’s house at this time and the number of people living there, an index was 
created by dividing the number of people in the house by the number of rooms); and lastly 
they were asked if they had indoor or outdoor toilet facilities at age 11. Social deprivation is 
well established to be associated with negative health outcomes, and therefore considering 
the role it has to play in muscle and brain ageing is crucial (Smith et al., 1998, Pickett and 
Pearl, 2001). 
3.6.4 Physical measures 
Sitting and standing systolic and diastolic blood pressure was recorded using an Omron 
705IT monitor, three times each. The average of the sitting systolic blood pressure was used 
for the analyses in this thesis.  
Brachial systolic pressure was measured in the right arm after 5 min of rest using a Doppler 
ultrasound and a random zero sphygmomanometer (to reduce the risk of digit preference) 
placed just above the elbow. Ankle systolic pressure was measured in the posterior tibial 
artery of the right leg using a Doppler ultrasound and a random zero sphygmomanometer 
with the cuff position just above the malleolus. The ABPI was calculated by dividing the 
systolic blood pressure in the ankle by that in the arm. 
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3.6.5 Comorbidity 
Disease history was recorded at wave 1 and 2 of the study and I used the data from wave 2 of 
the study for the analyses in this thesis. Participants were asked to answer yes or no to a 
series of questions, including: have you ever been treated for high blood pressure; have you 
ever been diagnosed as having diabetes; have you ever been told that you have high 
cholesterol in your blood; have you ever had a heart attack, angina, heart valve problem, 
abnormal heart rhythm or any other heart problem; and have you ever had a stroke or mini 
stroke? These answers were then coded as no=1 and yes=2 for history of hypertension, 
diabetes mellitus, hypercholesterolaemia, cardiovascular disease and stroke. 
3.6.6 Blood markers 
Blood samples were obtained on the same day as the psychological and physical testing.  
3.6.6.1 Total cholesterol and total cholesterol:high density lipoprotein ratio 
Non-fasting blood was analyzed with an enzymatic Quinoneimine dye method using the 
Abbott Architect c16000 General Chemistry analyser (Abbott Laboratories, USA) at the 
Western General Hospital, Edinburgh. An increased ratio of total cholesterol to HDL 
cholesterol (chol:HDL) provides a better prediction of coronary heart disease risk than the 
individual measures, because the components are related to risk in opposite directions 
(Castelli et al., 1983, Castelli, 1984).  
3.6.6.2 Glycated haemoglobin (HbA1c) 
Glycated haemoglobin can be used both to diagnose diabetes and to monitor glucose control 
in diabetic patients (Farmer, 2012). They act as a marker of blood glucose over the previous 
2-3months and are associated with both macro and microvascular disease in diabetes. HbA1c 
levels were measured using the Menarini HA8160 analyser, and results were reported in 
DCCT (Diabetes Control and Complications Trial) units which are expressed as a percentage 
with <6.5% considered normal. 
3.6.6.3 C reactive protein (CRP) 
CRP is an acute phase response protein synthesised in the liver, which has been found to be 
predictive of serious health outcomes, including cardiovascular disease and death (Ridker et 
al., 2003, Sigdel et al., 2014). CRP was measured using a dry slide immuno-rate method on 
the OrthoFusion 5.1 F.S. Analyser (Vitros Chemistry Products CRP slides, Ortho Clinical 
Diagnostics, Buckinghamshire, UK). As the CRP assay is designed for detecting raised levels 
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of CRP it cannot distinguish values less than 3 mg/L and all readings less than 3 mg/L (n = 
467) were assigned a value of 1.5 mg/L.  
3.6.6.4 Estimated glomerular filtration rate (eGFR) 
eGFR was calculated using the subject’s Creatinine, age and sex. Creatinine was measured 
using the Abbott Architect c16000 General Chemistry analyser (Abbott Laboratories, USA) 
at the Western General Hospital, Edinburgh. If the eGFR was greater than 60ml/min it was 
coded as 65.0. eGFR is known to be associated with cardiovascular and all-cause mortality 
(Matsushita et al., 2010). 
3.6.6.5 Cortisol 
Salivary cortisol was measured in a subset of the male participants (n=89). Saliva was 
collected using Salivette devices (Sarstedt, Numbrecht, Germany) at home on waking and at 
10 PM (ie evening) to characterize the diurnal cortisol profile. Diurnal slope was calculated 
by subtracting the waking measure from the evening measure. Thus, a negative value denotes 
a decreasing slope. The enzyme-linked immunosorbent assays (ELISAs) were carried out by 
Dresden LabService GmbH (Dresden, Germany) in accordance with a Material Transfer 
Agreement.  
3.6.6.6 S100 beta 
The calcium-binding protein S100 beta is predominantly expressed by astrocytes in the 
human brain and circulating levels are used as a marker of blood brain barrier permeability 
and central nervous system injury or disease (Sen and Belli, 2007). A two-site 
chemiluminescence immunoassay was used to quantify S100 beta in human serum on a 
Liaison chemiluminescence analyser (Diasorin, Berkshire, UK). The normal range for S100B 
protein is 0.02 - 0.2 µg/L 
3.6.6.7 Interleukin-6 (IL-6) 
IL-6 levels were analysed at the University of Glasgow using high sensitivity ELISA from 
R&D Systems. The minimum detectable dose ranged from 0.016-0.110 pg/mL (mean=0.039 
pg/mL). The intra-assay CV ranged from 6.9 to 7.8%, while the inter-assay coefficient of 
variance ranged from 6.6 to 9.6%. 
3.6.6.8 CMV serostatus and titres 
CMV was measured in plasma samples collected at age 70, using a CMV ELISA assay. 
Mock and viral-infected lysate was coated onto ELISA plates and incubated overnight. 
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Standards (a mixture of three CMV positive plasma samples) and plasma samples were added 
to the plates and incubated for one hour before washing. An anti-IgG horseradish peroxidase 
conjugated secondary antibody was then added to the plate to incubate for one hour. After 
washing, TMB substrate was added and the reaction stopped by addition of 1M HCL. The 
sample was assessed using an ELISA reader at 450nm. To determine CMV titres, mock 
values were first subtracted from lysate values. The data were then analysed in PRISM, and 
CMV titres were calculated with reference to the standard curve. Values above 10 were 
considered to be seropositive. To ensure accuracy, all samples were tested in duplicate. 
3.6.6.9 Telomere length 
Telomere shortening is associated with age-related diseases and mortality (Blasco, 2005). 
Telomere length was measured as abundance of telomeric template versus a single gene 
(glyceraldehyde 3-phosphate dehydrogenase) by quantitative real-time polymerase chain 
reaction (PCR). Four internal control DNA samples were run within each plate to correct for 
plate to plate variation. These internal controls are cell lines of known absolute telomere 
length whose relative ratio values (telomere starting quantity/glyceraldehyde 3-phosphate 
dehydrogenase starting quantity) were used to generate a regression line by which values of 
relative telomere length for the actual samples were converted into absolute telomere lengths. 
Measurements were performed in quadruplicate. All PCRs were carried out on an Applied 
Biosystems (Pleasonton, CA, USA) 7900HT Fast Real Time PCR machine with 384-well 
plate capacity. 
3.6.6.10 Apolipoprotein E4 genotype 
APOE4 carrier status is a well-established risk factor for Alzheimer’s dementia, vascular 
dementia and mild cognitive impairment (Chuang et al., 2010, Kim et al., 2009). It has also 
been associated with telomere shortening (Starr et al., 2008). DNA was isolated from whole 
blood, and the APOE SNPs rs7412 and rs429358 were genotyped with TaqMan technology. 
These two SNPs form the APOE E2/E3/E4 haplotype. Participants were then classified as 
either no E4 allele=0 or E4 allele present=1. 
3.6.7 Lifestyle factors 
As part of the initial interview at wave 2 alcohol and smoking history were recorded by the 
interviewer using a structured questionnaire. In the analyses I used current smoking status 
(never=0, ex=1, current=2) but decided not to use number of cigarettes smoked per day. This 
is because the percentage of participants who were current smokers in wave 2 was small 
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(8.4%) and it was felt this would lead to skewed results. For alcohol history I used three 
variables; whether the participant drank alcohol at all (no=0, yes=1); the number of days 
alcohol was consumed on per week and the number of units consumed per week. 
Participants were asked to fill in questionnaires after their clinic visit and return these to the 
study team using a stamped addressed envelope provided. Participants were sent a reminder if 
the questionnaires had not been received within 6 weeks of their clinic visit. In one of the 
questionnaires, participants were asked to indicate how many days in an average month they 
took part (for more than 20 minutes at a time) in any vigorous sport or physical exercise, 
which was recorded as “number of days exercise per month”.
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Chapter 4 Design and Validation of a Novel Method 
to Measure Cross-Sectional Area of 
Neck Muscles Included During Routine 
MR Brain Volume Imaging 
4.1 Introduction 
Low muscle mass secondary to disease and ageing is an important cause of excess mortality 
and morbidity (Roubenoff et al., 2003, Anker et al., 1997, Tisdale, 2002, Janssen et al., 
2002). Studies investigating correlates of muscle loss or potential interventions to slow or 
reverse muscle loss require accurate measurements of muscle size. Current imaging 
techniques used to measure muscle size include whole body or regional DEXA scans and 
volumetric or cross-sectional area measurements on MR or CT scans of the arm or leg (Cruz-
Jentoft et al., 2010). Arm and thigh cross-sectional area (CSA) have been used in previous 
studies as they are large and are viewed to be used in everyday tasks. However thigh muscle 
CSA has been shown to correlate well with total muscle mass and it may be that other muscle 
groups around the body are equally useful as a guide of general muscle bulk (Ohkawa et al., 
2000, Lerner et al., 1986). Whilst the above techniques remain the current gold standard, they 
are not commonly employed in clinical practice or in studies out with those directly 
investigating muscle mass (eg studies of sarcopenia or cachexia). Volumetric MR brain scans 
are commonly used in both research and clinical practice. These scans often include much of 
the posterior neck muscles. A technique to measure posterior neck muscle CSA on 
volumetric MR brain scans would therefore enhance the value of volumetric MR brains 
scans: both brain and muscle size could be measured without additional scanning. 
Recent studies have shown a correlation between grip strength and cognition, which has 
implications for studying rates of ageing (Boyle et al., 2009, Deary et al., 2011). However, 
few studies have investigated the relationship between muscle size and brain size. This is 
likely due in part to the fact that two different scans would be required in each subject to 
obtain these data. Both brain and muscle size are known to decrease with age, therefore 
studying the pattern of their inter-relationship would allow investigation of their shared risk 
factors which, in turn, may suggest underlying mechanisms. Many longitudinal ageing 
studies include a volumetric MR brain scan (Blumenthal et al., 1985, Deary et al., 2007b, 
Ellis et al., 2009). If it were possible to measure muscle CSA reliably from volumetric MR 
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brain scans and this measure was representative of general body muscle bulk, the relationship 
between muscle and brain size could be investigated using a single scan. 
MR measurement of neck muscle cross sectional area (CSA) has been shown to be feasible in 
young healthy adults using scans dedicated to this purpose (ie MR imaging of the neck), but 
older adults have not been studied (Elliott et al., 2007, Ulbrich et al., 2011, Cagnie et al., 
2010). These studies have demonstrated good inter-rater reliability (Ulbrich et al., 2011, 
Cagnie et al., 2010). Moreover, I found no previous studies documenting a technique to 
measure neck muscle size on MR brain scans. The limited data that are available suggest that 
neck muscle CSA and strength are correlated, indicating that neck muscle CSA has good 
construct validity (Tsuyama et al., 2001). I aimed to establish a novel method for measuring 
neck muscle CSAs from routine MR brain volume acquisitions. This chapter details the 
technique I developed and further studies to test its reliability, validity and repeatability. 
4.2 Methods 
4.2.1 Study 1: Feasibility study 
4.2.1.1 Goal 
To investigate whether it is feasible to measure neck muscle CSA on MRI volumetric brain 
scans. 
4.2.1.2 Ethics & Sample 
The volumetric MR brain scans used in this study had already been performed as part of the 
Lothian Birth Cohort 1936 (LBC) study (see chapter 3: Methods for cohort studies), as a 
primary outcome for that study was brain volume measurement. Twenty consecutive scans 
from a final total of 735 were selected between 02/02/09 and 30/03/09. Ethics gained for the 
LBC 1936 study covers this sub-study because the ethics approval included the use of the 
data for future research purposes. 
4.2.1.3 Imaging Protocol 
See chapter 3: Methods for the Lothian Birth Cohort 1936 study 
4.2.1.4 Development of neck muscle cross sectional area measurement 
technique 
The image data were transferred to a Kodak Carestream picture archiving and communication 
systems (PACS) workstation where 3-D multiplanar reconstructions were performed. 
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Freehand cursor was used to draw a region of interest (ROI) around the neck muscle of 
interest in the axial plane to obtain the cross sectional area on each side separately.  
Two raters tested feasibility in ten of the participants. I sought to develop a technique that 
ensured raters found the same level from which to make their CSA measurements. Our first 
attempt involved finding the MR slice in which the CSA of the obliquus capitis inferior was 
at its maximum in the axial plane. We chose the obliquus capitis inferior because it is a short 
muscle and its width varies more along its length than the other neck muscles in the scan. We 
then measured the CSAs for the largest muscles in that slice of the scan; sternocleidomastoid 
(SCM), obliquus capitis inferior, semispinalis capitis, splenius capitis and trapezius for both 
right and left sides (Figure 4.1). Although it was possible to measure the CSA of neck 
muscles using this technique, there were occasional large discrepancies between raters 
indicating that this method lacked reliability, particularly with regard to finding the level to 
take the measurements.  
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Figure 4-1: Figure of the posterior neck muscles and diagram demonstrating how the measurement plane 
was selected.  
A. Non-contrast T1-weighted MR of transverse plane of the neck at mid-infero-superior-C2 level.  
B. Outline diagram showing the neck muscles whose cross-sectional areas were measured. 
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Therefore, in the second attempt, we measured the neck muscles’ CSAs of a further ten 
participants, but this time we started with the images in the sagittal view with the volume 
images loaded into the multiplanar reformat view. We chose the slice where the C2 vertebral 
body height was at its maximum. We then identified the midpoint of the C2 vertebral body 
height including the odontoid by measuring along its vertical length from the odontoid tip to 
lower end plate using the cursor and then marked the midpoint. We then switched to the axial 
view of the multiplanar reformat at the vertical midpoint of C2 and measured the CSAs of the 
neck muscles in that axial image.  
We initially attempted to standardise the plane of the axial image on a line parallel to C2 end 
plates, but the variability of tilt in endplates meant that occasionally that line could go as high 
as suboccipital level posteriorly and thereby miss the muscles of interest. Setting the axial 
slice perpendicular to the vertical line of measurement through C2 did not work either as it 
proved difficult to manipulate the axial slice by small angle changes precisely enough. 
Therefore, we used the midpoint of C2 in the sagittal plane while viewing the images in the 
multiplanar reformat and then clicked on the corresponding axial image. This resulted in the 
axial slice being parallel to the lower border of the volume scan, but not related to any 
particular line in the participant. This time we measured the three posterior neck muscles 
(trapezius, splenius capitis and semispinalis capitis) individually and in combination. See 
Figure 4.2 for the chosen method. 
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Figure 4-2: Flowchart summarizing method to measure craniad muscles cross-sectional areas. 
 
4.2.2 Study 2: Study to measure inter-rater reliability 
4.2.3 Goal 
To investigate and quantify whether two raters using this technique would produce the same 
measurements. 
4.2.3.1 Sample 
A further 20 scans from the LBC 1936 study were studied in addition to the 20 from the 
feasibility study, to give us a total of 40 scans to measure with the newly-developed 
technique. 
4.2.3.2 Neck muscle cross sectional area measurements 
We performed the measurements with the chosen technique, as described in the feasibility 
study, on all 40 MRI scans (Figure 4.2). Each scan was measured three times by both raters 
and the median value for C2 body height and each of the three muscle measurements (SCM, 
obliquus capitis inferior and combined trapezius, splenius capitis and semispinalis capitis) 
were recorded separately for right and left sides for analysis. We noted that, unlike thigh 
muscles, there was only minimal intramuscular fat in the images of these neck muscles, so we 
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did not seek to adjust for this or the small area of interfascial fat between trapezius, splenius 
capitis and semispinalis capitis in the combined group measure.  
4.2.3.3 Analysis 
To compare inter-rater reliability, I calculated the percentage difference in CSA as measured 
by the two raters and the two-way random effects absolute agreement intraclass correlation 
coefficients. Multiple linear regression analysis was used to estimate effects of sex and body 
mass index (BMI) on neck muscle CSA. Principal components analysis was used to extract a 
general trait for neck muscle CSA from the three individual muscle CSA measures: I 
accepted components with eigenvalues greater than unity and inspected the scree plot to 
identify the number of components. All analyses were performed using the SPSS 16.0 
statistical package. 
4.2.4 Study 3: Study to measure repeatability of technique 
4.2.4.1 Goal 
To assess whether the technique would provide the same results on scans measured: 
 on the same subject and the same MRI scanner on different days 
 on the same subject and different MRI scanners on different days 
4.2.4.2 Ethics 
All subjects provided written consent and ethics approval was gained by the local ethics 
research committee for the original CaliBrain study (REC 05/S0801/105) (Gountouna et al., 
2010, Moorhead et al., 2009). This included further use of the data for research purposes and 
therefore further ethics permission for this study was not required. 
4.2.4.3 Sample 
The CaliBrain study investigated the reliability of repeat volumetric brain MR measures with 
the same scanner and between different scanners (Gountouna et al., 2010). We therefore used 
these data to test the reliability of repeat neck muscle CSA measurement from volumetric 
brain MR scans. The participants of the CaliBrain study were 14 normal volunteers from the 
three participating centres aged between 25 and 51 years, see below for details of the centres. 
As the data had been collected as part of the CaliBrain study no power calculations were 
carried out and we analysed all the available data. Exclusion criteria for the CaliBrain study 
were: previous history of a diagnosed neurological disorder or a major psychiatric disorder, 
treatment with psychotropic medication, including treatment for substance misuse and not 
meeting the MR safety criteria. 
 
Chapter 4  120 
4.2.4.4 Imaging protocol 
Each of the fourteen participants twice underwent a structural and functional MR brain scan 
at three imaging research centres around Scotland; The Department of Radiology, University 
of Aberdeen; The Brain Research Imaging Centre, Western General Hospital, University of 
Edinburgh; and The Neuroradiology Department, Southern General Hospital, NHS Greater 
Glasgow South University Hospitals Division. Therefore each participant underwent 6 
separate scans. Each scan took place on a separate day and there were nominally 2 weeks 
between the scans at the same site. We only used the structural data for our study. The three 
scanners used were all manufactured by General Electric (GE Healthcare, Milwaukee, 
Wisconsin) and had primary field strengths of 1.5T however the machines had differing 
software and hardware. Images were taken in the coronal plane at a slice thickness of 1.7mm 
with no slice gap. 3D reconstruction was used to make the measurements with our technique. 
Further details of the imaging protocol can be found in the paper by Moorhead et al 
(Moorhead et al., 2009). 
4.2.4.5 Cross-sectional area measurement technique 
The measurements were performed using Analyze, the biomedical image analysis software 
(Mayo Foundation, Rochester, Minnesota, USA).  
The CaliBrain images were aligned with the ACPC line, an anatomical line which runs 
between the superior surface of the anterior commissure and the centre of the posterior 
commissure. The feasibility and reliability studies had used images which were perpendicular 
to the MR table. Therefore the images underwent pre-processing prior to the measurements 
being made. This involved the images being tilted 15 degrees forward on the axial axis. This 
was actually preferable to the original study where the angle of the brain as viewed on PACS 
was not standardised, but just depended on how the patient placed their head in the scanner, 
as all the images in the CaliBrain study were standardised to an anatomical landmark, the 
ACPC line. Neck muscle CSA was measured as described in the feasibility study. 
4.2.4.6 Analysis 
ICCs were calculated for comparing within scanner and between scanner variations. When 
calculating the ICC for within scanner variation the measurements taken from the first and 
second scans were compared for each of the three individual measurements (ie combined 
group, SCM and obliquus) and the total neck muscle CSA (ie all three measurements for right 
and left sides added together). The ICC for between scanner variation were calculated using 
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the mean total muscle CSA for each measurement on that site (eg (Total neck muscle CSA 
Edinburgh scan 1 + Total neck muscle CSA Edinburgh scan 2)/2). 
All data were analysed using the SPSS 17.0 statistics package. Three nonsynchronous sets of 
measurements were taken for each scan and the median values were used for the analysis. 
4.2.5 Study 4: External validity study 
4.2.5.1 Goal 
To assess and quantify whether neck CSA is related to mid-thigh CSA, which has been 
previously shown to be related to general muscle mass (Dai et al., 2001, Ohkawa et al., 
2000). 
4.2.5.2 Ethics 
Ethics permission for the MR brain scans undertaken as part of the Lothian Birth Cohort 
(LBC) 1936 project had already been obtained as per study 1. A substantial amendment was 
submitted to allow us to recruit 25 subjects from the LBC 1936 pool and perform a MR scan 
of their mid-thigh. This was approved in April 2010. 
4.2.5.3 Sample 
735 LBC 1936 participants had brain MR data available. Power calculations indicated that for 
a minimum Pearson correlation coefficient of 0.6 at alpha=0.05, n=20 provided 80% power 
and n=26 provided 90% power. I therefore chose to scan 25 subjects. I contacted the subjects 
who had most recently had their MR brain scan, within a few weeks, to ensure that the effect 
of any variable on the thigh muscle bulk in the time lapsing between the MR brain and thigh 
scans was as small as possible. Participants were excluded if they had severe osteoarthritis 
affecting the knee or hip or a previous stroke, previous total hip replacement, or a history of 
any degenerative neurological disorder  
4.2.5.4 Imaging protocol 
The MR brain scans had been collected as part of the LBC 1936 study. See study 1 (above) 
for details of the protocol. 
I used anatomical landmarks to identify the midpoint of the femur. I palpated for the 
protuberance of the greater trochanter and the upper border of the patella and then measured 
down the lateral aspect of the thigh using these landmarks and marked the midpoint. A cod 
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liver oil capsule was then taped there to allow us to identify the corresponding MR slice. This 
was performed separately for each leg. 
The scan was performed using a 3.0 tesla Siemens Verio research MR scanner (Siemens 
Medical, Germany) at the Clinical Research Imaging Centre within the Queen’s Medical 
Research Institute. Images were acquired using a combination of body and spine matrix coil 
elements. The subjects lay supine for the scan. A coronal scouting scan was performed and 
then 5-10 axial images were taken with the cod liver oil capsules in the middle slices. Slice 
thickness was 3mm with no slice gap. 
4.2.5.5 Cross-sectional Area Measurements 
Measurements for sternocleidomastoid, obliquus and the combined group (trapezius, splenius 
and semispinalis) were made using the above described technique on a PACS workstation. 
The thigh muscle CSA measurements were also performed on a PACS workstation using the 
slice on each side where the cod liver oil capsule was at its widest which should indicate the 
anatomically chosen midpoint. Three measurements were taken on each leg: the anterior 
group, the medial group and the posterior group. The anterior group consisted of the 
quadriceps (vastus lateralis, intermedius and medialis and rectus femoris) and sartorius, the 
medial group of gracilis and the adductors (longus, brevis and magnus) and the posterior 
group of the hamstrings (biceps femoris, semitendinosus and semimembranosus). 
Both the thigh and neck measurements were repeated 3 times for the left and right sides. 
4.2.5.6 Analysis 
All data were analysed using the SPSS 17.0 statistics package. Three nonsynchronous sets of 
measurements were taken for each subject and the median values were used for the analysis. 
Please see figure 4.3 for a summary of the methods for the above four studies. 
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4.3 Results 
4.3.1 Study 1: Feasibility study 
The measurements made with the chosen technique were used to calculate intra-class 
correlation coefficients (ICC) to compare the median value of 3 measurements made by rater 
A against rater B. In this study we measured each of the three posterior muscles (trapezius, 
splenius and semispinalis) separately and together in a single measurement as a combined 
group. The boundaries between these three muscles are not clear and we thought that the 
differences in CSA measurements were a reflection of where the boundary was taken to be 
rather than true measurement differences in the size of the muscles themselves. The ICC and 
associated 95% confidence intervals support this view, as the values for the ICC for the three 
respective individual muscles were 0.78 (CI 0.16-0.94), 0.86 (CI 0.48-0.97) and 0.90 (CI 
0.60-0.97) and the combined group ICC was much stronger at 0.99 (CI 0.95-1.00). Therefore 
we decided to use the combined measurement from thereon with individual measurements of 
the stand alone muscle, obliquus and sternocleidomastoid.  
Table 4-1: Intra-class correlation coefficients for the second technique trialled in the feasibility study 
Measurement ICC 95% CI 
Trapezius 0.778 0.160-0.944 
Splenius 0.861 0.475-0.965 
Semispinalis 0.895 0.603-0.974 
Summation of 
trapezius, splenius & 
semispinalis 
0.978 0.916-0.994 
Single measurement of 
combined group 
0.986 0.946-0.996 
Obliquus 0.900 0.623-0.975 
SCM 0.894 0.598-0.973 
 
4.3.2 Study 2: Study to measure inter-rater reliability 
Of the 40 scans from the LBC 1936 cohort, one proved to be a duplicate and was excluded. 
One rater considered one scan to be unmeasurable whilst the other considered two scans 
unmeasurable. Scans were thus measured for 37 (18 male, 19 female) participants of mean 
age 72.0 (standard deviation 0.38) years when weighed and mean age 72.2 (sd 0.25) years 
when scanned. Men had a mean height of 1.73m (sd 0.07), mean weight of 85.0kg (sd 11.2) 
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and mean BMI of 28.2 kg/m
2
 (sd 3.2). Women had a mean height of 1.59m (sd 0.04), mean 
weight of 71.0kg (sd 14.0) and mean BMI of 27.9 kg/m
2
 (sd 5.2).  
Rater A measured mean C2 height as 3.7cm (sd 0.5) in men and 3.6cm (sd 0.2) in women. 
Rater B measured mean C2 height as 4.0cm (sd 0.4) in men and 3.7cm (sd 0.2) in women. 
These differences had no effect on slice chosen as midpoint of C2 for muscle CSA 
measurement (Figure 4.4).  
Figure 4-4: Plot of MR slice chosen as representing the mid-point of C2 for both raters 
 
Table 4.2 shows the mean CSAs per rater, absolute mean difference and mean difference as 
percentage of CSA.  
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Table 4-2: Mean cross-sectional areas (CSAs) as measured by each rater summed for left and right, together 






Mean CSA rater A (mm
2
) 1850 773 422 
Mean CSA rater B (mm
2
) 1847 753 376 




3 (-30, 36) 20 (-33, 73) 46 (-29, 63) 
Mean difference as percentage 
of mean CSA (95% CI) 
0.3 (-1.5, 2.0) 4.1 (-6.3, 14.4) 11.3 (7.1, 15.5) 
 
Intraclass correlation coefficients between raters were 0.99 (95% CI 0.98-1.00) for the 
combined group CSA, 0.92 (95% CI 0.85-0.96) for obliquus CSA and 0.92 (95% CI 0.85-
0.96) for sternocleidomastoid CSA (Table 4.3). Obliquus CSA was predicted by sex (beta=-
0.54 for women, p<.001) and BMI (beta=0.36, p=.01) adjusted R
2
 for model =0.40, 
sternocleidomastoid CSA by sex (beta=-0.60 for women, p<.001) and BMI (beta=0.41, 
p=.001) adjusted r
2
 for model =0.52, and combined CSA by sex (beta=-0.74 for women, 
p<.001 only) adjusted r
2
 for model =0.55.  
Table 4-3: Intra-class correlation coefficients with 95% confidence intervals for the reliability study 
Muscle Measurement ICC 95% Confidence 
Intervals 
Combined group 0.99 0.98-0.995 
Obliquus capitis inferior 0.92 0.85-0.96 
SCM 0.92 0.85-0.96 
 
There were no significant associations between inter-rater CSA difference and mean CSA for 
the combined group (r=0.08, p=.66), but larger inter-rater differences were significantly 
associated with smaller CSAs for both obliquus (r=-0.61, p<.001) and sternocleidomastoid 
(r=-0.39, p=.018). CSAs all correlated highly significantly with each other (p<.001): 
combined-obliquus (r=0.59), combined-sternocleidomastoid (r=0.66), obliquus-
sternocleidomastoid (r=0.50).  
A Bland-Altman plot for total neck muscle CSA demonstrates a degree of linear bias with 
Rater 2 reporting bigger measurements for the small neck muscle CSAs and smaller 
measurements for the bigger neck muscle CSAs (Figure 4.5A). If obliquus is removed, 
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leaving the combined group plus SCM, this linear bias appears to resolve (Figure 4.5B). 
However the bias of measurement is small for both graphs. 
Figure 4-5: Bland-Altman plots for total neck muscle CSA and SCM + combined CSA measured by 2 raters. 
Bias of measurement between 2 different raters (mean of the ordinate) and limits of agreement (2sd) are 
represented by a solid and two dashed lines respectively 
A. Bland-Altman plot for measurements of total neck muscle CSA by 2 different raters 
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B. Bland-Altman plot for measurements of SCM + combined CSA by 2 different raters 
 
 
Table 4.4 shows coefficients of variation (CV) for both raters and a Levene’s test for 
homogeneity which found no significant difference between the CV for the two raters for any 
of the muscle measurements. 
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Table 4-4: Coefficients of variation (%) with 95% CI and Levene’s significance test between the two raters 
Measurement Rater Coefficients of 
Variation (CV) 
(%) 




Combined group 1 28.1 22.9-36.5 0.96 
 2 28.5 23.2-37.0  
Obliquus 1 43.8 35.6-56.9 0.10 
 2 32.3 26.3-42.0  
SCM 1 31.0 25.2-40.3 0.82 
 2 29.8 24.2-38.7  
Total neck muscle 
CSA 
1 28.2 22.9-36.6 0.47 
 2 25.9 21.1-33.6  
 
The first unrotated principal component explained 72.2% of total CSA variance for the three 
muscles (loadings were 0.89 for the combined group, 0.81 for obliquus and 0.85 for 
sternocleidomastoid) and correlated positively with grip strength of both right (r=0.52, 
p=.001) and left (r=0.50, p=.002) hands. The second principal component had an eigenvalue 
of 0.51. 
4.3.3 Study 3: Study to measure repeatability of technique 
Data were analysed for all 14 participants. Thirteen of the participants had undergone all 6 
scans and one had undergone 5 of the scans having not completed their second scan in one 
location. There were 10 men and 4 women. The mean age was 36.3 years (range 25-51).  
Mean values (sd) for the measurements across all six scanners for right and left sides added 
together were: SCM 4.97cm
2
 (1.11), combined group 20.12cm
2
 (5.74), obliquus 9.88cm
2
 
(3.23) and total neck muscle CSA 34.97cm
2
 (8.67). ICCs were calculated for within scanner 
and between scanner variability (Tables 4.5 & 4.6). Within scanner ICCs for the Edinburgh 
scanner used for studies 1, 2 and 4 ranged from 0.83 for SCM to 0.96 for the combined 
group. 
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Table 4-5: Between scanner intra-class correlation coefficients for the repeatability study 
Groups ICC 95% Confidence Intervals Sig 
E, A & G Total means 0.94 0.86-0.98 p<0.001 
E, A & G SCM means 0.76 0.53-0.90 p<0.001 
E, A & G Comb means 0.95 0.89-0.98 p<0.001  
E, A & G Obliq means 0.78 0.56-0.92 p<0.001 
 
Table 4-6: Within scanner intra-class correlation coefficients for the repeatability study 
Groups ICC 95% Confidence 
Intervals 
Sig 
E1 & E2 Total 0.95 0.86-0.98 p<0.001 
A1 & A2 Total 0.97 0.92-0.99 p<0.001 
G1 & G2 Total 0.96 0.86-0.99 p<0.001 
E1 & E2 SCM 0.83 0.55-0.94 p<0.001 
A1 & A2 SCM 0.80 0.48-0.93 p<0.001 
G1 & G2 SCM 0.90 0.70-0.97 p<0.001 
E1 & E2 Comb 0.96 0.88-0.99 p<0.001 
A1 & A2 Comb 0.97 0.92-0.99 p<0.001 
G1 & G2 Comb 0.96 0.88-0.99 p<0.001 
E1 & E2 Obliq 0.93 0.79-0.98 p<0.001 
A1 & A2 Obliq 0.83 0.56-0.94 p<0.001 
G1 & G2 Obliq 0.83 0.53-0.95 p<0.001 
Key for Table 4.5 & 4.6: 
 E = scan performed in Edinburgh 
 A = Scan performed in Aberdeen 
 G = Scan performed in Glasgow 
 1 & 2 = 1st and 2nd scan on that site 
 SCM = Sternocleidomastoid 
 Comb = Combined group (Trapezius, Splenius capitis, Semispinalis capitis) 
 Obliq = Obliquus Capitis Inferior 
 Total = Total neck muscle CSA 
Bland-Altman plots show no definite linear bias between the Edinburgh and Glasgow 
scanners and the Aberdeen and Edinburgh scanners (Figures 4.6A & B). The Aberdeen-
Glasgow plot indicates that the Aberdeen scanner may overestimate larger neck muscle CSA 
and underestimate smaller neck muscle CSA (Figure 4.6C). However the numbers involved 
in this study were small (n=14). 
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Figure 4-6: Bland-Altman plots for total neck muscle CSA measured on 3 different MRI scanners. Bias of 
measurement between different MRI scanners (mean of the ordinate) and limits of agreement (2sd) are 
represented by a solid and two dashed lines respectively. 
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B. Bland-Altman plot for total neck muscle CSA measured on the Edinburgh and Glasgow MR images 
 
C. Bland-Altman plot for total neck muscle CSA measured on the Glasgow and Aberdeen MR images 
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Table 4.7 shows the coefficients of variance (CV) for the mean values for each of the three 
scanners and a Levene’s test of homogeneity which found no significant difference in CV for 
any of the three scanners, for any of the muscle measurements. 
Table 4-7: Coefficients of variation (%) with 95% CI and Levene’s significance test between the three MRI 
scanners 







Combined Aberdeen 32.2 23.3-51.9 0.89 
 Edinburgh 27.1 19.7-43.7  
 Glasgow 26.0 18.9-41.9  
Obliquus Aberdeen 30.6 22.2-49.3 0.53 
 Edinburgh 36.7 26.6-59.1  
 Glasgow 28.1 20.4-45.3  
SCM Aberdeen 21.7 15.7-35.0 0.95 
 Edinburgh 20.6 14.9-33.2  
 Glasgow 22.1 16.0-35.6  
Total neck muscle CSA Aberdeen 26.4 19.1-42.5 0.84 
 Edinburgh 25.5 18.5-41.1  
 Glasgow 22.3 16.2-35.9  
 
4.3.4 Study 4: External validity study 
25 subjects underwent the additional thigh scan; however, only 24 could be used in the 
analyses as one patient had not tolerated the full MR brain scan so we were unable to make 
the neck muscle CSA measurements. There was no overlap between subjects in study 2 and 
study 4. Of these 24 subjects, 11 were female and 13 male. Mean age (sd) was 73.8 years 
(0.27). Mean weight (sd) for the women was 63.2kg (15.4) and for the men was 85.6kg 
(10.9). 
Mean total neck muscle CSA (sd) was 22.5cm
2
 (3.7) for the female subgroup and 38.1cm
2
 
(6.3) for the male subgroup. Mean total thigh muscle CSA was 184.3cm
2
 (36.5) for the 
female subgroup and 277.0cm
2
 (31.3) for the male subgroup. An independent t test showed 
that both total neck muscle CSA (p<0.0005) and total thigh muscle CSA (p<0.0005) were 
significantly different between the female and male subgroups. The correlation coefficient for 
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all subjects for total thigh CSA and total neck CSA was 0.88 indicating that each explained at 
least 77.4% of the variance of the other. 
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4.4 Discussion 
4.4.1 Summary of findings 
This study sought to develop a technique to measure neck muscle cross-sectional area on 
volumetric MR brain scans. An initial feasibility study led to the formation of the technique 
(Figure 4.2). The reliability study then demonstrated that the technique had high inter-rater 
reliability for measurement of the CSA of the combined trapezius, splenius and semispinalis 
group in older adults. Obliquus capitis inferior and sternocleidomastoid CSAs are smaller 
muscles and measurements were less reliable between raters, though intraclass correlation 
coefficients remained high.  
Study 3 demonstrated that the technique has good within scanner and between scanner 
repeatability. The confidence intervals for the measurements of the combined group and the 
total neck muscle area are quite narrow however the confidence intervals for the SCM and 
obliquus capitis inferior measurements are wider. This is because the cross-sectional areas of 
the SCM and obliquus muscles are smaller than either the combined or the total 
measurements. This means that any measurement errors will account for a greater proportion 
of the CSA than for muscles with a large area.  
The obliquus is a short muscle whose cross-sectional area varies greatly over its length, 
unlike the other four muscles, as it has a wide belly and comparatively narrow tails. Our 
technique meant that in some subjects we were measuring across the belly of the obliquus 
and in some just the tail end. It also runs at an oblique angle and we identified that this angle 
varies between subjects. This meant that the area of obliquus we were measuring was an 
inexact proxy. For these reasons I conclude that the obliquus measurement should not be 
included in our technique. The ICCs are not as strong for the SCM as the combined group in 
the repeatability and reliability studies, which is likely a reflection of its small size. However 
as there are not the same intrinsic anatomical problems in measuring this muscle as there are 
with the obliquus and as total neck muscle CSA including the SCM appears to have stronger 
ICCs than the combined group alone, it is probably beneficial to include the SCM in addition 
to the combined group to provide a better estimate of general muscle bulk. 
The final study was designed to measure the external validity of the technique. It shows that 
there is a strong correlation between neck muscle cross sectional area and thigh muscle cross 
sectional area, which is often used as a proxy for general muscle mass (Kongsgaard et al., 
2004, Godard et al., 2002, McIntyre et al., 2006). The percentage variance (ie r-squared) is 
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76.7% and the 1
st
 unrotated principal component of neck muscle CSA was found in the 
reliability study to explain 72.2% of variance. Extracting principal components is useful to 
reduce random measurement errors that might be associated with individuals’ neck positions 
for example. The principal component correlated positively with grip strength, providing 
further support for neck muscle CSAs’ validity as an index of sarcopenia. This means that 
posterior neck muscles can be used equally as well as thigh muscles as an index of general 
muscle bulk (Ohkawa et al., 2000, Lerner et al., 1986). 
4.4.2 Previous research on quantifying muscle mass 
Previous studies quantifying neck muscle CSA have only focused on young subjects and 
have used scans performed specifically for that purpose. They have however shown good 
reliability in the techniques used (Cagnie et al., 2010, Ulbrich et al., 2011). I found no 
previous studies which measured neck muscle CSA on MRI scans on elderly subjects and 
none which used MRI brain scans for this purpose. 
When considering the validity of using a cross-sectional measurement of muscle size to infer 
general muscle bulk I referred to previous studies on body composition. Studies investigating 
how differing muscle groups relate to each other have tended to compare upper and lower 
limb muscle mass alone (Janssen et al., 2000, Gallagher et al., 1997, Gallagher and 
Heymsfield, 1998). I found no studies which compared muscle CSA, mass or volume 
between any other two or more areas of the body, including the neck. Three large studies on 
body composition suggest that the distribution of muscle between the upper and lower limbs 
varies with gender, age, height, weight and ethnicity (Janssen et al., 2000, Gallagher et al., 
1997, Gallagher and Heymsfield, 1998). 
4.4.3 Strengths and limitations of the studies 
Although there is no reason to suppose that this methodology is not applicable in younger 
adults and older adults (ie 75y+), three of the studies were restricted to a narrow age cohort 
around 72 years old and the study of younger subjects only had a n=14. The study 
participants were all community-resident volunteers and thus relatively healthy and were not 
diverse in terms of geography or ethnicity. The narrow geographical location of the subjects 
is important as it has been shown that anthropometric measurements vary across the UK. 
Bannerman et al collected data from residents of Edinburgh and compared their results with 
anthropometric reference data from South Wales and Nottingham. They found significant 
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differences between the three groups confirming their hypothesis that anthropometric 
measurements vary across geographical area (Bannerman et al., 1997). 
Skeletal muscle can be split into two groups; postural and phasic. Postural muscles have a 
larger percentage of type 1 fibres and show less fatigability. Phasic muscles are primarily 
involved in movement and have a higher proportion of type 2 muscle fibres. A feature of 
ageing muscle is that type 2 fibre width decreases more than type 1 fibre width, therefore the 
relation between neck CSA (mainly postural, ie more type 1 fibres) and thigh CSA (a mixture 
of postural and phasic) will change with age (Doherty, 2003, Larsson, 1978, Andersen, 2003, 
Lexell et al., 1988). Also, the neck muscles which we use in our final model may have 
differing percentages of type 1 and 2 fibres as a reflection of their differing roles: the 
sternocleidomastoid muscle is primarily used for rotation and flexion of the neck, whereas the 
three more posterior neck muscles (trapezius, splenius capitis and semispinalis capitis) are all 
primarily involved in neck extension. However, at present the fibre type composition of the 
neck muscles has not been studied and it seems likely that they all represent a mainly postural 
function with a lesser degree of phasic function. This could mean that by only studying neck 
muscles, changes which affect phasic muscles more with age may not be identified (ie 
affecting type 2 fibres more than type 1 fibres). 
Despite not standardising the angle of the axial measurement slice relative to the patient, we 
still achieved very high inter-rater reliability. However, it is possible that the measurement 
variability would be larger in a longitudinal study if the patients were in different positions in 
the scanner on each occasion. Such differences are usually only slight because head, neck and 
back are passively supported during scanning leaving the neck muscles in a relaxed state. 
Lateral changes are unlikely to have a major effect because muscle CSAs are summed for 
both left and right so that reductions on one side could be compensated by the accompanying 
increase on the other. Such compensation does not apply to antero-posterior positioning; 
however, small differences in this plane are also unlikely to be important. A difference in 
angle of C2 between two repeated scans in the sagittal plane of 5˚ would result in a CSA 
difference of 0.4%, 10˚ increases CSA by 1.5% and 15˚ by 3.5% all within the limits for 
inter-rater SCM CSA difference; even a 20˚ angle increases CSA by only 6.4%, probably at 
the limit of utility of the technique to detect medium effect sizes. If reliability in longitudinal 
studies was not acceptable (i.e. mean differences in plane angles measured at C2 >20˚), 
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increased positional standardization would be necessary which might include using more than 
one anatomical marker from a T1-weighted volume scan for standardization.  
Most of these limitations could be addressed by a larger study which included a wider spread 
of age, geographical area, ethnicity, health status and an equal gender balance. It would be 
interesting to look at muscles from elsewhere in the body also. For example including a 
measure of upper arm CSA and calf muscle CSA and to investigate how the comparative size 
of these muscles varies with age. 
4.4.4 Implications for future research 
This new technique is particularly interesting because several of the longitudinal studies 
investigating ageing involve an MR brain scan, therefore the method could be used to 
measure changes in muscle size and consequently estimate sarcopenia in these studies 
without any further imaging. This will allow the wealth of variables already collected as part 
of these studies to be researched as possible correlates of sarcopenia. Longitudinal studies are 
important sources of information for researchers interested in age associated disease to allow 
identification of key risk factors. These in turn allow hypotheses to be generated which can 
lead to both an understanding of the mechanisms underlying these diseases, which may lead 
on to development of treatments, and the possibility of generating advice to prevent or slow 
down some of the disease processes. Although we developed the technique on MR volume 
brain images, it is now common to acquire volume data when performing a CT brain scan 
and, as there is often good differentiation between muscle and fat in the neck, the same 
approach could possibly work on CT scans as well. Further testing is required. 
I then used this technique on two longitudinal studies to investigate correlates of sarcopenia 
and identify possible causative factors from lifestyle and biomedical data which have been 
collected concurrently with the MRI scans. 
4.5 Conclusion 
We have developed a feasible, valid and repeatable method for measuring neck muscle cross-
sectional area on MR brain scans which has good inter-rater reliability. This technique can be 
used to measure neck muscle CSA which can serve as a proxy measure of muscle bulk as 
shown by the above factor analysis and shared variance measures. We have demonstrated that 
neck muscle CSA correlates strongly with grip strength, a commonly used functional 
measure. The development of a reliable method to measure neck muscle CSA from 
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volumetric MR brain scans potentially opens up a new field of radiological ageing research. 
This in turn will allow sarcopenia to be investigated in studies which include a MR brain scan 
but no measure of muscle bulk without involving any additional scanning. This will be of 
particular use in studies wishing to investigate both brain and muscle ageing within subjects, 
and will allow synchronous measurements of brain and muscle structure using the same scan. 
I now plan to use this measurement technique on longitudinal ageing cohorts which have 
already included a volumetric MR brain scan to investigate the relationship between muscle 
and brain structure in these datasets. Longitudinal data will also allow further exploration of 
the common cause hypothesis by looking at the trajectories of change within brain and 
muscle structure over time. 
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Chapter 5 Neck muscle cross-sectional area, brain 
volume and cognition in healthy older 
men; a cohort study 
5.1 Background 
Chapter 2 identified only three studies investigating the relationship between brain and 
muscle structure and it was postulated that this was because the imaging required to 
investigate both measures does not overlap and only very few studies undertook imaging of 
both brain and muscle. In chapter 4 I described the development of a technique to measure 
neck muscle CSA, as a measure of muscle bulk, on volumetric MR brain scans, allowing 
quantification of brain and muscle size on one scan. Here I used this novel technique to 
investigate the relationship between muscle structure, brain structure and cognition in healthy 
older men. 
Until recently, muscle and brain ageing had rarely been studied in tandem; however, studies 
demonstrating improved cognition in later life with increased physical activity have 
highlighted this important area of research. For example a Cochrane review of randomised 
controlled trials found evidence that aerobic physical activities improved cognitive function 
in healthy older adults, with effects observed for motor function, cognitive speed, and 
auditory and visual attention (Angevaren et al., 2008). Observational studies have also found 
positive relationships between physical activity and cognitive function (Coley et al., 2008, 
Weuve et al., 2004). There is some evidence that both grey and white matter brain volume 
can be significantly improved by aerobic exercise in older adults (Colcombe et al., 2006). It 
was hypothesized that these relationships were due solely to cardiovascular fitness, and 
although this may play a role, animal studies have found other underlying mechanisms 
including: increased levels of brain-derived neurotrophic factor which may contribute to 
neurogenesis, effects on neurotransmitter systems and increased insulin-like growth factor 1 
(Kramer et al., 2006). 
It is known that muscle size and function (ie strength or power) do not age in parallel (Young 
et al., 1985, Skelton et al., 1994), therefore the association between muscle size and either 
brain structure (eg whole brain volume) or cognitive function requires independent study. We 
found only one study which investigated the relationship between muscle bulk and brain 
structure in older adults; however, this study included subjects with Alzheimer’s disease 
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along with normal controls (Burns et al., 2010). The studies investigating muscle size and 
cognition have largely relied on simple cognitive screening tools (eg Mini Mental State 
Examination (MMSE)) and do not usually contain a measure or estimate of prior cognitive 
ability (Auyeung et al., 2011, Wirth et al., 2011, Nourhashemi et al., 2002).  
Here we studied community-dwelling healthy older men, measuring: neck muscle cross-
sectional area (CSA), multiple cognitive domains including estimated prior cognitive ability 
and neuroimaging volumes. We hypothesised that lower muscle bulk is associated with 
structural markers of brain ageing, and poorer cognitive ability in healthy older people. 
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5.2 Methods 
5.2.1 Participants 
Participants were 51 community-dwelling men involved in a longitudinal ageing study 
investigating healthy ageing, glucocorticoid status and brain structure (MacLullich et al., 
2012, MacLullich et al., 2005). The study was approved by the Lothian Health Ethics 
Committee. All subjects gave written informed consent and the research was carried out in 
compliance with the Helsinki Declaration. Data from the second wave of the study were used 
because the smaller MR head coil used in the first wave excluded the neck muscles. 
Exclusion criteria were previously provided (MacLullich et al., 2005, MacLullich et al., 
2012). Participants were healthy, lacking of significant illness, including dementia, stroke, 
ischaemic heart disease, depressive illness, excessive alcohol intake, and cancer. No 
participants were taking psychotropic medication.  
5.2.2 MR brain imaging 
The full MR brain imaging protocol has been previously published (MacLullich et al., 2012). 
In summary, imaging was performed on a GE Signa LX 1.5 T (General Electric) MR scanner. 
Participants received a sagittal T1-weighted spin echo sequence covering the whole head (TR 
450msec, TE 9msec, FOV 24 cm, matrix 256 × 224, slice thickness 5 mm (no gap)) and a 
volume scan consisting of a T1-weighted 3D inversion recovery prepared sequence (3D 
IR_PREP) acquired in the coronal plane with slices perpendicular to the long axis of the 
hippocampus and covering the whole head (TI 600msec with TE set to minimum, FOV 22 
cm, matrix 256 × 192, slice thickness 1.7 mm (no gap)).  
5.2.3 Brain structure measurements 
Image analysis was performed using Analyze v7.0 for Windows (Mayo Clinic, Rochester, 
MA). Whole brain, hippocampal and ventricular volumes (MacLullich et al., 2012), and 
intracranial area (a validated estimate of intracranial volume (Ferguson et al., 2005)) were 
obtained by an experienced rater. 
5.2.4 Neck muscle cross-sectional area 
We used neck muscle cross-sectional area (CSA) as a measure of muscle size. We have 
previously shown in a study of 24 subjects that neck muscle CSA is strongly correlated with 
thigh muscle CSA (R
2
 0.77), which is often used as a proxy for general muscle bulk (Kilgour 
et al., 2012). Neck muscle CSA is generally available in brain MRI studies, whereas thigh 
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muscle CSA is not usually measured within longitudinal cognitive ageing studies. Neck 
muscle CSA was measured using a validated technique (Kilgour et al., 2012). Full details can 
be obtained in chapter 4; however, in summary, the mid-point of the C2-vertebra was located 
in the sagittal slice of a 3D reconstructed image. The image was then converted to a 
transverse view and the posterior neck muscles were outlined using a cursor. The software 
then calculated the contained area. The muscles measured were the semispinalis capitis, 
splenius capitis and trapezius (measured as a combined group), and the sternocleidomastoid.  
5.2.5 Tests of cognitive function 
The following tests of cognitive function were performed as part of the original study, as 
previously described (MacLullich et al., 2012): the Mini-Mental State Examination (MMSE, 
a screening test for cognitive impairment); the Controlled Word Association Test (CWAT, 
tests verbal fluency, which is an aspect of executive function); the Digit-Symbol Substitution 
Test (DSST, tests attention and processing speed) from the Wechsler Adult Intelligence 
Scale; Raven’s Standard Progressive Matrices (RSPM, tests non-verbal reasoning, an 
important aspect of fluid intelligence); Logical Memory (tests immediate and delayed verbal 
declarative memory); Visual Reproduction (tests immediate and delayed visual memory); 
Rey’s Auditory-verbal Learning Test (tests verbal memory and learning); Benton’s Visual 
Retention Test (tests visual memory); and the National Adult Reading Test (NART, provides 
an estimate of prior general cognitive ability). Due to the strong correlation between pre-
morbid cognitive ability (of which NART provides an estimate) and educational achievement 
(Deary et al., 2007a), it was decided to include only NART and not educational achievement 
as a predictor variable. One participant had a MMSE below 24 and was excluded from the 
analysis as this score may be reflective of an incipient diagnosis of dementia. 
5.2.6 Statistical analysis 
Descriptive statistics, exploratory analyses, general linear modelling (Analysis of Covariance; 
ANCOVA) and principal components analysis were performed on SPSS version 18.0 for 
Windows. Missing values were excluded listwise. For the ANCOVA we constructed baseline 
models with the measures of brain structure and cognitive ability as dependent (i.e. outcome) 
variables and neck muscle CSA as an independent variable, adjusting for intracranial area 
(ICA) and age. ICA is thought not to change after the onset of age-related neuronal loss, 
particularly in men, therefore can be used as a marker of peak brain size, thus allowing the 
outcome variable to be more reflective of brain atrophy (Mori et al., 1997). Also, without 
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adjusting for ICA it could be argued that those with bigger skulls require larger neck muscles 
for support or that they are just larger in proportion; therefore, this adjustment also controls 
for this. We also adjusted for NART since this was found to correlate significantly with neck 
muscle CSA, brain volumes and current cognition. Furthermore, in the models with current 
cognitive ability as an outcome variable, adjusting for the NART score allows the model to 
reflect the degree of cognitive ageing that has taken place.  
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5.3 Results 
All participants (n=51) were male with a mean age of 73.8 years (sd 1.5). Descriptive 
statistics for participant neuroimaging and neck muscle cross-sectional area data are in Table 
5.1. Of the 51 MR brain scans reviewed, we were unable to measure neck muscle CSA on 
one scan as the scan did not extend far enough inferiorly to include the neck muscles at the 
required level for measurement (the mid-point of the C2-vertebra). In a further two cases, the 
hippocampal volume could not be measured.  
Table 5-1: Neuroimaging and muscle cross-sectional area data 
 N Mean Std. Deviation 
Whole brain volume (cm
3
) 50 1149.8 90.4 
Intracranial area (cm
2
) 50 157.9 9.6 
Total Ventricular volume (cm
3
)* 50 31.2 24.0 
Total Hippocampal volume (cm
3
) 48 7.0 0.8 
Cerebellar volume (cm
3
) 50 135.4 14.3 
Total SCM muscle area (cm
2
) 49 5.1 1.1 
Total Comb muscle area (cm
2
) 49 22.8 3.1 
Total muscle area (cm
2
) 49 28.0 3.4 
Valid N (listwise) 47   
*Non-parametric data, median and inter-quartile range presented 
Table 5.2 contains the descriptive statistics for the cognitive test data. To reduce the risk of 
type 1 statistical error by testing multiple associations, we performed principal components 
analysis. The Kaiser-Meyer-Olkin measure verified sampling adequacy. Two principal 
components were extracted employing varimax rotation; the first had an eigenvalue of 2.58, 
explaining 36.9% of the variance and the second had an eigenvalue of 2.4, explaining 34.3% 
of the variance. For comprehensibility, we refer to these components as ‘factors’ as is general 
usage. Together, the factors explain 71.2% of the variance in the cognitive test scores. The 
cognitive tests which focused on memory (ie Logical Memory, Visual Reproduction, AVLT 
and BVRT) had high factor loadings for Factor 1; therefore, we hereafter call this factor the 
Memory Factor. Factor 2 had high factor loadings for the three other tests: CWAT, DSST and 
RSPM and hereafter is referred to as the Cognitive Processing Factor.  
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Table 5-2: Prior and current cognition data 
 N Mean Std. Deviation 
National Adult Reading Test * 47 42.0 13.0 
Mini Mental State Examination * 50 28.0 4.0 
Controlled Word Association Test 47 40.4 10.9 
Digit Symbol Substitution test 46 43.3 10.7 
Raven’s standard progressive matrices 46 40.0 9.1 
Logical Memory 47 51.6 15.0 
Visual Reproduction 47 46.4 14.8 
Auditory-Verbal Learning Test 47 49.9 9.0 
Benton Visual Retention Test * 47 17.0 4.0 
Factor 1 (Memory) 45 0.0 1.0 
Factor 2 (Cognitive processing) 45 0.0 1.0 
Valid N (listwise) 45   
*Non-parametric data, median and inter-quartile range presented 
Initially bivariate statistics were performed (Spearman’s rho) (Table 5.3). The only variable 
to significantly correlate with total neck muscle CSA was NART (rho -.36, p= .01). NART 
was also found to correlate strongly with the following variables: intracranial area; 
unadjusted whole brain, hippocampal, and cerebellar volumes; and the cognitive processing 
factor.  
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Table 5-3: Spearman’s rho correlations between neuroimaging, muscle and cognitive variables (p values) 








































A scatter plot confirmed no significant relationship between whole brain volume and total 
neck muscle CSA (figure 5-1).  
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Figure 5-1: Plot of whole brain volume against total neck muscle CSA 
 
ANCOVA was performed to check for shared variance among neck muscle CSA and the 
neuroimaging measures, the cognitive factors, and NART. Models were corrected for age, 
intracranial area (ICA, to correct for head size) and NART, except in the model for NART 
where only age and ICA were adjusted for. Total neck muscle CSA was found to predict 17% 
of the variance in whole brain volume (t=2.86, p=0.01) (Table 5.4). However, total neck 
muscle CSA did not significantly predict the variance in ventricular, hippocampal or 
cerebellar volumes (p>0.05). 
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Table 5-4: ANCOVA for whole brain volume with total neck muscle area, intracranial area, age and prior 
cognition as predictor variables 




t Sig. Partial Eta 
Squared 
Corrected Model 4 12.85   <.01 .56 
Intercept 1 1.06 491.40 1.03 .31 .03 





1 13.13 0.04 3.62 <.01 .24 
NART (Score out of 
50) 
1 8.43 3.85 2.90 .01 .17 




1 8.16 0.09 2.86 .01 .17 
Corrected total 45      
*Unstandardised B coefficients reflect change in whole brain volume in cm
3
 
Neck muscle CSA did not significantly predict variance in either the memory factor or the 
cognitive processing factor (p>0.05) (Tables 5.5 & 5.6). Using the NART score as an 
outcome variable, we found that total neck muscle CSA predicts 10% of the variance in the 
NART score (t=-2.12, p<0.05) after adjusting for ICA and age. 
Table 5-5: ANCOVA for Memory Factor with total neck muscle area, intracranial area, age and prior 
cognition as predictor variables 




t Sig. Partial Eta 
Squared 
Corrected Model 4 1.23   .31 .11 
Intercept 1 1.39 8.91 1.18 .25 .03 





1 0.02 <-.01 -.15 .88 .00 
NART (Score out of 
50) 
1 1.56 .03 1.25 .22 .04 




1 0.28 <.01 -.53 .60 .01 
Corrected total 43      
*Unstandardised B coefficients reflect change in factor score for the Memory Factor 
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Table 5-6: ANCOVA for General Processing Factor with total neck muscle area, intracranial area, age and 
prior cognition as predictor variables 




t Sig. Partial Eta 
Squared 
Corrected Model 4 5.19   <.01 .35 
Intercept 1 0.23 3.06 .48 .63 .01 





1 0.15 <.01 .39 .70 .00 
NART (Score out of 
50) 
1 11.86 .06 3.44 <.01 .23 




1 2.86 <.01 1.69 .10 .07 
Corrected total 43      
*Unstandardised B coefficients reflect change in factor score for the General Processing 
Factor  
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5.4 Discussion 
We found that in healthy elderly men, preservation of whole brain volume was associated 
with larger total neck muscle cross-sectional area. Therefore in an elderly cohort, those that 
have a smaller muscle bulk have undergone more brain atrophy. This finding supports the 
common cause hypothesis, by demonstrating that the rate of sarcopenia and ARCD may 
occur in parallel within individuals, driven by core underlying biological processes. However, 
we found no significant association between total neck muscle CSA and ventricular volume 
(a different measure of brain atrophy), or hippocampal or cerebellar volumes. Also, whilst the 
relationship between whole brain volume and total neck muscle CSA was significant when 
studied within a general linear model, the unadjusted Spearman’s correlation found no 
significant association for the same relationship; therefore it is possible that the relationship 
we found was a result of residual confounding rather than representing a true association. It 
will now be important to repeat these analyses using data from a different study to see if the 
results are repeatable to help investigate this complex relationship further.  
We unexpectedly found that total neck muscle CSA was negatively associated with estimated 
prior cognitive ability (NART) after adjustment for ICA and age, but we found no significant 
association between total neck muscle CSA and current cognitive abilities. This suggests that 
those with lower prior cognitive ability may have larger muscles in old age. Muscle mass in 
old age is determined by 2 factors. Firstly, peak muscle bulk obtained in young adulthood, 
and secondly, rate of muscle atrophy with ageing. Therefore we hypothesise that those with 
lower cognitive abilities may have undertaken more manual work (Neisser et al., 1996, 
Mackintosh, 1998) and therefore achieved a greater peak muscle bulk and a larger muscle 
mass in old age. We can find no plausible explanation as to why a lower prior cognitive 
ability would favour a slower rate of muscle atrophy. We unfortunately do not have 
sufficiently detailed previous occupational history or socio-economic class data for the 
participants to be able to test this theory further at this point.  
We found only one previous study which investigated the relationship between muscle size 
and brain size, and this study also found a positive relationship between muscle bulk and 
whole brain volume. Burns et al studied elderly people with early Alzheimer’s disease (AD) 
(n=70) or normal cognition (n=70) and found that whole brain volume, normalized for head 
size, was predictive of lean mass as measured by DEXA (beta 0.20, p<.001) in both groups 
(Burns et al., 2010). White matter volume was the primary driving factor for the relationship 
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(beta 0.19, p<.001) while grey matter volume showed no association with lean mass. This 
indicates that the cause of loss of lean muscle mass in AD may be different to normal ageing 
as it is primarily grey matter that is lost in AD.  
In the above study Burns et al also investigated the relationship between MMSE and a 
measure of global cognitive performance (a composite score made up of the results of a 
battery of tests, including the DSST and verbal fluency) with muscle mass (Burns et al., 
2010). They found a significant positive association between both the global cognitive 
performance score (beta 0.12, p=.007) and MMSE (beta 0.11, p=.009) and muscle mass, 
controlling for age and sex but not for prior cognition which we have shown to correlate with 
both brain and muscle size (Table 5.3). Our study was able to investigate the relationship 
between cognitive decline, by adjusting for prior cognition using the NART score, and 
current cognition, whereas this study only looked at cross-sectional data from current 
cognition. This may explain why they found an association between current cognition and 
muscle mass and we did not. 
Several large studies have also investigated the links between muscle size and cognition. In a 
large cross-sectional study of community dwelling women aged 75 or over (n=7105), 
Nourhashemi et al found that low cognitive function was associated with low fat free mass 
(Nourhashemi et al., 2002). However the cognitive test used was the Short Portable Mental 
Status Questionnaire (SPMSQ), which consists of only 10 questions and is mainly used as a 
screening test for cognitive impairment. 
Conversely, Wirth et al studied 4095 consecutive geriatric hospital patients and found that 
fat-free mass was not associated with cognitive dysfunction, measured using MMSE, after 
adjusting for age, sex and Barthel index (Wirth et al., 2011). Also, Auyeung et al studied 
2737 cognitively normal older people and found that appendicular skeletal muscle mass 
(ASM) was significantly predictive of MMSE 4 years later in men but not women (Auyeung 
et al., 2011). However, after adjustment for age, years of education and baseline MMSE 
score, the relationship in men was not significant either. 
Our study has the benefit of including tests of both prior and current cognitive function. This 
allows us to look at cognitive decline rather than purely at current cognitive ability, and is the 
only study we could find that specifically tested the relationship between prior cognition and 
muscle size. Also, the three large studies mentioned above used cognitive tests which are 
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primarily designed to screen for cognitive impairment (ie SPMSQ and MMSE) rather than to 
detect the subtleties of change in cognition with age (Auyeung et al., 2011, Wirth et al., 2011, 
Nourhashemi et al., 2002), for which our cognitive tests were specifically chosen. Burns et al 
used more detailed cognitive tests; however the numbers involved in their study are much 
smaller compared to the other three studies. Our study is the first to measure muscle cross-
sectional area and cognition or brain size; the above mentioned studies used either 
bioimpedance analysis or DEXA as the measure of muscle bulk. 
The main limitations of our study are the lack of longitudinal data and the small sample size. 
In ageing studies longitudinal data are crucial as it is the rate of loss of muscle size or brain 
size that is of interest rather than measurements at a cross-sectional time point. With brain 
size we can partially correct for this using intracranial area, but with muscle size we are 
unsure if someone has lost 10% of their lean body mass in the previous decade or 50%, as 
clearly the peak muscle bulk obtained will affect the final outcome greatly. The study also 
contained mainly white males and this will affect the generalisability of our results. 
5.5 Conclusion 
In healthy older men preservation of whole brain volume is associated with larger muscle size 
within a general linear model, however the relationship was not significant in the unadjusted 
correlation analyses therefore may represent residual confounding. Larger muscle size was 
associated with lower prior cognition, but not current cognition in both unadjusted 
correlations and general linear models. As we were unfortunately unable to use the data from 
wave 1 of this study due to the above mentioned technical issue, these data were again cross-
sectional and not longitudinal. Therefore despite offering some limited evidence of 
associations between muscle structure and brain structure and function this study was not 
able to advance forward the concept of the common cause hypothesis as I was unable to look 
at how the trajectories of decline compared with each other for brain and muscle. I next 
planned to use the neck muscle measurement technique on a larger longitudinal cohort study 
(LBC 1936) which includes both men and women, to attempt to replicate these results and 
investigate the role of muscle function within these relationships along with other important 
covariates recorded within that study. 
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Chapter 6 Interrelationships between brain and 
muscle structure and function using 
data from wave 2 of the Lothian Birth 
Cohort 1936 
6.1 Introduction 
Thus far I have investigated the interrelationship between brain and muscle structure and 
function using a systematic review and analysis of an all-male dataset (n=51). In the 
systematic review I found evidence of a relationship between brain size and muscle size, and 
evidence of a relationship between both grip strength and gait speed and brain volume (ie 
white matter volume, regional grey matter volume and whole brain volume), brain atrophy 
and accumulation of WMHs (Kilgour et al., 2014). Cognitive function was not found to be 
associated with muscle size and I did not look at the relationship between cognitive function 
and physical function as this positive relationship has previously been well described. In the 
cohort study I found that in healthy older men, preservation of whole brain volume (i.e. less 
atrophy) was associated with larger muscle size in a general linear model, but not in 
unadjusted analyses. I also found an interesting negative relationship between NART score (a 
measure of childhood cognitive ability) and neck muscle size, although this dataset had no 
measure of muscle strength. However, in none of these studies had the interrelationship 
between all four measures (ie brain and muscle structure and function) been investigated.  
Sarcopenia is described as both the loss of muscle size and function with age, with particular 
emphasis placed on the importance of grip strength and gait speed to aid diagnosis, which are 
the exact measures the LBC 1936 study contains (Roubenoff, 2001, Cruz-Jentoft et al., 2010, 
Muscaritoli et al., 2010). Within the field of cognitive ageing there is good evidence that 
brain structure (eg whole brain volume, markers of brain atrophy) and cognition are also 
related (McDaniel, 2005, Schmidt et al., 2005). Studying all four variables within one dataset 
allows us to understand the interrelationship between them which will allow a better 
understanding of how variations in one may affect another and the possible mediating role the 
other variables may play in this relationship. For example if we find that grip strength is 
associated with white matter (WM) volume, we can look to see if muscle size or cognition is 
the true mediator of this relationship or whether this is an independent effect. This should 
hopefully lead to a better understanding of potential mechanisms which may coexist within 
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brain and muscle ageing, and therefore potential therapies which may prove beneficial to 
both. 
6.2 Methods 
6.2.1 LBC 1936 
For methods regarding the LBC 1936 study please refer to chapter 3: Methods for the Lothian 
Birth Cohort 1936 study. 
6.2.2 Statistics 
All data were analysed using the SPSS 21.0 statistics package. Means, standard deviations 
and Pearson’s correlations were calculated for parametric variables and median, interquartile 
range and Spearman’s correlations for non-parametric variables. Multiple linear regression 
models were then tested, adjusting for important covariates (eg sex, age), before parameter 
estimates were calculated for significant relationships. Further testing for potential 
explanatory factors was then performed, searching for a meaningful change in partial eta 
squared in the chosen predictor variable (eg grip strength), which was taken to be a >1% 
change in partial eta squared. Multinomial logistic regression was then performed to test for 
associations between deep and periventricular Fazekas score (categorical variables) and 
measure of muscle size and function. Lastly Sobel’s test was used to test whether variables 
exerted a significant mediating effect on certain associations. A significance of <0.05 was 
taken to be significant, as I had 8 primary outcomes to test: the association of neck muscle 
CSA with WM, GM and WML volume and cognition, and the association of physical 
function with WM, GM and WML volume and cognition. The effect of covariates and the 
relationship with Fazekas scores were planned secondary outcomes. 
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6.3 Results 
6.3.1 Descriptive statistics and correlations 









) 5.0 (1.1) 3.9 (0.8) 4.5 (1.2) 
Combined group CSA (cm
2
) 20.8 (3.6) 14.3 (2.4) 17.7 (4.5) 
Total neck muscle CSA (cm
2
) 25.8 (4.2) 18.1 (2.8) 22.2 (5.3) 
Independent t tests between male and female for all neck muscle CSA measurements were all 
p<0.0001 
The Pearson correlation coefficient for grip strength in the dominant hand and non-dominant 
hand was 0.92 (p<0.000001), therefore grip strength for the dominant hand was used in all 
analyses. The dominant hand was: 94.2% right, 5.5% left and 0.4% ambidextrous (if 
ambidextrous, right hand measure was used for analyses). 
Table 6-2: Descriptive statistics for grip strength and 6 metre walk test, Mean (SD) 
 Male Female Total 












Independent t test comparing means for physical function variables between men and women 
were both p<0.0001 
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521.7 (84.1) 465.3 (70.0) 495.1 (82.5) 









 7.9 (3.8-17.2) 7.3 (3.2-16.7) 7.7 (3.6-17.0) 




1.35 (0.63) 1.36 (0.67) 1.36 (0.65) 
WML score: Fazekas deep (0-3)
a
 1.02 (0.63) 1.17 (0.71) 1.09 (0.67) 
Mean (SD) given except for * where median and interquartile range given 
a Independent t test comparing means for men and women p<0.0001 
b Independent samples Mann-Whitney U test comparing men and women p>0.05 
Table 6-4: Descriptive statistics for cognitive test scores 
 n Median (interquartile range) 
IQ age 11* 1028 101.7 (91.1-111.0) 
A Mann-Whitney U test found no significant difference between men and women for IQ age 
11 (p>0.05) 
The three factors measuring cognitive function were standardised to give a mean of 0 and a 
SD of 1.0. The sample sizes were as follows: G cognition (n=848); G processing speed 
(n=813); and G memory (n=823). Cognitive test scores did not significantly vary with sex 
(independent samples t test comparing men and women p>0.05). 
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Table 6-5: Descriptive statistics for covariates 
 n Mean (SD) 
Age at MR brain (years) 705 72.7 (0.7) 
Sex 1091 Male 50.2%, Female 49.8% 
Intracranial volume (cm
2
) 679 1451.0 (140.6) 
Systolic BP (sitting, mmHg) 863 148.7 (18.8) 
Diastolic BP (sitting, mmHg) 863 78.0 (9.8) 
ABPI 756 1.09 (0.18) 
Hypertension 866 No 50.9%, Yes 49.1% 
Hypercholesterolaemia 866 No 58.9%, Yes 41.1% 
Previous stroke 866 No 93.6%, Yes 6.4% 
Diabetes mellitus 866 No 89.0%, Yes 11.0% 
Cardiovascular disease 866 No 71.1%, Yes 28.9% 
Total chol (mmol/L) 832 5.15 (1.15) 
chol:HDL ratio 832 3.75 (1.12) 
HbA1c (%) 826 5.75 (0.66) 
CRP (mg/L)* 830 1.5 (1.5-6.0) 
eGFR (ml/min) 820 eGFR>60mL/min 87.1% 
eGFR<60mL/min 12.9% 
Salivary cortisol (waking) (nmol/L) 89 24.0 (10.6) 
Salivary cortisol (evening) (nmol/L) 89 5.3 (9.1) 
Salivary cortisol (diurnal slope) (nmol/L) 89 -18.7 (14.6) 
s100 (microg/L) 834 0.09 (0.05) 
IL-6 (pg/mL)* 815 1.55 (1.04-2.35) 
Years of education (years) 1091 10.7 (1.1) 
Social class 1070 I 17.8% 
II 37.6% 




Overcrowding index (people/room)* 1088 1.25 (0.80-1.67) 
Indoor vs. out toilet 1089 Indoor 88.4%, Outdoor 11.6% 
Alcohol consumption (yes/no) 866 No 12.0%, Yes 88.0% 
Alcohol frequency (days/week)* 759 2 (1-6) 
Alcohol units/week* 764 7.0 (1.5-16.0) 
Smoking status 866 Never smoked 47.2% 
Ex-smoker 44.3% 
Current smoker 8.4% 
Days of exercise/month* 956 5.75 (0.0-12.0) 
Telomere length (base pairs) 844 3966.3 (737.8) 
APOE4 1028 No E4 allele 70.2%, E4 allele 29.8% 
*median (interquartile range)
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*Correlation is significant at the 0.05 level (2-tailed), **Correlation is significant at the 0.01 level (2-tailed)
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6.3.2 Relationship between muscle size and cognition 




G cognition G processing speed G memory 
t sig Partial eta 
squared 
t sig Partial eta 
squared 
t sig Partial eta 
squared 
Age -2.47  0.01 1.1% -3.24  0.001 1.9% -1.21 >0.05 0.3% 
Sex (M=1, 
F=2) 
1.22 >0.05 0.3% 0.62 >0.05 0.1% 0.04 >0.05 <0.1% 
Age 11 IQ 17.09 <0.001 35.0% 10.20 <0.001 16.1% 14.2 <0.001 27.0% 
Total neck 
muscle CSA 
-0.29 >0.05 <0.1% -1.09 >0.05 0.2% -0.51 >0.05 <0.1% 
Pillai’s Trace for neck muscle CSA and overall model for three cognitive measures 
(F(3,541)=0.60, p>0.05, partial eta squared 0.3%) 
As there were no significant relationships between total neck muscle CSA and cognitive 
function, further testing of the model with potential covariates was not performed. 
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6.3.3 Relationship between muscle function and cognition 




G cognition G processing speed G memory 
t sig 
Partial eta 
squared t sig 
Partial eta 
squared t sig 
Partial eta 
squared 
Age -1.93 >0.05 0.6% -2.33 0.02 0.9% -0.83 >0.05 0.1% 
Sex (M=1, 
F=2) -2.36 0.019 0.9% -2.69 0.007 1.2% -2.02 0.044 0.7% 
Age 11 IQ 16.59 <0.001 31.9% 9.16 <0.001 12.5% 13.89 <0.001 24.8% 
Grip strength 2.98 0.003 1.5% 2.04 0.042 0.7% 1.66 >0.05 0.5% 
6MWT -3.61 <0.001 2.2% -5.70 <0.001 5.3% -1.93 >0.05 0.6% 
Pillai’s Trace for grip strength and overall model for three cognitive measures 
(F(3,584)=2.97, p=0.03, partial eta squared 1.5%) 
Pillai’s Trace for 6MWT and overall model for three cognitive measures (F(3,584)=10.87, 
p<0.001, partial eta squared 5.3%) 





G cognition G processing speed G memory 
B sig 95% CI B sig 95% CI B sig 95% CI 
Grip 
strength (kg) 
0.02 <0.01 0.01-0.03 0.01 0.04 0.00-0.02 0.01 >0.05 0.00-0.02 
6MWT 
(seconds) 
-0.10 <0.01 -0.15- -0.05 -0.18 <0.01 -0.24- -0.12 -0.06 >0.05 -0.12-0.00 
Potential covariates were added to the model to assess their role as a possible explanatory 
factor in the relationship. Potential covariates were identified through both hypothesis 
generated associations and identifying covariables through correlation matrices. The 
following covariates were investigated in each of the following models to see if they 
explained the association between the muscle and brain variables. 
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Table 6-10: Table listing the covariates which were tested to investigate whether they explained any found 
association between the muscle and brain variables in each of the following models 
Social factors Physical 
measures 









Hypertension Cholesterol Drink alcohol 
yes/no 









































(number of days 
active per 
month) 
   S100  
   Interleukin-6 
(IL-6), 
 
   Telomere length  










From the above covariates (table 6-10), only the four included in the table below were found 
to significantly predict the three cognitive measures in the multivariate model investigating 
the association between cognitive function, grip strength and the 6MWT.  
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Table 6-11: Effect of covariates added to Multivariate GLM of physical function predicting cognitive 
function 
Covariable n Sig Partial eta 
squared for 
covariate 
Δ partial eta 
squared for grip 
strength 





592 0.008 2.0% -0.2% 0.0% 
Social class 582 0.004 1.9% 0.0% -0.5% 
APOE4 
carrier 
563 0.003 2.4% 0.0% 0.2% 
Smoking 
status 
592 0.004 1.6% 0.0% 0.0% 
However, these covariates do not act as explanatory variables for the relationship between 
cognitive function and grip strength or 6MWT as they did not modify the partial eta squared 
by more than 1% (which I took as the minimum change required to show a meaningful 
effect).  
Evening salivary cortisol is not a significant predictor of overall cognitive function but it does 
act as an explanatory variable in the relationship between 6MWT and overall cognitive 
function (partial eta squared decreased from 11.7% to 9.0%). Within univariate models of 
cognitive function, evening salivary cortisol acts as explanatory variable between 6MWT and 
processing speed (partial eta squared 11.1% to 8.6%), but not for cognition or memory. The 
delta partial eta squared was calculated by first running the baseline model only including 
subjects where the covariable was measured and then running the model including the 
covariable. This was to ensure that any changes in partial eta squared were not just accounted 
for by changes in the sample size. However, evening cortisol does not mediate the effect of 
processing speed on 6MWT (Sobel’s test statistic -1.29 (SE 0.02) p>0.05).  
The other two measures of salivary cortisol did not act as explanatory variables for any of the 
other relationships between 6MWT or grip strength and either overall cognitive function or 
its univariate measures. 
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6.3.4 Relationship between muscle size and brain structure 





white matter volume Grey matter volume 
t sig 
Partial eta 
squared t sig 
Partial eta 
squared 
Age -5.92 <0.001 5.3% 4.21 <0.001 2.7% 
Sex (M=1, F=2) 0.38 >0.05 <0.1% -0.56 >0.05 <0.1% 
ICV 15.28 <0.001 27.0% 10.72 <0.001 15.4% 
Total neck 
muscle CSA -3.02 0.003 1.4% 1.04 >0.05 0.2% 
Pillai’s Trace for neck muscle CSA and overall model for two measures of brain structure 
(F(2,630)=4.56, p=0.01, partial eta squared 1.4%) 













B sig 95% CI B sig 95% CI 




-0.02 0.003 -0.04- -0.01 0.01 >0.05 -0.01- 0.02 
From the above listed covariates (table 6-10), only the six included in the table below were 
found to significantly predict the two measures of brain structure (ie white matter and grey 
matter volume) in the multivariate model. 
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Table 6-14: Effect of covariates added to Multivariate GLM of neck CSA predicting brain structure 
Covariable n Sig Partial eta squared 
for covariate 
Δ partial eta squared 
for neck CSA 
Diagnosis of diabetes 
mellitus 
636 0.04 1.0% -0.1% 
HbA1c 611 0.02 1.2% -0.3% 
CRP 613 <0.01 2.2% -0.1% 
IL-6 603 <0.01 2.1% -0.2% 
Alcohol (days consumed 
per week) 
498 0.04 1.3% 0.2% 
Smoking status 636 0.02 1.0% 0.1% 
However, none of these covariates act as explanatory variables for the relationship between 
overall brain structure and neck CSA or univariate measures of brain structure (ie WM or 
GM volume) and neck CSA.  
6.3.5 Relationship between muscle function and brain structure 





white matter volume Grey matter volume 
t sig 
Partial eta 
squared t sig 
Partial eta 
squared 
Age -4.97 <0.001 3.8% 3.97 <0.001 2.4% 
Sex (M=1, F=2) -3.09 0.002 1.5% -0.55 >0.05 0.0% 
ICV 14.36 <0.001 24.7% 11.12 <0.001 16.4% 
Grip strength 2.62 0.009 1.1% 0.89 >0.05 0.1% 
6MWT -2.01 0.045 0.6% -2.36 0.018 0.9% 
Pillai’s Trace for grip strength and overall model for two measures of brain structure 
(F(2,627)=5.40, p=0.005, partial eta squared 1.7%) 
Pillai’s Trace for 6MWT and overall model for two measures of brain structure 
(F(2,627)=7.58, p=0.001, partial eta squared 2.4%) 
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White matter volume (cm
3
) Grey matter volume (cm
3
) 
B sig 95% CI B sig 95% CI 
Grip strength (kg) 1.16 0.009 0.29-2.04 0.37 >0.05 -0.45- 1.18 
6MWT (seconds) -4.51 0.045 -8.92- -0.10 -4.95 0.018 -9.07- -0.84 
From the listed covariates (table 6-10), only the four included in the table below were found 
to significantly predict the two measures of brain structure (ie white matter and grey matter 
volume) in the multivariate model. 
Table 6-17: Effect of covariates added to Multivariate GLM of physical function predicting brain structure 
Covariable n Sig Partial eta 
squared for 
covariate 
Δ partial eta 
squared for 
grip strength 
Δ partial eta 
squared for 
6MWT 
HbA1c 610 0.02 1.3% 0.0% -0.2% 
CRP 612 0.02 1.3% -0.2% -0.4% 
Alcohol (days consumed 
per week) 
563 0.02 1.5% 0.0% 0.2% 
Smoking status 634 0.02 0.9% -0.1% -0.2% 
However, none of the covariates act as explanatory variables for the relationship between 
brain structure and grip strength or 6MWT in the multivariate or univariate models.  
Neither evening salivary or diurnal cortisol slope act as a significant predictor of brain 
volume, but they may act as explanatory variables in the relationship between 6MWT and 
brain structure (partial eta squared decreased from 5.5% to 4.1% for evening cortisol and 
from 5.4% to 3.8% for diurnal slope). However there was no univariate effect.  
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6.3.6 Relationship between muscle size and function and WML 
Table 6-18: Univariate GLM of neck muscle CSA predicting WML volume 




t sig Partial eta squared 
Age 3.36 0.001 1.8% 
Sex (M=1, F=2) -2.20 0.028 0.8% 
ICV 2.43 0.015 0.9% 
Total neck muscle CSA 1.28 >0.05 0.3% 
The partial eta squared for the corrected model is 2.7% (p 0.002).  
As there were no significant relationships between total neck muscle CSA and WML volume, 
further testing of the model with potential covariates was not performed. 







t sig Partial eta squared 
Age 3.29 0.001 1.7% 
Sex (M=1, F=2) -0.47 >0.05 0.0% 
ICV 2.94 0.003 1.4% 
Grip strength -0.90 >0.05 0.1% 
6MWT 2.88 0.004 1.3% 
The partial eta squared for the corrected model is 2.7% (p 0.002). 
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Table 6-20: Parameter estimates for the effect size of grip strength and 6MWT on WML volume 
Independent variables Dependent variables 
White matter lesion volume (mm
3
) 
B sig 95% CI 
Grip strength (kg) -72.7 >0.05 -235.8- 90.4 
6MWT (seconds) 1161.2 <0.01 366.7-1955.8 
From the listed covariates (table 6-10), only the three included in the table below were found 
to significantly predict white matter lesion volume in the univariate model. 
Table 6-21: Effect of covariates added to Univariate GLM of physical function predicting WML volume 
Covariable n Sig Partial eta 
squared for 
covariate 
Δ partial eta 
squared for 
grip strength 
Δ partial eta 
squared for 
6MWT 






636 <0.01 1.4% 0.0% -0.3% 1.3% 
Total chol:HDL 
ratio 




636 <0.01 1.7% 0.0% -0.1% 1.5% 
However, none of these covariates act as explanatory variables for the relationship between 
brain structure and grip strength or 6MWT.  
Interestingly adding waking salivary cortisol and diurnal cortisol slope to the model did 
increase the partial eta squared for the corrected model from 6.6% to 8.7% and from 6.6% to 
7.7% respectively, despite neither measure being a significant predictor of WML volume.  
 
Chapter 6  169 




Predictor Male Female 
n Sig Odds 
ratio 
95% CI for 
OR 
n Sig Odds 
ratio 




12 - - - 8 - - - 
1 Neck muscle 
CSA 
217 <0.01 0.998 0.997-0.999 193 >0.05 1.003 1.000-1.006 
2 Neck muscle 
CSA 
93 <0.01 0.998 0.997-0.999 73 >0.05 1.003 1.000-1.006 
3 Neck muscle 
CSA 
19 >0.05 0.999 0.997-1.000 22 >0.05 1.002 0.999-1.005 
Adjusted for age at MRI 




Predictor Male Female 










61 - - - 37 - - - 
1 Neck muscle 
CSA 
220 >0.05 0.999 0.997-
0.999 
181 >0.05 1.000 0.998-
1.002 
2 Neck muscle 
CSA 
55 >0.05 0.999 0.997-
0.999 
63 >0.05 1.000 0.998-
1.002 
3 Neck muscle 
CSA 
5 >0.05 0.999 0.997-
0.999 
15 >0.05 1.000 0.998-
1.002 
Adjusted for age at MRI 
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Predictor Male Female 










11 - - - 9 - - - 










































Adjusted for age at MRI 
Results not altered when performing regression separately for grip strength and 6MWT 




Grip/6MWT Male Female 










59 - - - 40 - - - 










































Adjusted for age at MRI 
Results not altered when performing regression separately for grip strength and 6MWT  
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6.3.7 Interrelationships between muscle structure and function and 
brain structure and function 
Figure 6-1: Model representing significant interrelationships between muscle structure and function, WM 
volume and cognition 
 
*But no significant relationship between grip strength and 6MWT and G memory 
Neck muscle CSA does not act as a mediator between grip strength and WM volume (Sobel 
test statistic -0.67, SE 269.47, p>0.05) but does act as a mediator between the 6MWT and 
WM volume (Sobel test statistic -2.17, SE 572.07, p=0.03). 
WM volume acts as a mediator in the relationship between grip strength and G cognition 
(Sobel test statistic 2.46, SE 0.003, p=0.01) and G processing speed (Sobel test statistic 2.54, 
SE 0.003, p=0.01), and in the relationship between 6MWT and both G cognition (Sobel test 
statistic 3.56, SE 0.008, p=0.0004) and G processing speed (Sobel test statistic -3.55, SE 
0.008, p=0.0004). 
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Figure 6-2: Model representing significant interrelationships between muscle structure and function, GM 
volume and cognition 
 
*But no significant relationship between grip strength and 6MWT and G memory 
GM volume does not act as a mediator between 6MWT and G cognition (Sobel test statistic -
1.26, SE 0.008, p>0.05) or G processing speed (Sobel test statistic -0.96, SE 0.008, p>0.05). 
Figure 6-3: Model representing significant interrelationships between muscle structure and function, WML 
volume and cognition 
 
* But no significant relationship with grip strength 
Neck muscle CSA does not act as a mediator between the 6MWT and WML volume (Sobel 
test statistic -0.87, SE 47.62, p>0.05). WML volume does act as a mediator between 6MWT 
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and G cognition (Sobel test statistic -2.21, SE 0.005, p=0.03) and G processing speed (Sobel 
test statistic -2.63, SE 0.006, p=0.009). 
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6.4 Discussion 
6.4.1 Relationship between neck muscle CSA and cognition 
This analysis found no significant association between neck muscle CSA and cognition either 
as a whole or as individual measures of cognition (see table 6.7). This adds to previous work 
identified in our systematic review which found no association between muscle size and 
cognitive function (Kilgour et al., 2014). Interestingly I did find a negative correlation 
between age 11 IQ and neck muscle CSA. I previously found a negative association between 
NART, a measure of crystallised intelligence which is an indicator of childhood intelligence, 
and neck muscle CSA using data from the MHEM study, and I had postulated that perhaps 
those with a lower IQ were more likely to have a manual job and therefore develop larger 
neck muscles throughout their adult life (Kilgour et al., 2013). I was able to test that theory 
here as the LBC 1936 study contains data on social class. A Spearman’s correlation does 
indeed find a significant association between social class and neck muscle CSA (rho 0.153, 
p<0.001), indicating that those from social class 5 have larger neck muscles than those from 
social class 1. Further detailed analyses of occupation may help explain this relationship 
further. 
6.4.2 Relationship between physical function and cognition 
There was a significant association between markers of physical function (grip strength and 
6MWT) and cognition as a whole and two of the individual measures. Those with stronger 
grip strength and faster 6MWT had better scores for G cognition and G processing speed, but 
there was no association with G memory. The relationships are stronger for 6MWT than grip 
strength, and whilst neither measure is a completely pure measure of muscle function, both 
being affected by joint problems, mood, comprehension and motivation, it may be considered 
that grip strength is a purer measure than 6MWT. Further analyses looking at predictors of 
6MWT (eg comorbidity, HADS score) might further elucidate the differences between the 
two tests of physical function. In fact I found that a 1kg increase in grip strength would 
account for a 0.02 increase in G cognition score and a 0.01 increase in G processing speed, 
and that a 1 second faster 6MWT would equate to an increase of 0.10 in G cognition score 
and 0.18 in G processing speed.  
Gait speed has previously been found to be associated with various markers of cognitive 
ability, including MMSE, DSST and a diagnosis of cognitive impairment/dementia (Abellan 
van Kan et al., 2009, Atkinson et al., 2007, Duff et al., 2008), but there is less evidence of the 
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relationship of gait speed to individual components of cognitive function. Similarly grip 
strength has previously been found to be associated with markers of cognitive ability 
including MMSE (Alfaro-Acha et al., 2006), the Community Screening Instrument of 
Dementia(Auyeung et al., 2008) and global cognition using multiple tests of cognitive 
function (Guerrero-Berroa et al., 2014). Interestingly the latter study found no association 
between episodic memory and grip strength, but did find an association with 
attention/working memory, language/semantic categorization and executive function. This 
supports our finding, that whilst certain components of cognition are associated with physical 
function, aspects of memory appear not to be. Studies of how cognition alters over the 
lifecourse have found that certain aspects decline over time whereas other aspects remain 
relatively robust. These studies are hampered by methodological issues; namely that either 
they are cross-sectional to allow researchers to look across the lifecourse or they are 
longitudinal and have mainly focused on older adults (Hedden and Gabrieli, 2004), therefore 
exact trajectories of individual cognitive functions across the lifecourse are yet to be firmly 
agreed upon. It is therefore interesting that we found a differential association of physical 
function with the different components of cognition, but difficult to speculate much further as 
to why this could be. It may be because the neural constructs underlying the variables overlap 
more for processing speed and cognition with walking and grip strength than they do with 
memory. Or it may be that factors which affect processing speed and cognition over the 
lifecourse, either intrinsic or extrinsic ageing factors, similarly affect gait speed and grip 
strength, whereas memory is more reliant on its trajectory of decline on factors which do not 
affect the other covariates. As larger longitudinal studies of cognition over the lifecourse 
emerge in the coming decades perhaps answers to these questions will become clearer. 
Ogata et al looked at the relationship between grip strength and cognitive function using 
monozygotic and dizygotic twins and found that whilst there does appear to be certain 
common genetic factors which affect grip strength and tests of cognitive function, the 
heritability of grip strength is only 6% whereas cognition is much more heritable (47-71%) 
(Ogata et al., 2014). Therefore environmental factors must play a large role and previous 
studies have found that these factors tend to have specific effects on individual tests rather 
than the common effect genetic traits have on most cognitive tests (Deary et al., 2006b). 
None of the twenty six covariates I studied were explanatory factors in the relationship 
between cognitive and physical function. However evening cortisol, despite not being a 
significant predictor of cognitive function in the multivariate model did act as an explanatory 
 
Chapter 6  176 
variable in the relationship between 6MWT and total cognitive score and the individual score 
for processing speed, but not for cognition or memory.  
The sample size for the cortisol measures was much smaller than for the other covariates 
(table 6-10), which does make the effect of the evening cortisol less comparable with the 
effect of the other covariates. However the partial eta squared for evening cortisol, and the 
other cortisol measures, for brain volume was much bigger than for the other covariates. 
Previous studies have found links between evening cortisol and gait speed (Gardner et al., 
2011) and waking cortisol and processing speed (Kuningas et al., 2007). These effects could 
be caused by direct tissue atrophy, as cortisol is known to cause both brain and muscle 
atrophy, or by brain and muscle cell dysfunction (MacLullich et al., 2005, Lupien et al., 1998, 
Falduto et al., 1990), however I found that evening cortisol does not act as a mediator 
between processing speed and 6MWT, which given the small delta partial eta squared is 
perhaps not surprising. 
6.4.3 Relationship between brain structure and neck muscle CSA 
There was no association between grey matter volume and neck muscle CSA but 
interestingly there was a negative relationship between white matter volume and neck muscle 
CSA. This was the opposite of what I had hypothesized according to the common cause 
hypothesis. I found that a 1cm
2
 increase in neck muscle CSA was associated with a 0.02cm
3
 
decrease in white matter volume; thereby the effect size is significant but small. One possible 
mechanism which might explain the direction of effect is that of postural control. Neck 
muscles are constantly in use even when sitting, unlike most peripheral muscles, and perhaps 
those with less healthy WM find it more difficult to maintain postural control and therefore 
their neck muscle have to work harder leading to larger neck muscles. It would be interesting 
to see if this relationship was replicated in other datasets. No covariates were found which 
acted as explanatory factors in this relationship. Previous studies looking at brain volume and 
muscle size again found no association with total GM volume, although regional grey matter 
volume may play a role, but there was evidence of a positive relationship between WM 
volume and muscle size (Kilgour et al., 2014). However these studies either looked at total 
muscle bulk (through DEXA or BIA) or muscle CSA of a limb (eg thigh CSA); no previous 
studies looking at neck or paraspinal muscles and brain volume which may have a different 
relationship. 
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6.4.4 Relationship between brain structure and physical function 
White matter volume was significantly associated with grip strength and 6MWT but gray 
matter volume was only associated with 6MWT and not grip strength. A 1kg increase in grip 
strength was associated with a 1.2cm
3
 increase in WM volume. A 1 second faster 6MWT was 
associated with a 4.5cm
3
 increase in WM volume and a 5.0cm
3
 increase in GM volume. 
Comparing partial eta squared results, whilst the 6MWT seems to be a more important 
predictor of cognition, grip strength has a more important role in predicting WM volume.  
In the systematic review, chapter 2, I found no studies investigating the association between 
grip strength and whole brain, WM or GM volume other than a study using data from wave 1 
and 2 of the LBC 1936 study (Aribisala et al., 2013), which found no association between 
WBV or GM volume and grip strength at either wave and a positive association with WM 
volume and grip strength only at wave 2, not at wave 1. This might indicate that the 
relationship between brain structure and grip strength changes with age and longitudinal 
studies would be useful in investigating this relationship further. Furthermore, studies have 
shown a relationship with brain atrophy (measured as an index of WBV against ICV, or as 
ventricular volume) and grip strength. 
There is evidence that gait speed is positively associated with whole brain volume; this 
relationship may be driven by total WM volume or regional GM volumes, specifically the 
hippocampus. Previous studies have also shown a negative relationship with brain atrophy 
(measured as above) and gait speed (Kilgour et al., 2014). Longitudinal studies will be able to 
determine if those with smaller brains or regional brain volumes have a faster decline in gait 
speed or whether those with a slow gait speed have faster brain atrophy or whether the two 
decline in parallel. The answer to this question would then allow further exploration of the 
possible underlying mechanisms. 
Testing for potential explanatory factors again led to no significant results in the multivariate 
model, but the univariate output found both evening cortisol and diurnal cortisol slope may 
act as explanatory factors in the relationship between 6MWT and brain volume, although 
there was no specific relationship with either white or grey matter volume found. Sample size 
again clouds this as the sample for the cortisol measures was much smaller than for the other 
covariates. As previously mentioned, cortisol has previously been shown to be associated 
with gait speed and brain volume (Gardner et al., 2011, Falduto et al., 1990), however further 
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larger studies are now needed to investigate the role of cortisol in the relationship between 
gait speed and brain volume, with the potential to lead on to possible therapeutic strategies. 
6.4.5 Relationship between white matter lesions and neck muscle 
CSA 
Our primary outcome for white matter disease was WML volume but as a secondary outcome 
I also looked at Fazekas score which gives an indication of WML burden location and extent. 
There was no significant association between neck muscle CSA and WML volume. There 
was a significant association between periventricular hyperintensity (PVH) Fazekas score and 
neck muscle CSA in men, with those scoring 1 or 2 having significantly smaller neck muscle 
CSA than those scoring 0. The comparison between group 3 and 0 was non-significant but 
both groups had a small n which may account for this. However there was no relationship 
between PVH score and neck muscle CSA in women and in both men and women there was 
no relationship between the deep WMH Fazekas score and neck muscle CSA. I found no 
previous studies looking at WMH and muscle size, which is interesting considering the large 
number of studies which have been published looking at muscle function and WMH (Kilgour 
et al., 2014). It may be that location of WMH is more important than absolute burden, but 
further longitudinal studies are required to investigate this area further. 
6.4.6 Relationship between white matter lesions and physical 
function 
Grip strength was not associated with WML volume but 6MWT was; a 1 second increase in 
6MWT was associated with a 1.16cm
2
 increase in WML volume. None of the potential 
covariates investigated were found to be significant explanatory factors in the multivariate 
model however the univariate analysis found that waking cortisol and diurnal cortisol slope 
may acts as explanatory variables. Along with gait speed (Gardner et al., 2011), white matter 
disease has also been found to be associated with cortisol (Cox et al., 2014). Elevated 
glucocorticoids may cause WMHs by impaired axonal sprouting in response to injury, 
decreased proliferation of oligodendrocytes, or reduced maintenance of axonal myelination 
following accumulated damage over time (Cox et al., 2014). However the direction of effect 
needs to be established as it could also be that WMHs develop leading to impaired supra-
thalamic regulation of the HPA axis and therefore increased cortisol levels. 
In women, a PVH Fazekas score of 3 was associated with significantly lower grip strength 
than a score of 0, but there was no significant relationship between PVH Fazekas score and 
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6MWT in either sex. In both men and women the deep Fazekas score was not associated with 
grip strength, however in men those with a score of 2 or 3 had a significantly slower 6MWT 
than those with a score of 0. The n for those who scored 0 or 3 was lower in the main than for 
those who scored 1 or 2, therefore it would be useful to repeat these associations in another 
cohort with a larger sample size. This may help to further explain the differences between the 
sexes and the importance of the location of WMHs to physical function.  
The relationship between increased WMH and slower gait speed is well established; however 
it is less clear-cut whether PVH or deep WMHs are more important with studies showing 
conflicting results (Soumare et al., 2009, Moscufo et al., 2012, Wolfson et al., 2005, Rosano 
et al., 2006, Rosano et al., 2005, Silbert et al., 2008, Marquis et al., 2002, Aribisala et al., 
2013, Rosano et al., 2010, Longstreth et al., 1996). Our study was the only one to look at the 
sexes separately and it may be that analysing other studies previous results by sex would alter 
outcomes. The relationship between grip strength and WMHs is less well studied, with one 
study showing a negative relationship between WMH volume and grip strength, with 
particular note that regional burden may play an important role (Sachdev et al., 2005), whilst 
two other studies found no significant relationship between WMH volume and grip strength, 
with one of these studies using the same data as here (ie LBC 1936) (Aribisala et al., 2013, 
Longstreth et al., 1996).  
6.4.7 The interrelationship between brain and muscle structure and 
function 
I identified previous studies which have looked at the relationship between 2 or 3 of the 4 
variables (brain structure, cognitive function, muscle structure and physical function) in 
chapter 2 (Kilgour et al., 2014), but studies looking at the relationship between all 4 variables 
are much less common. Here I was able to look at all 4 variables and the interrelationship 
between them.  
There are significant relationships between neck muscle CSA, WM volume and physical 
function (figure 6.1). Neck muscle CSA is a mediator between 6MWT and WM volume but 
is not a mediator between grip strength and WM volume. The relationship is complicated by 
the fact that there is a positive relationship between physical function and WM volume and 
physical function and neck muscle CSA but a negative relationship between neck muscle 
CSA and WM volume. However the effect size of the latter relationship was very small, 
therefore it seems that whilst a statistical effect exists for neck muscle CSA as a mediator, the 
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predominant association between physical function and WM volume is not through muscle 
size so must be mediated through other routes (eg motivation to perform the test well, 
maintaining good muscle quality, because strength and muscle size do not age in parallel) 
(Young et al., 1985, Skelton et al., 1994).  
WM volume is a significant mediator in the relationship between G cognition and G 
processing speed and both grip strength and 6MWT, but not with G memory. White matter 
comprises the myelin ensheathed axonal tracts radiating from grey matter to the periphery, so 
it would make logical sense that it played a role in the relationship between physical function 
and cognition, as loss of white matter volume can lead to impairment in both areas (Kilgour 
et al., 2014). 
I then looked at these same relationships but with grey matter volume (figure 6.2). As there 
was no association between neck muscle CSA and grey matter volume I did not look further 
at this relationship. GM does not act significantly as a mediator between 6MWT and 
cognition. Therefore other mechanisms must explain the relationship, including the role of 
WM volume as noted above and WML volume as discussed below. 
Lastly I looked at the role of WML volume in these relationships (figure 6.3). Neck muscle 
CSA is not a mediator between WML volume and 6MWT, mirroring the results for WM 
volume. Therefore WML affects 6MWT independent of neck muscle CSA, which, as a proxy 
for generalized muscle bulk (Kilgour et al., 2012), again highlights the non-parallel ageing of 
muscle size and function. This could also be through balance impairment, reaction time or 
motivation. As such a large volume of literature focuses on the relationship between WMHs 
and gait speed, further studies looking at the associations between muscle size, gait speed and 
WMHs would be useful in understanding these important relationships further. 
Interestingly WML volume was found to act as a mediator between 6MWT and both G 
cognition and G processing speed. WMHs have been found to be strongly associated with 
6MWT and cognition in both this study and previous studies (Mosley et al., 2005, Soumare et 
al., 2009, Moscufo et al., 2012, Wolfson et al., 2005, Rosano et al., 2006, Rosano et al., 2005, 
Silbert et al., 2008, Marquis et al., 2002, Aribisala et al., 2013, Rosano et al., 2010, 
Longstreth et al., 1996), and are thought to cause these effects by impairing signaling 
between brain areas and consequently the periphery also.  
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Therefore, neck muscle CSA does not act as a mediator between grip strength and WM 
volume but does act as a mediator for 6MWT and WM volume (but not WML volume). This 
may be because grip strength and the 6MWT represent very different types of physical 
function and therefore the effect the ageing process has on them will be very different.  
Both WM volume and WML volume are mediators of the relationship between 6MWT and 
cognition. It is plausible that as WML volume increases, so healthy WM volume decreases so 
perhaps it is not surprising that the majority of relationships are repeated but inverted 
between WM and WML volume, however this would also require that premorbid WM 
volume was not associated with risk of WML developing, which appears to be the case (Wen 
et al., 2006). 
6.4.8 Limitations and future directions 
Our study only included members of the LBC 1936, which means the population is very 
homogeneous. Whilst this means that comparisons between covariates are less likely to be 
affected by some outside influences, it affects the generalizability of our results, as the 
population is mainly white, all of the same age and all living in the same geographical 
location. Therefore it would be very interesting to repeat these associations in other studies 
which include measures of brain and muscle structure and function. Also, at the time of 
analysis I only had access to brain structure and neck muscle CSA from wave 2 of the study. 
A further wave has since been completed and it will be very interesting to look at these 
relationships over time. For example, neck muscle cross-sectional area is determined by peak 
muscle mass achieved and subsequent muscle loss, but the difference in neck muscle CSA 
between wave 2 and 3 will only relate to muscle loss, which is a purer measure of muscle 
ageing. The same will be true of the other measures and will allow us to look further at 
direction of effect within these relationships. This will allow us to look at sarcopenia within 
the LBC1936 cohort from the context of a lifecourse approach, by being able to separate out 
factors which only relate to ageing from those which contributed to peak muscle bulk 
achieved. This concept is an exact reflection of how osteoporosis and bone mineral density 
have been studied. There is now public health advice on how to reach a satisfactory peak 
bone mineral density (eg weight bearing exercise) and also medication and lifestyle advice to 
offer to those in older age groups who have developed low bone mineral density.  
However, even with the longitudinal data from wave 3 of the study the LBC13936 study still 
only covers a very narrow age spectrum with regard to muscle mass and function. It will be 
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very interesting to look at alternate data sets which include subjects from a different age 
bracket and re-test the associations in these groups also. Conversely, whilst we do not have 
data on muscle mass and function from childhood within the LBC1936 study we do have data 
from childhood related to socioeconomic factors. Interestingly we did not find any of these 
factors to have a role as an explanatory variable in the associations found between brain and 
muscle. This may be because the LBC1936 cohort is unusual in its overall health and 
socioeconomic status. For example in the 2001 Scottish Household Survey of those born 
between 1937-1975 42.1% of respondents identified themselves as from a professional or 
managerial social class whereas at the time of wave 1 of the LBC1936 study 55.4% of the 
respondents identified themselves in this group (Iannelli and Paterson, 2005). Whilst these 
figures are not totally comparable in view of the fact that social class is increasing with 
subsequent generations it would be fair to conclude that the percentage of LBC1936 subjects 
in this group was over-represented compared to the general population. 
Sarcopenia is defined as the loss of muscle mass and function with age (Cruz-Jentoft et al., 
2010), therefore it is important to investigate both aspects with respect to ageing muscle. 
However there are confounding factors associated with measuring both of them. As muscle 
ages, the relative amount of non-contractile tissue, which comprises adipose and connective 
tissue, increases significantly (Taaffe et al., 2009, Inacio et al., 2014). In older adults this 
represents around 15% of the total muscle CSA in some muscle groups, which is around 2.5-
fold greater than in young controls (∼6%). Therefore measurements of muscle CSA or 
volume which are not corrected for the amount of non-contractile tissue present may 
underestimate the degree of sarcopenia present in an individual. Techniques used to measure 
the non-contractile component of muscle have mainly used CT but there are processes for 
measuring it using MR images (eg K means clustering) (Gray et al., 2011). However none of 
the techniques we applied to the neck muscles for measuring the non-contractile component 
worked adequately, mainly due to the small volumes of the neck muscles and the difficulties 
the software had in detecting the muscle boundaries.  
Measurement of muscle function is also subject to confounding. For example in measuring 
gait speed multiple factors other than purely muscle function will contribute to the final score 
(eg joint disease, balance, vision). Even the purer measures of muscle strength measurement 
(eg isometric knee extensor strength) are subject to issues such as motivation, comprehension 
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and mood. Therefore whilst measurement of both muscle structure and function are subject to 
error, a combined measure is still the preferred method of detecting sarcopenia. 
Finally the measurement of neck muscle CSA in this study was used as a proxy for general 
muscle bulk and not because the neck muscles were of specific interest in this cohort. That is 
why we used the well-established measures recorded for muscle function as part of LBC1936 
(grip strength and 6MWT) as opposed to specific measures of neck muscle strength. However 
there are techniques for measuring specific neck muscle strength for 3 of the 4 muscles we 
studied. These include a technique to measure the strength of the sternocleidomastoid (Barton 
and Hayes, 1996), the semispinalis capitis (Rezasoltani et al., 2002) and the trapezius 
(Choudhari et al., 2012). No measurement technique was found to individually measure the 
strength of the splenius capitis muscle. It would be interesting to undertake a measure of neck 
muscle strength in a small sub-population to determine the relationship between neck muscle 
size and strength and also to correlate the other measures of muscle function with it to see if 
there is a consistent relationship or not, as it may be that neck muscles age in a different was 
to other muscle groups around the body in view of the fact they are in use for the vast 
majority of the waking day, even whilst sitting, unlike many other muscle groups. 
Conclusion 
This study used data from a large population based cohort study to look at the 
interrelationships between brain and muscle structure and function. Neck muscle CSA was 
negatively associated with WM volume and PVH Fazekas score in men. Grip strength was 
positively associated with cognitive ability (specifically general cognition and processing 
speed, but not memory) and WM volume, and was negatively associated with PVH Fazekas 
score in women. 6MWT was also associated with the same cognitive ability measures as grip 
strength, and also WM, GM and WML volume. 6MWT was also positively associated with 
deep Fazekas score in men.  
Neck muscle CSA was found to be a mediator between 6MWT and WM volume, and WM 
and WML volume both act as mediators between physical function and cognition. Brain 
ageing and muscle ageing therefore interact in a complex manner and understanding these 
interactions further could help reveal possible underlying mechanisms linking them; for 
example the role of cortisol, which we found to represent an explanatory factor between 
6MWT and brain structure and cognition.  
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Again as these relationships are largely cross-sectional it is difficult to use these results to 
comment further on their reflection on the common cause hypothesis. However, this study 
has identified some evidence of complex relationships between brain and muscle structure 
and function which may lend some support to the hypothesis. Nonetheless as the associations 
are mostly small there are clearly other important driving factors leading to the magnitude of 
all four variables within this age group. It may be that a less healthy, more diverse, older age 
group would have displayed stronger associations as these individuals would have been more 
affected by the ageing process, however the best way to assess if the organs are ageing in 
parallel or not will be the future waves of this study and longitudinal analyses which are 
future work that I now plan to do.  
.
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Chapter 7 Investigating the relationship between 
markers of immunosenescence (CMV 
and IL-6) and grip strength and muscle 
size in an elderly cohort study 
7.1 Introduction 
Sarcopenia is an important cause of morbidity and mortality in older adults (Lauretani et al., 
2003, Baumgartner et al., 1998, Rantanen, 2003), but despite its clinical importance, current 
understanding of the mechanisms underlying sarcopenia remains unclear. In the next two 
chapters I investigate two potential mechanisms underlying the development of sarcopenia: in 
this chapter the role of immunosenescence and inflammation and in the next chapter the role 
of glucocorticoids.  
I chose these two areas following on from the literature review performed in chapter 1 in 
which I identified several possible mechanistic pathways which could underlie the process of 
sarcopenia. Following on from this when the data was collected from wave 2 of the LBC 
1936 study I looked at the associations between these identified pathways and the markers of 
sarcopenia which LBC1936 contained (namely grip strength and neck muscle CSA). These 
preliminary analyses found that several of the pathways I had identified may be associated 
with the markers of sarcopenia, including some risk factors for vascular disease (eg total 
cholesterol, HDL cholesterol), the cortisol measures (as discussed in chapter 6) and the 
markers of immunosenescence (discussed in this chapter). Other markers which were looked 
at, for example markers of cell ageing (eg telomere length) and micronutrients (eg vitamin 
B12 and folate), did not show a significant association with the markers of sarcopenia and 
further analysis was not pursued. 
Immunosenescence and inflammation have both been identified as possible contributing 
factors. Immunosenescence is the age-associated impairment of immune function due to 
changes in both the innate and adaptive immune response (Pawelec et al., 2010). These 
changes lead to a decreased ability to respond to pathogens, although an agreement on 
clinical biomarkers and associated clinical outcomes requires further research (Pawelec et al., 
2010). 
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Seropositivity for cytomegalovirus (CMV, otherwise known as Human Herpes Virus 5), is 
common in older adults (Lubeck et al., 2010, Lopo et al., 2011). Most people are infected in 
childhood or young adulthood and become carriers of the virus in a latent state for the rest of 
their lives (Soderberg-Naucler and Nelson, 1999, Sinclair, 2008, Slobedman et al., 2010). 
The role of CMV status in immunosenescence is a topic of current research, and it remains 
unclear whether the relationship is causal or associative. However, latent CMV infection has 
been linked to several clinical outcomes, including frailty and increased mortality. Several 
studies have found an association between CMV seropositivity and/or CMV antibody titre 
and the presence of atherosclerosis and coronary heart disease, with some studies also 
demonstrating a correlation with survival time (Blankenberg et al., 2001, Muhlestein et al., 
2000, Strandberg et al., 2009). Other studies have found associations between CMV and 
cognitive decline in older adults, (Aiello et al., 2006) and all-cause mortality (Roberts et al., 
2010).  
There is also evidence of an association between CMV infection and frailty. Aiello et al 
found that CMV antibody titre is negatively associated with the ability to carry out activities 
of daily living (ADLs) in elderly Latino subjects, after correcting for gender and age (Aiello 
et al., 2008). However, this relationship became non-significant after adjusting for the total 
number of health conditions, body mass index, and household income. Schmaltz et al found 
an association between frailty, defined using the Fried criteria, and CMV serostatus in older 
women (Schmaltz et al., 2005). Studies investigating frailty vary widely on the criteria used 
for diagnosis and not all frailty scores contain a measure of muscle mass (Fried et al., 2001, 
Rockwood and Mitnitski, 2007). Therefore, in order for clear conclusions to be drawn about 
the possible underlying mechanisms of sarcopenia, it is important to study it as an 
independent variable rather than as a component of a frailty score. 
Interleukin 6 (IL-6) is a cytokine known to be part of the acute phase response, i.e. the initial 
immune system reaction to infection or trauma (Heinrich et al., 1990). Increasing age is 
associated with latent low grade inflammation; levels of IL-6 appear to increase with age, 
particularly following the andropause or menopause (Hager et al., 1994, Ershler and Keller, 
2000). In a large cross-sectional study of septuagenarians, raised IL-6 levels were associated 
with reduced muscle mass and strength (Visser et al., 2002). However, in a further 
longitudinal cohort higher IL-6 levels were associated with loss of muscle strength, although 
no association was found with muscle mass (Schaap et al., 2006).  
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Several studies investigating the effect of CMV on frailty and functional ability have adjusted 
for IL-6 to assess its role as a mediator, as CMV is known to increase IL-6 gene expression 
and production in peripheral blood mononuclear cells (Geist and Dai, 1996). Indeed in the 
above mentioned study, Schmaltz et al found that CMV positive subjects with high IL-6 
levels had a significantly higher prevalence of frailty than those with a low IL-6 level 
(Schmaltz et al., 2005). Also, data from the Women's Health and Aging Studies found that 
IL-6 appeared to modulate the effect of CMV antibody titre on frailty as an outcome 
(measured using the Fried criteria), although the effect did not reach statistical significance 
(Wang et al., 2010). 
I could find no previous studies which have looked at the association between muscle mass 
and CMV serostatus or antibody titre. Furthermore I found only one study which addressed 
the relationship between CMV serostatus and handgrip strength, an important marker of 
muscle function in older age, and that study only looked at women (Schmaltz et al., 2005). As 
detailed above, IL-6 may play an important mediatory role in these relationships and it is 
therefore important to study this in tandem with CMV status. In this study I investigated the 
relationship between latent CMV infection, IL-6 level and markers of sarcopenia (muscle size 
and strength) in a healthy older cohort of community-dwelling men and women. 
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7.2 Methods 
7.2.1 Participants – The Lothian Birth Cohort 1936 (LBC 1936) 
As per chapter 3. 
7.2.2 Neck muscle Cross-sectional Area 
As per chapter 4. 
7.2.3 Grip strength 
Grip strength was measured with a Jamar Hydraulic Hand Dynamometer, with all 
participants performing 3 trials with their right and left hands; the best of the 3 trials was used 
for the following analyses. 
7.2.4 CMV and IL-6 measures 
CMV was measured in plasma samples collected at age 70, using a CMV ELISA assay. 
Mock and viral-infected lysate was coated onto ELISA plates and incubated overnight. 
Standards (a mixture of three CMV positive plasma samples) and plasma samples were added 
to the plates and incubated for one hour before washing. An anti-IgG horseradish peroxidase 
conjugated secondary antibody was then added to the plate to incubate for one hour. After 
washing, TMB substrate was added and the reaction stopped by addition of 1M HCL. The 
sample was assessed using an ELISA reader at 450nm. To determine CMV titres, mock 
values were first subtracted from lysate values. The data were then analysed in PRISM, and 
CMV titres were calculated with reference to the standard curve. Values above 10 were 
considered to be seropositive. To ensure accuracy, all samples were tested in duplicate. IL-6 
levels were analysed at the University of Glasgow using high sensitivity ELISA from R&D 
Systems. The minimum detectable dose ranged from 0.016-0.110 pg/mL (mean=0.039 
pg/mL). The intra-assay CV ranged from 6.9 to 7.8%, while the inter-assay coefficient of 
variance ranged from 6.6 to 9.6%.  
7.2.5 Childhood deprivation 
At the age 70 assessment, participants were asked to provide background demographic and 
environmental information about their childhood, specifically for when they were aged about 
11 years. Participants reported the number of people they lived with and the number of rooms 
in the house, which was used to calculate an overcrowding index (people/room). Participants 
also reported: whether their household had indoor or outdoor toilet facilities; their father’s 
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occupation to allow father’s social class to be coded (categorised from I, professional, to V, 
unskilled); and the number of years they spent in full-time, formal education.  
7.2.6 Statistical Analysis 
Descriptive statistics, exploratory analyses and general linear modelling (Analysis of 
Covariance; ANCOVA) were performed using SPSS version 18.0 for Windows (SPSS Inc., 
Chicago, Ill, USA). Missing values were excluded listwise for the ANCOVA analyses. For 
the ANCOVA, I constructed baseline models with the measures of neck muscle CSA and 
grip strength (right and left) as dependent (i.e. outcome) variables and CMV serostatus, CMV 
antibody titre and IL-6 level as independent variables, adjusting for age, gender and either 
height or weight, as a measure of body size, and the four measures of childhood deprivation. 
Total neck muscle CSA was found to correlate more strongly with weight (P<0.001), whereas 
both right and left grip strength correlated more strongly with height (p<0.001). Therefore I 
used the respective measures for adjustment in each of the analyses. 
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7.3 Results 
There were 866 participants in wave 2 of the LBC 1936 study; 448 men (mean age 72.48 
years, sd 0.70) and 418 women (mean age 72.51 years, sd 0.72). This represents 79.4% of the 
participants who attended at the first wave of testing aged 70 years (n=1091). Baseline data 
for neck muscle CSA, right and left grip strength, CMV serostatus, CMV antibody titre and 
IL-6 levels are shown in Table 7.1. Baseline data for measures of childhood deprivation are 
shown in Table 7.2. 
Table 7-1: Muscle size and strength, CMV and IL-6 baseline data 
Variable Statistic/Group Men Women 
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Table 7-2: Childhood deprivation baseline data 
Variable Statistic/Group Men Women 
Overcrowding 



















































I assessed associations between IL-6 and CMV antibody titre (using Spearman’s rho 
correlations) and CMV serostatus (using the Wilcoxon independent samples test) with age, 
height, weight, the muscle variables and the measures of childhood deprivation (Table 7.3). 
The association between CMV serostatus and indoor/outdoor toilet was analysed using the 
chi-square test. In men, being CMV seropositive or having a high CMV titre is associated 
with all the markers of childhood deprivation. In women, being CMV seropositive or having 
a high CMV titre is associated with a higher overcrowding index and lower social class of 
their father, and in addition a high CMV titre is associated with fewer years of formal 
education. In men, IL-6 levels only significantly correlate with the number of years of full 
time education (i.e. the more years of education the lower the IL-6 level), whereas in women 
all the markers of childhood deprivation correlate with a higher IL-6 level, except for the 
indoor/outdoor toilet question. 
If IL-6 was acting as mediator for CMV infection (i.e. CMV infection causes inflammation, 
raising IL-6 levels, which causes increased sarcopenia), I would expect a correlation between 
the two variables. However, the Spearman’s rho correlation between IL-6 and CMV antibody 
titre was non-significant (rho=0.06, p=0.07), while a Wilcoxon independent samples test for 
IL-6 and CMV serostatus was also non-significant (test statistic 1.28, p=0.20). 
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Table 7-3: Wilcoxon independent samples test (CMV serostatus) and Spearman’s rho correlations (CMV 
antibody titre and IL-6 level) (p values) 










































































































































































Indoor=1 or outdoor=2 















 Wilcoxon independent samples test statistic (and associated p values) for CMV status and 
all predictor variables except indoor/outdoor toilet age 11, which was analysed using the chi-
square test and shows *the odds ratio for being CMV seropositive if indoor toilet age 11 
b
 The columns for CMV titre and IL-6 titre show the Spearman’s rho correlation with the 
predictor variables (and the associated p value) 
General linear models (ANCOVAs) were then created for each muscle variable separately 
with each measure of immune status (ie CMV status, CMV titre and IL-6 level) before 
rerunning the models of CMV status and antibody titre adjusting for IL-6 status also. Tables 
7.4 and 7.5 present the results for the ANCOVA for CMV serostatus and neck muscle CSA, 
and IL-6 and grip strength. The p value gives the significance of the independent variable's 
association and the partial eta squared gives a measure of effect size, for which Cohen 
(Cohen, 1988) indicates the following: small ≥0.0099; medium ≥0.0588; large ≥0.1379. 
I found that CMV seropositivity was associated with a smaller neck muscle CSA in men but 
not in women (p = 0.028, partial eta squared = 0.01) (Table 7.4). In this model, lower weight 
and female sex were also associated with smaller neck muscle CSA. When this model was 
corrected for IL-6 level the effect remained significant (p = 0.047). The model for neck 
muscle CSA and CMV antibody titre showed no significant association, both with and 
without adjustment for IL-6 level, nor did the model with IL-6 as predictor variable, without 
adjusting for CMV infection. 
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Table 7-4: ANCOVA for CMV status and Total Neck Muscle CSA 
Source Sig. Partial 
Eta 
Squared 
Age in days at Wave 
2 
.38 <.01 








outdoor=2 toilet at 
age 11 
.88 <.01 
Father's job class as 
a number 
.70 <.01 











Weaker grip strength in both right and left hands was found to be associated with higher IL-6 
level; right grip strength p<0.00001, partial eta squared = 0.032 and left grip strength 
p<0.00001, partial eta squared = 0.027 (Table 7.5). The associations remain strongly positive 
even after adjustment for CMV status (p<0.0001) and CMV antibody titre (p<0.0001). In 
these models (shown in table 7.5), older age, shorter stature and female sex were also 
significantly associated with weaker grip strength in both hands. The models using CMV 
status and antibody titre alone were not significantly associated with grip strength in either 
hand. 
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Table 7-5: ANCOVA for IL-6 titre and Grip Strength Right and Left Hands 
 Right Hand Left Hand 






Age in days at Wave 
2 
.005 .01 .004 .01 
Height <.001 .08 <.001 .07 
Sex 
(Male=1, Female=2) 
<.001 .28 <.001 .34 
Overcrowding index 
age 11 
.72 .00 .25 .00 
Indoor=1 or 
outdoor=2 toilet at 
age 11 
.75 .00 .64 .00 
Father's job class as 
a number 
.95 .00 .65 .00 
No. of years of full-
time education 
.051 .01 .10 .00 
IL-6 Level <.001 .03 <.001 .03 
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7.4 Discussion 
This report used data from waves 1 and 2 of a population-based elderly cohort study, to 
investigate the relationship between latent CMV infection, IL-6 levels and sarcopenia, 
measured using neck muscle CSA and grip strength in both hands. There was no significant 
group difference for sex, age or CMV status and titre between those who participated in wave 
1 but not wave 2 (n=225) and those who participated in both waves (n=866) (independent t 
tests, p>0.05). I found that men who were seropositive for CMV antibody at age 70 years had 
a neck muscle CSA on average 4% smaller at age 73 than men who were seronegative. This 
effect remained positive whether adjusting for IL-6 level or not. It is well documented that 
muscle mass is lost at roughly 1% per year (Goodpaster et al., 2006, Visser et al., 2003), 
therefore being a man who is CMV seropositive in your 70s confers the same risks of low 
muscle bulk as being 4 years older. I did not detect a significant association in women 
between CMV serostatus and neck muscle CSA, or between CMV serostatus and grip 
strength in either hand. This may reflect the restricted range of social class seen within the 
LBC1936 cohort study, as the vast majority of participants in the study were from social class 
I to III in childhood (see table 7-2) and as mentioned previously CMV serostatus is associated 
with social class. Other studies have postulated that as CMV seropositivity is so common in 
older adults it may be more important to measure CMV antibody titre itself. However, I 
found no association between CMV antibody titre and either neck muscle CSA or grip 
strength. This result may indicate that latent CMV infection leads to increased muscle loss 
over an extended period, as CMV is commonly acquired in childhood, and the titre reflects 
the current situation, which may have less impact on muscle bulk. Longitudinal studies will 
be able to explore these relationships further. 
IL-6 levels were found to strongly predict grip strength in both right and left hands in men 
and women. IL-6 predicted 3.2% of the variance in right-sided grip strength and 2.7% of the 
variance in left-sided grip strength. These associations remained significant when adjusting 
for CMV serostatus or antibody titre. I found no significant association between IL-6 levels 
and neck muscle CSA. Therefore our findings do not support previous work that has found 
that IL-6 may act as a mediator by which latent CMV infection causes frailty (Schmaltz et al., 
2005, Wang et al., 2010). 
It is widely accepted that muscle size and strength do not decline in a parallel manner (Young 
et al., 1985, Skelton et al., 1994), therefore they are not purely a function of each other and it 
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may be that different factors cause decline in one parameter more than the other, as our 
results have shown. Similarly, a study looking at the effect of IL-6 levels on muscle found a 
significant association with decline in grip strength but not muscle mass (Schaap et al., 2006), 
again indicating parameter-specific effects. Also, these results are based on cross-sectional 
data and therefore do not necessarily reflect changes with age. Therefore it could be that 
individuals with latent CMV infection or lifelong raised IL-6 levels have always had 
smaller/weaker muscles, rather than an increased rate of decline in muscle mass or function 
with age. However, as sarcopenia is currently diagnosed using reference to peers or a healthy 
young population, having a lower peak muscle mass and function should still be considered 
risk factors for sarcopenia. Again, longitudinal studies may help elucidate these relationships 
further.  
The sole previous study I found that investigated the relationship between CMV status and 
grip strength only included women (Schmaltz et al., 2005). They found no significant 
difference in grip strength between seropositive and seronegative women. I have replicated 
this finding, but found a sex specific effect between male sex and CMV serostatus. There is 
evidence that men lose more muscle mass than women with age even after correction for 
body stature (Gallagher et al., 1997), therefore differing factors may play more or less of a 
role between the genders. Additionally, their muscles are larger to start with and therefore a 
reduction may be easier to detect. 
It is unclear how CMV might directly influence physical functioning, however latent CMV 
infection has been identified as an important component of an immune risk phenotype that is 
associated with immunosenescence, inflammation, and several latent health conditions 
observed with ageing (Pawelec et al., 2006). All these may represent possible contributory 
mechanisms to sarcopenia. For example, if CMV infection predisposes to cardiovascular 
disease this, in turn, might limit exercise and hence loss of muscle strength and size. Should 
our findings be confirmed, exploration of potential causal pathways will be warranted. 
Raised plasma IL-6 levels are known to increase proteolysis within muscle, by upregulating 
the proteolytic UPP pathway (Skipworth et al., 2006), however it is not known if the degree 
of increase seen with ageing is enough to cause atrophy and it is thought that proteolysis is 
not a major factor in normal ageing muscle (Tsujinaka et al., 1996). However, IL-6 may exert 
its effect through less direct routes. It is known that IL-6 causes anorexia, which would lead 
to decreased protein substrate. Also, IL-6 can both activate cortisol secretion and induce 
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11beta-hydroxysteroid type 1 expression, so it may exert its effect via the steroid pathway 
(Weber et al., 1997, Tomlinson et al., 2001). Furthermore, animal studies have demonstrated 
that inflammatory cytokines can induce muscle apoptosis by DNA fragmentation (Skipworth 
et al., 2006), though such models may not represent low level inflammatory changes 
occurring over a prolonged period.  
The narrow geographic, age and ethnic mix within the LBC 1936 cohort means this study 
may not prove generalisable. However, the narrow age range helps to reduce the powerful 
effect of advancing age on many of the parameters measured in this and other studies and 
which may have led to the impression of stronger direct relationships between co-associated 
variables than is actually the case. Additionally the size of the sample studied and the fact 
that I replicated results in some of our analyses found in other work is reassuring. The high 
correlation between the markers of childhood deprivation and CMV status were as predicted 
and raise the possibility that other correlates of childhood socioeconomic deprivation may be 
mediated by CMV infection, although this relationship may be less strong in other 
populations. Also, when studying sarcopenia it is important to consider rate of decline rather 
than solely cross-sectional measures. Therefore in the future, longitudinal studies will be 
crucial in developing an understanding of these relationships. Finally, the concept of a 
homogeneous model of sarcopenia, whereby all muscle throughout the body ages at the same 
rate, is proving increasingly unlikely to be valid with studies showing varying rates of muscle 
ageing around the body (Janssen et al., 2000, Gallagher et al., 1997, Gallagher and 
Heymsfield, 1998). Therefore whilst our measure of neck muscle CSA has previously been 
shown to correlate strongly to mid-thigh muscle CSA, it is important to consider that 
different factors may worsen or ameliorate muscle ageing in different muscle groups 
throughout the body. 
7.5 Conclusion 
In a large population-based elderly cohort study I found that men who were seropositive for 
CMV had smaller neck muscle CSA than men who were seronegative, and this effect was 
independent of IL-6 level. I also found that higher IL-6 levels, but not CMV levels, were 
strongly associated with lower grip strength in both hands in men and women. These 
associations were not attenuated when the model was adjusted for CMV serostatus or 
antibody titre. These findings support the hypothesis that there may be a relationship between 
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immunosenescence and muscle size and longitudinal studies are now required to investigate 
this relationship further. 
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Chapter 8 Investigating the relationship between 
plasma cortisol, urinary glucocorticoid 
metabolites, GR and 11βHSD1 mRNA 
expression in skeletal muscle, and 
muscle size and strength 
8.1 Introduction 
After investigating the role of immunosenescence and inflammation in the development of 
sarcopenia in the previous chapter, I next went on to research another possible underlying 
mechanism: glucocorticoid dysregulation. It is well known that glucocorticoids at 
pharmacological levels or in spontaneous Cushing’s syndrome cause myopathy, with a 
combination of muscle atrophy and dysfunction. However, it is believed that corticosteroids 
may cause greater atrophy of type 1 muscle fibres and a relative increase in number of type 
2b muscle fibres (Rebuffe-Scrive et al., 1988, Krotkiewski and Bjorntorp, 1986, 
Danneskiold-Samsoe and Grimby, 1986), whereas in sarcopenia there is no change in the 
ratio between type 1:type2b muscle fibre number with age (Sato et al., 1984, Mitchell et al., 
2012). However, these studies all looked at the effect of cortisol within specific conditions 
(eg obesity, Cushing’s disease or pharmacological studies of the effects of corticosteroids), 
therefore the role of minor elevations in endogenous corticosteroids in the development of 
sarcopenia out with these conditions now requires further study. 
Glucocorticoids are believed to cause myopathy through a combination of increased protein 
breakdown (particularly through the ubiquitin-proteasome system) (Schakman et al., 2008), 
decreased protein synthesis (by inhibiting transport of amino acids into muscle and inhibiting 
the action of insulin and IGF-1) (Shah et al., 2000) and decreasing production of IGF-1 and 
myostatin (Schakman et al., 2008). In the context of sarcopenia, this mechanism could occur 
via elevated circulating glucocorticoids due to age-related hypothalamic-pituitary-adrenal 
(HPA) axis dysregulation. Alternatively, it could occur selectively within the muscle, by 
increased activity of the glucocorticoid receptor (GR) or the enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11βHSD1). 11βHSD1 converts inactive cortisone to active cortisol 
and is known to be present and biologically active in human muscle as well as many other 
tissues (Jang et al., 2006, Whorwood et al., 2001, Hughes et al., 2012). Indeed a recent study 
by Tiganescu et al found that elevated 11βHSD1 activity was increased in skin biopsies from 
older adults compared to younger adults and that this increased activity was associated with 
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markers of skin ageing (eg dermal atrophy and deranged collagen structural organization) 
(Tiganescu et al., 2013). Establishing links between GC and sarcopenia could lead to novel 
therapies, as several 11βHSD1 inhibitors are currently in clinical development for type 2 
diabetes and other degenerative diseases, including cognitive dysfunction (Hughes et al., 
2008). 
There is some evidence of an association between increased plasma and salivary cortisol and 
lower muscle mass and strength but these data are inconsistent (Waters et al., 2008, Peeters et 
al., 2008, Izquierdo et al., 2001, Gardner et al., 2011). Glucocorticoid metabolites in a 24 
hour urine sample may be more informative than plasma cortisol levels since they reflect 
glucocorticoid status over the diurnal cycle. Additionally ratios of the metabolites can be used 
as an index of peripheral 11βHSD activity (Best and Walker, 1997). However, no studies to 
date have examined the relationship between urinary glucocorticoid metabolites and 
sarcopenia. Similarly, there are no published data examining the relationship between GR and 
11βHSD1 expression and muscle loss and function in older adults. Importantly, expression of 
11βHSD1 and GR mRNA has been shown to reflect glucocorticoid activity, for example 
there is a correlation between 11βHSD1 mRNA expression and enzyme function (Wake et 
al., 2003).  
The aim of this study was to investigate the relationship between plasma and urinary 
glucocorticoid metabolites and levels of mRNA encoding GR and 11βHSD1 in skeletal 
muscle, with muscle size and strength. I hypothesized that increased glucocorticoid signalling 
in skeletal muscle acting through GR by, (a) elevated circulating cortisol, (b) increased 
expression of 11βHSD1 or (c) increased expression of GR, is associated with reduced muscle 
size and strength.  
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8.2 Methods 
8.2.1 Participants 
Participants were healthy volunteers recruited at two sites in Scotland: young and older men 
were recruited in Aberdeen (Group 1) and older men and women were recruited in Edinburgh 
(Group 2). This allowed us to test for possible age and gender effects. Participants were 
defined as healthy after applying previously published health selection criteria to the 
responses to a questionnaire (Greig et al., 1994). Existing samples were available from two 
nearby cities in Scotland so these were used for analysis, rather than beginning a new de novo 
cohort collection. No comparisons were made between these two independent cohorts. 
8.2.2 Ethics Statement 
Written informed consent was obtained and all procedures received local ethical committee 
approval. In Edinburgh this was by the Lothian Local Research Ethics Committee 02 and in 
Aberdeen this was by the North of Scotland Research Ethics Committees. The study 
conformed to the standards set by the Declaration of Helsinki.  
8.2.3 Anthropometry 
Body weight was measured with participants in light clothing using a beam scale (Seca, UK). 
Height was measured using a wall mounted stadiometer. 
8.2.4 Muscle function 
Maximum voluntary isometric knee extensor strength was measured using an established 
method (Edwards and Hyde, 1977). Following instruction, the participant made a maximum 
voluntary contraction (Newtons) which was held for 5 seconds. Three separate measurements 
were obtained and the highest value was used in subsequent analysis.  
8.2.5 Muscle size 
Mid-thigh quadriceps cross-sectional area (CSA) was measured using a 1.5T MR scanner 
(Phillips Gyroscan Intera). T1-weighted axial images were taken with the isocentre of the 
magnetic field located at the mid-femur point which was landmarked prior to the scan 
according to International Standards of Anthropometric Assessment (ISAK) guidelines 2001. 
Imaging parameters were: slice thickness 10 mm; acquisition matrix 512 x 512; echo time 
(TE) 15 ms; repetition time (TR) 425 ms; and flip angle 90°. The CSA of the quadriceps was 
quantified using Analyze 8.0 (Mayo Clinic, Rochester, USA) according to a previously 
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published technique (Gray et al., 2011). Two of the subjects from Group 2 did not undergo 
MRI due to claustrophobic symptoms.  
8.2.6 Plasma cortisol 
Blood samples were obtained from participants in the morning after overnight fast (mean 
time 0945h, range 0915-1030h). Plasma cortisol was measured by competitive immunoassay 
with direct chemiluminescent technology using the Bayer Advia Centaur method (see 
http://labmed.ucsf.edu/labmanual/db/resource/Centaur_Cortisol.pdf). 
8.2.7 Quadriceps muscle biopsy 
Quadriceps femoris samples were obtained from the region of vastus lateralis via 
percutaneous needle biopsy using a Bergstrom needle (Bergström, 1975). The biopsy was 
obtained in a sterile environment by sharp dissection under local anaesthetic using 1% 
lidocaine. The samples were then snap frozen in liquid nitrogen and stored at -80 
o
C before 
analysis (Stephens et al., 2010). 
8.2.8 RNA Isolation 
Total RNA was isolated from quadriceps muscle biopsies using the Qiazol reagent (Qiagen, 
Crawley, UK) and miRNeasy RNA isolation columns (Qiagen, Crawley, UK). Briefly 
biopsies were homogenised in 1400ul or 700ul Qiazol depending on the size of the tissue 
sample using a Polytron PT1200E (Kinematica AG). Total RNA was isolated from the 
homogenised muscle using miRNEasy columns with an on column DNAse treatment step 
using the RNase-Free DNase Set (Qiagen, Crawley, UK). After elution from the column into 
30ul nuclease free H2O, RNA was quantified using the Nanodrop instrument (Labtech, UK) 
and quality assessed using the Bioanalyzer (Agilent, UK). All samples had 260/280 ratios 
above 1.8, and RIN scores above 7.5. 
8.2.9 cDNA preparation and qPCR 
RNA samples were converted to cDNA using the Ovation RNA Amplification kit (Nugen, 
Netherlands). RNA was diluted to 10ng/ul and 50ng total RNA was used in the amplification 
reaction carried out according to the manufacturer’s instructions, yielding between 3ug and 
11ug cDNA. For qPCR, cDNA was diluted to ~50ng/ul. Quantitative RT-PCR reactions were 
run, in triplicate, on an Applied Biosystems Step One Plus system. The reaction mix was 
POWER SYBR Green x2 Master mix 12.5ul, forward primer (10uM) 1ul, reverse primer 
(10uM) 1ul, H2O 9.5ul and cDNA 1ul. Reaction conditions were 95
o
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15s, 60
o





values were examined and within triplicates any value greater than 0.3 Ct were removed 
before means were calculated. Data were then analysed using the delta Ct method with HPRT 
as a normaliser. After normalisation data were inverted and scaled such that the largest value 
for each gene was set to 100. 
Primer sequences used were NR3C1 FP – CTGTCGCTTCTCAATCAGACTC; RP – 
GCATTGCTTACTGAGCCTTTTG; 11βHSD1 FP – AGGCTGCTGCCTGCTTAGGA; RP 
– AGCCCCAGAATGGGGAGGAGA; HPRT FP – TGACACTGGCAAAACAATGCA; 
RP- GGTCCTTTTCACCAGCAAGCT. HPRT was chosen as a normaliser as preliminary 
analysis of housekeeping gene performance showed HPRT to be stable across samples and 
expressed at a similar level to genes of interest compared to b-actin, GAPDH, b2M and 18S. 
8.2.10 Urinary glucocorticoid metabolism 
24 hour urine samples were collected to quantify urinary glucocorticoid metabolites using gas 
chromatography electron impact mass spectrometry following solid phase extraction, 
hydrolysis of conjugates and formation of their methoxime-trimethylsilyl derivatives, as 
described previously (Best and Walker, 1997).  
Two composites of the data were used in subsequent analyses. Firstly, total urinary steroids, 
comprising the sum of 5β-tetrahydrocortisol (5βTHF), 5α-tetrahydrocortisol (5αTHF), the 
main urinary metabolites of cortisol, and tetrahydrocortisone (THE), the main urinary 
metabolite of cortisone (total urinary GC = 5βTHF + 5αTHF + THE). Secondly, an indirect 
indicator of systemic 11βHSD activity, comprising the ratio of 5βTHF and 5αTHF to THE 
(ratio of cortisol to cortisone metabolites = (5βTHF + 5αTHF)/THE).  
8.2.11 Statistical Analysis 
Statistical analysis was performed using SPSS version 18.0. Bivariate correlations were 
performed using Spearman’s rho to allow analysis of the non-parametric variables. Forced 
entry multiple linear regression was performed and the data from the two groups were 
analysed separately, when possible, to test reproducibility. Due to the large difference in age 
between the older and younger groups, age was analysed as a binary variable in the 
multivariate regression. Group 1 (n=52) had 80% power at the p=0.05 level to detect a 
correlation of r=0.38 and Group 2 (n=30) had 80% power at the p=0.05 level to detect a 
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correlation of r=0.49. In view of the power calculations and the exploratory nature of the 
study, adjusting for multiple hypotheses testing was not deemed to be appropriate. 
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8.3 Results 
In total, 82 participants were recruited. Table 8.1 shows numbers of participants and their 
age, height, BMI, and the main outcome variables for each group. Independent t tests found 
significant sex and age related differences for height, muscle size and muscle strength but not 
for BMI or any measure of glucocorticoid status (Table 8.1).  
Table 8-1: Group characteristics 





















Age (years) 22.2 (1.7) 70.2 (4.4) <0.001 79.1 (3.4) 80.1 (3.7) n/s 
Height (cm) 177.6 (6.7) 171.9 (5.4) 0.001 171.3 (6.1) 157.6 (5.9) <0.001 
BMI (kg/m
2

























1.12 (0.37) 1.15 (0.45) n/s 1.28 (0.79) 0.81 (0.49) n/s 
Plasma cortisol 
(nmol/litre) 
- -  349 (106) 321 (65) n/s 
GR mRNA - -  59.4 (24.5) 58.3 (18.8) n/s 
11βHSD1 
mRNA 
- -  25.3 (19.7) 32.2 (31.8) n/s 
Data are mean (SD) except *non-parametric data therefore median and IQ range shown 
a. Independent t test between younger and older men in Group 1 
b. Independent t test between men and women in Group 2 
n/s = not significant 
Table 8.2 shows bivariate correlations, which confirmed that measures of body size (height 
and BMI) were significantly associated with muscle size and strength.  
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Table 8-2: Bivariate correlations including muscle size and strength 
 Group 1 muscle 
size 
Group 1 muscle 
strength 
Group 2 muscle 
size 





















-.09 -.05 .35 .16 
Plasma cortisol - - -.20 -.31 
GR mRNA - - .11 .04 
11βHSD1 
mRNA 
- - -.15 -.29 
Data are Spearman’s Rho Correlation Coefficients 
**p<0.01 (2-tailed) 
*p<0.05 (2-tailed) 
Therefore in constructing multivariate models I adjusted for body size as well as age and 
gender, which had been selected a priori due to their accepted relationships with muscle size 
and strength. BMI correlated with total urinary GC (rho=0.60, p=0.0005) and plasma cortisol 
(rho= -0.52, p=0.006), whereas height did not significantly correlate with total urinary GC or 
plasma cortisol (p>0.05 for both). Therefore in multivariate analyses with urinary GC and 
plasma cortisol as predictor variables I adjusted for potential confounding by BMI, gender 
and age (see Tables 8.3 & 8.4). Neither BMI nor height correlated with the muscle GR or 
11βHSD1 mRNA expression levels. Therefore because height correlated more significantly 
with muscle size and strength than BMI (Table 8.1), I adjusted for height and gender for the 
multivariate analyses with muscle GR and 11βHSD1 mRNA as predictor variables (Table 
8.4). 
Plasma cortisol was measured in Group 2 only. There were no significant association 
between fasting morning plasma cortisol and muscle size and a non-significant negative trend 
with muscle strength (β -0.35, p=0.08) (Table 8.4). In both groups neither total urinary 
glucocorticoids nor the ratio of cortisol:cortisone metabolites were associated with muscle 
size or strength (Tables 8.3 & 8.4).  
I used muscle biopsies from a subset of Group 2 to examine the relationships between GR 
and 11βHSD1 mRNA levels and muscle size and strength. Increased 11βHSD1 mRNA was 
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significantly associated with lower muscle strength after adjustment for sex and height (β -
0.35, p=0.039, n=22: 12 men mean age 79.8 (sd 3.6) and 10 women, mean age 80.5 (sd 4.1)). 
There were no significant relationships between GR mRNA and muscle size or strength, or 
between 11βHSD1 mRNA and muscle size (Table 8.4). 
Table 8-3: Regression coefficients for the glucocorticoid measures in models predicting muscle 
size/strength (Group 1) 
Glucocorticoid Measure             Muscle Size 
Beta (sig, n) 
   Muscle Strength 
Beta (sig, n) 
Total Urinary GC
a
 -0.10 (p=0.24, 52) <-0.01 (p=0.97, 52) 
THFs:THE
a
 <0.01 (p=0.95, 52) 0.04 (p=0.66, 52) 
a
 adjusting for age and BMI 
Table 8-4: Regression coefficients for the glucocorticoid measures in models predicting muscle 
size/strength (Group 2) 
Glucocorticoid Measure             Muscle Size 
Beta (sig, n) 
   Muscle Strength 
Beta (sig, n) 
Plasma Cortisol
a
 -0.12 (p=0.38, 25) -0.35 (p=0.08, 27) 
Total Urinary GC
a
 0.23 (p=0.10, 28) 0.18 (p=0.38, 30) 
THFs:THE
a
 0.08 (p=0.47, 28) 0.10 (p=0.55, 30) 
GR mRNA
b
 0.03 (p=0.84, 20) 0.04 (p=0.81, 22) 
11βHSD1 mRNA
b
 -0.17 (p=0.17, 20) -0.35 (p=0.04, 22) 
a
 adjusting for gender and BMI 
b
 adjusting for gender and height 
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8.4 Discussion 
This study investigated the relationship between circulating and tissue indices of 
glucocorticoid status and muscle size and strength in two groups. Group 1 allowed 
comparison of older with younger men. There were no age differences in urinary cortisol 
metabolites, although muscle biopsies were not obtained in this group so I did not test the 
effect of ageing per se on muscle mRNA levels. Group 2 allowed comparison of older men 
with older women. There were no differences in plasma cortisol, urinary glucocorticoid 
metabolites or muscle GR or 11βHSD1 mRNA levels between the sexes in this relatively 
small sample. Within each group I explored associations between glucocorticoid variables 
and muscle size and strength after adjustment for potential confounding effects of age, gender 
and body size as appropriate. In these analyses, indices of HPA axis function, including 
morning plasma cortisol and 24 h urinary cortisol metabolite excretion, were not associated 
with muscle strength or size. Additionally urinary cortisol:cortisone metabolite ratios, which 
principally reflect 11βHSD activity in the major organs of liver and kidney, were not 
associated with muscle strength or size. However, in muscle itself, higher levels of mRNA 
encoding the cortisol-amplifying enzyme 11βHSD1 were associated with reduced muscle 
strength. This finding is consistent with the hypothesis that enhanced glucocorticoid 
signalling within muscle contributes to sarcopenia.  
To our knowledge there have been no previous investigations of muscle glucocorticoid 
signalling in human sarcopenia. I hypothesized that because 11βHSD1 and GR regulate the 
exposure of target tissues to glucocorticoids, increased expression of 11βHSD1 and GR could 
therefore contribute to sarcopenia in the absence of an increase in circulating GCs. I found 
that increased 11βHSD1 mRNA expression in muscle is associated with lower muscle 
strength. This is consistent with this hypothesis. I did not find a relationship between 
11βHSD1 mRNA expression and muscle size, but in normal ageing, muscle strength is 
reported to deteriorate more rapidly than muscle size; suggesting a decline in force generating 
capacity with age (Goodpaster et al., 2006, Young et al., 1985). A number of contributory 
mechanisms have been proposed to explain this (eg increased muscle fibre stiffness); our data 
suggest a possible role for increased GC action at the muscle level. GC may affect strength 
more than muscle mass by exacerbating glycation of the myosin molecule, which appears to: 
slow the intrinsic shortening velocity of the muscle fibre; decrease force per cross-sectional 
area; and increase intramuscular collagen cross-linking which can cause muscle stiffness 
(Hook et al., 2001, Haus et al., 2007). In addition, GC may cause mitochondrial dysfunction 
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and reduced oxidative capacity, which would similarly result in a decrease in force generating 
capacity (Mitsui et al., 2002). Furthermore an association between insulin resistance and 
sarcopenia has been found (Haus et al., 2007, Janssen and Ross, 2005) and there is evidence 
that the morphological changes seen with steroid induced myopathy may be associated with 
insulin resistance, as indicated by low glycogen synthase activity, indicating a further 
possible pathway (Rebuffe-Scrive et al., 1988). 11βHSD1 is known to act locally within 
muscle, resulting in measurable production of cortisol in samples from veins draining human 
muscle, and therefore increased 11βHSD1 mRNA expression is likely to increase 
myocellular cortisol levels thereby mediating these effects (Hughes et al., 2012).  More 
research with larger samples and with a wider range of severity of sarcopenia is required to 
investigate the relationship between 11βHSD1 expression and activity and muscle ageing.  
I found no relationship between GR mRNA expression and muscle mass or strength. It is 
possible that polymorphisms of GR modulate the effect of GC on muscle, and that level of 
expression is less important than genotype. For example male carriers of the ER22/23EK 
polymorphism in GR, which is associated with relative GC resistance, have greater muscle 
mass and strength than non-carriers (van Rossum et al., 2004).  
There are no published studies investigating the association between urinary GC and muscle 
size or strength. However, there are studies reporting associations between salivary and 
plasma GCs and muscle size and function. In a previous study of men and women >75 years 
higher salivary, but not serum, cortisol was associated with lower appendicular skeletal mass 
(ASM) measured using DEXA (Waters et al., 2008). Similarly, in a large longitudinal ageing 
study higher salivary but not serum cortisol predicted loss of grip strength over 6 years, but 
there was no association of cortisol with baseline grip strength or ASM (Peeters et al., 2008). 
A smaller study including both young and older men found that increased serum cortisol 
correlated with lower knee extensor strength in both age groups and with quadriceps cross-
sectional area only in the older group (Izquierdo et al., 2001). The Caerphilly Prospective 
Study, which included measurements of cortisol status and physical performance over 20 
years, found that higher mid-life plasma cortisol predicted faster walking speeds in older age, 
although salivary cortisol did not correlate with walking speed or balance in older age 
(Gardner et al., 2011). Collectively, these studies provide contradictory evidence relating 
salivary or plasma cortisol to muscle strength and mass. Taken with our data, there does not 
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appear to be a consistent association between activation of the HPA axis and age-associated 
sarcopenia. These negative findings are important in excluding this plausible hypothesis. 
Some limitations of this study should be acknowledged. I examined the effect of GC on 
ageing muscle using a younger and older group of volunteers separated in age by nearly 50 
years and by many lifestyle factors; a problem inherent to cross-sectional studies. 
Longitudinal studies investigating rate of decline of muscle mass and function and measures 
of GC would be more informative but are difficult to conduct due to the slow decline of 
muscle mass and strength during ageing. The sample sizes were relatively modest, 
particularly with respect to muscle GC data which were obtained from only a subset of Group 
2 who underwent muscle biopsy. It has also been shown that sarcopenia affects the upper and 
lower limbs differently and our study investigated only the lower limbs (Janssen et al., 2000, 
Aniansson et al., 1983, Aniansson et al., 1986, Aniansson et al., 1992). Also, our healthy 
older volunteers constituted a sample which may be not fully representative of the ageing 
population; this may influence the generalisability of our results. Finally, I used mRNA 
expression as a marker of activity rather than a direct measure of 11βHSD1 activity, however 
several studies have found correlations between mRNA expression and enzyme activity in 
rodents and humans, so I regard mRNA as an appropriate indicator of 11β-HSD1 activity 
(Wake et al., 2003). 
8.5 Conclusion 
Sarcopenia is one of the major causes of frailty and disability in older people. It is associated 
with greatly increased risk of loss of independence and institutionalization. In this novel 
investigation of healthy old and young people I found a significant association between 
increased muscle 11βHSD1 expression and lower quadriceps strength. I found no significant 
associations between plasma cortisol, urinary GC metabolites or GR expression and muscle 
mass or strength. Longitudinal studies are now required to investigate these relationships and 
to further explore the possibility of 11βHSD1 inhibitors as a novel treatment for sarcopenia. 
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Chapter 9 A novel technique to measure 11-
hydroxysteroid dehydrogenase activity 
in human brain in vivo 
9.1 Introduction 
In the last two chapters I investigated potential underlying mechanisms for the development 
and progression of sarcopenia. In the latter chapter the role of glucocorticoid dysregulation 
was researched. Within the field of cognitive ageing there has been considerable interest in 
the role of glucocorticoid dysregulation, particularly with regard to 11beta-hydroxysteroid 
dehydrogenase type 1. The 11beta-hydroxysteroid dehydrogenases (11βHSDs) are 
intracellular enzymes that catalyse interconversion of inactive cortisone and active cortisol; 
11HSD type 1 is a predominant reductase, regenerating cortisol from cortisone, while 
11HSD type 2 is an exclusive dehydrogenase, inactivating cortisol to cortisone. An 
extensive literature documents the role of the 11HSDs in regulating intracellular 
glucocorticoid concentrations and hence modulating tissue-specific activation of 
corticosteroid receptors (reviewed in (Seckl and Walker, 2001, Stewart and Krozowski, 
1999)). 11HSD1 amplifies glucocorticoid action in liver, adipose tissue, inflammatory cells 
and vasculature, providing a therapeutic target for inhibition in type 2 diabetes. 11HSD2 
limits cortisol action, and thereby facilitates aldosterone action in the distal nephron and a 
few other sites, explaining the mineralocorticoid excess state which ensues when 11HSD2 is 
inhibited by liquorice.  
Both 11HSD isozymes also contribute to systemic turnover of cortisol. Activity of the two 
isozymes has been quantified in humans using stable isotope (deuterated) glucocorticoid 
tracers (figure 9.1). Production of cortisone can be measured by the rate of dilution of 1,2-
[
2
H]2-cortisone (d2-cortisone) by cortisone, and is inhibited by liquorice (Hughes et al., 
2012). A more complex tracer is used to measure regeneration of cortisol by 11HSD1: 
9,11,12,12-[
2
H]4-cortisol (d4-cortisol) is infused and production of cortisol is measured by 
the rate of dilution of d4-cortisol by cortisol (an index of net cortisol production from all 
sources, including the adrenal gland) and by 9,12,12-[
2
H]3-cortisol (d3-cortisol, a specific 
measure of cortisol regeneration by 11HSD1) (Andrew et al., 2002). Using these tracers in 
combination with selective venous catheterisation and measurement of blood flow has 
allowed quantification in humans of cortisol-cortisone interconversion in splanchnic (Hughes 
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et al., 2012, Basu et al., 2004, Andrew et al., 2005), subcutaneous adipose (Hughes et al., 
2012, Stimson et al., 2009) and skeletal muscle (Hughes et al., 2012) circulations, and 
exclusion of significant 11HSD activity in the myocardium (Iqbal et al., 2014). These 
studies reveal rapid shuttling between cortisol and cortisone such that in healthy men at rest, 
remarkably, the magnitude of extra-adrenal regeneration of cortisol by 11HSD1 is greater 
than the magnitude of adrenal cortisol secretion. They also suggest, surprisingly, that 
11HSD1 may catalyse both reductase and dehydrogenase activity in vivo, resulting in 
‘recycling’ between cortisol and cortisone even in tissues where 11HSD2 is not expressed 
(Hughes et al., 2012). 
11HSDs may also play key roles in the brain (Yau and Seckl, 2012). 11βHSD2 is expressed 
in the developing but not the adult brain (Brown et al., 1996). 11βHSD1 is expressed more 
widely in the adult brain, and notably in the prefrontal cortex, hippocampus and cerebellum, a 
distribution confirmed in humans by a small study (n=4) (Sandeep et al., 2004). Larger post 
mortem studies on human brain would now be useful to validate this finding. Increased local 
regeneration of cortisol by 11HSD1 may cause glucocorticoid-dependent neurotoxicity and 
hence contribute to cognitive ageing and dementia, while inhibition of 11HSD1 has been 
proposed as a therapeutic strategy to treat age- and dementia-associated cognitive 
dysfunction. In mice, 11βHSD1 levels in the hippocampus and parietal cortex rise with age 
and correlate with impaired cognitive performance, while transgenic overexpression of 
11HSD1 in the forebrain accelerates age-associated cognitive decline (Holmes et al., 2010). 
Conversely, 11βHSD1 knockout mice are protected from age-related learning impairment 
(Yau et al., 2001, Sooy et al., 2010). Moreover, selective 11HSD1 inhibitors, after either 
systemic or intracerebroventricular administration, improve cognitive function in aged mice 
(Sooy et al., 2010). Indeed in humans, the non-selective 11βHSD inhibitor carbenoxolone 
improved cognitive performance in healthy elderly and diabetic men (Sandeep et al., 2004). 
However, a recent Phase II clinical trial of a selective 11HSD1 inhibitor, ABT384, in 
patients with mild-moderate Alzheimer’s disease was halted prematurely because of lack of 
efficacy (Marek et al., 2014). It is uncertain whether this reflected selection of patients whose 
cognitive dysfunction is no longer responsive to reducing cortisol action, or inadequate 
inhibition of brain 11HSD1 by ABT384. 
Against this background, quantification of brain 11HSD1 activity in vivo in humans would 
be highly desirable. Here, we aimed: (i) to determine whether, as a major organ by mass, 
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brain 11HSD1 contributes to cortisol/cortisone turnover in vivo; (ii) to establish whether 
11HSD1, as the only 11HSD isozyme expressed in adult brain (Sandeep et al., 2004), 
catalyses only regeneration of cortisol or also recycling between cortisol and cortisone; (iii) 
to provide a tool with which to quantify changes in human brain 11HSD1 activity with 
dementia, and to use as a pharmacodynamics biomarker to quantify enzyme inhibition during 
clinical development of selective 11HSD1 inhibitors for treating dementia. We therefore 
extended the previous studies using arteriovenous sampling with stable isotope tracer 
infusions in vivo to quantify 11βHSD activities in human brain.  
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Figure 9-1: Stable isotope tracers for measuring cortisol-cortisone interconversion by 11-HSDs 
 
 
11-HSD2 is a unidirectional enzyme catalysing the dehydrogenase conversion of 
cortisol to cortisone. 11-HSD1 is a potentially reversible enzyme catalysing 
interconversion of cortisol and cortisone, predominantly in the reductase (cortisone to 
cortisol) direction. The shaded boxes on left and right represent the circulating pools of 
cortisol and cortisone, respectively. Production of cortisone can be measured by infusing 
a tracer, d2-cortisone, into the cortisone pool and measuring its dilution by cortisone. 
Similarly, production of cortisol can be measured by infusing a tracer, d4-cortisol, into 
the cortisol pool. When d4-cortisol is metabolised by 11-HSD2, the deuterium in the 
11 position is removed, producing d3-cortisone; when this d3-cortisone is converted 
back to cortisol by 11-HSD1 it is highly unlikely that a deuterium rather than a proton 
will be reincorporated, so that d3-cortisol is produced. Dilution of d4-cortisol with d3-
cortisol therefore indicates 11-HSD1 reductase activity. 
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9.2 Materials and Methods 
9.2.1 Participants 
Participants were recruited through advertisements in the local press and around the 
University campus. Participants were healthy male volunteers between 18-70 years old. 
Exclusion criteria were: glucocorticoid medication (by any route of administration) within the 
past three months; diabetes mellitus, cerebrovascular disease or other significant chronic 
illness; history of recent heavy alcohol or illegal drug use; current use of any 
immunosuppressive medication; abnormal screening liver, thyroid, renal or coagulation 
function (ie INR>1.5 or platelets <50 x 10
9
/L) or abnormal full blood count or random blood 
glucose; research participant in the previous 3 months; any contraindication to magnetic 
resonance (MR) imaging. The study complied with the Declaration of Helsinki; ethical 
approval was obtained from the local Research Ethics Committee (Scotland A REC, 
reference 12/SS/0079) and all participants gave written informed consent. 
9.2.2 Reagents 
Reagents were obtained from Sigma (Poole, U.K.), Steraloids (Newport, RI), or VWR 
(Lutterworth, UK). 1,2 [
2
H]2-cortisone (d2-cortisone) and 9,11,12,12 [
2
H]4-cortisol (d4-
cortisol) were from Cambridge Isotope Laboratories (Andover, MA). Solvents were high-
performance liquid chromatography grade from Fisher Scientific (Loughborough, UK).  
9.2.3 Clinical protocol 
Screening tests were performed within the 2 weeks prior to the procedure. On the day of the 
study subjects attended the Clinical Research Facility around 0830h. They were allowed to 
eat a light breakfast at home but were only allowed water after their arrival at the research 
facility. They first underwent an ECG-gated phase contrast MR neck scan, which lasted 20-
30 minutes. After this, a cannula was inserted into the left antecubital fossa and blood was 
taken to measure baseline endogenous steroids and their background isotopomers. At t=-
5mins a 0.7mg loading bolus of d4-cortisol was given intravenously, followed by an infusion 
at 0.35mg/hour (15.94 nmol/min) at t=0mins. A cannula was inserted into a vein in the 
dorsum of the right hand in a retrograde direction and when required the hand was placed in a 
hot box at 60
o
C to arterialise the blood. Arterialisation of the blood was accepted if the 
oxygen saturation was >98%.  
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A jugular bulb cannula was inserted in the dominant internal jugular vein (assessed by MR 
venography) under ultrasound guidance. Placement was checked using a plain lateral C-spine 
x-ray: the tip of the catheter was visualised to ensure it was above the second cervical 
vertebra (Ali et al., 2001). The oxygen saturation of the blood was checked to ensure it was 
<85%.  
At t=145 min a 76.0μg bolus of d2-cortisone was administered intravenously, followed by an 
infusion at 105.3μg/hour (4.88 nmol/min). From t=180 min four sets of simultaneous blood 
samples were taken from the arterialized and jugular bulb cannulae at ten minute intervals 
(t=180, 190, 200 and 210 mins) into Lithium heparin and plasma separated and stored at -
80°C until analysis. 
Figure 9-2: Schematic diagram depicting set up of: subject, tracers and arteriovenous sampling with hot box 
 
9.2.4 Magnetic resonance scanning 
The MR imaging was performed with participants in the supine position on a 1.5 Tesla MR 
imaging unit (Signa HDxt, GE Healthcare, Milwaukee, USA) at the Brain Research Imaging 
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Centre (www.bric.ed.ac.uk). An eight channel neurovascular array coil was used. A non-
contrast MR angiogram of the carotids from the level of the exterior auditory meatus down to 
the angle of the mandible was performed, followed by an MR venogram over the same area 
with a saturation band over the inferior aspect of the slices. The MR venogram was used to 
select the level for the ECG-gated phase-contrast MR scan by measuring a quarter of the way 
down from the jugular bulb to where the facial vein enters the internal jugular vein; axial 
images were taken perpendicular to the table. This level was chosen to ensure blood flow was 
measured in the vessel before any of the tributaries entered, the facial vein being the first, and 
to avoid measuring flow dynamics in the bulb itself, which may not be representative of the 
rest of the vessel as there may be some pooling of blood where it first enters the bulb. Sixteen 
phase and magnitude images were taken at this level over one cardiac cycle. The flip angle 
was 25°, bandwidth 15.63 KHz, echo time (TE) 6ms, repetition time (TR) 25 ms and 
encoding velocity (Venc) 100cm/s. Data were checked at the point of acquisition for any 
aliasing artefact. The field of view (FOV) was 25.6 cm×25.6 cm and slice thickness 5 mm. 
These images took approximately 8 minutes to acquire per patient, depending on heart rate. 
The image analysis software Medis Q flow (Medis medical imaging systems; Leiden, the 
Netherlands) was used to calculate jugular venous blood flow in mL/min on the side which 
was cannulated.  
9.2.5 Laboratory analysis 
Steroids (cortisol, d4-cortisol, 9,12,12 [
2
H]3-cortisol (d3-cortisol), cortisone and d2-cortisone) 
were quantified using liquid chromatography–tandem mass spectrometry (LC-MS). An 
internal standard solution (0.5microg epicortisol (Steraloids; Newport, RI), 0.25microg 
2,2,4,6,6,9,12,12 [
2
H]8-cortisone (d8-cortisone, Santa Cruz Biotechnology; Heidelberg, 
Germany) and 0.25microg 2,2,4,6,6,17A,21,21 [
2
H]8-corticosterone (d8-corticosterone, 
Cambridge Isotope Laboratories; Andover, MA) with 9µL methanol) was added to 1.5 mL of 
plasma, before 15 mL of chloroform was added for extraction of the steroids. The organic 
phase was then reduced to dryness under oxygen free nitrogen at 60
o
C before being 
reconstituted in mobile phase (acetonitrile: water (35:65) with 0.1% formic acid). Samples 
were injected on to a Sunfire C18 column (150mm x 4.6mm x 5µm), with a column 
temperature of 10
0
C and a mobile phase flow rate of 1.5 mL/min using an Acquity Ultra 
Performance Liquid Chromatograph (Waters, Manchester, UK) coupled to a Qtrap 5500 mass 
spectrometer (AB Sciex, Warrington, UK). Ionization was achieved in positive electrospray 
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mode. The following transitions (precursor→product mass-to-charge ratios) used were as 
follows: cortisol (363→121), d2-cortisol (365→121), d3-cortisol (366→121), d4-cortisol 
(367→121), cortisone (361→77), d3-cortisone (364→164) and d2-cortisone (363→165). 
Steroid concentrations and tracer/tracee ratios were calculated from calibration curves and 
corrected for background isotopomer enrichments as described previously (Boonen et al., 
2013). 
9.2.6 Data analysis and kinetic calculations 
Whole-body rate of appearance (Ra) of cortisol, d3-cortisol and cortisone were calculated by 
dividing the rate of tracer infusion by the relevant tracer/tracee ratio (d4-cortisol/cortisol, d4-
cortisol/d3-cortisol and d2-cortisone/cortisone, respectively) (Hughes et al., 2012, Andrew et 
al., 2002). Brain tissue production of cortisol was calculated using data from arterial (A) and 
internal jugular vein (V) samples and corrected for cerebral blood flow using equation 1. 
Brain tissue production of d3-cortisol and cortisone were also calculated with equation 1, 
substituting arterial concentrations of d3-cortisol or cortisone and the relevant arterial and 
venous tracer:tracee ratios, as appropriate (Hughes et al., 2012). Net release or uptake of 
cortisol across the brain was calculated using equation 2. Net release or uptake of d4-cortisol 
or cortisone were also calculated with equation 2, substituting arterial and venous 




Net cortisol release = ([cortisolV] – [cortisolA]) x (blood flow) 
9.2.7 Statistical analysis 
There were no prior data for cortisol or cortisone production or uptake across the brain on 
which to base a power calculation, therefore we used previous data from a study on cortisol 
and cortisone production in skeletal muscle in healthy men (Hughes et al., 2012). We 
calculated that in order to detect the same magnitude of difference from zero for net uptake or 
release across brain of cortisol, d3-cortisol or cortisone, with a similar variance to that in 
skeletal muscle, would require sample sizes of 3, 5 and 7, respectively (for alpha 0.05, power 
80% in a two-tailed test). We therefore considered a sample size of 8 to be reasonable. 
=   (blood flow x [cortisolA]) x   
d4-cortisol: cortisolA  
d4-cortisol: cortisolV  
Tissue cortisol 
production 
- (blood flow x [cortisolA]) 
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Using SPSS, Student’s t test was used to detect a difference from zero in brain production of 
cortisol, d3-cortisol and cortisone. The small n in the study required the use of parametric 
tests despite being unable to fully check the assumptions because it has been shown that in 
small study samples non-parametric tests are not sensitive enough to pick up even a large 
effect size (Bland and Altman, 2009). However, on visual inspection there were no obvious 
outliers and the data appeared to meet the assumptions of normality. 
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9.3 Results 
Eight healthy men were recruited with a mean age of 38.1years (sd 16.5) and mean BMI of 
24.9kg/m
2
 (sd 3.7).  
Table 9-1: Demographics for the subjects 










1 46.6 1.76 62.5 20.3 
2 31.8 1.82 77.9 23.5 
3 45.1 1.87 97.4 28.0 
4 25.0 1.79 81.4 25.4 
5 48.8 1.74 95.2 31.4 
6 21.5 1.71 65.0 22.2 
7 67.0 1.78 85.0 26.8 
8 19.2 1.79 69.4 21.7 
Mean (SD) 38.1 (16.5) 1.78 (0.05) 79.2 (13.1) 24.9 (3.7) 
 
In 7 of the 8 subjects, the right internal jugular was found to be dominant or co-dominant on 
the MR scan and was used for cannulation and measurement of blood flow; in one subject the 
left internal jugular vein (IJV) was dominant and was cannulated instead. Mean blood flow in 
the selected IJV for all subjects was 481 mL/min (sd 232).  
Endogenous cortisol and cortisone concentrations in both arterialized and jugular venous 
samples reduced from baseline to 180 mins of infusion, when the first set of arteriovenous 
samples were obtained, which is consistent with diurnal variation (figure 9.3A, D). In both 
arterialized and jugular venous samples, concentrations of cortisol and cortisone and 
tracer/tracee ratios were similar at all four sampling time points between 180 and 210 mins of 
infusion, consistent with steady state being achieved (figure 9.3).   
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Figure 9-3: Arterialized and jugular venous steroid concentrations and tracer/tracee ratios during steady 
state stable isotope tracer infusion.  
Data are mean ± SEM for n=8. A) Cortisol concentration; B) cortisone concentration; C) d4-
cortisol/cortisol ratio; D) d4-cortisol/d3-cortisol ratio; E) d2-cortisone/cortisone ratio. 
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Mean values in arterialized samples in steady state were used to calculate whole body rates of 
appearance of cortisol, d3-cortisol and cortisone (table 9.1), all of which were readily 
detectable, confirming technical success of the tracer infusions. Mean steady state data from 
arterialized and jugular venous samples were combined with blood flow measurements to 
calculate net release (or uptake) of cortisol and cortisone (equation 2) and to estimate cortisol, 
d3-cortisol and cortisone production across the brain (equation 1) (table 9.2). Surprisingly, 
d4-cortisol concentrations were higher in jugular vein than arterialized samples, so that there 
was net release of d4-cortisol across the brain in steady state. No other indices of brain 
steroid release / uptake or production were significantly different from zero.  
Table 9-2: Calculated steady state kinetics for cortisol and cortisone for whole body and brain 
 Whole body Brain 
Cortisol:   
Rate of appearance of cortisol 47.5 (29.9 to 65.1)
a
 0.43 (-0.27 to 1.12) 
Rate of appearance of d3-cortisol 22.5 (19.8 to 25.3)
a
 0.21 (-0.20 to 0.62) 
Net brain release of cortisol - -0.54 (-3.75 to 2.66) 
Net brain release of d4-cortisol - 0.46 (0.22 to 0.70)
b 
Net brain release of d3-cortisol - 0.12 (-0.36 to 0.60) 
Cortisone:   
Net rate of appearance of cortisone 14.4 (10.8 to 17.9)
a
 -0.02 (-0.35 to 0.30) 
Net brain release of cortisone - -0.23 (-0.69 to 0.23) 
Net brain release of d2-cortisone - -0.01 (-0.05 to 0.02) 
Data are nmol/min shown as mean (95% CI) for n=8, except for net brain release of d2-




 p<0.005 vs. zero using Student’s one-sample t test.  
All other associations p>0.05.  
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9.4 Discussion 
We found no detectable interconversion of cortisol and cortisone across the human brain in 
eight healthy male volunteers, using deuterated glucocorticoid tracers and arteriovenous 
sampling. Previous studies using this approach have detected interconversion of cortisol plus 
or minus cortisone within liver, adipose tissue and skeletal muscle (Hughes et al., 2012, Basu 
et al., 2004, Andrew et al., 2005, Stimson et al., 2009). Systemic cortisol/cortisone turnover 
values were similar in the subjects reported here to those observed in previous studies, so the 
approach was technically successful. The lack of statistically significant net production or 
release of cortisol, d3-cortisol or cortisone across the brain could not be attributed to 
variability in blood flow, either methodological due to the magnetic resonance method used 
or biological due to asymmetry of internal jugular blood flow, since we did not observe 
expected gradients in relevant steroid concentrations from arterialized to jugular venous 
blood, and we sampled from the dominant jugular vein and therefore from venous drainage of 
a substantial proportion of brain tissue. Any contribution of 11HSD in brain to whole body 
turnover between cortisol and cortisone is, therefore, negligible. It remains possible that, had 
we sampled from discreet brain subregions, 11HSD activity might have been measurable, 
but this remains a speculation. The consequences of brain 11HSD1 activity are likely to be 
confined to the sub-regions in which the enzyme is highly expressed (Sandeep et al., 2004).  
In the absence of arteriovenous gradients in cortisol or cortisone concentrations, we did find a 
net release of d4-cortisol across the brain. It is unclear why there was release of tracer from 
the brain but it may indicate over-priming and higher circulating d4-cortisol levels earlier in 
the infusion, with resulting re-release from brain during steady state; however, this 
speculation cannot be tested in the absence of earlier samples.  
One previous study has evaluated in vivo 11HSD1 activity in brain, by measuring peripheral 
venous plasma and cerebrospinal fluid (CSF) steroid concentrations during d4-cortisol 
infusion (Katz et al., 2013). Unfortunately, data were presented for only two subjects without 
administration of a potent 11HSD1 inhibitor; strangely, these subjects did not appear to 
reach steady state of tracer enrichment after 4 hours of infusion and tracer/tracee ratios in 
plasma were not adjusted for d4-cortisol infusion to calculate rate of appearance of cortisol 
and d3-cortisol and establish if the results were comparable with other published studies. CSF 
d3-cortisol concentrations were shown to be higher, relative to d4-cortisol, than plasma d3-
cortisol concentrations, but only by comparing CSF data with plasma obtained 60 minutes 
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earlier; this adjustment was applied on the grounds of closer correlation between plasma and 
CSF steroid concentrations separated by 60 minutes than those separated by shorter or longer 
intervals, but again indicates that steady state was not achieved in CSF. The authors attributed 
the apparent excess of d3-cortisol in CSF to brain 11HSD1, partly on the basis that it was 
abolished in a dose-dependent fashion by administration of the 11HSD1 inhibitor ABT384. 
However, ABT384 dramatically lowered plasma d3-cortisol concentrations, consistent with 
potent inhibition of systemic 11HSD1 activity; the associated fall in CSF d3-cortisol 
concentrations, which fell below the limit of quantification in most samples, can be explained 
by the dramatic fall in plasma d3-cortisol without invoking any contribution of brain 
11HSD1. Against this background, it has not been established whether activity of 11HSD1 
in brain is sufficient in magnitude to affect CSF cortisol concentrations. 
We took a different approach, measuring steroids in jugular venous blood and calculating 
arteriovenous differences during steady state tracer infusion. With measurement of blood 
flow, this allows absolute quantification of 11HSD activities for all tissue draining to the 
cannulated internal jugular vein. 11βHSD1 is known to be expressed in specific neuronal 
subregions of the human brain: hippocampus (in particular the dentate gyrus and the cornu 
ammonis), prefrontal cortex and, the area of highest expression, the granule cell layer of the 
cerebellum (Sandeep et al., 2004). The venous drainage of the human brain is complex and 
appears to display considerable inter-individual differences. Cerebellar venous blood drains 
to the superior and inferior cerebellar veins and usually ultimately into the internal jugular 
veins. However, posture affects cerebrovenous drainage such that in the supine position the 
internal jugular veins drain around 95% of blood flow from the intracerebral structures, 
whilst in the erect position this can drop to as little as 25%, with the remainder draining 
through the vertebral venous plexus (Valdueza et al., 2000). Our subjects were reclining at an 
angle of 45 degrees for the arteriovenous sampling, but the measure of internal jugular vein 
blood flow was performed supine within a magnetic resonance imaging machine. It could be 
that during blood sampling more of the cerebellar venous drainage was to the vertebral 
venous system rather than to the internal jugular veins, and that brain 11HSD1 was 
underestimated as a result. Moreover, the forebrain subregions where 11HSD1 is expressed 
represent a minority, by mass, of forebrain tissue and hence any contribution of these 
subregions to the plasma steroid pool may be diluted by blood from elsewhere. More 
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selective venous cannulation might therefore detect 11HSD1 activity which was not 
measurable here, but this is unlikely to be feasible in healthy volunteers.  
As there were no previous data on brain release or uptake of cortisol or cortisone, sample size 
was calculated using data from a previous study on skeletal muscle (Hughes et al., 2012). 
With the current novel results from brain in hand, we have performed new power calculations 
which show that to demonstrate that the observed mean differences are statistically 
significantly different from zero for Ra cortisol, Ra d3-cortisol and net Ra cortisone we 
would need sample sizes of 40, 57 and 4006 respectively (for alpha 0.05, power 90% in a 
two-tailed test). We do not consider it justified to undertake invasive studies in this large 
number of subjects in order to more precisely quantify any small amount of cortisol 
production in brain, having shown its mean magnitude to be negligible relative to other 
tissues. 
If 11HSD activity in brain had been detectable with the approach used here, this could have 
provided a useful pharmacodynamic tool to quantify brain enzyme inhibition by selective 
11HSD1 inhibitors in development for treatment of dementia (Katz et al., 2013, Sooy et al., 
2010). As things stand, neither this approach nor the CSF approach attempted by Katz et al. 
appear well suited for this purpose in healthy volunteers. Given that 11HSD1 expression 
increases with age in mice and is predictive of cognitive decline (Holmes et al., 2010), it 
remains possible that arteriovenous sampling could be used to detect cortisol regeneration by 
11HSD1 in the brains of patients with dementia or with risk factors for cognitive decline (eg 
diabetes, older age).  
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Chapter 10 Assessing asymmetry and prominence 
of the internal jugular venous and 
internal carotid artery blood flow in 
healthy adult men 
10.1 Background 
Chapter 9 used magnetic resonance (MR) phase contrast imaging to quantify internal jugular 
vein and internal carotid artery blood flow. Within this study marked asymmetry was noted 
within the venous system along with large variations in the prominence of each system. In 
this chapter I describe these findings and their importance for future research and clinical 
practice. 
Advances in imaging technology have greatly improved current understanding of the cerebral 
vascular system. MR phase contrast imaging allows accurate quantification of blood flow in 
even extremely narrow vessels, and as there is no radiation exposure, imaging can be 
undertaken at multiple levels and therefore within multiple vessels. Prior to the development 
of this technology, studies had to rely on either Doppler ultrasound, methods using 
indocyanine green or thermodilution techniques, in all of which it is almost impossible to 
measure arterial and venous flow simultaneously or to measure more than one vessel at a 
time (Griffiths et al., 2001). Also as MR phase contrast imaging measures flow throughout a 
cardiac cycle it generates a mean measurement rather than instantaneous values provided by 
other techniques. Improved understanding of the cerebral vasculature is not only interesting 
from an anatomical and physiological point of view but also has clinical implications for: 
choice of placement for catheterisation of the internal jugular vein; studying the effect 
changes in anatomy can have on jugular venous oxygen saturation (SjO2); and planning of 
neurosurgical procedures (Beards et al., 1998, Samy Modeliar et al., 2008).  
Whilst studies using MR phase contrast imaging of the cerebrovascular system have been 
performed on patients (eg in multiple sclerosis) the flow of the main arterial and venous 
vessels supplying and draining the brain in a healthy population has been much less 
researched (ElSankari et al., 2013, Feng et al., 2012). I therefore undertook to measure blood 
flow in the internal jugular veins and internal carotid arteries in healthy men and to assess 
their asymmetry and inter-relationship.  
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10.2 Methods 
10.2.1 Participants 
Participants were recruited as per chapter 9. The study complies with the Declaration of 
Helsinki; ethical approval was obtained from the local Research Ethics Committee (Scotland 
A REC, reference 12/SS/0079) and all participants gave written informed consent. 
10.2.2 MR protocol 
The MR imaging protocol is described in chapter 9. 
10.2.3 Image analysis 
The image analysis software Medis Q flow (Medis medical imaging systems; Leiden, the 
Netherlands) was used to calculate jugular venous blood flow on the side which was 
cannulated. The outline of the internal jugular vein was traced on each of the magnitude 
images from the cardiac cycle and blood flow calculated using data from the corresponding 
phase images. For completeness the blood flow for the opposite internal jugular vein and both 
common carotid arteries were also measured. 
10.2.4 Statistical analysis 
All statistical analysis was performed on SPSS version 21.0. Non-parametric tests were used 
to make comparison across groups as the assumptions for parametric tests were violated for 
some of the variables.  
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10.3 Results 
Eight healthy men were recruited to the study with a mean age of 38.1 years (sd 16.5) and a 
mean BMI of 24.9kg/m
2
 (sd 3.7). Cross-sectional area and velocity for all four vessels are 
shown in tables 10.1 & 10.2.  
Table 10-1: Cross sectional area for all subjects for ICA and IJV with median and interquartile range (mm
2
) 












1 32.0 34.7 66.7 97.9 71.5 169.4 
2 39.7 38.4 78.1 72.9 11.1 83.9 
3 56.3 39.1 95.4 60.3 18.2 78.5 
4 32.1 41.0 73.0 66.2 38.2 104.4 
5 35.6 34.2 69.8 70.2 17.1 87.4 
6 33.1 39.7 72.8 42.2 150.0 192.2 
7 31.4 40.1 71.5 88.8 9.0 97.7 
8 25.7 37.7 63.5 104.2 6.1 110.3 
Median 32.6 38.7 72.2 71.5 17.7 101.1 
IQ range 31.5-38.7 35.4-40.0 67.5-76.8 61.7-95.6 9.5-63.2 84.8-154.6 
Coefficient 
of variation 
0.26 0.06 0.13 0.27 1.23 0.36 
 
Right and left IJV CSA were significantly different (p=0.038, Mann-Whitney U Test), but 
right and left ICA CSA were not significantly different (p>0.05, Mann-Whitney U Test). 
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Table 10-2: Mean velocity for all subjects for ICA and IJV with median and interquartile range (cm/second) 












1 17.4 15.4 16.4 6.7 4.8 5.8 
2 13.1 12.4 12.7 6.4 7.3 6.8 
3 10.6 10.5 10.5 19.8 0.3 10.1 
4 14.2 17.2 15.7 18.7 9.3 14.0 
5 16.4 17.1 16.8 7.1 7.5 7.3 
6 18.8 14.5 16.7 2.1 8.2 5.1 
7 16.3 13.4 14.8 2.6 2.1 2.3 
8 12.9 12.4 12.6 5.3 1.1 3.2 
Median 15.2 13.9 15.2 6.5 6.1 6.3 
IQ range 12.9-17.1 12.4-16.7 12.6-16.6 3.3-15.8 1.4-8.0 3.7-9.4 
Coefficient 
of variation 
0.18 0.17 0.16 0.80 0.69 0.55 
 
Neither right and left IJV velocity nor right and left ICA velocity were significantly different 
(p>0.05, Mann-Whitney U Test). The IQ range for the right IJV velocity was wider than for 
the left IJV velocity.  
Spearman’s correlation coefficients were calculated for each vessel between the CSA and the 
velocity; there were no significant correlations between CSA and velocity for any of the 
vessels. 
Table 10-3: Spearman’s correlation coefficients between each vessel’s CSA and velocity 
 Right ICA Left ICA Total ICA Right IJV Left IJV Total IJV 
rho 0.67 -0.10 -0.33 -0.21 0.52 0.38 
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Table 10.4 shows median blood flow for the internal jugular veins and internal carotid 
arteries. Right and left IJV blood flows were significantly different (p=0.028, Mann-Whitney 
U Test), whereas right and left ICA blood flows were not significantly different (p>0.05, 
Mann-Whitney U Test).  
Table 10-4: Blood flow for all subjects for ICA and IJV with median and interquartile range (ml/min) 












1 327 315 642 385 203 587 
2 308 289 596 277 48 324 
3 353 241 593 709 5 714 
4 274 420 694 742 215 957 
5 299 304 603 534 32 565 
6 369 349 718 54 732 785 
7 307 322 629 137 11 148 
8 199 284 483 333 4 337 
Median 307 309 616 359 40 576 
IQ range 286-340 287-336 594-681 207-621 8-209 331-750 
Coefficient 
of variation 
0.17 0.17 0.12 0.63 1.59 0.49 
In all but one of our subjects, the right internal jugular vein was dominant. In the only subject 
who was left IJV dominant, blood flow in the right IJV was only 7.3% of total IJV blood 
flow. The dominant IJV blood flow had a median value of 93.0% of total IJV blood flow (IQ 
range 81.4-96.7%, coefficient of variation 0.13). The dominant IJV had a blood flow around 
double or more the non-dominant IJV in all our subjects (ie ratio of dominant to non-
dominant IJV blood flow was ≥0.66). 
The ICA blood flow was more symmetric. In four of the subjects the right ICA had a faster 
blood flow and in the other four the left ICA had a faster blood flow. The dominant ICA had 
a median blood flow of 51.5% total ICA blood flow (IQ range 51.0-59.3%, coefficient of 
variation 0.08). Also, the inter-quartile range for total ICA was narrower, showing less inter-
individual variation than IJV blood flow. 
The ratio of total IJV blood flow to total ICA blood flow also showed considerable variation 
(see figure 10.1). In three of the subjects the IJVs had a combined larger blood flow than the 
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ICAs and in the other 5 subjects the ICAs had a larger blood flow than the IJVs. Median total 
IJV blood flow as a percentage of total ICA blood flow was 92.6% (IQ range 62.1-114.8; 
minimum 23.5%; maximum 137.9%, coefficient of variation 0.42). 
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10.4 Discussion 
Eight healthy men underwent phase contrast ECG-gated MR scans to calculate blood flow in 
the internal jugular veins and internal carotid arteries. I used this data to look at the 
asymmetry of the IJVs and ICAs and the ratio of IJV:ICA blood flow. I found a significant 
difference between right and left sided IJV blood flow, with the right IJV being dominant in 7 
of our 8 subjects. The dominant IJV had a blood flow at least double the non-dominant IJV in 
all our subjects; significant asymmetry in IJV blood flow should therefore be considered 
normal.  
Asymmetry in the internal jugular veins has been inferred from cross sectional areas (CSA) 
of vessels in previous studies using different imaging modalities. We found median left IJV 
CSA to be significantly bigger than median right IJV CSA (table 10.1). Using ultrasound, 
Modeliar et al measured the CSA of the IJVs in 60 subjects with a mean age of 62 years (sd 
19) and found that in more than 65% of subjects the right sided IJV was larger (Samy 
Modeliar et al., 2008). In a similar study of 80 ICU patients with a mean age of 59 years 
Lichtenstein et al. defined a dominant IJV as more than twice the CSA of the contralateral 
IJV; they found that 62.5% of subjects had a dominant IJV and of these, 68% were right side 
dominant and 32% left. They also noted that in 21% of their subjects, the right IJV was 
0.4cm
2
 or less, making cannulation difficult or impossible (Lichtenstein et al., 2001). In 
another study MR angiography was used to measure IJV CSA in 64 participants with a wide 
age range (mean 48.4 years, range 16-76) and found that 64% of subjects had a larger right 
IJV than left (Kopelman et al., 2013). 
However, vessel CSA does not always accurately reflect blood flow and we found this here 
also. Vessel CSA was not significantly correlated with velocity in any of the four blood 
vessels we studied (table 10.3), the two parameters used to calculate blood flow. More recent 
studies have used phase contrast MR imaging (PC-MRI) and two such studies have examined 
asymmetry in IJV blood flow. Beards et al examined 25 healthy subjects with an age range of 
22-34 years, showing a significant difference between right (mean 302ml/min) and left (mean 
210ml/min) IJV blood flow (p=0.0036) (Beards et al., 1998). They also measured blood flow 
within the transverse sinus and found that in 4 subjects there was complete atresia of one 
transverse sinus and in 13 there was significant asymmetry (52%). ElSankari et al used PC-
MRI to measure blood flow in the transverse sinus, IJV, ICAs and vertebral arteries in 
subjects with multiple sclerosis and in 21 healthy controls, who had a median age of 33 
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(ElSankari et al., 2013). In the healthy controls the dominant vessel was on the right in 12 
subjects (ie 60%) and left in 4 subjects (20%), with equal flow in 4 subjects (20%). 
Interestingly, they found that the dominant transverse sinus did not correspond with IJV 
dominance, with transverse sinus dominant side being the right in 9 subjects (ie 47%), left in 
4 subjects (21%) and equal in 6 subjects (32%).  
Our study confirms this previous work that significant asymmetry of the IJV is common even 
in a healthy population. This has implications for both clinical and research practice. In the 
clinical setting, ultrasound visualisation of the IJV prior to cannulation is now recommended, 
as it decreases failure rate and rates of complication (eg arterial puncture) (8), however our 
study highlights the value of imaging both IJVs prior to cannulation. Cannulation of the left 
IJV has been found to be more time consuming and associated with a higher rate of 
complications than right IJV cannulation, and it is likely that asymmetry in the vessels 
contributes to this (9). Therefore we recommend ultrasound imaging of both right and left 
IJVs prior to cannulation to assess asymmetry and aid selection of which vessel to cannulate. 
I found no significant difference between right and left ICA blood flow. Also, the 
interquartile range and coefficients of variation were much smaller for ICA blood flow than 
IJV (table 10.4), indicating that there is less anatomical variation in the arterial blood supply 
to the brain than there is in the venous drainage. This is consistent with one previous paper 
which reported PC-MRI of ICA blood flow and found no significant difference between right 
and left sided ICA blood flow in any of their healthy subjects (ElSankari et al., 2013). 
Interestingly, they did find asymmetry in vertebral artery blood flow, with a dominant 
vertebral artery being on the right in 20%, left in 40% and co-dominant in 40%. So whilst 
ICA blood flow seems symmetrical, vertebral artery blood flow may not be. 
I also found that the IJVs drain a variable amount of the cerebral arterial blood supply, with 
the IJVs having a blood flow between 24 and 138% of the total ICA blood flow in our study. 
The arterial blood supply to the brain is largely made up of the right and left internal carotid 
arteries and the right and left vertebral arteries. It is thought that the vertebral arteries 
contribute around 27% to global cerebral blood flow and the internal carotid arteries 
contribute around 73% (Sato et al., 2011). Cerebrovenous drainage is more complex and our 
data show that non-jugular venous systems must be of differing importance to total cerebral 
venous drainage between individuals, however detailed studies of these non-jugular venous 
systems are lacking. Kopelman et al named all non-jugular venous flow seen on a PC-MRI as 
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vertebral venous plexus if it lay behind a line intersecting the two IJVs in the sagittal plane at 
the level of the jugular bulb, and pterygopalatine plexus if the vessel lay anterior to this line 
(Kopelman et al., 2013). These plexi interconnect with the IJV venous system too, so that 
depending on blood flow and position (ie supine or erect) each system may drain a varying 
proportion of the total cerebral arterial blood flow. They measured IJV and non-jugular 
venous vessels CSA and found that there was an inverse correlation between the two sets of 
CSAs (r
2
 -0.25, p<0.0001), meaning that in subjects with larger IJVs the non-jugular venous 
systems were less important to total cerebrovenous drainage (Kopelman et al., 2013). This 
finding is consistent with our data where the subjects with the biggest total IJV blood flow 
also have the smallest ratio of IJV:ICA blood flow and vice versa in the subjects with the 
largest total IJV blood flow.  
I found only one other study which looked at the proportion of ICA blood flow drained by the 
cerebrovenous system. Stoquart-ElSankari et al measured cerebral blood flow using PC-MRI 
in 12 healthy elderly subjects (mean age 71.9 years) and 19 young healthy volunteers (mean 
age 27.5 years) (Stoquart-ElSankari et al., 2007). The IJVs drained 60.7% of the total arterial 
(ICA and vertebral arterial) blood flow in the elderly group and 60.3%, in the young group; 
which is remarkably stable across the lifespan. Coefficients of variation in this study, total 
arterial blood flow 0.19 elderly, 0.14 young and IJV blood flow 0.48 elderly, 0.52 young, are 
also comparable with ours and confirm a greater variability in IJV blood flow than cerebral 
arterial blood flow between subjects. These findings in combination with ours have 
implications for both clinical and research practice. In the clinical setting, when measuring 
SjO2 as a marker for brain oxygen delivery, depending on the degree of blood drained by the 
jugular venous system, results could vary widely (Andrews et al., 1991, Chan et al., 1992, 
Andrews and Colquhoun, 1994, McKeating et al., 1998, Grune et al., 2014). Also, in rare 
cases where a double resection of the internal jugular veins is required, different subjects may 
respond very differently depending on the capacity of their non-jugular venous system. In the 
research setting, it will be important to consider when sampling from the jugular veins that 
the side chosen and the degree of non-jugular venous drainage present may affect results.  
In our study I did not measure vertebral arterial blood flow or non-jugular venous drainage, 
so I am not able to give a full picture of the cerebral arterial and venous relationships. As yet, 
no study has done this, mainly due to difficulty measuring blood flow in the non-jugular 
venous system. However with improving image analysis tools this may be possible in the 
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future. Also, due to the constraints of our MR scanner, all measurements were performed on 
subjects whilst they were supine. It may well be that measurements taken at an angle of 45 or 
90 degrees to the horizontal would give different results which may be more physiologically 
important. With advances in MR scanning, including vertical MR scanners, this may be 
possible. 
10.5 Conclusion 
I used phase contrast ECG-gated MR scans to calculate blood flow in the internal jugular 
veins and internal carotid arteries in eight healthy men. There is significant asymmetry of 
blood flow within the healthy jugular venous system, and considerable inter-individual 
variation in the proportion of ICA blood flow drained by the IJVs. This is likely to be due to 
variations in the contribution of the vertebral venous plexus to cerebrovenous drainage 
between individuals. This may have important implications for both intensive care and 
neurosurgery and future research studies which use a measure of cerebrovascular blood flow, 




Chapter 11 Summary and Conclusions 
This thesis set out to investigate the relationship between sarcopenia and age-related 
cognitive decline (ARCD) and their potential biological correlates, with particular focus on 
the role of glucocorticoids. The field of cognitive ageing is well established with many 
advanced longitudinal studies looking at potential mechanisms and covariates; sarcopenia by 
contrast is a relatively new field, although there is a rapidly expanding body of literature 
examining this important area.  
I started the thesis by discussing current diagnostic criteria for both conditions, detailing what 
is known about the structural changes associated with them and performing a literature 
review of current evidence for possible underlying mechanistic processes. This was to enable 
me to identify possible common areas which might explain any relationships I identified 
between brain and muscle ageing. This literature review helped form the hypotheses that then 
directed further studies within the thesis by identifying gaps in the current literature and 
possible common mechanistic pathways. Key areas identified were: further research into the 
relationship between sarcopenia and ARCD given the potential multiple common causative 
areas identified; the role of glucocorticoids and their intracellular amplifier 11βHSD1 in 
sarcopenia and ARCD; and the contribution and relative importance of inflammation, 
immunosenescence, genetic factors, environmental and lifestyle factors in the aetiology and 
progression of sarcopenia and ARCD. 
This led on to a systematic review of the literature on the relationship between brain and 
muscle structure and/or function. The review did not include the relationship between 
physical (ie muscle) function and cognition (ie brain function) because there are already 
reviews of this area, whereas much less has been published on the role of structure in the 
relationship between brain and muscle (Abellan van Kan et al., 2009, Atkinson et al., 2007, 
Scherder et al., 2007, Drago et al., 2011, Moran et al., 2013).  
The review found that the literature supported a positive association between whole brain 
volume (WBV) and total white matter volume with muscle size, and also evidence that some 
areas of regional grey matter volume (right temporal pole and bilateral ventromedial 
prefrontal cortex) may be negatively associated with muscle size (Honea et al., 2009, Burns 
et al., 2010, Wetmore et al., 2011, Heymsfield et al., 2012, Kilgour et al., 2013, Weise et al., 




structure. This is most likely because studies either involved a brain scan or a measure of 
muscle structure. Clearly one scan which measured both would be extremely useful for this 
emerging field. Longitudinal studies would allow this relationship to be further investigated, 
to determine whether those who have lost more brain tissue have a greater reduction in 
muscle mass, or whether brain atrophy leads to decreased muscle mass, or if sarcopenia leads 
on to greater brain atrophy. 
There was no association between grip strength and WBV, but there was an association with 
brain atrophy. None of the papers contained a longitudinal measure of muscle mass, so whilst 
brain atrophy can estimate degree of loss of brain tissue from peak size, there is no 
corresponding measure for muscle. Greater white matter (WM) volume and lower white 
matter hyperintensity (WMH) volume were also both associated with grip strength (Doi et al., 
2012, Aribisala et al., 2013, Sachdev et al., 2005). 
Gait speed was found to be positively associated with whole brain volume; this relationship 
may be driven by total WM volume or regional grey matter (GM) volumes, specifically the 
hippocampus (Silbert et al., 2008, Marquis et al., 2002, Aribisala et al., 2013). Like grip 
strength, gait speed is also associated with markers of brain ageing; WMH accumulation, 
brain atrophy and WM atrophy all show evidence of either a temporal association with gait 
speed or change in gait speed with time, with periventricular hyperintensities (PVH) and 
brainstem WMHs playing a particularly important role, but not subcortical WMH (Rosano et 
al., 2005, Soumare et al., 2009, Callisaya et al., 2013). However, only one of these studies 
looked at brain structure change over time and further longitudinal studies like this will prove 
very informative but are expensive to conduct (Callisaya et al., 2013).  
There was no evidence found for an association between cognition and muscle size, except in 
studies where MMSE was used as the cognitive test, with evidence both for and against a 
significant association (Kilgour et al., 2013, Wetmore et al., 2011, Pedersen et al., 2012, 
Berryman et al., 2013, Bites et al., 2013, Auyeung et al., 2013, Magri et al., 2006, Liu et al., 
2014). Whilst the MMSE is used as a screening tool for dementia it has both a ceiling and a 
floor effect and is not considered a useful test of cognitive function other than for its primary 
function (Franco-Marina et al., 2010). 
The systematic review identified a relative paucity of evidence for a relationship between 




technique to measure both variables on one scan was recognised as being extremely useful 
within the field. I next went on to describe the process of developing such a technique. 
The technique I developed uses volumetric MR brain scans, which are a good method for 
measuring brain volume and other markers of brain ageing (eg WMH accumulation), to 
measure neck muscle cross-sectional area (CSA) (Kilgour et al., 2012). I demonstrated 
through a series of studies that the technique is feasible and repeatable with good inter-rater 
reliability. I also demonstrated that neck muscle CSA can be used as a proxy for general 
muscle bulk by showing it has a strong correlation with thigh muscle CSA. I have organised 
for wave 3 from the LBC 1936 study to undergo neck muscle CSA measurement on its MR 
brain scans and in this wave I have also arranged for the subjects to undergo estimation of 
lean mass using a BIA machine. I plan to use this data to further test the validity of neck 
muscle CSA as a useful indicator of general muscle bulk, in addition to using it for 
longitudinal analysis of the measured variables. 
It is interesting to note that not all muscles appear to age at the same rate. For example more 
muscle appears to be lost from the lower than the upper limbs (Janssen et al., 2000) and even 
within a limb, deep muscles may be less affected than superficial muscles (Ikezoe et al., 
2011). It would be informative to look at the longitudinal decrease in size of the neck 
muscles, which are used even in seated postural control, in relation to peripheral muscles (eg 
quadriceps or the calf muscles). Wave 4 of the LBC 1936 study is shortly to be commenced 
and the subjects are undergoing volumetric MR brain scanning and BIA measurement again 
and using the wave 3 plus this data I will be able to look at the longitudinal relationship 
between neck muscle CSA and total lean mass, and estimate whether or not they are 
declining in a proportionate manner. 
After developing the neck muscle CSA measurement technique it was first utilised on a 
cohort of healthy older men (Kilgour et al., 2013). Data on brain volume and cognitive 
function had already been collected as part of the original study and I measured the neck 
muscle CSA on the volumetric MR brain scans. These data showed that in healthy older men 
preservation of whole brain volume (ie the ratio of WBV corrected for intracranial area) is 
associated with larger muscle size. Interestingly I also found that larger muscle size was 
associated with lower prior cognition but not current cognition. I postulated that this may be a 
reflection of an association between occupation and cognitive ability; that is that subjects 




therefore would have built up a larger peak muscle mass. Unfortunately this study did not 
have data on occupation or social class, so I was not able to test that theory here, but on 
looking at the wave 2 LBC 1936 data I was able to show a positive correlation between social 
class and neck muscle size (ie those from social class I had a smaller neck muscle CSA than 
those from social class V). 
Next I performed neck muscle CSA measurement on the wave 2 volumetric MR brain scans 
from LBC 1936 (n=641), a large population based cohort study with data on cognition age 11 
years old, to look at the interrelationships between brain and muscle structure and function. In 
this larger study I also had measures of muscle function: grip strength and six metre walk 
time.  
I found that neck muscle CSA was not associated with cognition, GM volume or WML 
volume, but that it was negatively associated with normal WM volume and PVH Fazekas 
score in men. I had postulated that larger brain volumes would be associated with larger neck 
muscle CSA (after controlling for ICV as a proxy for skull size) under the common cause 
hypothesis. So finding that smaller WM volume was associated with larger neck muscle CSA 
contradicted this. One possible explanation could be that those with a smaller WM volume 
find it more difficult to maintain their postural control and therefore are required to make 
constant small postural adjustments thus increasing their neck muscle CSA. However it is 
worth noting that the effect size was small. It will be very interesting to look at the wave 3 
LBC 1936 data and see if there is the same or opposite association with total lean mass 
(which will include central and peripheral muscle bulk) and WM volume.  
There is a well-established association between gait speed and WMHs, but in my systematic 
review I found no previous studies looking at the association between WMHs and muscle 
size (Soumare et al., 2009, Moscufo et al., 2012, Wolfson et al., 2005, Rosano et al., 2006, 
Rosano et al., 2005, Silbert et al., 2008, Marquis et al., 2002, Aribisala et al., 2013, Rosano et 
al., 2010, Longstreth et al., 1996). Therefore there was no evidence addressing the question of 
whether muscle size mediates the relationship between WMHs and gait speed. I found a 
relationship between PVH Fazekas score and neck muscle CSA in men and not in women, 
and I found no association between deep WMH Fazekas score and neck muscle CSA in either 
sex. Location of WMH may be important in determining their impact on muscle function 
(Kilgour et al., 2014), therefore it makes sense that location may also affect muscle size. The 




cognition than the average population of that age, partly predetermined by their willingness to 
undergo multiple tests and have ongoing input with a longitudinal study. Therefore there 
were relatively low numbers of subjects for men and women with Fazekas scores of 2 or 3. It 
may be that in an older or less healthy cohort a stronger relationship would be found between 
WMH and muscle size. It will again be interesting to look at the lean muscle mass results in 
wave 3 and 4 of LBC 1936 and its association with WMH volume and location. 
Grip strength was positively associated with cognitive ability (general cognition and 
processing speed, but not memory) and WM volume and was negatively associated with PVH 
Fazekas score in women, but was not associated with GM or WML volume. In this case PVH 
Fazekas score again proved more important than deep WMH score, but in women this time 
and not in men. The same caveat of a low number of subjects scoring 2 or 3 hold true for this 
data also. However the only previous study I found which looked at WMH location and grip 
strength also found that regional burden may play an important role (Sachdev et al., 2005). 
Previous studies have also found an association between grip strength and some aspects of 
cognition (Guerrero-Berroa et al., 2014), but the only study I found looking at the 
relationship between grip strength and brain volume also used data from wave 2 of LBC 1936 
(Aribisala et al., 2013).  
The six metre walk test (6MWT) was associated with the same cognitive ability measures as 
grip strength (general cognition and processing speed but not memory), and also WM, GM 
and WML volume. 6MWT was also positively associated with deep Fazekas score in men. 
Whilst gait speed has previously been shown to be associated with cognition (eg MMSE, 
DSST and cognitive impairment) (Abellan van Kan et al., 2009, Atkinson et al., 2007, Duff et 
al., 2008), studies looking at its association with other specific cognitive domains are 
currently lacking. Our results show that WMH location may prove important in the 
relationship with 6MWT, but further studies are now needed from other datasets to assess this 
relationship further. 
With measures from all four variables in this dataset (brain structure and function, and 
muscle structure and function) I was able to look at the inter-relationships between them and 
test for possible explanatory factors. I found that neck muscle CSA is a mediator between 
6MWT and WM volume. This means that neck muscle CSA partially explains the 




predictor of 6MWT independent of WM volume. Neck muscle CSA is not a mediator 
between 6MWT and WML volume, or grip strength and WM volume.  
WM, GM and WML volume all act as mediators between physical function and cognition, so 
brain structure clearly plays a key part in this relationship. I found only one significant 
explanatory factor in all the relationships that were looked at in this study, which was salivary 
cortisol. Evening salivary cortisol was found to be an explanatory factor between 6WMT and 
cognition, with a particular role in the relationship between 6MWT and processing speed. 
Also, evening salivary cortisol and the diurnal slope between morning and evening salivary 
cortisol were found to be explanatory variables in the relationship between 6MWT and total 
brain volume. This would indicate that cortisol may be one of the factors underlying the 
common cause hypothesis; that ageing progresses in all organs at a similar rate due to 
common underlying mechanisms. Salivary cortisol was only assessed on 89 of the subjects in 
the LBC 1936 study and they were all male, so further confirmatory studies are now required. 
In the first chapter of the thesis I described the theory of the common cause hypothesis. This 
theory postulates that the same intrinsic factors driving ageing in one organ will similarly be 
acting in all the other organs, meaning that in those with a faster rate of intrinsic ageing 
(secondary to free radical generation, mitochondrial ageing etc) the trajectory of decline 
facing each organ will be similarly steep, only being altered by extrinsic factors having 
differential effects on the separate organs (eg smoking and lung function). Conversely in 
those subjects with a slower intrinsic rate of ageing the trajectory of decline with ageing 
affecting each organ should be similarly slow. If this theory was proven to be correct then 
preventative advice or novel treatments found to slow down the intrinsic rate of ageing in one 
organ should similarly improve ageing within other organs also, which has exciting 
ramifications for treating age-related conditions. In this thesis I studied evidence which 
would support or refute this interesting concept both within the systematic review and within 
the studies I performed on the longitudinal cohorts I had access to. The systematic review 
identified mainly studies using cross-sectional analyses but some of the longitudinal data it 
looked at, and similarly markers for brain ageing within the cross-sectional studies (eg WMH 
accumulation and brain atrophy), were found to have associations with muscle function. Due 
to a technical issue with regard to the MHEM study I was unable to use wave 1 of its data, as 
we were unable to measure the neck muscle CSA on these scans and data completion of wave 




needed, therefore in neither of the studies I had access to was I able to analyse the 
relationships between muscle and brain longitudinally. However, again there was evidence of 
a relationship between markers of brain ageing and muscle variables, but the findings were 
not fully consistent across the datasets and in fact one finding was the converse to what we 
had predicted with the common cause hypothesis (ie we found that smaller WM volume was 
associated with larger neck muscle CSA). Ultimately without the benefit of having 
longitudinal data with which to study the ageing trajectories of muscle and brain it is difficult 
to draw any firm conclusions on the validity of the common cause hypothesis at present, 
although using the limited data I had access to (ie the few longitudinal studies in the 
systematic review and markers of brain ageing in the cohort studies) it appears that even if 
there is a common rate of ageing shared between muscle and brain, there is a larger 
component of individual ageing within each organ, caused by either the relative importance 
or presence of particular intrinsic or extrinsic ageing factors. 
I next went on to look at some of these possible factors and the role they may play in muscle 
and brain ageing. I looked at the role of immunosenescence and inflammation in sarcopenia 
within the LBC 1936 study and found that men who were seropositive for CMV had smaller 
neck muscle CSA than men who were seronegative and this effect was independent of IL-6 
level, however there was no significant relationship between CMV titre and neck muscle 
CSA. This may be because the effect of chronic CMV infection (which usually initially 
occurs in childhood) may affect muscle size over a long period, so that increasing titres in 
older age play less of a role. I also found that higher IL-6 levels, but not CMV levels, were 
strongly associated with lower grip strength in both hands in men and women; these 
associations were not attenuated when the model was adjusted for CMV serostatus or 
antibody titre. All the findings were independent of markers of childhood deprivation, which 
is known to be associated with CMV infection. These findings support the hypothesis that 
there is a relationship between immunosenescence and markers of sarcopenia. 
I then analysed data from a cohort study of elderly and young subjects from two Scottish 
cities to investigate further the relationship between glucocorticoid status and sarcopenia. I 
found a significant association between increased muscle 11βHSD1 expression (which 
converts inactive cortisone to active cortisol) and lower quadriceps strength in older men and 
women (Kilgour et al., 2012). However I found no significant associations between plasma 




seems that whilst circulating levels of glucocorticoids may not play an important role in the 
aetiology of sarcopenia in this dataset, tissue specific levels do play a role. This study raises 
the possibility of 11βHSD1 inhibitors as a novel treatment for sarcopenia, but further larger 
confirmatory studies of the association are now required. 
I then performed a clinical study on healthy men to determine if it is possible to detect 
11βHSD1 activity in the human brain in vivo. This technique would be very useful in further 
development of 11βSHD1 inhibitors as a potential treatment in cognitive impairment. 
Unfortunately I found no measurable release or production of cortisol, d3-cortisol or 
cortisone across the human brain, using arterial and venous blood samples and deuterated 
glucocorticoid tracers. If I had included subjects with cognitive impairment or risk factors for 
cognitive impairment (eg type 2 DM or older age) I may have found a significant result due 
to increased 11βHSD1 activity in these subjects, however in view of the invasive nature of 
this technique alternative approaches will be required to quantify the effects of selective 
11βHSD1 inhibitors on enzyme activity in human brain. Furthermore it is known that 
11βHSD1 activity is limited to particular subregions (Sandeep et al., 2004), for example the 
hippocampus, therefore any technique which allowed measurement of the enzyme activity 
within specific areas of the brain would be an extremely useful development in the future. 
As part of the above study I decided to sample venous blood from just below the jugular 
venous bulb on the right side of each subject. However, as the study progressed it became 
increasingly apparent how asymmetric jugular venous drainage is, unlike carotid arterial 
supply which was not statistically different between the right and left side. Also after 
measuring blood flow in both carotid arteries and both internal jugular veins on the ECG-
gated phase magnitude MR brain scan, I noticed that the percentage of blood supplied by the 
carotid arteries which was drained by the internal jugular veins was again remarkably 
variable. This means that in the different individuals in our study (some of whom showed 
production of cortisol across the brain), more or less of the brain tissue known to express 
11βHSD1 activity may have drained to the IJV we were sampling from. This has implications 
for future studies which use blood sampled from the jugular venous bulb as a proxy for 





11.1 Chapter order within the thesis 
In this thesis the chapter order largely represents the work in the chronological manner it was 
performed, however some of the work in the chapters was completed non-chronologically but 
it was felt that the flow of results from general to specific still suited the chosen chapter 
order. For example, chapter 1 was performed at the outset of the PhD, whilst chapter 2 was 
commenced at the outset of the PhD but not finally completed until halfway through the third 
year of my PhD. This was partly because: the number of studies which were screened as part 
of the review was very large (n>22,000); the researcher who was helping me screen the titles 
was working full time in a clinical role, therefore there was some delay in completing 
longlisting and shortlisting; and also because the journal where we published the review 
asked for an update on the review prior to publication as there had been a significant time 
lapse between the original search and submission to the journal. This meant that the 
systematic review subsequently included a publication which formed the basis for chapter 5 
(Kilgour et al., 2013), despite the results from the original version of the review being 
available to me earlier than the publication of this chapter, and these early results had 
informed the chosen analyses particularly with regard to the LBC1936 data. Chapters 4, 5, 6 
and 7 are presented in the chronological order they were performed. Chapters 8 and 9 were 
performed concurrently with the preceding chapters and were grouped at the end of the thesis 
as they both looked at the role of glucocorticoids. Chapter 10 is based on the analysis of data 
gained from chapter 9 and therefore appears after it.  
11.2 Limitations 
I described limitations in each of the studies within the specific chapters; however certain 
themes are apparent across the chapters. Current evidence for whether an association exists 
between brain structure and muscle structure is limited, and is largely reliant on cross-
sectional studies. Therefore conclusions drawn within the systematic review are sometimes 
based on only a small selection of studies. Longitudinal studies would prove very useful as 
the trajectory of how the ageing process is affecting the two organs (brain and muscle) could 
then be examined. These data could be used to assess whether ARCD predicts sarcopenia or 
vice versa, or whether the two decline in parallel.  
The technique I developed to measure neck muscle CSA on volumetric brain scans will be 
useful for such studies but it has a number of limitations. Firstly it can only be used on 




found it could not be used on volumetric CT scans either after accessing a stroke study with 
such scans. This is because as radiation is used in these scans the field of view is kept as 
small as possible and therefore extension into the neck is inadequate. Furthermore the 
technique is relatively time consuming and requires a degree of operator knowledge; however 
I am currently investigating the possibility of making the technique semi-automated using 
computer based learning algorithms.  
Within all the cohort studies I used, subjects were screened for certain conditions (eg 
dementia) and there might also be a degree of subject self-selection (ie it is likely that 
subjects with certain conditions would be less likely to take part in cohort studies). This 
means that whilst the studies are less affected by confounding comorbidities, they may not be 
truly reflective of the general population. In fact by the time subjects are in their eight decade 
it would be assumed that certain levels of obesity, dementia and mobility problems would be 
present, all of which may be under-represented in these studies. This is reflected in certain 
aspects of the LBC 1936 study where the number of subjects with Fazekas scores of 2 or 3 
was lower than might be expected for this age group. 
11.3 Summary 
The interrelationship between muscle and brain structure and function was investigated using 
a systematic review and analysis of data from cohort studies in healthy elderly people 
(MHEM and LBC 1936). I consistently found a relationship between: some measures of brain 
structure and muscle size; markers of brain structure and muscle function, mostly grip 
strength and gait speed; and cognition and muscle function. However I found no relationship 
between current cognition and muscle size in any of the above studies. These data therefore 
partly support the common cause hypothesis.  
Cortisol was identified as a possible explanatory factor in the relationship between gait speed 
and cognition, and also gait speed and brain volume. I found an association between markers 
of immunosenescence and markers of sarcopenia (neck muscle CSA and grip strength) and 
also an association between expression of the cortisol amplifying enzyme 11βHSD1 and 
quadriceps strength. Therefore both glucocorticoid dysfunction and immunosenescence may 
be possible mechanisms underlying the common cause hypothesis, but other pathways must 




I developed a technique to measure 11βHSD1 activity in the whole human brain; however the 
amount of cortisol produced within the brain was not detectable, indicating that specific 
regional testing may be required. This study also generated novel data on asymmetries within 
the IJV system and variability in the cerebrovascular venous system with implications for 
research and clinical practice. 
Further longitudinal studies investigating the association between sarcopenia and ARCD are 
now required to improve understanding of these important relationships further. I plan to use 
the data collected from LBC 1936 wave 3 and the data to be collected from wave 4 to explore 
these relationships in longitudinal analyses. Hopefully this will generate research hypotheses 
for future studies investigating potential underlying mechanisms and ultimately improve 
treatment options for these two important age related conditions. As the population of the 
world ages, increasing attention is paid to improving healthy life expectancy, which includes 
delaying two of the most feared consequences of growing older: poor mobility and falls, and 
cognitive decline. I hope to contribute to this existing body of research in the hope that 
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Abstract
Introduction: Low muscle mass secondary to disease and ageing is an important cause of excess mortality and morbidity.
Many studies include a MR brain scan but no peripheral measure of muscle mass. We developed a technique to measure
posterior neck muscle cross-sectional area (CSA) on volumetric MR brain scans enabling brain and muscle size to be
measured simultaneously.
Methods: We performed four studies to develop and test: feasibility, inter-rater reliability, repeatability and external validity.
We used T1-weighted MR brain imaging from young and older subjects, obtained on different scanners, and collected mid-
thigh MR data.
Results: After developing the technique and demonstrating feasibility, we tested it for inter-rater reliability in 40 subjects.
Intraclass correlation coefficients (ICC) between raters were 0.99 (95% confidence intervals (CI) 0.98–1.00) for the combined
group (trapezius, splenius and semispinalis), 0.92 (CI 0.85–0.96) for obliquus and 0.92 (CI 0.85–0.96) for sternocleidomastoid.
The first unrotated principal component explained 72.2% of total neck muscle CSA variance and correlated positively with
both right (r = 0.52, p = .001) and left (r = 0.50, p = .002) grip strength. The 14 subjects in the repeatability study had had two
MR brain scans on three different scanners. The ICC for between scanner variation for total neck muscle CSA was high at
0.94 (CI 0.86–0.98). The ICCs for within scanner variations were also high, with values of 0.95 (CI 0.86–0.98), 0.97 (CI 0.92–
0.99) and 0.96 (CI 0.86–0.99) for the three scanners. The external validity study found a correlation coefficient for total thigh
CSA and total neck CSA of 0.88.
Discussion: We present a feasible, valid and reliable method for measuring neck muscle CSA on T1-weighted MR brain
scans. Larger studies are needed to validate and apply our technique with subjects differing in age, ethnicity and
geographical location.
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Introduction
Low muscle mass secondary to disease and ageing is an
important cause of excess mortality and morbidity [1–4]. Studies
investigating correlates of muscle loss or potential interventions to
slow or reverse muscle loss require accurate measurements of
muscle size. Current imaging techniques used to measure muscle
size include whole body or regional DEXA scans and volumetric
or cross-sectional area measurements on MR or CT scans of the
arm or leg [5]. Arm and thigh cross-sectional area (CSA) have
been used in previous studies as they are large and are viewed to
be used in everyday tasks. However thigh muscle CSA has been
shown to correlate well with total muscle mass and it maybe that
other muscle groups around the body are equally useful as a guide
of general muscle bulk [6,7]. Whilst the above techniques remain
the current gold standard, they are not commonly employed in
clinical practice or in studies out with those directly investigating
muscle mass (eg studies of sarcopenia or cachexia). Volumetric
MR brain scans are commonly used in both research and clinical
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34444
practice. These scans often include much of the posterior neck
muscles. A technique to measure posterior neck muscle CSA on
volumetric MR brain scans would therefore enhance the value of
volumetric MR brains scans: both brain and muscle size could be
measured without additional scanning.
Recent studies have shown a correlation between grip strength
and cognition, which has implications for studying rates of ageing
[8,9]. However, few studies have investigated the relationship
between muscle size and brain size. This is likely due in part to the
fact that two different scans would be required in each subject to
obtain these data. Both brain and muscle size are known to
decrease with age, therefore studying the pattern of their inter-
relationship would allow investigation of their shared risk factors
which, in turn, may suggest underlying mechanisms. Many
longitudinal aging studies include a volumetric MR brain scan
[10–12]. If it were possible to measure muscle CSA reliably from
volumetric MR brain scans and this measure was representative of
general body muscle bulk, the relationship between muscle and
brain size could be investigated using a single scan.
MR measurement of neck muscle cross sectional area (CSA) has
been shown to be feasible in young healthy adults using scans
dedicated to this purpose (ie MR Imaging of the neck), but older
adults have not been studied [13–15]. These studies have
demonstrated good inter-rater reliability [14,15]. Moreover, we
found no previous studies documenting a technique to measure
neck muscle size on MR brain scans. The limited data that are
available suggest that neck muscle CSA and strength are
correlated, indicating that neck muscle CSA has good construct
validity [16]. We aimed to establish a novel method for measuring
neck muscle CSAs from routine MR brain volume acquisitions.
This paper details the technique we developed and further studies
to test its reliability, validity and repeatability.
Methods
Study 1: Feasibility study
Goal. To investigate whether it is feasible to measure neck
muscle CSA on MRI volumetric brain scans.
Ethics & Sample. The volumetric MR brain scans used in
this study had already been performed as part of the Lothian Birth
Cohort 1936 (LBC) study, as a primary outcome for that study was
brain volume measurement. Ethics permission for the LBC1936
study protocol was obtained from the Multi-Centre Research
Ethics Committee for Scotland (MREC/01/0/56) and from the
Lothian Research Ethics Committee (LREC/2003/2/29) and
covers this sub-study because the ethics approval included the use
of the data for future research purposes. The research was carried
out in compliance with the Helsinki Declaration. All participants
gave written, informed consent. Twenty consecutive scans from a
final total of 735 were selected between 02/02/09 and 30/03/09.
Participants were community-resident, all born in 1936 and
without any known major musculoskeletal disease. Height, weight
and grip strength in both hands were measured by trained
research nurses at a clinical research facility [11].
Imaging Protocol. The MR imaging was performed with
participants in the supine position on a 1.5 tesla MR imaging unit
(Signa HDxt, GE Healthcare, Milwaukee, USA) at the Brain
Research Imaging Centre (www.bric.ed.ac.uk). A phased array
eight channel head coil was used and inversion recovery prepared
volumetric T1 weighted images were acquired on a coronal plane
for each patient. For this set of images, the alignment was
perpendicular to the long axis of the hippocampus determined
from a preliminary T2 weighted sagittal sequence. The flip angle
was 8u, bandwidth 15.63 KHz, echo time (TE) 4 ms minimum to
13 ms maximum, repetition time (TR) 9.6 ms and inversion or
preparation time (TI) 500 ms. The field of view (FOV), fixed
superiorly at the cranial vertex, was 25.6 cm625.6 cm, slice
thickness 1.3 mm with no slice gap leading to 160 slices, displayed
on a 1926192 matrix. These images took 8.13 minutes to acquire
per patient. Full details of imaging protocol [17].
Development of neck muscle cross sectional area
measurement technique. The image data were transferred
to a Kodak Carestream picture archiving and communication
systems (PACS) workstation where 3-D multiplanar
reconstructions were performed. Freehand cursor was used to
draw a region of interest (ROI) around the neck muscle of interest
in the axial plane to obtain the cross sectional area on each side
separately.
Two raters tested feasibility in ten of the participants. We sought
to develop a technique that ensured raters found the same level
from which to make their CSA measurements. Our first attempt
involved finding the MR slice in which the CSA of the obliquus
capitis inferior was at its maximum in the axial plane. We chose
the obliquus capitis inferior because it is a short muscle and its
width varies more along its length than the other neck muscles in
the scan. We then measured the CSAs for the largest muscles in
that slice of the scan; sternocleidomastoid (SCM), obliquus capitis
inferior, semispinalis capitis, splenius capitis and trapezius for both
right and left sides (Figure 1). Although it was possible to measure
the CSA of neck muscles using this technique, there were
occasional large discrepancies between raters indicating that this
method lacked reliability, particularly with regard to finding the
level to take the measurements.
Therefore, in the second attempt, we measured the neck
muscles’ CSAs of a further ten participants, but this time we
started with the images in the sagittal view with the volume images
loaded into the multiplanar reformat view. We chose the slice
where the C2 vertebral body height was at its maximum. We then
identified the midpoint of the C2 vertebral body height including
the odontoid by measuring along its vertical length from the
odontoid tip to lower end plate using the cursor and then marked
the midpoint. We then switched to the axial view of the
multiplanar reformat at the vertical midpoint of C2 and measured
the CSAs of the neck muscles in that axial image.
We initially attempted to standardise the plane of the axial
image on a line parallel to C2 end plates, but the variability of tilt
in endplates meant that occasionally that line could go as high as
suboccipital level posteriorly and thereby miss the muscles of
interest. Setting the axial slice perpendicular to the vertical line of
measurement through C2 did not work either as it proved difficult
to manipulate the axial slice by small angle changes precisely
enough. Therefore, we used the midpoint of C2 in the sagittal
plane while viewing the images in the multiplanar reformat and
then clicked on the corresponding axial image. This resulted in the
axial slice being parallel to the lower border of the volume scan,
but not related to any particular line in the participant. This time
we measured the three posterior neck muscles (trapezius, splenius
capitis and semispinalis capitis) individually and in combination.
See Figure 2 for the chosen method.
Study 2: Study to measure inter-rater reliability
Goal. To investigate and quantify whether two raters using
this technique would produce the same measurements.
Sample. A further 20 scans from the LBC 1936 study were
studied in addition to the 20 from the feasibility study, to give us a
total of 40 scans to measure with the newly-developed technique.
Neck muscle cross sectional area measurements. We
performed the measurements with the chosen technique, as
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described in the feasibility study, on all 40 MRI scans.(Figure 2)
Each scan was measured three times by both raters and the
median value for C2 body height and each of the three muscle
measurements (SCM, obliquus capitis inferior and combined
trapezius, splenius capitis and semispinalis capitis) were recorded
separately for right and left sides for analysis. We noted that, unlike
thigh muscles, there was only minimal intramuscular fat in the
images of these neck muscles, so we did not seek to adjust for this
or the small area of interfascial fat between trapezius, splenius
capitis and semispinalis capitis in the combined group measure.
Analysis. To compare inter-rater reliability, we calculated the
percentage difference in CSA as measured by the two raters and
the two-way random effects absolute agreement intraclass
correlation coefficients. Multiple linear regression analysis was
used to estimate effects of sex and body mass index (BMI) on neck
muscle CSA. Principal components analysis was used to extract a
general trait for neck muscle CSA from the three individual muscle
CSA measures: we accepted components with eigenvalues greater
than unity and inspected the scree plot to identify the number of
components. All analyses were performed using the SPSS 16.0
statistical package.
Study 3: Study to measure repeatability of technique
Goal. To assess whether the technique would provide the
same results on scans measured:
N on the same subject and the same MRI scanner on different
days
N on the same subject and different MRI scanners on different
days
Ethics. All subjects provided written consent and ethics
approval was gained by the local ethics research committee for
the original CaliBrain study (REC 05/S0801/105) [18,19]. This
included further use of the data for research purposes and
therefore further ethics permission for this study was not required.
Sample. The CaliBrain study investigated the reliability of
repeat volumetric brain MR measures with the same scanner and
between different scanners [8]. We therefore used these data to test
the reliability of repeat neck muscle CSA measurement from
volumetric brain MR scans. The participants of the CaliBrain
study were 14 normal volunteers from the three participating
centres aged between 25 and 51 years, see below for details of the
centres. As the data had been collected as part of the CaliBrain
study no power calculations were carried out and we analysed all
the available data. Exclusion criteria for the CaliBrain study were:
previous history of a diagnosed neurological disorder or a major
psychiatric disorder, treatment with psychotropic medication,
including treatment for substance misuse and not meeting the MR
safety criteria.
Imaging protocol. Each of the fourteen participants twice
underwent a structural and functional MR brain scan at three
imaging research centres around Scotland; The Department of
Radiology, University of Aberdeen; The Brain Research Imaging
Centre, Western General Hospital, University of Edinburgh; and
The Neuroradiology Department, Southern General Hospital,
NHS Greater Glasgow South University Hospitals Division.
Therefore each participant underwent 6 separate scans. Each
scan took place on a separate day and there were nominally 2
weeks between the scans at the same site. We only used the
structural data for our study. The three scanners used were all
manufactured by General Electric (GE Healthcare, Milwaukee,
Wisconsin) and had primary field strengths of 1.5 T however the
machines had differing software and hardware. Images were taken
in the coronal plane at a slice thickness of 1.7 mm with no slice
gap. 3D reconstruction was used to make the measurements with
our technique. Further details of the imaging protocol can be
found in the paper by Moorhead et al. [19]
Cross-sectional area measurement technique. The
measurements were performed using Analyze, the biomedical
image analysis software (Mayo Foundation, Rochester, Minnesota,
USA).
The CaliBrain images were aligned with the ACPC line, an
anatomical line which runs between the superior surface of the
anterior commissure and the center of the posterior commissure.
The feasibility and reliability studies had used images which were
perpendicular to the MR table. Therefore the images underwent
pre-processing prior to the measurements being made. This
involved the images being tilted 15 degrees forward on the axial
axis. This was actually preferable to the original study where the
angle of the brain as viewed on PACS was not standardised, but
just depended on how the patient placed their head in the scanner,
as all the images in the CaliBrain study were standardised to an
Figure 1. Figure of the posterior neck muscles and diagram
demonstrating how the measurement plane was selected. A.
Non-contrast T1-weighted MR of transverse plane of the neck at mid-
infero-superior-C2 level. B. Outline diagram showing the neck muscles
whose cross-sectional areas were measured. C. Outline diagram
demonstrating how measurement plane is selected with an example
C2 height of 42 mm.
doi:10.1371/journal.pone.0034444.g001
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anatomical landmark, the ACPC line. Neck muscle CSA was
measured as described in the feasibility study.
Analysis. ICCs were calculated for comparing within scanner
and between scanner variations. When calculating the ICC for
within scanner variation the measurements taken from the first
and second scans were compared for each of the three individual
measurements (ie combined group, SCM and obliquus) and the
total neck muscle CSA (ie all three measurements for right and left
sides added together). The ICC for between scanner variation
were calculated using the mean total muscle CSA for each
measurement on that site (eg (Total neck muscle CSA Edinburgh
scan 1+Total neck muscle CSA Edinburgh scan 2)/2).
All data were analysed using the SPSS 17.0 statistics package.
Three nonsynchronous sets of measurements were taken for each
scan and the median values were used for the analysis.
Study 4: External validity study
Goal. To assess and quantify whether neck CSA is related to
mid-thigh CSA, which has been previously shown to be related to
general muscle mass [6,20].
Ethics. Ethics permission for the MR brain scans undertaken
as part of the Lothian Birth Cohort (LBC) 1936 project had
already been obtained as per study 1. A substantial amendment
was submitted to allow us to recruit 25 subjects from the LBC
1936 pool and perform a MR scan of their mid-thigh. This was
approved in April 2010.
Sample. 735 LBC1936 participants had brain MR data
available. Power calculations indicated that for a minimum
Pearson correlation coefficient of 0.6 at alpha = 0.05, n = 20
provided 80% power and n = 26 provided 90% power. We
therefore chose to scan 25 subjects. We contacted the subjects who
had most recently had their MR brain scan, within a few weeks, to
ensure that the effect of any variable on the thigh muscle bulk in
the time lapsing between the MR brain and thigh scans was as
small as possible. Participants were excluded if they had severe
osteoarthritis affecting the knee or hip or a previous stroke,
previous total hip replacement, or a history of any degenerative
neurological disorder
Imaging protocol. The MR brain scans had been collected
as part of the LBC 1936 study. See study 1 (above) for details of
the protocol.
We used anatomical landmarks to identify the midpoint of the
femur. We palpated for the protuberance of the greater trochanter
and the upper border of the patella and then measured down the
lateral aspect of the thigh using these landmarks and marked the
midpoint. A cod liver oil capsule was then taped there to allow us
to identify the corresponding MR slice. This was performed
separately for each leg.
The scan was performed using a 3.0 tesla Siemens Verio
research MR scanner (Siemens Medical, Germany) at the Clinical
Research Imaging Centre within the Queen’s Medical Research
Institute. Images were acquired using a combination of body and
spine matrix coil elements. The subjects lay supine for the scan. A
coronal scouting scan was performed and then 5–10 axial images
were taken with the cod liver oil capsules in the middle slices. Slice
thickness was 3 mm with no slice gap.
Cross-sectional Area Measurements. Measurements for
sternocleidomastoid, obliquus and the combined group (trapezius,
splenius and semispinalis) were made using the above described
technique on a PACS workstation.
The thigh muscle CSA measurements were also performed on a
PACS workstation using the slice on each side where the cod liver
oil capsule was at its widest which should indicate the anatomically
chosen midpoint. Three measurements were taken on each leg: the
anterior group, the medial group and the posterior group. The
anterior group consisted of the quadriceps (vastus lateralis,
intermedius and medialis and rectus femoris) and sartorius, the
medial group of gracilis and the adductors (longus, brevis and
magnus) and the posterior group of the hamstrings (biceps femoris,
semitendinosus and semimembranosus).
Both the thigh and neck measurements were repeated 3 times
for the left and right sides.
Figure 2. Flowchart summarizing method to measure craniad muscles cross-sectional areas.
doi:10.1371/journal.pone.0034444.g002
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Analysis. All data were analysed using the SPSS 17.0
statistics package. Three nonsynchronous sets of measurements
were taken for each subject and the median values were used for
the analysis.
Please see figure 3 for a summary of the methods for the above
four studies.
Results
Study 1: Feasibility study
The measurements made with the chosen technique were used
to calculate intra-class correlation coefficients (ICC) to compare
the median value of 3 measurements made by rater A against rater
B. In this study we measured each of the three posterior muscles
(trapezius, splenius and semispinalis) separately and together in a
single measurement as a combined group. The boundaries
between these three muscles are not clear and we thought that
the differences in CSA measurements were a reflection of where
the boundary was taken to be rather than true measurement
differences in the size of the muscles themselves. The ICC and
associated 95% confidence intervals support this view, as the
values for the ICC for the three respective individual muscles were
0.78 (CI 0.16–0.94), 0.86 (CI 0.48–0.97) and 0.90 (CI 0.60–0.97)
and the combined group ICC was much stronger at 0.99 (CI 0.95–
1.00). Therefore we decided to use the combined measurement
from thereon with individual measurements of the stand alone
muscle, obliquus and sternocleidomastoid. For full results please
see table 1.
Study 2: Study to measure inter-rater reliability
Of the 40 scans from the LBC 1936 cohort, one proved to be a
duplicate and was excluded. One rater considered one scan to be
unmeasurable whilst the other considered two scans unmeasur-
able. Scans were thus measured for 37 (18 male, 19 female)
participants of mean age 72.0 (standard deviation 0.38) years when
weighed and mean age 72.2 (sd 0.25) years when scanned. Men
had a mean height of 1.73 m (sd 0.07), mean weight of 85.0 kg (sd
11.2) and mean BMI of 28.2 kg/m2 (sd 3.2). Women had a mean
height of 1.59 m (sd 0.04), mean weight of 71.0 kg (sd 14.0) and
mean BMI of 27.9 kg/m2 (sd 5.2).
Rater A measured mean C2 height as 3.7 cm (sd 0.5) in men
and 3.6 cm (sd 0.2) in women. Rater B measured mean C2 height
as 4.0 cm (sd 0.4) in men and 3.7 cm (sd 0.2) in women. These
differences had no effect on slice chosen as midpoint of C2 for
muscle CSA measurement (Figure 4).
Figure 3. Diagram summarizing the methods for the four studies.
doi:10.1371/journal.pone.0034444.g003
Table 1. Intra-class correlation coefficients for the second
technique trialled in the feasibility study (Study 1).




Summation of Trapezius, Splenius &
Semispinalis
0.978 0.916–0.994
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Table 2 shows the mean CSAs per rater, absolute mean
difference and mean difference as percentage of CSA. Intraclass
correlation coefficients between raters were 0.99 (95% confidence
intervals 0.98–1.00) for the combined group CSA, 0.92 (95% C.I.
0.85–0.96) for obliquus CSA and 0.92 (95% C.I. 0.85–0.96) for
sternocleidomastoid CSA (Table 3). Obliquus CSA was predicted
by sex (beta = 20.54 for women, p,.001) and BMI (beta = 0.36,
p = .01) adjusted R2 for model = 0.40, sternocleidomastoid CSA by
sex (beta = 20.60 for women, p,.001) and BMI (beta = 0.41,
p = .001) adjusted r2 for model = 0.52, and combined CSA by sex
(beta = 20.74 for women, p,.001 only) adjusted r2 for mod-
el = 0.55.
There were no significant associations between inter-rater CSA
difference and mean CSA for the combined group (r = 0.08,
p = .66), but larger inter-rater differences were significantly
associated with smaller CSAs for both obliquus (r = 20.61,
p,.001) and sternocleidomastoid (r = 20.39, p = .018). CSAs all
correlated highly significantly with each other (p,.001): com-
bined-obliquus (r = 0.59), combined-sternocleidomastoid (r = 0.66),
obliquus-sternocleidomastoid (r = 0.50).
A Bland-Altman plot for total neck muscle CSA demonstrates a
degree of linear bias with Rater 2 reporting bigger measurements
for the small neck muscle CSAs and smaller measurements for the
bigger neck muscle CSAs (Figure 5A). If obliquus is removed,
leaving the combined group plus SCM, this linear bias appears to
resolve (Figure 5B). However the bias of measurement is small for
both graphs.
Table 4 shows coefficients of variation (CV) for both raters and
a Levene’s test for homogeneity which found no significant
Figure 4. Plot of MR slice chosen as representing the mid-point of C2 for both raters.
doi:10.1371/journal.pone.0034444.g004
Table 2. Mean cross-sectional areas (CSAs) as measured by each rater summed for left and right, together with absolute mean
difference and mean difference as percentage of CSA between raters (Study 2).
Combined Group Obliquus Capitis Inferior Sternocleidomastoid
Mean CSA rater A (mm2) 1850 773 422
Mean CSA rater B (mm2) 1847 753 376
Mean inter-rater difference (95% CI) (mm2) 3 (230, 36) 20 (233, 73) 46 (229, 63)
Mean difference as percentage of mean CSA
(95% CI)
0.3 (21.5, 2.0) 4.1 (26.3, 14.4) 11.3 (7.1, 15.5)
doi:10.1371/journal.pone.0034444.t002
Table 3. Intra-class correlation coefficients with 95%
confidence intervals for the reliability study (Study 2).
Muscle Measurement ICC 95% Confidence Intervals
Combined group 0.99 0.98–0.995
Obliquus capitis inferior 0.92 0.85–0.96
SCM 0.92 0.85–0.96
doi:10.1371/journal.pone.0034444.t003
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difference between the CV for the two raters for any of the muscle
measurements.
The first unrotated principal component explained 72.2% of
total CSA variance for the three muscles (loadings were 0.89 for
the combined group, 0.81 for obliquus and 0.85 for sternocleido-
mastoid) and correlated positively with grip strength of both right
(r = 0.52, p = .001) and left (r = 0.50, p = .002) hands. The second
principal component had an eigenvalue of 0.51.
Study 3: Study to measure repeatability of technique
Data were analysed for all 14 participants. Thirteen of the
participants had undergone all 6 scans and one had undergone 5
of the scans having not completed their second scan in one
location. There were 10 men and 4 women. The mean age was
36.3 years (range 25–51).
Mean values (sd) for the measurements across all six scanners for
right and left sides added together were: SCM 4.97 cm2 (1.11),
combined group 20.12 cm2 (5.74), obliquus 9.88 cm2 (3.23) and
total neck muscle CSA 34.97 cm2 (8.67). ICCs were calculated for
within scanner and between scanner variability (Tables 5 & 6).
Within scanner ICCs for the Edinburgh scanner used for studies 1,
2 and 4 ranged from 0.83 for SCM to 0.96 for the combined
group.
Bland-Altman plots show no definite linear bias between the
Edinburgh and Glasgow scanners and the Aberdeen and
Edinburgh scanners (Figures 6A & 6B). The Aberdeen-Glasgow
plot indicates that the Aberdeen scanner may overestimate larger
neck muscle CSA and underestimate smaller neck muscle CSA
(Figure 6C). However the numbers involved in this study were
small (n = 14).
Table 7 shows the coefficients of variance (CV) for the mean
values for each of the three scanners and a Levene’s test of
homogeneity which found no significant difference in CV for any
of the three scanners, for any of the muscle measurements.
Study 4: External validity study
25 subjects underwent the additional thigh scan; however, only
24 could be used in the analyses as one patient had not tolerated
the full MR brain scan so we were unable to make the neck muscle
CSA measurements. There was no overlap between subjects in
study 2 and study 4. Of these 24 subjects, 11 were female and 13
male. Mean age (sd) was 73.8 years (0.27). Mean weight (sd) for the
women was 63.2 kg (15.4) and for the men was 85.6 kg (10.9).
Mean total neck muscle CSA (sd) was 22.5 cm2 (3.7) for the
female subgroup and 38.1 cm2 (6.3) for the male subgroup. Mean
total thigh muscle CSA was 184.3 cm2 (36.5) for the female
subgroup and 277.0 cm2 (31.3) for the male subgroup. An
independent t test showed that both total neck muscle CSA
(p,0.0005) and total thigh muscle CSA (p,0.0005) were
significantly different between the female and male subgroups.
The correlation coefficient for all subjects for total thigh CSA and
total neck CSA was 0.88 indicating that each explained at least
77.4% of the variance of the other.
Discussion
Summary of findings
This study sought to develop a technique to measure neck
muscle cross-sectional area on volumetric MR brain scans. An
initial feasibility study led to the formation of the
technique.(Figure 2) The reliability study then demonstrated that
the technique had high inter-rater reliability for measurement of
the CSA of the combined trapezius, splenius and semispinalis
group in older adults. Obliquus capitis inferior and sternocleido-
mastoid CSAs are smaller muscles and measurements were less
reliable between raters, though intraclass correlation coefficients
remained high.
Study 3 demonstrated that the technique has good within
scanner and between scanner repeatability. The confidence
intervals for the measurements of the combined group and the
total neck muscle area are quite narrow however the confidence
intervals for the SCM and obliquus capitis inferior measurements
are wider. This is because the cross-sectional areas of the SCM
and obliquus muscles are smaller than either the combined or the
total measurements. This means that any measurement errors will
account for a greater proportion of the CSA than for muscles with
a large area.
The obliquus is a short muscle whose cross-sectional area varies
greatly over its length, unlike the other four muscles, as it has a
wide belly and comparatively narrow tails. Our technique meant
Figure 5. Bland-Altman plots for total neck muscle CSA and SCM+combined CSA measured by 2 raters. Bias of measurement between 2
different raters (mean of the ordinate) and limits of agreement (2sd) are represented by a solid and two dashed lines respectively. A. Bland-Altman
plot for measurements of total neck muscle CSA by 2 different raters. B. Bland-Altman plot for measurements of SCM+combined CSA by 2 different
raters.
doi:10.1371/journal.pone.0034444.g005
Table 4. Coefficients of variation (%) with 95% CI and Levene’s significance test between the two raters (Study 2).
Measurement Rater
Coefficients of Variation (CV)
(%) 95% CI for CV Levene’s test (Significance)
Combined group 1 28.1 22.9–36.5 0.96
2 28.5 23.2–37.0
Obliquus 1 43.8 35.6–56.9 0.10
2 32.3 26.3–42.0
SCM 1 31.0 25.2–40.3 0.82
2 29.8 24.2–38.7
Total neck muscle CSA 1 28.2 22.9–36.6 0.47
2 25.9 21.1–33.6
doi:10.1371/journal.pone.0034444.t004
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that in some subjects we were measuring across the belly of the
obliquus and in some just the tail end. It also runs at an oblique
angle and we identified that this angle varies between subjects.
This meant that the area of obliquus we were measuring was an
inexact proxy. For these reasons we conclude that the obliquus
measurement should not be included in our technique. The ICCs
are not as strong for the SCM as the combined group in the
repeatability and reliability studies, which is likely a reflection of its
small size. However as there are not the same intrinsic anatomical
problems in measuring this muscle as there are with the obliquus
and as total neck muscle CSA including the SCM appears to have
stronger ICCs than the combined group alone, it is probably
beneficial to include the SCM in addition to the combined group
to provide a better estimate of general muscle bulk.
The final study was designed to measure the external validity of
the technique. It shows that there is a strong correlation between
neck muscle cross sectional area and thigh muscle cross sectional
area, which is often used as a proxy for general muscle mass [21–
23]. The percentage variance (ie r-squared) is 76.7% and the 1st
unrotated principal component of neck muscle CSA was found in
the reliability study to explain 72.2% of variance. Extracting
principal components is useful to reduce random measurement
errors that might be associated with individuals’ neck positions for
example. The principal component correlated positively with grip
strength, providing further support for neck muscle CSAs’ validity
as an index of sarcopenia. This means that posterior neck muscles
can be used equally as well as thigh muscles as an index of general
muscle bulk [6,7].
Previous research on quantifying muscle mass
Previous studies quantifying neck muscle CSA have only
focused on young subjects and have used scans performed
specifically for that purpose. They have however shown good
reliability in the techniques used [14,15]. We found no previous
studies which measured neck muscle CSA on MRI scans on
elderly subjects and none which used MRI brain scans for this
purpose.
When considering the validity of using a cross-sectional
measurement of muscle size to infer general muscle bulk we
referred to previous studies on body composition. Studies
investigating how differing muscle groups relate to each other
have tended to compare upper and lower limb muscle mass alone
[24–26]. We found no studies which compared muscle CSA, mass
or volume between any other two or more areas of the body,
including the neck. Three large studies on body composition
suggest that the distribution of muscle between the upper and
lower limbs varies with gender, age, height, weight and ethnicity
[24–26].
Strengths and limitations of the studies
Although there is no reason to suppose that this methodology is
not applicable in younger adults and older adults (ie 75 y+), three
of the studies were restricted to a narrow age cohort around 72
years old and the study of younger subjects only had a n = 14. The
study participants were all community-resident volunteers and
thus relatively healthy and were not diverse in terms of geography
or ethnicity. The narrow geographical location of the subjects is
important as it has been shown that anthropometric measure-
ments vary across the UK. Bannerman et al collected data from
residents of Edinburgh and compared their results with anthro-
pometric reference data from South Wales and Nottingham. They
found significant differences between the three groups confirming
their hypothesis that anthropometric measurements vary across
geographical area [27].
Skeletal muscle can be split into two groups; postural and
phasic. Postural muscles have a larger percentage of type 1 fibres
and show less fatigability. Phasic muscles are primarily involved in
movement and have a higher proportion of type 2 muscle fibres. A
feature of ageing muscle is that type 2 fibre width decreases more
than type 1 fibre width, therefore the relation between neck CSA
(mainly postural, ie more type 1 fibres) and thigh CSA (a mixture
of postural and phasic) will change with age [28–31].
Despite not standardising the angle of the axial measurement
slice relative to the patient, we still achieved very high inter-rater
reliability. However, it is possible that the measurement variability
would be larger in a longitudinal study if the patients were in
different positions in the scanner on each occasion. Such
differences are usually only slight because head, neck and back
are passively supported during scanning leaving the neck muscles
in a relaxed state. Lateral changes are unlikely to have a major
effect because muscle CSAs are summed for both left and right so
that reductions on one side could be compensated by the
accompanying increase on the other. Such compensation does
not apply to antero-posterior positioning; however, small differ-
Table 5. Between scanner intra-class correlation coefficients




E, A & G Total means 0.94 0.86–0.98 p,0.001
E, A & G SCM means 0.76 0.53–0.90 p,0.001
E, A & G Comb means 0.95 0.89–0.98 p,0.001
E, A & G Obliq means 0.78 0.56–0.92 p,0.001
doi:10.1371/journal.pone.0034444.t005
Table 6. Within scanner intra-class correlation coefficients for
the repeatability study (Study 3).
Groups ICC 95% Confidence Intervals Sig
E1 & E2 Total 0.95 0.86–0.98 p,0.001
A1 & A2 Total 0.97 0.92–0.99 p,0.001
G1 & G2 Total 0.96 0.86–0.99 p,0.001
E1 & E2 SCM 0.83 0.55–0.94 p,0.001
A1 & A2 SCM 0.80 0.48–0.93 p,0.001
G1 & G2 SCM 0.90 0.70–0.97 p,0.001
E1 & E2 Comb 0.96 0.88–0.99 p,0.001
A1 & A2 Comb 0.97 0.92–0.99 p,0.001
G1 & G2 Comb 0.96 0.88–0.99 p,0.001
E1 & E2 Obliq 0.93 0.79–0.98 p,0.001
A1 & A2 Obliq 0.83 0.56–0.94 p,0.001
G1 & G2 Obliq 0.83 0.53–0.95 p,0.001
Key for Table 5& 6:
N E = scan performed in Edinburgh.
N A = Scan performed in Aberdeen.
N G = Scan performed in Glasgow.
N 1 & 2 = 1st and 2nd scan on that site.
N SCM = Sternocleidomastoid.
N Comb = Combined group (Trapezius, Splenius capitis, Semispinalis capitis).
N Obliq = Obliquus Capitis Inferior.
N Total = Total neck muscle CSA.
doi:10.1371/journal.pone.0034444.t006
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ences in this plane are also unlikely to be important. A difference
in angle of C2 between two repeated scans in the sagittal plane of
5u would result in a CSA difference of 0.4%, 10u increases CSA by
1.5% and 15u by 3.5% all within the limits for inter-rater SCM
CSA difference; even a 20u angle increases CSA by only 6.4%,
probably at the limit of utility of the technique to detect medium
effect sizes. If reliability in longitudinal studies was not acceptable
(i.e. mean differences in plane angles measured at C2.20u),
increased positional standardization would be necessary which
might include using more than one anatomical marker from a T1-
weighted volume scan for standardization.
Most of these limitations could be addressed by a larger study
which included a wider spread of age, geographical area, ethnicity,
health status and an equal gender balance. It would be interesting
to look at muscles from elsewhere in the body also. For example
including a measure of upper arm CSA and calf muscle CSA and
to investigate how the comparative size of these muscles varies
with age.
Implications for future research
This new technique is particularly interesting because several of
the longitudinal studies investigating ageing involve an MR brain
scan, therefore the method could be used to measure changes in
muscle size and consequently estimate sarcopenia in these studies
without any further imaging. This will allow the wealth of
variables already collected as part of these studies to be researched
as possible correlates of sarcopenia. Longitudinal studies are
important sources of information for researchers interested in age
associated disease to allow identification of key risk factors. These
in turn allow hypotheses to be generated which can lead to both an
understanding of the mechanisms underlying these diseases, which
may lead on to development of treatments, and the possibility of
generating advice to prevent or slow down some of the disease
processes. Although we developed the technique on MR volume
brain images, it is now common to acquire volume data when
performing a CT brain scan and, as there is often good
differentiation between muscle and fat in the neck, the same
approach could possibly work on CT scans as well. Further testing
is required.
We now plan to use this technique on two longitudinal studies to
allow us to investigate correlates of sarcopenia and identify
possible causative factors from lifestyle and biomedical data which
have been collected concurrently with the MRI scans.
Conclusion
We have developed a feasible, valid and repeatable method for
measuring neck muscle cross-sectional area on MR brain scans
which has good inter-rater reliability. This technique can be used
to measure neck muscle CSA which can serve as a proxy measure
of muscle bulk as shown by the above factor analysis and shared
variance measures. We have demonstrated that neck muscle CSA
correlates strongly with grip strength, a commonly used functional
measure. The development of a reliable method to measure neck
muscle CSA from volumetric MR brain scans potentially opens up
Figure 6. Bland-Altman plots for total neck muscle CSA
measured on 3 different MRI scanners. Bias of measurement
between different MRI scanners (mean of the ordinate) and limits of
agreement (2sd) are represented by a solid and two dashed lines
respectively. A. Bland-Altman plot for total neck muscle CSA measured
on the Aberdeen and Edinburgh MR images. B. Bland-Altman plot for
total neck muscle CSA measured on the Edinburgh and Glasgow MR
images. C. Bland-Altman plot for total neck muscle CSA measured on
the Glasgow and Aberdeen MR images.
doi:10.1371/journal.pone.0034444.g006
How to Measure Neck Muscle Area on MR Brain Scans
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34444
a new field of radiological aging research. This in turn will allow
sarcopenia to be investigated in studies which have involved a
brain scan but no measure of muscle bulk without involving any
additional scanning. Additional studies are needed to investigate
these important relationships further with particular reference to
how the relationships change with age.
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http://www.biomedcentral.com/1471-2318/13/20RESEARCH ARTICLE Open AccessNeck muscle cross-sectional area, brain volume
and cognition in healthy older men; a cohort
study
Alixe HM Kilgour1,2*, Karen J Ferguson1,2, Calum D Gray3,6, Ian J Deary1,4, Joanna M Wardlaw1,3,5,6,
Alasdair MJ MacLullich1,2 and John M Starr1,2Abstract
Background: Two important consequences of the normal ageing process are sarcopenia (the age-related loss of
muscle mass and function) and age-related cognitive decline. Existing data support positive relationships between
muscle function, cognition and brain structure. However, studies investigating these relationships at older ages are
lacking and rarely include a measure of muscle size. Here we test whether neck muscle size is positively associated
with cognition and brain structure in older men.
Methods: We studied 51 healthy older men with mean age 73.8 (sd 1.5) years. Neck muscle cross-sectional area
(CSA) was measured from T1-weighted MR-brain scans using a validated technique. We measured multiple
cognitive domains including verbal and visuospatial memory, executive functioning and estimated prior cognitive
ability. Whole brain, ventricular, hippocampal and cerebellar volumes were measured with MRI. General linear
models (ANCOVA) were performed.
Results: Larger neck muscle CSA was associated with less whole brain atrophy (t = 2.86, p = 0.01, partial eta squared
17%). Neck muscle CSA was not associated with other neuroimaging variables or current cognitive ability. Smaller neck
muscle CSA was unexpectedly associated with higher prior cognition (t = −2.12, p < 0.05, partial eta squared 10%).
Conclusions: In healthy older men, preservation of whole brain volume (i.e. less atrophy) is associated with larger
muscle size. Longitudinal ageing studies are now required to investigate these relationships further.
Keywords: Sarcopenia, Cognition, Aging, Muscle cross-sectional area, Brain volumeBackground
As the population of the world ages, governments, re-
search funding bodies and the general public are becom-
ing increasingly interested in promoting healthy ageing.
Healthy ageing is not just the avoidance of pathology
but also the slowing down of the natural rate of ageing,
mainly through lifestyle adaptations. Two important
consequences of the normal ageing process are sarco-
penia and age-related cognitive decline (ARCD).
Sarcopenia is the loss of muscle mass and function
with advancing age [1-3]. It is a main component of the* Correspondence: a.kilgour@ed.ac.uk
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reproduction in any medium, provided the orfrailty syndrome, and greater degrees of sarcopenia are
associated with increased levels of falls, disability, mor-
bidity and death [4-6]. Muscle mass is lost from the third
decade at a rate of 1-2% per year, increasing with age
[7-9]. Muscle function deteriorates more quickly, with
studies showing strength to decline by 1-4% per year and
power to decline by 3-4% per year [8,10]. ARCD is the
normal and universal change in cognition seen with in-
creasing age [11]. Such changes mainly affect the so-called
‘fluid’ abilities (eg working memory, speed of processing,
reasoning). Crystallised abilities (eg. vocabulary, know-
ledge, autobiographical memory) remain largely intact
[12,13]. Studies have shown that the decline seen in fluid
cognitive abilities begins in early adulthood, with some de-
terioration seen by the early 20s [14].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2318/13/20Until recently, muscle and brain ageing had rarely
been studied in tandem; however, studies demonstrating
improved cognition in later life with increased physical
activity have highlighted this important area of research.
For example a Cochrane review of randomised controlled
trials found evidence that aerobic physical activities
improved cognitive function in healthy older adults, with
effects observed for motor function, cognitive speed, and
auditory and visual attention [15]. Observational studies
have also found positive relationships between physical
activity and cognitive function [16,17]. There is some
evidence that both grey and white matter brain volume
can be significantly improved by aerobic exercise in older
adults [18]. It was hypothesized that these relationships
were due solely to cardiovascular fitness, and although this
may play a role, animal studies have found other under-
lying mechanisms including: increased levels of brain-
derived neurotrophic factor which may contribute to
neurogenesis, effects on neurotransmitter systems and
increased insulin-like growth factor 1 [19].
Several studies have also demonstrated a positive rela-
tionship between muscle function (eg handgrip strength,
gait speed) and cognition [20-23]. Possible mechanisms
which might account for the shared variance in muscle
and brain size and function with healthy ageing include:
the role of hormones and growth factors (eg gluco-
corticoids) [24,25]; immunosenescence and inflamma-
tion (eg IL6 and CRP) [26,27]; oxidative stress and
mitochondrial ageing [28,29]; decreased stem cell activity
[30,31]; and environmental and lifestyle factors (eg
smoking) [32,33].
The above findings showing association between brain
and muscle structure and function add support to
the common cause hypothesis, that core underlying
processes determine the rate of ageing in each organ
throughout the body. If we are able to demonstrate an
association between muscle size and brain size and func-
tion, this could add further weight to the common cause
hypothesis [34-37]. This would have large implications
for future treatments designed to modify the rate of age-
ing, which could possibly target several organs at once
(eg muscle and brain) as opposed to individualised
treatments being developed.
It is known that muscle size and function (ie strength
or power) do not age in parallel [10,38], therefore the as-
sociation between muscle size and either brain structure
(eg whole brain volume) or cognitive function requires
independent study. We found only one study which has
investigated the relationship between muscle bulk and
brain structure in older adults; however, this study
included subjects with Alzheimer’s disease along with
normal controls [39]. The studies investigating muscle
size and cognition have largely relied on simple cognitive
screening tools (eg Mini Mental State Examination(MMSE)) and do not contain a measure or estimate of
prior cognitive ability [40-42].
Here we studied community-dwelling healthy older
men, measuring: neck muscle cross-sectional area (CSA),
multiple cognitive domains including estimated prior cog-
nitive ability and neuroimaging volumes. We hypothesised
that lower muscle bulk is associated with structural




Participants were 51 community-dwelling men involved
in a longitudinal ageing study investigating healthy age-
ing, glucocorticoid status and brain structure [43,44].
The study was approved by the Lothian Health Ethics
Committee. All subjects gave written informed consent
and the research was carried out in compliance with the
Helsinki Declaration. Data from the second wave of the
study were used because the smaller MR head coil used
in the first wave excluded the neck muscles. Exclusion
criteria were previously provided [43,44]. Participants
were healthy, lacking of significant illness, including
dementia, stroke, ischaemic heart disease, depressive illness,
excessive alcohol intake, and cancer. No participants were
taking psychotropic medication.
MR brain imaging
The full MR brain imaging protocol has been previously
published [43]. In summary, imaging was performed on
a GE Signa LX 1.5 T (General Electric) MR scanner.
Participants received a sagittal T1-weighted spin echo
sequence covering the whole head (TR 450 msec, TE
9 msec, FOV 24 cm, matrix 256 × 224, slice thickness
5 mm (no gap)) and a volume scan consisting of a
T1-weighted 3D inversion recovery prepared sequence
(3D IR_PREP) acquired in the coronal plane with slices
perpendicular to the long axis of the hippocampus and
covering the whole head (TI 600 msec with TE set to
minimum, FOV 22 cm, matrix 256 × 192, slice thickness
1.7 mm (no gap)).
Brain structure measurements
Image analysis was performed using Analyze v7.0 for
Windows (Mayo Clinic, Rochester, MA). Whole brain,
hippocampal and ventricular volumes [43], and intracra-
nial area (a validated estimate of intracranial volume
[45]) were obtained by an experienced rater.
Neck muscle cross-sectional area
We used neck muscle cross-sectional area (CSA) as a
measure of muscle size. We have previously shown in a
study of 24 subjects that neck muscle CSA is strongly
correlated with thigh muscle CSA (R2 0.77), which is
Table 1 Neuroimaging and muscle cross-sectional
area data
N Mean Std. Deviation
Whole brain volume (cm3) 50 1149.8 90.4
Intracranial area (cm2) 50 157.9 9.6
Total ventricular volume (cm3)* 50 31.2 24.0
Total hippocampal volume (cm3) 48 7.0 0.8
Cerebellar volume (cm3) 50 135.4 14.3
Total SCM muscle area (cm2) 49 5.1 1.1
Total comb muscle area (cm2) 49 22.8 3.1
Total muscle area (cm2) 49 28.0 3.4
Valid N (listwise) 47
*Non-parametric data, median and inter-quartile range presented.
Table 2 Prior and current cognition data
N Mean Std. Deviation
National adult reading test * 47 42.0 13.0
Mini mental state Examination * 50 28.0 4.0
Controlled word association test 47 40.4 10.9
Digit symbol substitution test 46 43.3 10.7
Raven’s standard progressive matrices 46 40.0 9.1
Logical memory 47 51.6 15.0
Visual reproduction 47 46.4 14.8
Auditory-verbal learning test 47 49.9 9.0
Benton visual retention test * 47 17.0 4.0
Factor 1 (Memory) 45 0.0 1.0
Factor 2 (Cognitive processing) 45 0.0 1.0
Valid N (listwise) 45
*Non-parametric data, median and inter-quartile range presented.
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muscle CSA is generally available in brain MRI studies,
whereas thigh muscle CSA is not usually measured within
longitudinal cognitive ageing studies. Neck muscle CSA
was measured using a validated technique [46]. Full details
can be obtained in the technique paper; however, in sum-
mary, the mid-point of the C2-vertebra was located in the
sagittal slice of a 3D reconstructed image. The image was
then converted to a transverse view and the posterior neck
muscles were outlined using a cursor. The software then
calculated the contained area. The muscles measured were
the semispinalis capitis, splenius capitis and trapezius
(measured as a combined group), and the sternoclei-
domastoid.
Tests of cognitive function
The following tests of cognitive function were performed
as part of the original study, as previously described
[43]: the Mini-Mental State Examination (MMSE, a
screening test for cognitive impairment); the Controlled
Word Association Test (CWAT, tests verbal fluency,
which is an aspect of executive function); the Digit-
Symbol Substitution Test (DSST, tests attention and
processing speed) from the Wechsler Adult Intelligence
Scale; Raven’s Standard Progressive Matrices (RSPM,
tests non-verbal reasoning, an important aspect of fluid
intelligence); Logical Memory (tests immediate and
delayed verbal declarative memory); Visual Reproduction
(tests immediate and delayed visual memory); Rey’s
Auditory-verbal Learning Test (tests verbal memory and
learning); Benton’s Visual Retention Test (tests visual
memory); and the National Adult Reading Test (NART,
provides an estimate of prior general cognitive ability).
Due to the strong correlation between pre-morbid cog-
nitive ability (of which NART provides an estimate) and
educational achievement [47], it was decided to include
only NART and not educational achievement as a pre-
dictor variable. One participant had a MMSE below 24
and was excluded from the analysis as this score may be
reflective of an incipient diagnosis of dementia.
Statistical analysis
Descriptive statistics, exploratory analyses, general linear
modeling (Analysis of Covariance; ANCOVA) and prin-
cipal components analysis were performed on SPSS ver-
sion 18.0 for Windows. Missing values were excluded
listwise. For the ANCOVA we constructed baseline
models with the measures of brain structure and cogni-
tive ability as dependent (i.e. outcome) variables and
neck muscle CSA as an independent variable, adjusting
for intracranial area (ICA) and age. ICA is thought not
to change after the onset of age-related neuronal loss,
particularly in men, therefore can be used as a marker of
peak brain size, thus allowing the outcome variable to bemore reflective of brain atrophy [48]. Also, without
adjusting for ICA it could be argued that those with big-
ger skulls require larger neck muscles for support or that
they are just larger in proportion; therefore, this adjust-
ment also controls for this. We also adjusted for NART
since this was found to correlate significantly with neck
muscle CSA, brain volumes and current cognition. Fur-
thermore, in the models with current cognitive ability as
an outcome variable, adjusting for the NART score
allows the model to reflect the degree of cognitive ageing
that has taken place.
Results
All participants (n = 51) were male with a mean age of
73.8 years (sd 1.5). Descriptive statistics for participant
neuroimaging and neck muscle cross-sectional area data
are in Table 1. Of the 51 MR brain scans reviewed, we
were unable to measure neck muscle CSA on one scan as
the scan did not extend far enough inferiorly to include
the neck muscles at the required level for measurement
Table 3 Spearman’s rho correlations between
neuroimaging, muscle and cognitive variables
(with p values)
Total neck muscle CSA NART
Age .21 -.03
(.15) (.82)
Whole brain volume .07 .49
(.62) (<0.001)
Intracranial area -.11 .56
(.44) (<0.001)
Total ventricular volume .13 .10
(.10) (.50)
Hippocampal volume -.07 .48
(.67) (<0.001)
Cerebellar volume .03 .46
(.83) (<0.001)
Memory factor -.28 .13
(.07) (.40)
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the hippocampal volume could not be measured.
Table 2 contains the descriptive statistics for the cog-
nitive test data. To reduce the risk of type 1 statistical
error by testing multiple associations, we performed
principal components analysis. The Kaiser-Meyer-Olkin
measure verified sampling adequacy. Two principal
components were extracted employing varimax rotation;
the first had an eigenvalue of 2.58, explaining 36.9% of
the variance and the second had an eigenvalue of 2.4,
explaining 34.3% of the variance. For comprehensibility,
we refer to these components as ‘factors’ as is general
usage. Together, the factors explain 71.2% of the vari-
ance in the cognitive test scores. The cognitive tests
which focused on memory (ie Logical Memory, VisualTable 4 ANCOVA for whole brain volume with total neck mus
as predictor variables
Source Degrees of freedom F
Corrected model 4 12.85
Intercept 1 1.06
Age (years) 1 0.79
Intracranial area (cm2) 1 13.13
NART (Score out of 50) 1 8.43
Total neck muscle CSA (cm2) 1 8.16
Corrected total 45
*Unstandardised B coefficients reflect change in whole brain volume in cm3.Reproduction, AVLT and BVRT) had high factor loadings
for Factor 1; therefore, we hereafter call this factor the
Memory Factor. Factor 2 had high factor loadings for the
three other tests: CWAT, DSST and RSPM and hereafter
is referred to as the Cognitive Processing Factor.
Initially bivariate statistics were performed (Spearman’s
rho) (Table 3). The only variable to significantly correlate
with total neck muscle CSA was NART (rho -.36,
p = .01). NART was also found to correlate strongly with
the following variables: intracranial area; unadjusted
whole brain, hippocampal, and cerebellar volumes; and
the cognitive processing factor.
ANCOVA was performed to check for shared variance
among neck muscle CSA and the neuroimaging measures,
the cognitive factors, and NART. Models were corrected
for age, intracranial area (ICA, to correct for head size)
and NART, except in the model for NART where only age
and ICA were adjusted for. Total neck muscle CSA was
found to predict 17% of the variance in whole brain vol-
ume (t = 2.86, p = 0.01) (Table 4). However, total neck
muscle CSA did not significantly predict the variance in
ventricular, hippocampal or cerebellar volumes (p > 0.05).
Neck muscle CSA did not significantly predict variance
in either the memory factor or the cognitive processing
factor (p > 0.05) (Tables 5 & 6). Using the NART score as
an outcome variable, we found that total neck muscle
CSA predicts 10% of the variance in the NART score
(t = −2.12, p < 0.05) after adjusting for ICA and age.Discussion
We found that in healthy elderly men, preservation of
whole brain volume was associated with larger total neck
muscle cross-sectional area. Therefore in an elderly co-
hort, those that have a smaller muscle bulk have under-
gone more brain atrophy. This finding supports the
common cause hypothesis, by demonstrating that the
rate of sarcopenia and ARCD may occur in parallel
within individuals, driven by core underlying biological
processes. However, we found no significant association
between total neck muscle CSA and ventricular volumecle area, intracranial area, age and prior cognition
Unstandardised B* t Sig. Partial Eta squared
<.01 .56
491.40 1.03 .31 .03
-5.64 -.89 .38 .02
0.04 3.62 <.01 .24
3.85 2.90 .01 .17
0.09 2.86 .01 .17
Table 5 ANCOVA for Memory factor with total neck muscle area, intracranial area, age and prior cognition as predictor
variables
Source Degrees of freedom F Unstandardised B* t Sig. Partial Eta squared
Corrected model 4 1.23 .31 .11
Intercept 1 1.39 8.91 1.18 .25 .03
Age (years) 1 1.30 -.12 -1.14 .26 .03
Intracranial area (cm2) 1 0.02 <-.01 -.15 .88 .00
NART (Score out of 50) 1 1.56 .03 1.25 .22 .04
Total neck muscle CSA (cm2) 1 0.28 <.01 -.53 .60 .01
Corrected total 43
*Unstandardised B coefficients reflect change in factor score for the Memory Factor.
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or cerebellar volumes.
We unexpectedly found that total neck muscle CSA
was significantly negatively associated with estimated
prior cognitive ability (NART) after adjustment for ICA
and age, but we found no significant association between
total neck muscle CSA and current cognitive abilities.
This suggests that those with lower prior cognitive abil-
ity may have larger muscles in old age. Muscle mass in
old age is determined by 2 factors. Firstly, peak muscle
bulk obtained in young adulthood, and secondly, rate of
muscle atrophy with ageing. Therefore we hypothesise
that those with lower cognitive abilities may have under-
taken more manual work [49,50] and therefore achieved
a greater peak muscle bulk and a larger muscle mass in
old age. We can find no plausible explanation as to why
a lower prior cognitive ability would favour a slower rate
of muscle atrophy. We unfortunately do not have
sufficiently detailed previous occupational history or
socio-economic class data for the participants to be able
to test this theory further at this point.
We found only one previous study which investigated
the relationship between muscle size and brain size, and
this study also found a positive relationship between
muscle bulk and whole brain volume. Burns et al. stud-
ied elderly people with early Alzheimer’s disease (AD)
(n = 70) or normal cognition (n = 70) and found that
whole brain volume, normalized for head size, wasTable 6 ANCOVA for General Processing Factor with total nec
as predictor variables
Source Degrees of freedom F
Corrected model 4 5.19
Intercept 1 0.23
Age (years) 1 1.60
Intracranial area (cm2) 1 0.15
NART (Score out of 50) 1 11.86
Total neck muscle CSA (cm2) 1 2.86
Corrected total 43
*Unstandardised B coefficients reflect change in factor score for the General Procespredictive of lean mass as measured by DEXA (Beta .20,
p < .001) in both groups [39]. White matter volume was
the primary driving factor for the relationship (Beta .19,
p < .001) while grey matter volume showed no associ-
ation with lean mass. This indicates that the cause of loss
of lean muscle mass in AD may be different to normal
ageing as it is primarily grey matter that is lost in AD.
In the above study Burns et al. also investigated the re-
lationship between MMSE and a measure of global cog-
nitive performance (a composite score made up of the
results of a battery of tests, including the DSST and
verbal fluency) with muscle mass [15]. They found a
significant positive association between both the global
cognitive performance score (Beta .12, p = .007) and
MMSE (Beta .11, p = .009) and muscle mass, controlling
for age and sex but not for prior cognition which we
have shown to correlate with both brain and muscle size
(Table 3). Our study was able to investigate the relation-
ship between cognitive decline, by adjusting for prior
cognition using the NART score, and current cognition,
whereas this study only looked at cross-sectional data
from current cognition. This may explain why they
found an association between current cognition and
muscle mass and we did not.
Several large studies have also investigated the links
between muscle size and cognition. In a large cross-
sectional study of community dwelling women aged 75
or over (n = 7105), Nourhashemi et al. found that lowk muscle area, intracranial area, age and prior cognition
Unstandardised B* t Sig. Partial Eta squared
<.01 .35
3.06 .48 .63 .01
-.11 -1.26 .21 .04
<.01 .39 .70 .00
.06 3.44 <.01 .23
<.01 1.69 .10 .07
sing Factor.
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[41]. However the cognitive test used was the Short
Portable Mental Status Questionnaire (SPMSQ), which
consists of only 10 questions and is mainly used as a
screening test for cognitive impairment.
Conversely, Wirth et al. studied 4095 consecutive geri-
atric hospital patients and found that fat-free mass was
not associated with cognitive dysfunction, measured
using MMSE, after adjusting for age, sex and Barthel
index [42]. Also, Auyeung et al. studied 2737 cognitively
normal older people and found that appendicular skel-
etal muscle mass (ASM) was significantly predictive of
MMSE 4 years later in men but not women [40]. How-
ever, after adjustment for age, years of education and
baseline MMSE score, the relationship in men was not
significant either.
Our study has the benefit of including tests of both
prior and current cognitive function. This allows us to
look at cognitive decline rather than purely at current
cognitive ability, and is the only study we could find that
specifically tested the relationship between prior cogni-
tion and muscle size. Also, the three large studies
mentioned above used cognitive tests which are prima-
rily designed to screen for cognitive impairment (ie
SPMSQ and MMSE) rather than to detect the subtleties
of change in cognition with age [40-42], for which our
cognitive tests were specifically chosen. Burns et al. used
more detailed cognitive tests; however the numbers
involved in their study are much smaller compared to
the other three studies. Our study is the first to measure
muscle cross-sectional area and cognition or brain size;
the above mentioned studies used either bioimpedence
analysis or DEXA as the measure of muscle bulk.
The main limitations of our study are the lack of lon-
gitudinal data and the small sample size. In ageing stud-
ies longitudinal data are crucial as it is the rate of loss of
muscle size or brain size that is of interest rather than
measurements at a cross-sectional time point. With
brain size we can partially correct for this using intracra-
nial area, but with muscle size we are unsure if someone
has lost 10% of their lean body mass in the previous
decade or 50%, as clearly the peak muscle bulk obtained
will affect the final outcome greatly. The study also
contained mainly white males and this will affect the
generalisability of our results.Conclusion
In healthy older men preservation of whole brain vol-
ume is associated with larger muscle size and larger
muscle size was associated with lower prior cognition,
but not current cognition. These results support previ-
ous work in this area which has also found associations
between brain and muscle variables in older adults.Longitudinal ageing studies are now required to investi-
gate these relationships further.
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http://www.immunityageing.com/content/10/1/33RESEARCH Open AccessSeropositivity for CMV and IL-6 levels are
associated with grip strength and
muscle size in the elderly
Alixe HM Kilgour1,2,5*, Charlotte Firth6, Rowan Harrison2, Paul Moss6, Mark E Bastin1,3, Joanna M Wardlaw1,3,
Ian J Deary1,4 and John M Starr1,2Abstract
Background: Sarcopenia is an important cause of morbidity and mortality in older adults, with immunosenescence
and inflammation being possible underlying mechanisms. We investigated the relationship between latent
cytomegalovirus (CMV) infection, Interleukin 6 (IL-6) levels, muscle size and strength in a group of healthy older
community-dwelling people.
Methods: Participants were healthy volunteers from the Lothian Birth Cohort 1936 study. Participants had IL-6 level
and CMV antibody titre measured at age 70 years and grip strength and a volumetric T1-weighted MRI brain scan
(allowing measurement of neck muscle cross-sectional area (CSA)) at age 73. Markers of childhood deprivation were
adjusted for in the analysis due to correlations between childhood deprivation and latent CMV infection.
Results: 866 participants were studied; 448 men (mean age 72.48 years, sd 0.70) and 418 women (mean age 72.51
years, sd 0.72). In men, CMV seropositivity was associated with smaller neck muscle CSA (p = 0.03, partial eta
squared = 0.01), even after adjustment for IL-6 levels. Neck muscle CSA was not associated with CMV seropositivity
in women, or CMV antibody titre or IL-6 level in either sex. Grip strength associated negatively with IL-6 level (right
grip strength p<0.00001, partial eta squared 0.032 and left grip strength p<0.00001, partial eta squared 0.027) with
or without adjustment for CMV serostatus or antibody titre. CMV status and antibody titre were not significantly
associated with grip strength in either hand.
Conclusion: These findings support the hypothesis that there is a relationship between markers of
immunosenescence (i.e. CMV serostatus and IL6 level) and low muscle mass and strength and longitudinal studies
in older cohorts are now required to investigate these relationships further.
Keywords: Sarcopenia, Grip strength, Cytomegalovirus, Interleukin-6, ImmunosenescenceIntroduction
Sarcopenia refers to the decline in both muscle mass and
function that occurs with age [1-3]. It is an important
cause of morbidity and mortality in older adults [4-6].
Longitudinal studies have shown muscle mass to be lost at
approximately 1% per annum and strength to be lost at
2-4% per annum in older adults [7,8]. Despite its clinical
importance, current understanding of the mechanisms* Correspondence: a.kilgour@ed.ac.uk
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reproduction in any medium, provided the orunderlying sarcopenia remains unclear. Immunose-
nescence and inflammation have both been identified as
possible contributing factors. Immunosenescence is the
age-associated impairment of immune function due to
changes in both the innate and adaptive immune response
[9]. These changes lead to a decreased ability to respond
to pathogens, although an agreement on clinical bio-
markers and associated clinical outcomes requires further
research [9].
Seropositivity for cytomegalovirus (CMV, otherwise
known as Human Herpes Virus 5), is common in older
adults [10,11]. Most people are infected in childhood or
young adulthood and become carriers of the virus in aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Muscle size and strength, CMV and IL-6 baseline
data
Variable Statistic/group Men Women
Total neck muscle CSA (mm2) Mean 2576.6 1814.5
SD 421.0 281.2
n 343 298
Right grip strength (kg) Mean 35.49 21.28
SD 6.82 5.54
n 448 416
Left grip strength (kg) Mean 34.69 19.93
SD 6.57 5.13
n 447 416
CMV status Positive (%) 60.6 69.0
Negative (%) 39.4 31.1
n 439 409
CMV antibody titre Median 60.56 132.11
IQ range 0.47-214.00 2.40-277.78
n 437 406
IL-6 level Median 1.60 1.48
IQ range 1.05-2.42 1.01-2.29
n 425 390
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CMV status in immunosenescence is a topic of current
research, and it remains unclear whether the relationship
is causal or associative. However, latent CMV infection
has been linked to several clinical outcomes, including
frailty and increased mortality. Several studies have
found an association between CMV seropositivity and/or
CMV antibody titre and the presence of atherosclerosis
and coronary heart disease, with some studies also dem-
onstrating a correlation with survival time [15-17].
Other studies have found associations between CMV
and cognitive decline in older adults [18], and all cause
mortality [19].
There is also evidence of an association between CMV
infection and frailty. Aiello et al. [20] found that CMV
antibody titre is negatively associated with the ability to
carry out activities of daily living (ADLs) in elderly Latino
subjects, after correcting for gender and age. However,
this relationship became non-significant after adjusting
for the total number of health conditions, body mass
index, and household income. Schmaltz et al. found an
association between frailty, defined using the Fried cri-
teria, and CMV serostatus in older women [20]. Studies
investigating frailty vary widely on the criteria used for
diagnosis and not all frailty scores contain a measure of
muscle mass [21,22]. Therefore, in order for clear con-
clusions to be drawn about the possible underlying
mechanisms of sarcopenia, it is important to study it as
an independent variable rather than as a component of
a frailty score.
Interleukin 6 (IL-6) is a cytokine known to be part of
the acute phase response, i.e. the initial immune system
reaction to infection or trauma [23]. Increasing age is as-
sociated with latent low grade inflammation; levels of IL-6
appear to increase with age, particularly following the
andropause or menopause [24,25]. In a large cross-
sectional study of septuagenarians, raised IL-6 levels were
associated with reduced muscle mass and strength [26].
However, in a further longitudinal cohort higher IL-6
levels were associated with loss of muscle strength, al-
though no association was found with muscle mass [27].
Several studies investigating the effect of CMV on
frailty and functional ability have adjusted for IL-6 to as-
sess its role as a mediator, as CMV is known to increase
IL-6 gene expression and production in peripheral blood
mononuclear cells [28]. Indeed in the above mentioned
study, Schmaltz et al. found that CMV positive subjects
with high IL-6 levels had a significantly higher preva-
lence of frailty than those with a low IL-6 level [20].
Also, data from the Women’s Health and Aging Studies
found that IL-6 appeared to modulate the effect of CMV
antibody titre on frailty as an outcome (measured using
the Fried criteria), although the effect did not reach stat-
istical significance [29].We could find no previous studies which have looked
at the association between muscle mass and CMV
serostatus or antibody titre. Furthermore we found only
one study which addressed the relationship between
CMV serostatus and handgrip strength [21], an import-
ant marker of muscle function in older age, and that
study only looked at women. As detailed above, IL-6
may play an important mediatory role in these relation-
ships and it is therefore important to study this in tan-
dem with CMV status. In this study we investigated the
relationship between latent CMV infection, IL-6 level
and markers of sarcopenia (muscle size and strength) in
a healthy older cohort of community-dwelling men and
women.
Results
There were 866 participants in wave 2 of the LBC1936
study; 448 men (mean age 72.48 years, sd 0.70) and 418
women (mean age 72.51 years, sd 0.72). This represents
79.4% of the participants who attended at the first wave
of testing aged 70 years (n=1091). Baseline data for neck
muscle CSA, right and left grip strength, CMV
serostatus, CMV antibody titre and IL-6 levels are shown
in Table 1. Baseline data for measures of childhood
deprivation are shown in Table 2.
We assessed associations between IL-6 and CMV anti-
body titre (using Spearman’s rho correlations) and CMV
serostatus (using the Wilcoxon independent samples test)
with age, height, weight, the muscle variables and the
Table 2 Childhood deprivation baseline data
Variable Statistic/group Men Women
Overcrowding index (age 11) Median 1.20 1.20
IQ range 0.86-1.67 0.80-1.67
n 447 416
Indoor/outdoor toilet (age 11) Indoor (%) 87.5 90.0
Outdoor (%) 12.5 10.0
n 447 418
Father’s social class I (%) 6.9 7.3
II (%) 21.5 17.2
III (%) 56.7 54.7
IV (%) 6.9 13.3
V (%) 7.9 7.6
n 404 384
Years spent in full time education Median 10 10
IQ range 10-12 10-12
n 448 418
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ation between CMV serostatus and indoor/outdoor toilet
was analysed using the chi-square test. In men, being
CMV seropositive or having a high CMV titre is associated
with all the markers of childhood deprivation. In women,Table 3 Wilcoxon independent samples test (CMV serostatus)
and IL-6 level) (p values)
Male
CMV status (pos/neg)a CMV tit
Age in days at wave 2 .68
(.50) (.
Height in cm −2.08 -
(.04) (.
Weight in kg 1.44
(.15) (.
Total neck muscle CSA (mm2) −1.60 -
(.11) (.
Grip strength right hand (kg) -.62 -
(.54) (.
Grip strength left hand (kg) −1.95 -
(.05) (.
Overcrowding index age 11 4.53
(<.001) (<.00
Father’s job class as a number 3.82
(<.001) (<.00
No. of years of full-time education −3.07 -
(<.01) (<.00
Indoor=1 or outdoor=2 toilet at age 11 0.47*
(.02) (.
aWilcoxon independent samples test statistic (and associated p values) for CMV stat
analysed using the chi-square test and shows *the odds ratio for being CMV seropo
bThe columns for CMV titre and IL-6 titre show the Spearman’s rho correlation withbeing CMV seropositive or having a high CMV titre is as-
sociated with a higher overcrowding index and lower so-
cial class of their father and in addition a high CMV titre
is associated with fewer years of formal education. In men,
IL-6 levels only significantly correlate with the number of
years of full time education (i.e. the more years of educa-
tion the lower the IL-6 level), whereas in women all the
markers of childhood deprivation correlate with a higher
IL-6 level, except for the indoor/outdoor toilet question. If
IL-6 was acting as mediator for CMV infection (i.e. CMV
infection causes inflammation, raising IL6 levels, which
causes increased sarcopenia), we would expect a correl-
ation between the two variables. However, the Spearman’s
rho correlation between IL-6 and CMV antibody titre was
non-significant (rho=0.06, p=0.07), while a Wilcoxon inde-
pendent samples test for IL-6 and CMV serostatus was
also non-significant (test statistic 1.28, p=0.20).
General linear models (ANCOVAs) were then created
for each muscle variable separately with each measure of
immune status (ie CMV status, CMV titre and IL-6 level)
before rerunning the models of CMV status and antibody
titre adjusting for IL-6 status also. Tables 4 and 5 contain
the results for the ANCOVA for CMV serostatus and neck
muscle CSA, and IL-6 and grip strength. The p value gives
the significance of the independent variable’s associationand Spearman’s rho correlations (CMV antibody titre
Female
reb IL-6 titreb CMV status (pos/neg)a CMV titreb IL-6 titreb
.09 .09 2.32 .17 .08
06) (.08) (.02) (<.01) (.14)
.11 -.12 −2.50 -.09 .00
02) (.01) (.01) (.07) (.95)
.07 .16 −1.06 .02 .30
15) (<.01) (.29) (.71) (<.001)
.06 .09 1.02 .09 .21
26) (.10) (.31) (.12) (<.001)
.05 -.25 −2.81 -.10 -.07
34) (<.001) (.01) (.04) (.16)
.10 -.25 −2.04 -.08 -.08
03) (<.001) (.04) (.12) (.11)
.17 .03 3.56 .16 .10
1) (.56) (<.001) (<.01) (.04)
.19 .03 2.51 .14 .16
1) (.55) (.01) (<.01) (<.01)
.17 -.13 −1.57 -.11 -.10
1) (.01) (.12) (.01) (.04)
.10 .04 0.69* .06 .05
03) (.37) (.33) (.18) (.30)
us and all predictor variables except indoor/outdoor toilet age 11, which was
sitive if indoor toilet age 11.
the predictor variables (and the associated p value).
Table 4 ANCOVA for CMV status and total neck muscle CSA
Source Sig. Partial eta squared
Age in days at wave 2 .38 <.01
Weight in kg <.001 .22
Sex (Male=1, Female=2) <.001 .42
Overcrowding index age 11 .29 <.01
Indoor=1 or outdoor=2 toilet at age 11 .88 <.01
Father’s job class as a number .70 <.01
No. of years of full-time education .43 <.01
CMV serostatus (neg=1, pos=2) .10 .01
Sex by CMV serostatus .028 .01
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for which Cohen [30] says the following: small ≥0.0099;
medium ≥0.0588; large ≥0.1379.
We found that CMV seropositivity was associated with
a smaller neck muscle CSA in men but not in women
(p = 0.028, partial eta squared = 0.01) (Table 4). In this
model, lower weight and female sex were also associated
with smaller neck muscle CSA. When this model was
corrected for IL-6 level the effect remained significant
(p = 0.047). The model for neck muscle CSA and CMV
antibody titre showed no significant association, both
with and without adjustment for IL-6 level, nor did the
model with IL-6 as predictor variable, without adjusting
for CMV infection.
Weaker grip strength in both right and left hands was
found to be associated with higher IL-6 level; right grip
strength p<0.00001, partial eta squared = 0.032 and left
grip strength p<0.00001, partial eta squared = 0.027
(Table 5). The associations remain strongly positive even
after adjustment for CMV status (p<0.0001) and CMV
antibody titre (p<0.0001). In these models (shown in
Table 5), older age, shorter stature and female sex wereTable 5 ANCOVA for IL-6 titre and grip strength right and
left hands
Right hand Left hand




Age in days at Wave 2 .005 .01 .004 .01
Height <.001 .08 <.001 .07
Sex (Male=1, Female=2) <.001 .28 <.001 .34
Overcrowding index age 11 .72 .00 .25 .00
Indoor=1 or outdoor=2 toilet
at age 11
.75 .00 .64 .00
Father’s job class as a
number
.95 .00 .65 .00
No. of years of full-time
education
.051 .01 .10 .00
IL-6 Level <.001 .03 <.001 .03also significantly associated with weaker grip strength in
both hands. The models using CMV status and antibody
titre alone were not significantly associated with grip
strength in either hand.
Discussion
This report used data from waves 1 and 2 of a
population-based elderly cohort study, to investigate the
relationship between latent CMV infection, IL-6 levels
and sarcopenia, measured using neck muscle CSA and
grip strength in both hands. There was no significant
group difference for sex, age or CMV status and titre be-
tween those who participated in wave 1 but not wave 2
(n=225) and those who participated in both waves
(n=866) (independent t tests, p>0.05). We found that
men who were seropositive for CMV antibody at age 70
years had a neck muscle CSA on average 4% smaller at
age 73 than men who were seronegative. This effect
remained positive whether adjusting for IL-6 level or
not. It is well documented that muscle mass is lost at
roughly 1% per year [7,8], therefore being a man who is
CMV seropositive in your 70 s confers the same risks of
low muscle bulk as being 4 years older. We did not de-
tect a significant association in women between CMV
serostatus and neck muscle CSA, or between CMV
serostatus and grip strength in either hand. Other stud-
ies have postulated that as CMV seropositivity is so com-
mon in older adults it may be more important to
measure CMV antibody titre itself. However, we found
no association between CMV antibody titre and either
neck muscle CSA or grip strength. This result may indi-
cate that latent CMV infection leads to increased muscle
loss over an extended period, as CMV is commonly ac-
quired in childhood, though there is the possibility of
temporary reactivations of CMV throughout life, and
that the titre reflects the current situation, which may
have less impact on muscle bulk. Longitudinal studies
will be able to explore these relationships further.
IL-6 levels were found to strongly predict grip strength
in both right and left hands in men and women. IL-6 pre-
dicted 3.2% of the variance in right-sided grip strength
and 2.7% of the variance in left-sided grip strength. These
associations remained significant when adjusting for CMV
serostatus or antibody titre. We found no significant asso-
ciation between IL-6 levels and neck muscle CSA. There-
fore our findings do not support previous work that has
found that IL-6 may act as a mediator by which latent
CMV infection causes frailty [20,29].
It is widely accepted that muscle size and strength do
not decline in a parallel manner [31,32], therefore they are
not purely a function of each other and it may be that dif-
ferent factors cause decline in one parameter more than
the other, as our results have shown. Similarly, a study
looking at the effect of IL-6 levels on muscle found a
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not muscle mass [27], again indicating parameter-specific
effects. Also, these results are based on cross-sectional
data and therefore do not necessarily reflect changes with
age. Therefore it could be that individuals with latent
CMV infection or lifelong raised IL6 levels have always
had smaller/weaker muscles, rather than an increased rate
of decline in muscle mass or function with age. However
as sarcopenia is currently diagnosed using reference to
peers or a healthy young population, having a lower peak
muscle mass and function should still be considered risk
factors for sarcopenia. Longitudinal studies may help elu-
cidate these relationships further.
The sole previous study we found that investigated the
relationship between CMV status and grip strength only
included women [21]. They found no significant difference
in grip strength between seropositive and seronegative
women. We have replicated this finding, but found a sex
specific effect between male sex and CMV serostatus.
There is evidence that men lose more muscle mass than
women with age even after correction for body stature
[33], therefore differing factors may play more or less of a
role between the genders. Additionally, their muscles are
larger to start with and therefore a reduction may be easier
to detect.
It is unclear how CMV might directly influence physical
functioning, however latent CMV infection has been iden-
tified as an important component of an immune risk
phenotype that is associated with immunosenescence, in-
flammation, and several latent health conditions observed
with aging [34]. All these may represent possible contribu-
tory mechanisms to sarcopenia. For example, if CMV in-
fection predisposes to cardiovascular disease this, in turn,
might limit exercise and hence loss of muscle strength and
size. Should our findings be confirmed, exploration of po-
tential causal pathways will be warranted.
Raised plasma IL-6 levels are known to increase prote-
olysis within muscle, by upregulating the proteolytic UPP
pathway [35], however it is not known if the degree of in-
crease seen with ageing is enough to cause atrophy and it
is thought that proteolysis is not a major factor in normal
ageing muscle [36]. However, IL-6 may exert its effect
through less direct routes. It is known that IL-6 causes an-
orexia, which would lead to decreased protein substrate.
Also, IL-6 can both activate cortisol secretion and induce
11beta-hydroxysteroid type 1 expression, so it may exert
its effect via the steroid pathway [37,38]. Furthermore, ani-
mal studies have demonstrated that inflammatory cyto-
kines can induce muscle apoptosis by DNA fragmentation
[35], though such models may not represent low level in-
flammatory changes occurring over a prolonged period.
The narrow geographic, age and ethnic mix within the
LBC1936 cohort means this study may not prove gener-
alisable. However, the narrow age range helps to reducethe powerful effect of advancing age on many of the pa-
rameters measured in this and other studies and which
may have lead to the impression of stronger direct rela-
tionships between co-associated variables than is actually
the case. Additionally the size of the sample studied and
the fact that we replicated results in some of our analyses
found in other work is reassuring. The high correlation
between the markers of childhood deprivation and CMV
status were as predicted and raise the possibility that other
correlates of childhood socioeconomic deprivation may be
mediated by CMV infection, although this relationship
may be less strong in other populations. Also, when study-
ing sarcopenia it is important to consider rate of decline
rather than solely cross-sectional measures. Therefore in
the future, longitudinal studies will be crucial in develop-
ing an understanding of these relationships. Finally, the
concept of a homogeneous model of sarcopenia, whereby
all muscle throughout the body ages at the same rate, is
proving increasingly unlikely to be valid with studies
showing rates of muscle ageing to vary around the body
[33,39,40]. Therefore whilst our measure of neck muscle
CSA has previously been shown to correlate strongly to
mid-thigh muscle CSA, it is important to consider that
different factors may worsen or ameliorate muscle ageing
in different muscle groups throughout the body.
Conclusion
In a large population-based elderly cohort study we found
the men who were seropositive for CMV had smaller neck
muscle CSA than men who were seronegative, and this ef-
fect was independent of IL-6 level. We also found that
higher IL-6 levels, but not CMV levels, were strongly asso-
ciated with lower grip strength in both hands in men and
women. These associations were not attenuated when the
model was adjusted for CMV serostatus or antibody titre.
These findings support the hypothesis that there is a rela-
tionship between immunosenescence and markers of
sarcopenia and longitudinal studies are now required to
investigate these relationships further.
Methods
Participants – The Lothian Birth Cohort 1936 (LBC1936)
The LBC1936 study consists of 1091 relatively healthy,
age-homogeneous older people who, at the age of 11
years, participated in the Scottish Mental Survey of
1947, when they sat a general mental ability test, the
Moray House Test number 12 (MHT). The cohort, in-
cluding the imaging protocol, has been described previ-
ously in detail [41,42] At age 70 years they underwent a
series of cognitive tests (including retaking the MHT),
and physical and biochemical tests, at the Wellcome
Trust Clinical Research Facility (WTCRF) at the West-
ern General Hospital, Edinburgh, where 866 returned
for further testing at age 73. All participants gave
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were Caucasian and almost all lived independently in
the Lothian region (Edinburgh city and surrounding
area) of Scotland.
Neck muscle cross-sectional area
In this study we use neck muscle cross-sectional area
(CSA) as a validated measure of muscle size [32]. We have
previously shown in a study of 24 subjects that neck
muscle CSA is strongly correlated with thigh muscle CSA
(R2 = 0.77), which is often used as a proxy for general
muscle bulk. Neck muscle CSA is generally available in
brain MRI studies, whereas thigh muscle CSA is not usu-
ally measured within longitudinal cognitive ageing studies.
Participants underwent a volumetric brain MRI scan as
part of the LBC1936 study. MRI was performed with par-
ticipants in a supine position using a 1.5 T clinical scanner
(Signa HDxt, GE Healthcare, Milwaukee, USA) at the
Brain Research Imaging Centre, University of Edinburgh
(www.bric.ed.ac.uk). A phased array eight channel head
coil was used and inversion recovery prepared volumetric
T1 weighted images were acquired in a coronal plane for
each participant; the scan alignment was perpendicular to
the long axis of the hippocampus determined from a pre-
liminary T2-weighted sagittal sequence. The flip angle was
8°, bandwidth 15.63 KHz, echo time (TE) 4 to 13 ms, repe-
tition time (TR) 9.6 ms and inversion or preparation time
(TI) 500 ms. The field of view (FOV), fixed superiorly at
the cranial vertex, was 25.6 × 25.6 cm, the acquisition
matrix was 192×192, with 160 slices acquired with a slice
thickness of 1.3 mm with no slice gap. These data took
8.13 minutes to acquire per patient.
Neck muscle CSA was measured using a validated tech-
nique as described previously [43]. In summary, the mid-
point of the C2-vertebra was located in the sagittal slice of
a 3D reconstructed image. The image was then converted
to a transverse view and the posterior neck muscles were
outlined using a cursor on a dedicated workstation. The
software then calculated the contained area. The muscles
groups measured were the semispinalis capitis, splenius
capitis and trapezius (measured as a combined group),
and the sternocleidomastoid. Each measurement was
performed three times and the median for each value was
used for the following analyses.
Grip strength
Grip strength was measured with a Jamar Hydraulic
Hand Dynamometer, with all participants performing 3
trials with their right and left hands; the best of the 3 trials
was used for the following analyses.
CMV and IL-6 measures
CMV was measured in plasma samples collected at age
70, using a CMV ELISA assay. Mock and viral-infectedlysate was coated onto ELISA plates and incubated over-
night. Standards (a mixture of three CMV positive
plasma samples) and plasma samples were added to the
plates and incubated for one hour before washing. An
anti-IgG horseradish peroxidase conjugated secondary
antibody was then added to the plate to incubate for one
hour. After washing, TMB substrate was added and the
reaction stopped by addition of 1M HCL. The sample
was assessed using an ELISA reader at 450 nm. To de-
termine CMV titres, mock values were first subtracted
from lysate values. The data were then analysed in
PRISM, and CMV titres were calculated with reference
to the standard curve. Values above 10 were considered
to be seropositive. To ensure accuracy, all samples were
tested in duplicate. IL-6 levels were analysed at the Uni-
versity of Glasgow using high sensitivity ELISA from
R&D Systems. The minimum detectable dose ranged
from 0.016-0.110 pg/mL (mean=0.039 pg/mL). The
intra-assay CV ranged from 6.9 to 7.8%, while the inter-
assay coefficient of variance ranged from 6.6 to 9.6%.Childhood deprivation
At the age 70 assessment, participants were asked to
provide background demographic and environmental in-
formation about their childhood, specifically for when
they were aged about 11 years. Participants reported the
number of people they lived with and the number of
rooms in the house, which was used to calculate an
overcrowding index (people/room). Participants also
reported: whether their household had indoor or out-
door toilet facilities; their father’s occupation to allow
father’s social class to be coded (categorised from I, pro-
fessional, to V, unskilled); and the number of years they
spent in full-time, formal education.Statistical analysis
Descriptive statistics, exploratory analyses and general
linear modeling (Analysis of Covariance; ANCOVA)
were performed using SPSS version 18.0 for Windows
(SPSS Inc, Chicago, Ill, USA). Missing values were ex-
cluded listwise for the ANCOVA analyses. For the
ANCOVA, we constructed baseline models with the
measures of neck muscle CSA and grip strength (right
and left) as dependent (i.e. outcome) variables and CMV
serostatus, CMV antibody titre and IL-6 level as inde-
pendent variables, adjusting for age, gender and either
height or weight, as a measure of body size, and the four
measures of childhood deprivation. Total neck muscle
CSA was found to correlate more strongly with weight
(P<0.001), whereas both right and left grip strength cor-
related more strongly with height (p<0.001). Therefore
we used the respective measures for adjustment in each
of the analyses.
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Abstract
Background: Sarcopenia, the loss of muscle mass and function with age, is associated with increased morbidity and
mortality. Current understanding of the underlying mechanisms is limited. Glucocorticoids (GC) in excess cause muscle
weakness and atrophy. We hypothesized that GC may contribute to sarcopenia through elevated circulating levels or
increased glucocorticoid receptor (GR) signaling by increased expression of either GR or the GC-amplifying enzyme 11beta-
hydroxysteroid dehydrogenase type 1 (11bHSD1) in muscle.
Methods: There were 82 participants; group 1 comprised 33 older men (mean age 70.2years, SD 4.4) and 19 younger men
(22.2years, 1.7) and group 2 comprised 16 older men (79.1years, 3.4) and 14 older women (80.1years, 3.7). We measured
muscle strength, mid-thigh cross-sectional area, fasting morning plasma cortisol, quadriceps muscle GR and 11bHSD1
mRNA, and urinary glucocorticoid metabolites. Data were analysed using multiple linear regression adjusting for age,
gender and body size.
Results: Muscle strength and size were not associated with plasma cortisol, total urinary glucocorticoids or the ratio of
urinary 5b-tetrahydrocortisol +5a-tetrahydrocortisol to tetrahydrocortisone (an index of systemic 11bHSD activity). Muscle
strength was associated with 11bHSD1 mRNA levels (b -0.35, p = 0.04), but GR mRNA levels were not significantly associated
with muscle strength or size.
Conclusion: Although circulating levels of GC are not associated with muscle strength or size in either gender, increased
cortisol generation within muscle by 11bHSD1 may contribute to loss of muscle strength with age, a key component of
sarcopenia. Inhibition of 11bHSD1 may have therapeutic potential in sarcopenia.
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Introduction
Sarcopenia is the loss of muscle mass and function which
accompanies even healthy ageing [1–3]. Both muscle mass and
function (i.e., power and strength) begin to decline from the third
decade with mass reducing by 1–2% per year and strength
reducing by around 2% per year [4–8]. Sarcopenia is associated
with an increased risk of falls and fractures, disability, loss of
independence and mortality [9–11]. Despite this public health
problem, current understanding of the mechanisms underlying
sarcopenia is limited, hampering progress in the development of
novel treatments for maintenance of muscle mass and physical
independence in old age. Theories underlying the development of
sarcopenia include: inflammation, cellular senescence, hormones
and growth factors and lifestyle factors (eg nutrition) [12,13].
One possible mechanism within the field of hormones and
growth factors is glucocorticoid dysregulation. It is well known that
glucocorticoids at pharmacological levels or in spontaneous
Cushing’s syndrome cause myopathy, with a combination of
muscle atrophy and dysfunction. Glucocorticoids are believed to
effect these changes on muscle through a combination of increased
protein breakdown (particularly through the ubiquitin-proteasome
system) [14], decreased protein synthesis (by inhibiting transport of
amino acids into muscle and inhibiting the action of insulin and
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IGF-1) [15] and decreasing production of IGF-1 and myostatin
[14]. In the context of sarcopenia, this mechanism could occur via
elevated circulating glucocorticoids due to age-related hypotha-
lamic-pituitary-adrenal (HPA) axis dysregulation. Alternatively, it
could occur selectively within the muscle, by increased activity of
the glucocorticoid receptor (GR) or the enzyme 11b-hydroxyste-
roid dehydrogenase type 1 (11bHSD1). 11bHSD1 converts
inactive cortisone to active cortisol and is known to be present
and biologically active in human muscle as well as many other
tissues [16–18]. Indeed a recent study by Tiganescu et al found
that elevated 11bHSD1 activity was inceased in skin biopsies from
older adults compared to younger adults and that this increased
activity was associated with markers of skin ageing (eg dermal
atrophy and deranged collagen structural organization) [19].
Establishing links between GC and sarcopenia could lead to novel
therapies, as several 11bHSD1 inhibitors are currently in clinical
development for type 2 diabetes and other degenerative diseases,
including cognitive dysfunction [20].
There is some evidence of an association between increased
plasma and salivary cortisol and lower muscle mass and strength
but these data are inconsistent [21–24]. Glucocorticoid metabo-
lites in a 24 hour urine sample may be more informative than
plasma cortisol levels since they reflect glucocorticoid status over
the diurnal cycle. Additionally ratios of the metabolites can be
used as an index of peripheral 11bHSD activity [25]. However, no
studies to date have examined the relationship between urinary
glucocorticoid metabolites and sarcopenia. Similarly, there are no
published data examining the relationship between GR and
11bHSD1 expression and muscle loss and function in older adults.
Importantly, expression of 11bHSD1 and GR mRNA has been
shown to reflect glucocorticoid activity, for example there is a
correlation between 11bHSD1 mRNA expression and enzyme
function [26].
The aim of this study was to investigate the relationship between
plasma and urinary glucocorticoid metabolites and levels of
mRNA encoding GR and 11bHSD1 in skeletal muscle, with
muscle size and strength. We hypothesized that increased
glucocorticoid signaling in skeletal muscle acting through GR
by, (a) elevated circulating cortisol, (b) increased expression of
11bHSD1 or (c) increased expression of GR, is associated with
reduced muscle size and strength.
Methods
Participants
Participants were healthy volunteers recruited at two sites in
Scotland: young and older men were recruited in Aberdeen
(Group 1) and older men and women were recruited in Edinburgh
(Group 2). This allowed us to test for possible age and gender
effects. Participants were defined as healthy after applying
previously published health selection criteria to the responses to
a questionnaire [27]. Existing samples were available from two
nearby cities in Scotland so these were used for analysis, rather
than beginning a new de novo cohort collection. No comparisons
were made between these two independent cohorts.
Ethics Statement
Written informed consent was obtained and all procedures
received local ethical committee approval. In Edinburgh this was
by the Lothian Local Research Ethics Committee 02 and in
Aberdeen this was by the North of Scotland Research Ethics
Committees. The study conformed to the standards set by the
Declaration of Helsinki.
Anthropometry
Body weight was measured with participants in light clothing
using a beam scale (Seca, UK). Height was measured using a wall
mounted stadiometer.
Muscle Function
Maximum voluntary isometric knee extensor strength was
measured using an established method [28]. Following instruction,
the participant made a maximum voluntary contraction (Newtons)
which was held for 5 seconds. Three separate measurements were
obtained and the highest value was used in subsequent analysis.
Muscle Size
Mid-thigh quadriceps cross-sectional area (CSA) was measured
using a 1.5T MR scanner (Phillips Gyroscan Intera). T1-weighted
axial images were taken with the isocentre of the magnetic field
located at the mid-femur point which was landmarked prior to the
scan according to International Standards of Anthropometric
Assessment (ISAK) guidelines 2001. Imaging parameters were:
slice thickness 10 mm; acquisition matrix 5126512; echo time
(TE) 15 ms; repetition time (TR) 425 ms; and flip angle 90u. The
CSA of the quadriceps was quantified using Analyze 8.0 (Mayo
Clinic, Rochester, USA) according to a previously published
technique [29]. Two of the subjects from Group 2 did not undergo
MRI due to claustrophobic symptoms.
Plasma Cortisol
Blood samples were obtained from participants in the morning
after overnight fast (mean time 0945h, range 0915–1030h). Plasma
cortisol was measured by competitive immunoassay with direct




Quadriceps femoris samples were obtained from the region of
vastus lateralis via percutaneous needle biopsy using a Bergstrom
needle [30]. The biopsy was obtained in a sterile environment by
sharp dissection under local anaesthetic using 1% lidocaine. The
samples were then snap frozen in liquid nitrogen and stored at
280uC before analysis [31].
RNA Isolation
Total RNA was isolated from quadriceps muscle biopsies using
the Qiazol reagent (Qiagen, Crawley, UK) and miRNeasy RNA
isolation columns (Qiagen, Crawley, UK). Briefly biopsies were
homogenised in 1400 ul or 700 ul Qiazol depending on the size of
the tissue sample using a Polytron PT1200E (Kinematica AG).
Total RNA was isolated from the homogenised muscle using
miRNEasy columns with an on column DNAse treatment step
using the RNase-Free DNase Set (Qiagen, Crawley, UK). After
elution from the column into 30 ul nuclease free H2O, RNA was
quantified using the Nanodrop instrument (Labtech, UK) and
quality assessed using the Bioanalyzer (Agilent, UK). All samples
had 260/280 ratios above 1.8, and RIN scores above 7.5.
cDNA Preparation and qPCR
RNA samples were converted to cDNA using the Ovation RNA
Amplification kit (Nugen, Netherlands). RNA was diluted to
10 ng/ul and 50 ng total RNA was used in the amplification
reaction carried out according to the manufacturer’s instructions,
yielding between 3 ug and 11 ug cDNA. For qPCR, cDNA was
diluted to ,50 ng/ul. Quantitative RT-PCR reactions were run,
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in triplicate, on an Applied Biosystems Step One Plus system. The
reaction mix was POWER SYBR Green x2 Master mix 12.5 ul,
forward primer (10 uM) 1 ul, reverse primer (10 uM) 1 ul, H2O
9.5 ul and cDNA 1 ul. Reaction conditions were 95uC for 10
mins, 95uC for 15s, 60uC for 60s (40 cycles) followed by melting
curve generation from 60uC to 95uC. Ct values were examined
and within triplicates any value greater than 0.3 Ct were removed
before means were calculated. Data were then analysed using the
delta Ct method with HPRT as a normaliser. After normalisation
data were inverted and scaled such that the largest value for each
gene was set to 100.
Primer sequences used were NR3C1 FP –
CTGTCGCTTCTCAATCAGACTC; RP – GCATTGCT-
TACTGAGCCTTTTG; 11bHSD1 FP –
AGGCTGCTGCCTGCTTAGGA; RP – AGCCCCA-
GAATGGGGAGGAGA; HPRT FP – TGACACTGGCAAAA-
CAATGCA; RP- GGTCCTTTTCACCAGCAAGCT. HPRT
was chosen as a normaliser as preliminary analysis of housekeep-
ing gene performance showed HPRT to be stable across samples
and expressed at a similar level to genes of interest compared to b-
actin, GAPDH, b2M and 18S.
Urinary Glucocorticoid Metabolism
24 hour urine samples were collected to quantify urinary
glucocorticoid metabolites using gas chromatography electron
impact mass spectrometry following solid phase extraction,
hydrolysis of conjugates and formation of their methoxime-
trimethylsilyl derivatives, as described previously [25].
Two composites of the data were used in subsequent analyses.
Firstly, total urinary steroids, comprising the sum of 5b-tetra-
hydrocortisol (5bTHF), 5a-tetrahydrocortisol (5aTHF), the main
urinary metabolites of cortisol, and tetrahydrocortisone (THE), the
main urinary metabolite of cortisone (total urinary GC = 5bTHF
+5aTHF+THE). Secondly, an indirect indicator of systemic
11bHSD activity, comprising the ratio of 5bTHF and 5aTHF
to THE (ratio of cortisol to cortisone metabolites = (5bTHF
+5aTHF)/THE).
Statistical Analysis
Statistical analysis was performed using SPSS version 18.0.
Bivariate correlations were performed using Spearman’s rho to
allow analysis of the non-parametric variables. Forced entry
multiple linear regression was performed and the data from the
Table 1. Group characteristics.
Group 1 younger
men (n = 19)
Group 1 older
men (n = 33) p-valuea
Group 2 older
men (n = 16)
Group 2 older
women (n = 14) p-valueb
Age (years) 22.2 (1.7) 70.2 (4.4) ,0.001 79.1 (3.4) 80.1 (3.7) n/s
Height (cm) 177.6 (6.7) 171.9 (5.4) 0.001 171.3 (6.1) 157.6 (5.9) ,0.001
BMI (kg/m2) 24.0 (2.5) 25.2 (2.5) n/s 25.3 (3.9) 24.1 (3.1) n/s
Muscle Size (cm2) 92.7 (11.5) 67.3 (7.4) ,0.001 63.5 (7.3) 43.8 (6.8) ,0.001
Muscle Strength (Newton) 774.9 (136.6) 525.2 (73.6) ,0.001 364.7 (79.7) 273.4 (73.4) 0.003
Total Urinary GC* (microg/
day)
9887 (7721–18372) 10224 (7841–17000) n/s 8192 (5534–12506) 4925 (3699–6806) n/s
11bHSD activity (urine
THFs:THE)
1.12 (0.37) 1.15 (0.45) n/s 1.28 (0.79) 0.81 (0.49) n/s
Plasma cortisol (nmol/litre) – – 349 (106) 321 (65) n/s
GR mRNA – – 59.4 (24.5) 58.3 (18.8) n/s
11bHSD1 mRNA – – 25.3 (19.7) 32.2 (31.8) n/s
Data are mean (SD) except *non-parametric data therefore median and IQ range shown.
a. Independent t test between younger and older men in Group 1.
b. Independent t test between men and women in Group 2.
n/s = not significant.
doi:10.1371/journal.pone.0084057.t001
Table 2. Bivariate correlations including muscle size and strength.
Group 1 muscle size Group 1 muscle strength Group 2 muscle size Group 2 muscle strength
Height .34* .22 .68** .42*
BMI –.04 –.07 .32 .38*
Total urinary GC –.04 .01 .61** .45*
11bHSD activity –.09 –.05 .35 .16
Plasma cortisol – – –.20 –.31
GR mRNA – – .11 .04
11bHSD1 mRNA – – –.15 –.29
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two groups were analysed separately, when possible, to test
reproducibility. Due to the large difference in age between the
older and younger groups, age was analysed as a binary variable in
the multivariate regression. Group 1 (n = 52) had 80% power at
the p = 0.05 level to detect a correlation of r = 0.38 and Group 2
(n = 30) had 80% power at the p = 0.05 level to detect a correlation
of r = 0.49. In view of the power calculations and the exploratory
nature of the study, adjusting for multiple hypotheses testing was
not deemed to be appropriate.
Results
In total, 82 participants were recruited. Table 1 shows numbers
of participants and their age, height, BMI, and the main outcome
variables for each group. Independent t tests found significant sex
and age related differences for height, muscle size and muscle
strength but not for BMI or any measure of glucocorticoid status
(Table 1). Table 2 shows bivariate correlations, which confirmed
that measures of body size (height and BMI) were significantly
associated with muscle size and strength. Therefore in constructing
multivariate models we adjusted for body size as well as age and
gender, which had been selected a priori due to their accepted
relationships with muscle size and strength. BMI correlated with
total urinary GC (rho = 0.60, p = 0.0005) and plasma cortisol
(rho = 20.52, p = 0.006), whereas height did not significantly
correlate with total urinary GC or plasma cortisol (p.0.05 for
both). Therefore in multivariate analyses with urinary GC and
plasma cortisol as predictor variables we adjusted for potential
confounding by BMI, gender and age (see Tables 3 & 4). Neither
BMI nor height correlated with the muscle GR or 11bHSD1
mRNA expression levels. Therefore because height correlated
more significantly with muscle size and strength than BMI
(Table 2), we adjusted for height and gender for the multivariate
analyses with muscle GR and 11bHSD1 mRNA as predictor
variables (Table 4).
Plasma cortisol was measured in Group 2 only. There were no
significant association between fasting morning plasma cortisol
and muscle size and a non-significant negative trend with muscle
strength (b 20.35, p = 0.08) (Table 4). In both groups neither total
urinary glucocorticoids nor the ratio of cortisol:cortisone metab-
olites were associated with muscle size or strength (Tables 3 & 4).
We used muscle biopsies from a subset of Group 2 to examine
the relationships between GR and 11bHSD1 mRNA levels and
muscle size and strength. Increased 11bHSD1 mRNA was
significantly associated with lower muscle strength after adjust-
ment for sex and height (b 20.35, p = 0.039, n = 22:12 men mean
age 79.8 (sd 3.6) and 10 women, mean age 80.5 (sd 4.1)). There
were no significant relationships between GR mRNA and muscle
size or strength, or between 11bHSD1 mRNA and muscle size
(Table 4).
Discussion
This study investigated the relationship between circulating and
tissue indices of glucocorticoid status and muscle size and strength
in two groups. Group 1 allowed comparison of older with younger
men. There were no age differences in urinary cortisol metabolites,
although muscle biopsies were not obtained in this group so we did
not test the effect of ageing per se on muscle mRNA levels. Group 2
allowed comparison of older men with older women. There were
no differences in plasma cortisol, urinary glucocorticoid metabo-
lites or muscle GR or 11bHSD1 mRNA levels between the sexes
in this relatively small sample. Within each group we explored
associations between glucocorticoid variables and muscle size and
strength after adjustment for potential confounding effects of age,
gender and body size as appropriate. In these analyses, indices of
HPA axis function, including morning plasma cortisol and 24 h
urinary cortisol metabolite excretion, were not associated with
muscle strength or size. Additionally urinary cortisol:cortisone
metabolite ratios, which principally reflect 11bHSD activity in the
major organs of liver and kidney, were not associated with muscle
strength or size. However, in muscle itself, higher levels of mRNA
encoding the cortisol-amplifying enzyme 11bHSD1 were associ-
ated with reduced muscle strength. This finding is consistent with
the hypothesis that enhanced glucocorticoid signalling within
muscle contributes to sarcopenia.
To our knowledge there have been no previous investigations of
muscle glucocorticoid signaling in human sarcopenia. We
Table 3. Regression coefficients for the glucocorticoid measures in models predicting muscle size/strength (Group 1).
Glucorticoid Measure Muscle Size Beta (sig, n) Muscle Strength Beta (sig, n)
Total Urinary GCa 20.10 (p.0.05, 52) ,20.01 (p.0.05, 52)
THFs:THEa ,0.01 (p.0.05, 52) 0.04 (p.0.05, 52)
aadjusting for age and BMI.
doi:10.1371/journal.pone.0084057.t003
Table 4. Regression coefficients for the glucocorticoid measures in models predicting muscle size/strength (Group 2).
Glucorticoid Measure Muscle Size Beta (sig, n) Muscle Strength Beta (sig, n)
Plasma Cortisola 20.12 (p.0.05, 25) 20.35 (p.0.05, 27)
Total Urinary GCa 0.23 (p.0.05, 28) 0.18 (p.0.05, 30)
THFs:THEa 0.08 (p.0.05, 28) 0.10 (p.0.05, 30)
GR mRNAb 0.03 (p.0.05, 20) 0.04 (p.0.05, 22)
11bHSD1 mRNAb 20.17 (p.0.05, 20) 20.35 (p = 0.04, 22)
aadjusting for gender and BMI.
badjusting for gender and height.
doi:10.1371/journal.pone.0084057.t004
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hypothesized that because 11bHSD1 and GR regulate the
exposure of target tissues to glucocorticoids, increased expression
of 11bHSD1 and GR could therefore contribute to sarcopenia in
the absence of an increase in circulating GCs. We found that
increased 11bHSD1 mRNA expression in muscle is associated
with lower muscle strength. This is consistent with this hypothesis.
We did not find a relationship between 11bHSD1 mRNA
expression and muscle size, but in normal ageing, muscle strength
is reported to deteriorate more rapidly than muscle size; suggesting
a decline in force generating capacity with age [5,32]. A number of
contributory mechanisms have been proposed to explain this (eg
increased muscle fibre stiffness); our data suggest a possible role for
increased GC action at the muscle level. GC may affect strength
more than muscle mass by exacerbating glycation of the myosin
molecule, which appears to slow the intrinsic shortening velocity of
the muscle fibre, decrease force per cross-sectional area and
increase intramuscular collagen cross-linking which can cause
muscle stiffness [33,34]. In addition, GC may cause mitochondrial
dysfunction and reduced oxidative capacity, which would similarly
result in a decrease in force generating capacity [35]. 11bHSD1 is
known to act locally within muscle, resulting in measurable
production of cortisol in samples from veins draining human
muscle, and therefore increased 11bHSD1 mRNA expression is
likely to increase myocellular cortisol levels thereby mediating
these effects [18]. More research with larger samples and with a
wider range of severity of sarcopenia is required to investigate the
relationship between 11bHSD1 expression and activity and
muscle ageing.
We found no relationship between GR mRNA expression and
muscle mass or strength. It is possible that polymorphisms of GR
modulate the effect of GC on muscle, and that level of expression
is less important than genotype. For example male carriers of the
ER22/23EK polymorphism in GR, which is associated with
relative GC resistance, have greater muscle mass and strength
than non-carriers [36].
There are no published studies investigating the association
between urinary GC and muscle size or strength. However, there
are studies reporting associations between salivary and plasma
GCs and muscle size and function. In a previous study of men and
women .75 years higher salivary, but not serum, cortisol was
associated with lower appendicular skeletal mass (ASM) measured
using DEXA [21]. Similarly, in a large longitudinal ageing study
higher salivary but not serum cortisol predicted loss of grip
strength over 6 years, but there was no association of cortisol with
baseline grip strength or ASM [22]. A smaller study including both
young and older men found that increased serum cortisol
correlated with lower knee extensor strength in both age groups
and with quadriceps cross-sectional area only in the older group
[23]. The Caerphilly Prospective Study, which included measure-
ments of cortisol status and physical performance over 20 years,
found that higher mid-life plasma cortisol predicted faster walking
speeds in older age, although salivary cortisol did not correlate
with walking speed or balance in older age [24]. Collectively, these
studies provide contradictory evidence relating salivary or plasma
cortisol to muscle strength and mass. Taken with our data, there
does not appear to be a consistent association between activation
of the HPA axis and age-associated sarcopenia. These negative
findings are important in excluding this plausible hypothesis.
Some limitations of this study should be acknowledged. We
examined the effect of GC on ageing muscle using a younger and
older group of volunteers separated in age by nearly 50 years and
by many lifestyle factors; a problem inherent to cross-sectional
studies. Longitudinal studies investigating rate of decline of muscle
mass and function and measures of GC would be more
informative but are difficult to conduct due to the slow decline
of muscle mass and strength during ageing. The sample sizes were
relatively modest, particularly with respect to muscle GC data
which were obtained from only a subset of Group 2 who
underwent muscle biopsy. It has also been shown that sarcopenia
affects the upper and lower limbs differently and our study
investigated only the lower limbs [4,37–39]. Also, our healthy
older volunteers constituted a sample which may be not fully
representative of the ageing population; this may influence the
generalisability of our results. Finally, we used mRNA expression
as a marker of activity rather than a direct measure of 11bHSD1
activity, however several studies have found correlations between
mRNA expression and enzyme activity in rodents and humans, so
we regard mRNA as an appropriate indicator of 11b-HSD1
activity [26].
Conclusion
Sarcopenia is one of the major causes of frailty and disability in
older people. It is associated with greatly increased risk of loss of
independence and institutionalization. In this novel investigation
of healthy old and young people we found a significant association
between increased muscle 11bHSD1 expression and lower
quadriceps strength. We found no significant associations between
plasma cortisol, urinary GC metabolites or GR expression and
muscle mass or strength. Longitudinal studies are now required to
investigate these relationships and to further explore the possibility
of 11bHSD1 inhibitors as a novel treatment for sarcopenia.
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http://www.biomedcentral.com/1471-2318/14/85RESEARCH ARTICLE Open AccessA systematic review of the evidence that brain
structure is related to muscle structure and their
relationship to brain and muscle function in
humans over the lifecourse
Alixe HM Kilgour1,2*, Oliver M Todd2 and John M Starr1,2Abstract
Background: An association between cognition and physical function has been shown to exist but the roles of
muscle and brain structure in this relationship are not fully understood. A greater understanding of these relationships
may lead to identification of the underlying mechanisms in this important area of research. This systematic review
examines the evidence for whether: a) brain structure is related to muscle structure; b) brain structure is related to
muscle function; and c) brain function is related to muscle structure in healthy children and adults.
Methods: Medline, Embase, CINAHL and PsycINFO were searched on March 6th 2014. A grey literature search was
performed using Google and Google Scholar. Hand searching through citations and references of relevant articles was
also undertaken.
Results: 53 articles were included in the review; mean age of the subjects ranged from 8.8 to 85.5 years old. There is
evidence of a positive association between both whole brain volume and white matter (WM) volume and muscle size.
Total grey matter (GM) volume was not associated with muscle size but some areas of regional GM volume were
associated with muscle size (right temporal pole and bilateral ventromedial prefrontal cortex). No evidence was found
of a relationship between grip strength and whole brain volume however there was some evidence of a positive
association with WM volume. Conversely, there is evidence that gait speed is positively associated with whole brain
volume; this relationship may be driven by total WM volume or regional GM volumes, specifically the hippocampus.
Markers of brain ageing, that is brain atrophy and greater accumulation of white matter hyperintensities (WMH), were
associated with grip strength and gait speed. The location of WMH is important for gait speed; periventricular
hyperintensities and brainstem WMH are associated with gait speed but subcortical WMH play less of a role. Cognitive
function does not appear to be associated with muscle size.
Conclusion: There is evidence that brain structure is associated with muscle structure and function. Future studies
need to follow these interactions longitudinally to understand potential causal relationships.Background
Maintaining good levels of brain and muscle function across
the lifespan is crucial to achieving a good quality of life
[1-3]. There is substantial evidence showing an association
between cognition and muscle function [4-8], however the
role of muscle and brain structure within this association is
less well understood. A greater understanding of this role* Correspondence: a.kilgour@ed.ac.uk
1Centre for Cognitive Ageing and Cognitive Epidemiology, University of
Edinburgh, Room F2, 7 George Square, Edinburgh EH8 9JZ, UK
2Geriatric Medicine Unit, University of Edinburgh, Edinburgh, UK
© 2014 Kilgour et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.will help to improve current knowledge of the mechanisms
linking brain and muscle function over the lifecourse.
Several theories have been proposed as to why rela-
tionships between brain and muscle structure and func-
tion may exist. The common cause hypothesis postulates
that there are core common underlying processes which
drive ageing throughout the human body. The construct
was originally described in a paper by Lindenberger and
Baltes in 1994 who noted that measures of visual and
auditory acuity accounted for variance in intelligence in
old age [9]. Since then experiments in caloric restrictionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2318/14/85have demonstrated that the ageing process can be slo-
wed down in multiple systems throughout the body by
one intervention [10,11]. However, environmental fac-
tors also impact on how tissues change across the life-
course and another theory by Mitnitski et al. proposes
that the number of environmental stressors experienced
(e.g. disease, smoking) and the ability to recover from
them, vary the level of deficit accumulation experienced
in multiple organ systems, and hence how tissues like
brain and muscle change with age [12]. Potential under-
lying mechanisms include: pro-inflammatory cytokines
(e.g. TNF-alpha and IL-6); the role of glucocorticoids and
their intracellular amplifier 11beta-hydroxysteroid de-
hydrogenase type 1 [13-15]; the role of vitamin D [16,17];
exercise as a way to improve cardiovascular fitness in
addition to its beneficial effect through hormones and cy-
tokines [18-20]; and cellular senescence (e.g. through oxi-
dative stress) [21,22].
In view of these theories, there should be a correlation
between the structure and function of brain and muscle
throughout our lifetime in the absence of significant
pathology. This systematic review will search for studies
that test the hypotheses that brain structure is related to
muscle structure and/or function and that muscle struc-
ture is related to brain function in healthy children and
adults. Previous studies and reviews have looked at evi-
dence relating brain function (e.g. MMSE score) to
muscle function (e.g. walking speed) therefore this sep-
arate but closely related field of literature will not be
included in this review [5,23-25].
Methods





All human subjects regardless of age were included in
the study; from newborn babies to the oldest old, includ-
ing post-mortem studies. This study is examining the re-
lationship between brain and muscle in health, not
within the effects of pathology therefore studies looking
at how a disease affects brain or muscle were excluded.
However studies which included a healthy control group,
where the data from these subjects can be or was ana-
lysed separately were included. As morbidity increases in
frequency with age it would be very restrictive to include
solely those studies which include only participants who
are free from any disease, therefore studies will be in-
cluded provided the subjects have been recruited in a
way that did not pre-dispose to morbidity being more
prevalent than in the general population (e.g. from a dia-
betes clinic).It was planned that subgroup analysis would be
undertaken where possible and would include data be-
ing extracted to investigate the effects of gender, age,
socioeconomic status and ethnicity.
Interventions/Comparators




 Whole brain volume (WBV) or total brain volume
(TBV)
 Volume or cross sectional area of regions within the
brain (e.g. hippocampus, frontal lobes)
 White matter integrity (e.g. White matter
hyperintensities (WMH) or white matter signal
abnormalities (WMSA)
 Histological findings about brain structure on
autopsy
Brain function
 Any recognised measure of cognitive function
including: memory, attention, executive function,
language and processing speed
 Reaction time will not be used as this is dependent
on aspects of brain and muscle structure and
function
Muscle structure
 Muscle cross sectional area on CT, MRI or USS
 Muscle volume (using CT or MRI)
 Whole body lean tissue mass using DEXA, giving:
total lean mass (TLM) or appendicular lean mass
(ALM)
 Bioimpedance analysis (BIA)
 Histological findings on muscle biopsy or on autopsy
Muscle function
 Any recognised test of muscle strength, including
isometric, isotonic, isokinetic tests
 Any recognised test of muscle power
 Functional tests of muscle function (e.g. usual or
maximum gait speed)
Study design
As this review is studying a physiological relationship, inter-
vention studies were not included, unless they contained ei-
ther a control arm with extractable data with no placebo
treatment or baseline data prior to the intervention.
Kilgour et al. BMC Geriatrics 2014, 14:85 Page 3 of 35
http://www.biomedcentral.com/1471-2318/14/85Observational studies including cohort studies and cross
sectional studies were included and the control arm of case
control studies. Case reports were excluded as these would
not contain evidence of normal physiological relationships
out with pathology. The only other limiter used was “hu-
man” in Medline, Embase and PsycINFO but not Cinahl as
it appears to screen out human studies erroneously.
Search strategy
Database searches of Medline, Embase, CINAHL and
PsycINFO were undertaken. All languages were included
in the search. The Medline search strategy can be found
in Appendix 1. The searches were all performed on 6th
March 2014. A grey literature search was performed using
Google and Google Scholar. Hand searching through cita-
tions and references of relevant articles was also undertaken.
Study selection
The search was undertaken by two independent re-
searchers. Titles +/− abstracts found using our search
strategy were independently screened for relevance. The
full text of the selected studies was reviewed against the
inclusion criteria, and reasons for exclusion at this stage
were recorded. At this point the two researchers met to
discuss shortlists and discuss any articles which only one
researcher had selected to decide if they should be in-
cluded or not. Disagreements were resolved by consen-
sus or adjudication by a third party (a Professor in
Geriatric Medicine).
Data extraction
The Clinical Fellow (AK) performed the data extraction
using a data extraction sheet written by the Clinical Fel-
low and approved by the two co-authors (OT, JS).
Contacting authors
Of the 84 studies found through our search, we wrote to
79 to request data or associations which were not given
in the text. Five of the studies had given all the associa-
tions for the variables listed in the text. A letter was sent
by email to either the corresponding author (after check-
ing they were still working at the study location) or the
last author (after the same checking process). Only one
author was written to from each study (e.g. all articles
arising from the Kansas Brain Aging Project, were
grouped together when requesting extra data/associa-
tions). After the initial email a further email was sent
around 2 weeks later to act as a reminder. Studies were
given a minimum of around 1 month to reply.
Out of the 79 studies we wrote to: 25 studies (32%)
sent either the requested data or associations; 22 (28%)
replied stating they would try and send the data or asso-
ciations to us but then never did; 12 studies (15%) re-
plied stating they either no longer had access to the dataor did not want to send either the requested data or as-
sociations to us; and 20 (25%) never replied to either of
the emails.
Quality assessment and risk of bias
All papers included in the study had their inclusion and ex-
clusion criteria reviewed to check for possible bias in the
study selection. The topic of the review is not looking at an
intervention, therefore the risk of reporting bias for an in-
dividual paper is small. Also, in most of the papers, the re-
lationship between muscle and brain was not the primary
topic of the paper, further decreasing the risk of reporting
bias. However when contacting the authors, asking for ei-
ther the data or the associations, it was considered that the
studies which replied may show some bias. The authors
may look at their data and only reply if an association was
found, or if they found a strong relationship they may not
want this to be initially reported within a systematic review,
but rather in a paper in its own right. All summary mea-
sures were included (e.g. odds ratio, beta).
Data analysis
A narrative synthesis was completed. It was thought un-
likely that the data would be comparable enough to
allow meta-analysis (i.e. different measures of cognition,
different muscle groups studied using different ma-
chines) and this proved correct. It was hoped that sub-
group analysis would be undertaken, either in the form
of a meta-analysis or more likely as a narrative synthesis
for the reasons mentioned in the above paragraph.
Results
The search results are presented in the PRISMA flow
diagram in Figure 1. Reasons for exclusion of articles
after reviewing the full text are reported in Table 1. After
applying the inclusion and exclusion criteria 84 articles
were identified; 53 articles either reported the appropri-
ate associations or sent us the data or associations re-
quested (Tables 2, 3 and 4), and 31 articles contained
the required data but did not report the association be-
tween them and did not supply either the data or associ-
ations requested (Table 5). Out of the 53 articles which
could be included in the review; 6 contained data on
brain structure and muscle structure (Table 2); 33 con-
tained data on brain structure and muscle function
(Table 3); and 14 contained data on brain function and
muscle structure (Table 4).
Association of brain structure and muscle structure
Of the six articles which looked at the relationship be-
tween brain structure and muscle structure, three were
from the Kansas Brain Aging Project [28-30], and the
others were from Germany, UK and USA, Phoenix
[26,27,31] (Table 2).
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(n = 4)
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Figure 1 PRISMA flow diagram showing study selection.
Table 1 Full-text articles excluded, with reasons
Reason Number
Selected subjects (e.g. all had hip fracture,
all had dementia etc.)
73
No measure brain or muscle structure 57
Review article, no relevant references 56
No measure muscle structure or function 47
Abstract, no published results within timeframe or
irrelevant
34
No measure brain structure or function 19
Protocol paper, no published results within timeframe 12
Anthropometry only measure of structure 10
Letter or editorial, no results 7
Technique or theory paper 5
Case Report 2
No full text available 1
Total 323
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http://www.biomedcentral.com/1471-2318/14/85The Kansas Brain Aging Project was set up to deter-
mine the effects of exercise and cardiorespiratory fitness
on age-related brain changes. Only one of the papers
from this project reported the relationship between
brain and muscle structure [29]: Burns et al. reported a
positive relationship between WBV and TLM (beta 0.20,
p < 0.001) when control and subjects with Alzheimer’s
disease (AD) were grouped together, adjusting for age
sex and intracranial volume (ICV), and they note that
this was driven by WM volume [29]. They state that this
relationship persists in just the control group but do not
give any statistics for this relationship. A General Linear
Model (GLM) was performed on the data from the non-
demented group supplied to us by the study authors
from the Kansas Brain Aging Project [28-30]. WBV, grey
matter (GM) volume and hippocampal volume were not
predicted by TLM adjusting for age, sex and ICV +/−
education. White matter (WM) volume was predicted by
TLM (t 3.12, p = 0.003, partial eta squared 14%) adjust-
ing for age, sex and ICV. Adjusting for total years of for-
mal education only slightly attenuated the results (t 2.99,
p = 0.004, partial eta squared 13%).
Kilgour et al. also looked at older subjects however
they used neck muscle CSA as a measure of muscle bulk
[27]. They found that total neck muscle CSA predicted
17% of the variance in whole brain volume (p = 0.01),but they found no significant association between total
neck muscle CSA and ventricular, hippocampal or cere-
bellar volumes (p > 0.05), adjusting for age, sex, ICV and
NART (a measure of childhood intelligence).
The other two studies looked at younger subjects.
Heymsfield et al. specifically set out to investigate the
Table 2 Studies identified with brain structure (+/− brain function) and muscle structure
Authors Year Country and
dataset
n Study design Mean age (sd) Male (%) Brain structure/Function Muscle structure Associations*
1. Heymsfield
et al. [26]




43.1 Structure: Brain volume
transformed into mass
using 1.036 g/cm3
DEXA for FFM Study: Linear regression models
found that after adjusting for age
and fat mass, FFM predicted brain
mass in men (beta 0.023, R2 5%,
p = 0.01) and women (beta 0.003,
R2 6%, p = <0.0001).
Function: not measured





73.8 (1.5) 100 Structure: Whole brain,
hippocampal, ventricular,
cerebellar volumes and ICV
Neck muscle CSA
on MR head scan
Study: Total neck muscle CSA was
found to predict 17% of the
variance in whole brain volume
(t = 2.86, p = 0.01). However, total
neck muscle CSA did not significantly
predict the variance in ventricular,
hippocampal or cerebellar volumes
(p > 0.05). Total neck muscle CSA
did not significantly predict variance
in either the memory factor or the
cognitive processing factor (p > 0.05),
however, it did predict 10% of the
variance in the NART score (t =−2.12,
p < 0.05). Adjusting for age, sex, ICV
and NART where appropriate.
Function: 9 tests of cognitive












73.0 (7.2) 43.4 Structure: MRI for WM,
GM, CSF, WBV and ICV





I & II, Free & Cued Selective
Reminding Task, Boston
naming test, Verbal fluency,
Digit span forward and
backward, Letter-number
sequencing, Trail making
A & B, Stroop color-word
test and Block design, MMSE
Calculated: Non-demented group
only. WBV, GM volume and
hippocampal volume not predicted
by TLM adjusting for age, sex and
ICV +/− education. WM volume was
predicted by TLM (t 3.12, p = 0.003,
partial eta squared 14%) adjusting
for age, sex and ICV. TLM did not
significantly predict global cognitive
score or MMSE, adjusting for age
and sex. Adjusting for height and
education did not affect this.








73.3 (7.3) 42.9 Structure: MRI for WM, GM,
CSF, WBV and ICV
DEXA for total
lean mass
Study: Positive relationship between
WBV and TLM when control and
AD subjects grouped together
(beta = 0.20, p < 0.001), adjusting
for ICV, age and sex. This appears
to be driven by WM (beta 0.19,
p < 0.001) rather than GM (beta 0.06,
p = 0.27) States this persists in just
the control group but doesn’t give
any statistics for this. Positive
relationship between MMSE and
global cognitive score (composite
Function: Logical Memory
I & II, Free & Cued Selective
Reminding Task, Boston
naming test, Verbal fluency,
Digit span forward and
backward, Letter-number
sequencing, Trail making
A & B, Stroop color-word


















Table 2 Studies identified with brain structure (+/− brain function) and muscle structure (Continued)
of the cognitive tests) and lean
mass when grouping AD and
control subjects together. States
that controlling for dementia status
attenuates these results, but no
specific statistics given. Calculated:
See Wetmore et al. (2011) for Kansas
Brain Aging Project data analysis.










73.3 (6.2) 41.1 Structure: MRI for GM, WM,





Function: MMSE Calculated: See Wetmore et al.
(2011) for Kansas Brain Aging
Project data analysis.
6. Weise et al. [31] 2013 USA, Phoenix 76 Cross-sectional
study
32.1 (8.8) 31.6 Structure: MRI brain




Study: Fat-free mass index (FFMI)
was negatively associated with
GMV of the bilateral temporal
lobes, ventromedial prefrontal
cortex (vmPFC) (mainly subgenual
portion of the ACC) and
caudolateral orbitofrontal cortex
and unilaterally with the left insular
cortex (all p < 0.01). After adjusting
for percentage body fat and fat
mass, negative associations of FFM
with GMV of the right temporal pole
and bilateral vmPFC remained. All
models adjusted for age, sex and
handedness.
Function: not measured


















Table 3 Studies identified with brain structure and muscle function
Author Year Country and
dataset
n Study design Mean age (sd) Male (%) Brain structure# Muscle function Associations*










52.8 Volumes of GM, WM and
CSF, ICV and TBV (GM





Study: Total brain WMH volume
predicted grip strength in men
(beta −0.140, delta R2 0.019,
p < 0.05) but not in women














Study: Grip strength adjusted for
sex and ICV was found to correlate
with CC midbody area (r = 0.103,
p < 0.05), however CC total area
and anterior and posterior CC
areas did not significantly correlate










51.8 Volumes of GM, WM and
CSF, ICV and TBV (GM





Study: None, see other articles
from the PATH through life











52.3 WMH, ICV Grip strength
in writing hand
Study: Total brain WMH significantly
predicted grip strength (beta −0.09,
p = 0.002) adjusted for age, sex
and depression. Correcting for
comorbidity, cognition and brain
atrophy did not attenuate the
results (beta −0.13, p =0.001).
5. Doi et al.
[36]
2012 Japan 110 Cross-sectional
study
75.4 (7.1) 50 GM, WM, CSF, brain atrophy
(measured using healthy
volunteers)
Grip strength Study: A MLR model found that
grip strength is not related to brain
atrophy (beta −0.082 (SE 0.005)
p = 0.54). Adjusting for age, gender,
BMI, education, MMSE, Tokyo
Metropolitan Institute of
Gerontology Index of Competence,
geriatric depression scale and
change in walking whilst dual
tasking. No other associations given.
6. Hardan
et al. [37]
2003 USA, Philadelphia 41 controls Case–control
study
18.6 (8.6) Not given Caudate, putamen and
total brain volume
Grip strength Study: Non-significant trends
showed a negative correlation
between right grip strength and
total caudate volume (r = −0.303,
p = 0.05) and left grip strength
(r = −0.28, p = 0.07) in the control
group. Not corrected for age or



















Table 3 Studies identified with brain structure and muscle function (Continued)











54.5 Cerebellar vermis area,




5 m, adjusted for
lower limb arthritis
Study: None of the brain size
measures (cerebellar vermis area,
cerebellar volume or cerebral
volume) significantly predicted
timed walk (p > 0.05) after
adjustment for age (but not sex,

















Study: MLR were performed to
investigate the relationship of
longitudinal change in brain
volumes and gait speed. They
found that white matter atrophy
(beta 0.25 (CI 0.09-0.40) p = 0.001),
greater WML progression
(beta −0.89 (CI −1.75- -0.02)
p = 0.045), grey matter atrophy
(beta 0.25 (CI 0.00-0.19) p = 0.06)
and hippocampal atrophy (beta 0.01
(CI 0.00-0.02) p = 0.006) were all




2010 Australia, TASCOG 385 Longitudinal
cohort study
72.2 (7.1) 56 WMLV, TBV Gait speed using
4.2 m GAITRite
system
Study: none, see Callisaya et al.




2009 Australia, TASCOG 294 Longitudinal
cohort study
72.3(7.0) 55.4 WMLV, TBV Gait speed using
4.2 m GAITRite
system
Study: none, see Callisaya et al.
(2013) for analysis using the
TASCOG dataset.




4010 Cohort study 73.4 (4.6) 38.4 WML volumes 6 metre walk speed
(usual and maximum)
Study: Logistic regression stratified
by education found that high WML
volumes were not associated with
slow walking speed among highly
educated participants (OR = 0.72),
but were associated with a
2-fold-increased risk of slow walking
speed among those with low
education (OR = 3.19/1.61 = 1.99)
(p interaction = 0.026), adjusted
for sex, age and total WM volume.
Results remained unchanged after
adjustment for height, BMI, and
MMSE score.
Given: WM volume did not predict
walking speed at baseline, adjusted
for age, gender and ICV in a MLR
(p > 0.05, n = 1510), or decline in
walking speed over 7 years,


















Table 3 Studies identified with brain structure and muscle function (Continued)
baseline walking speed, (p > 0.05,
n = 928). A logistic regression
found that WM volume was not
significantly associated with an
increased risk of being in the
quartile with the highest walking
















speed over 6 metres
Study: A linear regression found
that only basal ganglia volume
(beta 0.075 (SE 0.025) p = 0.003)
was significantly associated with
walking speed; driven by caudate
nucleus volume (beta 0.114
(SE 0.024) p < 0.001). All other
regional GM volumes were not
significantly associated with
walking speed. A semi-bayes
model found again only the
basal ganglia volume (beta 0.061
(SE 0.028) p = 0.03) was significantly
associated with walking speed;
driven by caudate nucleus volume
(beta 0.050 (se 0.019) p = 0.007).
There was found to be a linear
relationship between quartiles of
caudate nucleus volume and
faster walking speed (p for linear
trend (0.001). These relationships
were attenuated slightly for total
basal ganglia volume by adjusting
for MMSE and comorbidity plus
smoking but not for caudate
nucleus volume. All models
adjusted for; age, sex, BMI,
education level, ICV, volume of
WMLs and silent infarcts. Given:







f/u at 4y 1774




WMH volume Maximum walking
speed over 6 metres,
1st and 4th follow up,
mean 7 years
Study: none
Given: See Elbaz et al. (2013) for










speed over 6 metres,
1st and 4th follow up,
mean 7 years
Study: A significantly lower mean
walking speed was found in those
with a total WMH volume above
the 75th percentile compared to
those below the 25th (Beta −0.026,
p = 0.0003). A similar relationship
was found for both deep WMH
and PVH. A WMH volume greater
than the 90th percentile more


















Table 3 Studies identified with brain structure and muscle function (Continued)
in walking speed compared with
subjects with lower volumes of
WMH (OR 2.6 (1.5-4.5), p = 0.001).
This finding was replicated when
looking at PVH but not for deep
WMH volume. Given: See Elbaz
et al. (2013) for Three-City Study
data analysis.






78-79years 59.8 WMH in deep/subcortical,




Study: A slower 6metre walk test
was associated with increased
brain stem lesions (F 7.11, p = 0.009,
partial eta2 0.070), but not with
WMH (deep) (F 3.33, p = 0.071)
or PVH (F 2.47, p = 0.12). Doesn’t
state if age and sex are adjusted for
in these models. If HADS score
and Raven’s score are adjusted





2012 USA, Boston, 89 in control group Case–control
study
65.3 (8.2) 48.3 GM, WM, CSF, regional
GM volumes; precentral




75 metre walk test
at preferred pace
Study: Within linear regression
models, global GM volume and all
of the regional GM volumes were
not associated with walking speed
in the control group (p > 0.005,
Bonferroni adjusted). Adjusted for
age, sex and body mass.
17. Hajjar et al.
[48]




Non-stroke group 43 Case–control
observational
study






Study: Gait speed was not
significantly associated with
GM volume (p = 0.85), but was
significantly associated with WM
volume (B = 1.30, p = 0.03) adjusting
for age, gender, BMI and
antihypertensive use.







64.7 (7.2) 47.4 GM, WM, CSF, WMH all






Study: Gait speed was significantly
associated with frontal WM
normalized for brain tissue
volume (R = 0.4, p = .003). Gait
speed was significantly associated
with frontal GM normalized for
brain tissue volume (R = 0.3, p = .01).
Adjusted for age and BMI (but
not gender). Doesn’t say about
other regional brain volumes,
ie temporal etc. WMH volumes
and PVH and punctuate scores



















Table 3 Studies identified with brain structure and muscle function (Continued)
19. Moscufo
et al. [50]
2012 USA, Boston, Moscufo
study – 2 year f/u
77 Longitudinal
cohort study
84 (3.9) 40 WMH volume as % of ICV
and regional WMH burden
expressed as % of ROI






baseline and 2y f/u.
Study: Total WMH burden was
significantly associated with usual
walking speed at baseline but
not at follow-up, and maximum
walking speed was not associated
with total WMH at baseline or
follow up. At baseline, regional
WMH burden in the splenium
of corpus callosum and anterior
and superior corona radiata, was
significantly associated with both
walking measures (p < 0.05) and in
addition the body of the corpus
callosum was also associated with
usual walking speed (p < 0.05). At
follow-up, WMH burden in the
splenium was significantly
associated with both walking
measures (p < 0.05) and in the
body with maximum walking
speed. Change in WMH burden,
either total or in any of the 7
regional areas, over 2 years was
not associated with a decline in
usual walking speed (p > 0.1).
Given: WMH burden is significantly
associated with lower gait speed
after adjustment for age, sex and
BMI (rho = −0.327, p = 0.0008).
WM/ICV is not significantly
associated with gait speed with
or without adjustment (p > 0.05).
GM/ICV is significantly associated
with gait speed with adjustment
for age, gender and BMI (rho= 0.232,
p < 0.05). CSF/ICV is significantly
associated with gait speed with
adjustment for age, sex, BMI
(rho = −0.285, p = 0.004).
20. Moscufo
et al. [51]





83(4) 42.4 WM, GM, WMH and CSF
volumes all corrected for
ICC. Brain atrophy.
Regional WMH burden




as part of SPPB)
Study: Total WMH burden (i.e. %
of ICV) correlates with gait speed
(rho =−0.288, p = 0.004). Also all
9x regional burden measurements
correlate with gait speed score too
except sup. longitudinal fasciculus.
No adjustment.
Given: See Moscufo et al. (2012) for


















Table 3 Studies identified with brain structure and muscle function (Continued)
21. Wolfson
et al. [52]
2005 USA, Boston, WML
and mobility













Study: Slower baseline gait velocity
predicted more WMSA at visit 1
(p < 0.05), but not change in
WMSA volume between visit 1
and 2 (p < 0.07). Significant negative
relationship of between-visit change
in gait velocity to CSF volume
(r = 0.733, p < 0.005) and a positive
relationship of between-visit change
in gait velocity to WM volume
(r = 0.558, p < 0.05). Betas not
given. Brain volumes normalized




2000 USA, Boston, WML
and mobility
28 (12 with SPPB




SPPB > 10 79(5)
SPPB < 9 83(6)




Study: Gait velocity was not
significantly predicted by age
nor WMSA volume (no figures
given or p value) adjusted with








72.3 (3.8) 35.5 Brain volumes (GM,
WMH, Prefrontal area,
WM, CSF)
Timed 15 ft walk
at usual pace
Study: Prefrontal area volume
significantly predicted time to
walk in a stepwise forward model
















Study: none, see Rosano (2012),
Rosano (2006), Rosano (2005) and
Longstreth (1996) for analysis
















Study: Gait speed was significantly
correlated to total WMAs (r = −.18,
p < 0.0001) and white matter
lesions in the brainstem (r = −.18,
p = 0.01). After adjusting for age,
slower gait speed was still
significantly associated with
white matter grade (p = 0.02).
Logistic regression found that
those in the lowest two quartiles
of gait speed (ie < 1.02 m/s) had
double the likelihood of having
WMH graded 3 or above (p = 0.03),
after adjustment for age, race,
gender, and prevalent clinical CVD.
VE graded >4 was not found to be
significantly predicted by gait
speed, however VE graded > 5
was, independent of age, gender,
race and presence of CVD (OR= 2.91
for 1st vs. 4th quartile, OR 3.82 for
































15 ft at usual pace,
starting from
standing still
Study: Grade of ventricular
enlargement was associated with
baseline gait speed and mean
change in gait speed/year. Gait
speed decline was 2.5x that for
those with severe VE than minimal
VE. (p < 0.001). Grade of WMH was
associated with baseline gait
speed and mean change in gait
speed/year (p = 0.003). In both
analyses adjustment had been
made for age, sex, race and
education and CV risk factors
(BMI, systolic BP, antihypertensive
meds, internal carotid wall
thickness, and ETOH intake) and
prevalent CV disease.
27. Silbert et al.
[58]





85.1 (5.6) 38.5 PV WMH and s/c WMH,






Study: Adjusted for age and ICV,
higher baseline total WMH vol.
was associated with increased
rate of change in timed walking
in seconds (r2 = 0.08, p = 0.0052).
This relationship became
non-significant after adjustment
for multiple comparisons to
threshold p value. PVH volume is
associated with increased rate of
change in timed walk in seconds
(r2 = 0.12, p = .0039). However,
baseline subcortical WMH vol. was
not related to change in gait
performance over time. Higher
rate of PVH accumulation is
associated with increased rate
of change of time to walk 9 m
(r2 = 0.15, p = .0453). Adjusted
for age, ICV and baseline WMH
volume:
Calculated: In an unadjusted GLM,
gait speed was predicted by
total brain, WMH and hippocampal
volume (p < 0.001). The relationship
remained significant after adjusting
for sex, age, ICV and height, for total
brain volume (t = 3.61, p = .004,
partial eta squared 4.3%) and
WMH (t = −2.80,
p = 0.006, partial eta squared 4.4%)


















Table 3 Studies identified with brain structure and muscle function (Continued)
28. Marquis
et al. [59]













and time to walk 30 ft (r = −.12).
No p value given.
Calculated: See Silbert et al. (2008)
for Oregon Brain Aging Study
data analysis.









41.1 MTR, ICV, brain parenchyma
volume, semiquantitative
subcortical WMH and PVH
and total WMH volume,
brain atrophy index
Gait speed over




Study: In men: Time to walk 6metres
predicted by WMH volume (beta
0.13, p = 0.02) but not brain atrophy
or peak height MTR (adjusted for
age and brain size as includes
measure of brain atrophy). In
women: Usual walking speed
predicted by lower MTR height
(i.e. indicating abnormal brain
tissue) (beta −0.14 (p = 0.01),
increased WMH (beta 0.12,
p = 0.003) and greater brain
atrophy (beta 0.15, p = 0.01)
(adjusted for age and brain size).
Lower muscle strength associated




2013 UK, LBC 1936 study 694 Longitudinal
cohort study
69.5 (0.7) wave 1
and 72.5 (0.7)
wave 2
52.9 TBV, ventricular volume,
GM, NAWM and WML
at wave 2
6 metre walk (normal
walking pace) and
grip strength at wave
1 and 2
Study: Grip strength at wave 1
significantly predicts ventricular
volume at wave 2 (standardized
beta −0.10), however there was
no significant association with
other brain volumes. 6metre walk
at wave 1 predicted TBV (−0.07),
ventricular volume (0.09), NAWM
(−0.07) and WML (0.11) all p < 0.05.
Grip strength at wave 2 was
associated with ventricular volume
(−0.11) and NAWM (0.08). 6 MW at
wave 2 was associated with TBV
(−0.07), NAWM (−0.09) and WML
(0.11) all p < 0.05. Change in
physical function between wave 1
and 2 (i.e. decrease in grip strength
or increase in 6 MW) was not
significantly associated with any
brain volume measure. GM volume
did not significantly associate with
any of the physical function
variables at wave 1 or 2. All analyses
were adjusted for age, ICV, age 11
IQ, years of education, social class,
comorbidity and smoking status.




































Study: none, see Rosano (2012),
Rosano (2006), Rosano (2005) and
Longstreth (1996) for analysis














Gait speed over 15 ft
and grip strength in
dominant hand
Study: none, see Rosano (2012),
Rosano (2006), Rosano (2005) and
Longstreth (1996) for analysis









70.7 (no sd) 41.7 MR WMSA graded 0-9 Time to walk 15feet,
grip strength in dom
and non-dom hand
Study: Time to walk 15 ft correlated
with white matter grade (0–9)
(r = 0.153, p < 0.001), with
adjustment for age, sex and
presence of clinically silent stroke
on MRI. Same model showed no
significant associated between
grip strength in dom hand or
non-dom hand and white matter
grade (p > 0.05).
#All brain structure variables performed using MRI.


















Table 4 Studies identified with brain function and muscle structure
Author Year Country and
dataset












from a large physical
training intervention
study
70.8 (5.4) 41.67 MMSE & modified
Stroop test
LBM (DEXA) Study: none
Calculated: A GLM showed no
association between LBM and
MMSE, Stroop naming, reading
or inhibition tasks, adjusted for
sex and age. However there
was an association between
the Stroop flexibility task and
LBM (t 2.126, p = 0.039, partial
eta squared 9.3%), however after
adjusting for education and
height the effect was attenuated
(p > 0.05).
2. Bites et al.
[66]
2013 Chile 306 Retrospective study M 74.9 (61–91),
F 75.5 (69–90)




Calculated: Authors sent one data
sheet for this study and Bunout
et al., as there is a large amount
of overlap between the studies.
N = 401, mean age 75.3 (sd 4.8),
males 28.7%. GLM performed
adjusting for sex and gender. Total
LM (t 2.38, p = 0.018, partial eta
squared 1.4%) and Leg LM (t 3.53,
p < 0.001, partial eta squared 3.1%)
were both associated with MMSE
score but Arm LM is not. After
adjusting for height the relationship
between total LM and MMSE is
non-significant and between leg
LM and MMSE is attenuated (t 2.09,
p = 0.038, partial eta squared 1.1%).
3. Bunout
et al. [67]
2005 Chile 298 RCT M 75.4 (4.8)
F 75.8 (4.7)




Calculated: See Bites et al. 2013 for










49.7 CSI-D and MMSE ASM, LLMM,
FFM (DEXA)
Study: none
Given: CS-CSID did not predict TLM
or ASM at baseline or at 4 years (all
p > 0.05). However baseline MMSE
was associated with baseline TLM
(rho = 0.058, p = 0.002) and ASM
(rho = 0.061, p = 0.001) and at follow-
up (TLM rho = 0.058, p = 0.002, ASM
rho = 0.054, p = 0.005). MMSE at
follow up was not associated with





























55.3 CSI-D and MMSE ASM (DEXA) Study: In men, low baseline ASM
predicted lower MMSE score after
4 years (B = 0.246, p < 0.01) however
after adjustment for age, years of
education and baseline MMSE it no
longer did (p > 0.05). In women,
ASM did not significantly predict
MMSE after 4 years, either before
adjustment or after (p > 0.05).
Given: see Auyeung et al. (2013) for
analysis using this dataset








50 CSI-D and MMSE ASM, LLMM,
FFM (DEXA)
Study: none
Given: see Auyeung et al. (2013) for










50 CSI-D and MMSE ASM (DEXA) Study: none
Given: see Auyeung et al. (2013) for





Cross-sectional study Median 53
(48–60 inter
quartile range)
46 DART, WAIS-III information
subtest, TMT-A&B, Rey
Auditory Verbal Learning
Test (RAVLT), Symbol Digit
Modalities Test (SDMT), and
fluency tests
FFM (DEXA) Study: None
Calculated: FFM did not predict the
cognitive z score with or without
adjusting for BMI and childhood
intelligence (Danish Adult Reading
Test, DART). The six individual
cognitive tests were then analysed:
FFM did not predict RAVLT, SDMT,
category fluency (using animals) or
TMT-b test, with or without adjusting
for BMI and childhood intelligence
(DART). Unadjusted, there was no
significant association between the
letter fluency test (using “s”) and FFM
(P > 0.05), however after adjustment
for BMI and DART, letter fluency was
significantly associated with FFM
(t 2.34, p = 0.02, partial eta squared
7.7%). TMT-a test did significantly
predict FFM (t 3.08, p = 0.003, partial
eta squared 12.3%). After adjusting
for BMI and DART the relationship
became non-significant.








0 MMSE FFM (BIA) Study: none
Calculated: FFM did not significantly
predict MMSE (p > 0.05), adjusting for
age. Adjustments for BMI and



























66.2(6.3) 0 TMT-A and B and digit
span
FFM (BIA) Study: none
Calculated: FFM does not significantly
predict TMT-A or B adjusting for
age +/− height (p > 0.05). Trend with
FFM predicting digit span (t 1.96,
p = 0.06, partial eta squared 13%) but
attenuated when adjusted for height
in addition to age (p = 0.37).





983 Population based ageing
cohort study
65.2 (9.3) 50.6 MMSE LBM and Relative
ASM (=ASM/
height2) (DEXA)
Study: A t test comparing mean MMSE
in those with normal RASM and those
within the lowest 20 % of RASM found
a significant difference in men and
women of all ages (p < 0.05).
Given: In a MLR, RASM did not predict
MMSE after adjusting for age and sex
(beta −0.003, p = 0.940). Adjusting for







786 Longitudinal cohort study 66.3 (range
26–96)
51.9 California Verbal Learning
Test (CVLT), digit-span test,




Given: In a linear regression, none of
the cognitive tests predicted thigh CSA,
adjusting for age and gender. After
adjusting for age, gender and height,
the digit-span backward test became
significantly associated with thigh










obese and healthy weight
children)
8.8 (0.6) 46 Kaufman Brief Intelligence
Test (K-BIT)
TLM (DEXA) Study: none
Calculated: Authors sent one data
sheet for the FITKids study as there is
considerable overlap in subjects
between the two Kamijo et al. papers
[77,78], (n = 139, mean age 8.8 (sd 0.6),
male 51.1%). A GLM found that TLM did
not predict K-BIT after adjustment for
age and gender (p > 0.05). Adjusting for





126 Cross-sectional study 8.9 (0.5) 50 Kaufman Brief Intelligence
Test (K-BIT)
TLM (DEXA) Study: none
Calculated: as per Kamijo et al. [77]



















Table 5 Studies identified with measures of brain structure or function and muscle structure or function but no associations given in paper or on request
Authors Year Country and dataset n Study design Mean age (sd) Male (%) Brain structure or
function
Muscle structure or function
Studies with brain structure and muscle structure (re: Table 2)
1. Chowdhury
et al. [79]
1994 Sweden 8 Methodology paper 35 (8) 100 Brain volume (CT) Calculated skeletal muscle
volume (CT)
Studies with brain structure and muscle function (re: Table 3)
2. Liu-Ambrose
et al. [80]
2010 Canada, Exercise RCT
in Vancouver
155 RCT, prospective over
52 weeks






20 controls Cross-sectional substudy
of longitudinal study
75 (9) 40 Score on Age-Related
White Matter Change
Scale (MRI)




2005 USA, California, Stanford 51 Case–control study 45.2 (13.9) 100 Caudate, putamen, nucleus
accumbens and medial
septal / diagonal band
volumes and ICV (MRI)
Bilateral grip strength
Studies with brain function and muscle structure (re: Table 4)
5. Guthrie
et al. [83]
2004 Australia, The Melbourne
Women's Midlife Health
Project
1897 9 year prospective,
observational population
based sample
Median 50 0 Episodic verbal memory
using a 10 word recall task
(CERAD)
Body composition (DEXA)








study (AD vs MCI vs
normal)
70.0 (7.0) 43 CVLT-II, Logical memory,
RCFT, digit span, digit
symbol coding, D-KEFS
verbal fluency, BNT, clock,
WTAR, Stroop.
Body composition (DEXA) in
subgroup in Perth
7. Dao et al.
[85]
2013 Canada, Exercise RCT in
Vancouver
114 Secondary analysis of
RCT data














2004 Denmark, PERF study 5607 Prospective, observational
cohort study




2013 France, EPIDOS study 3025 Prospective multi-centre
cohort study
80.51(3.9) 0 SPMSQ Lean mass and ALM (DEXA)
11. Nourhashemi
et al. [89]
2002 France, EPIDOS study 7105 Cross-sectional study 80.3 (3.65)
(SPMSQ > =8)











0 Pfeiffer’s test (aka SPMSQ) Body composition (DEXA)
13. Paolisso
et al. [91]
1997 Italy, Naples 30 (>50y), 30
(75-99y) 19
(>99y)
Observational study 44.5(1.8), 78(0.7),
102(0.8)



























31.8 MMSE Total muscle mass (BIA)
15. Jacobsen
et al. [93]
2012 Netherlands 318 RCT Mean for each arm
given range 73.4-74.0









9 year f/u visit
1999 M 71.7(5.2) 1999 49.3 MMSE FFM (BIA), ASMM (DEXA) and
BCM (total body potassium)





1996 USA, Baltimore 73 Cross-sectional study 68.8 (7.2) 31.5 MMSE FFM (DEXA)
18. Bove et al.
[96]
2013 USA, Boston, Harvard 12 Cross-sectional study 31.6 (6.4) 0 Multiple tests broken
down to 5 cognitive
domains




1995 USA, California, San
Francisco
104 Cross-sectional study 75.5(4.9) 100 MMSE, Trails B and DSST Lean tissue mass (DEXA)
20. Janssen [98] 2006 USA, Cardiovascular
health study
Baseline 5036 Longitudinal observational




43.6 MMSE Whole body muscle mass (BIA)
and normalized for height to









CNS vital signs battery FFM (BIA)
22. Houston
et al. [100]
2012 USA, Health, Aging, and
Body Composition study
2641 Longitudinal cohort study 74.7 (2.9) 48.9 MMSE Lean mass (DEXA)
23. Middleton
et al. [101]
2011 USA, Health, Aging, and
Body Composition study
197 Cross-sectional study from





Not given 3MS FFM (DEXA)
24. Koster et al.
[102]
2010 USA, Health, Aging, and
Body Composition study
2949 Cross-sectional study from
a 9 year longitudinal
cohort study
Age 70–79 at baseline 48.5 3MS Total bone-free lean mass,




2003 USA, Health, Aging, and
Body Composition study
2926 Baseline data from a
9 year longitudinal cohort
study
Diabetes mellitis (DM)





MMSE and DSST Lean mass and lean soft tissue









Baseline data from a
9 year longitudinal cohort
study





Total muscle mass and skeletal
muscle mass in the legs (DEXA)
27. Watts et al.
[105]

























Table 5 Studies identified with measures of brain structure or function and muscle structure or function but no associations given in paper or on request
(Continued)
28. Canon et al.
[106]





Range 60-85 44.8 Digit-symbol coding test Lean tissue mass (DEXA)
29. Garry et al.
[107]










40 3MS (annual), WAIS R digit
span, Fuld object memory
evaluation, Color Trails 1
and 2, clock drawing (all
less than annual)
Annual skeletal tissue mass
(DEXA)
30. Haren et al.
[108]




56.1(4.4) 100 MMSE, TMT A&B TLM and ASM (DEXA)
31. Dvorak et al.
[109]


















Kilgour et al. BMC Geriatrics 2014, 14:85 Page 22 of 35
http://www.biomedcentral.com/1471-2318/14/85relationship between brain mass and body composition
[26]. They performed multiple linear regression and
found that after adjusting for age and fat mass, FFM pre-
dicted brain mass in men (beta 0.023, R2 5%, p = 0.01)
and women (beta 0.003, R2 6%, p = <0.0001). Fat mass
or bone mineral content did not significantly predict
brain mass in either sex. So they conclude that it is FFM
that drives the relationship between body size and brain
size not bone or fat mass. Weise et al. investigated the
associations between regional grey matter volume and
fat free mass index (FFMI = FFM/height2) [31]. They
found several areas of grey matter volume that were sig-
nificantly associated with FFMI (p < 0.01, see Table 2),
however after adjusting for percentage body fat or fat
mass only two areas remained significant (the right tem-
poral pole and bilateral ventromedial prefrontal cortex).
Association of brain structure and muscle function
Thirty three studies which included measures of brain
structure and muscle function were identified (Table 3).
The muscle function variables most commonly studied
were grip strength and gait speed. Only one study was
identified which used a different measure of muscle
function and that was maximal isometric knee extension
strength (IKES) [60]. The brain structure variables in-
clude: corpus callosum area, and volumes for total and
regional GM and WM, cerebrospinal fluid (CSF), cere-
bellum, hippocampus, basal ganglia and whole brain
volume and measures of prevalence of WMH, either
volume or scoring systems (e.g. Fazekas).
Brain structure and grip strength
The PATH through life project [32-35], the Cardiovascu-
lar Health Study [55-57,62-64], the Lothian Birth Cohort
1936 study [61], a study from japan [36] and a study
from Philadelphia [37] all looked at the relationship be-
tween grip strength and brain structure.
There are four papers identified by our search strategy
from the PATH through life project, which was set up to
track and define the lifespan course of depression, anx-
iety, substance use and cognitive ability. In one paper
from this project, Anstey et al. (2007) studied the rela-
tionship between the area of the corpus callosum (CC)
(measured in three sections: anterior, midbody and pos-
terior; and total area) and grip strength [33]. They used
the grip strength from the hand the subject wrote with
and adjusted for age, sex and ICV. They found no sig-
nificant relationship between total, anterior or posterior
CC area and grip strength however they found a positive
relationship between midbody CC area and grip strength
(beta −0.09, p < 0.05). They conclude that this is due to
the association between midbody CC and the motor cor-
tices. Another paper from the PATH through life project
studied the association between grip strength and thepercentage of WM occupied by WMH in different brain
areas [35]. They found that a larger percentage of WMH
per WM volume is associated with decreased grip
strength for both the total brain and several brain areas
(frontal, temporal, parietal, anterior horn and periven-
tricular body (all p < 0.01)). However, the amount of
WMH in the occipital lobe, the cerebellum and the pos-
terior horn was not associated with grip strength. The
2009 paper from this study further investigated the rela-
tionship between WMH and grip strength [32]. This
time they looked at the relationship in men and women
separately. They found that larger amounts of WMH
was associated with reduced grip strength, adjusting for
age, depression severity and brain atrophy index, in men
(p < 0.05) but not in women (n/s). However they com-
ment that they feel that the relationship between WMH
volume and motor function is likely to be the same in
both sexes and that their finding may be due to the dif-
ference in WMH amount between men and women in
their study population. Sachdev’s 2006 paper from this
study did not look at the relationship between motor
function and brain structure and the authors did not re-
spond to our data request [34].
The Cardiovascular Health Study (CHS) is a large, lon-
gitudinal, observational study of risk factors for cardio-
vascular disease in adults 65 years or older, which
commenced in 1989 [52]. The CHS measured grip
strength and gait speed and WMSA, however only one
paper from this study looked at the relationship between
grip strength and WMSA [64]. In this paper Longstreth
et al. (1996) performed a partial correlation which found
no significant association between grade of WMSA
(graded on a scale of 0–9) and grip strength in either
the dominant or non-dominant hand (p > 0.05) after
adjusting for age, sex and presence of clinically silent
stroke on MRI [64].
The Lothian Birth Cohort 1936 study measured grip
strength at baseline and 3 years later at which point
brain volumes were also measured [61]. It is the only
study to look at longitudinal changes in muscle strength
and brain structure. Grip strength at wave 1 predicted
ventricular volume at wave 2 (standardized beta −0.10),
however there was no significant association with other
brain volumes and grip strength at wave 2 predicted
ventricular volume (−0.11) and NAWM (0.08). There-
fore, increased grip strength was associated with less
brain atrophy in this wave. However, decreased grip
strength over 3 years was not significantly associated
with any brain volume measure.
The paper by Doi et al. used multiple linear regression
to show that grip strength is not related to brain atrophy
(beta −0.082 (SE 0.005) p = 0.54) [36]. They measured
brain atrophy by mapping the MR brain scans from their
subjects to those from healthy controls. Most studies
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of brain atrophy. No associations with the other mea-
sured brain volumes were included in the paper.
The paper by Hardan et al. looked at the association
between caudate volume and grip strength in both hands
in children and young adults [37]. They found non-
significant statistical trends using Pearson’s correlation
between total caudate volume and mean grip strength in
the right (r = −0.303, p = 0.05) and left (r = −0.28, p =
0.07) hands. The relationships are negative, therefore
there is a trend that those with larger caudate nuclei
were found to have lower grip strength in both hands.
Gait speed and brain structure
The Sydney Older Person’s Study [38], the TASCOG
study [39-41], the Three-City Study [42-45], the AGES-
Reykjavik study [60], ABC1921 study [46], WML and
mobility study [52,53], further studies from Boston
[47-51], the Cardiovascular Health Study [54-57,62-64],
the Oregon Brain Aging Study [58,59], the LBC1936
study [61] all looked at the relationship between struc-
tural brain measures and gait speed. There were 27 stud-
ies identified to include in this section, making it the
most researched association in our review. The measure-
ment of gait speed varied considerably, with studies vari-
ously using maximum speed or usual pace, and some
studies requiring a turn halfway through the measure-
ment and others not. The distance used for the measure-
ment also varied from 2.5 to 75 metres, however the
most commonly used measure was usual pace over 6
metres.
The Sydney Older Person’s Study was set up to investi-
gate the environmental, biological and social determi-
nants of healthy ageing. Within it Piguet et al. looked at
the relationship between timed walk over 5 meters, ad-
justed for lower limb arthritis, and cerebellar vermis area
(broken down into V1, V2 , V3 and total), and total cere-
bellar volume. None of the measures of cerebellar size/
volume significantly predicted the timed walk [38].
The Tasmanian Study of Cognition and Gait was set
up to examine the role of age-related brain changes in
causing problems with walking, balance and cognitive
abilities in the general community. It measured brain
volumes and usual walking speed over 4.6 metres at
baseline and 31 months [39]. They found that a greater
decline in gait speed over this period was associated with
more WM atrophy and hippocampal atrophy and
greater accumulation of WML (p < 0.05). There was a
non-significant trend with GM atrophy and decline in
gait speed (p = 0.06).
The Three-City study is a longitudinal study of the re-
lation between vascular diseases and dementia in per-
sons aged 65 years and older in France, which includes
measures of WM volume and maximum walking speedover 6 metres and a repeat walking speed test at the
fourth follow up assessment (i.e. roughly 7 years after the
first). There were four papers identified from this study
which contained reference to these variables.
Soumare et al. looked at the association between
WMH volume and both baseline walking speed and de-
cline in walking speed over the 7 year follow up period
[45]. They adjusted for age, gender, education and brain
white matter volume. They found a significantly lower
mean walking speed in those with a total WMH volume
above the 75th percentile compare to those below the
25th. They found similar relationships for both deep
WMH and periventricular hyperintensities (PVH), how-
ever further analyses revealed that PVH may have more
of an effect on walking speed than deep WMH. They
also looked at WMH volume and the decline in walking
speed over the follow up period. They found that having
a WMH volume greater than the 90th percentile, more
than doubled the risk of decline in walking speed com-
pared with subjects with lower volumes of WMH. This
finding was replicated when looking at PVH but not for
deep WMH volume. Elbaz et looked at this association
further and found that large WMH volumes were not
associated with slow walking speed among highly edu-
cated participants (OR = 0.72), but were associated
with a 2-fold-increased risk of slow walking speed
among those with low education (OR = 3.19/1.61 =
1.99) (p interaction = 0.026) [42]. Results remained un-
changed after adjustment for height, BMI, and MMSE
score.
Dumurgier et al. looked at GM volumes and gait speed
in the same cohort and found that only basal ganglia
volume (beta 0.075 (SE 0.025) p = 0.003) was signifi-
cantly associated with walking speed; driven by caudate
nucleus volume (beta 0.114 (SE 0.024) p < 0.001) [43].
All other regional GM volumes were not significantly as-
sociated with walking speed.
The authors from the Three-City study provided fur-
ther associations between the variables of interest on
written request [39-41]. They looked at the relationship
between WM volume and maximal walking speed at
baseline, and walking speed decline over 31 months
using a multiple linear regression (MLR) and found no
significant association. Finally they performed a logistic
regression between a one standard deviation increase in
WM volume and the risk of having the highest walking
speed decline, which was again not significant.
The AGES-Reykjavik study is a longitudinal cohort
study which includes an MRI brain and usual walking
pace over 6 metres [60]. The MR brain imaging included
a magnetization transfer imaging sequence, which can
be used to calculate the magnetisation transfer ratio
(MTR), which can detect normal and diseased brain tis-
sue by looking at the homogeneity of the brain tissue
Kilgour et al. BMC Geriatrics 2014, 14:85 Page 24 of 35
http://www.biomedcentral.com/1471-2318/14/85being studied. They found that in men usual walking
speed was predicted by WMH volume (beta 0.13, p =
0.02) but not by degree of brain atrophy or peak MTR
height (both p > 0.05) (adjusted for age and brain size)
[60]. However in women slower walking speed was asso-
ciated with: lower MTR height (i.e. indicating abnormal
brain tissue) (beta −0.14 (p = 0.01); increased WMH
(beta 0.12, p = 0.003); and greater brain atrophy (beta
0.15, p = 0.01) [60]. Additionally they comment that iso-
metric knee extension strength was found to positively
correlate with peak height MTR (p < 0.005) however they
do not give the strength of the correlation or say what it
was adjusted for.
The Aberdeen Birth Cohort 1921 study is a longitu-
dinal study which includes a measure of gait speed (self-
paced walk time over 6 metres) and a MR brain scan,
which was assessed for WMH. Lower gait speed was sig-
nificantly associated with increased WMH in the brain-
stem (p = 0.009, partial eta squared 7%), but not in the
cerebral white matter or with PVHs [46].
Seven studies were identified which met the inclusion
criteria from the Boston area in the United States. These
include two papers from the WML and mobility obser-
vational follow up study [52,53], two papers looking at
mobility, brain changes and cardiovascular risk factors at
baseline [51] and follow up at 2 years [50], two papers
conducted at the Beth Israel Deaconess Medical Centre,
where it seems there may be overlap between the study
volunteers [48,49] and a case–control study about dia-
betic peripheral neuropathy [47]. The two studies from
the WML and mobility study recorded variables at base-
line [53] and after a period of follow up (19–22 months)
[52]. The baseline paper comments that gait velocity was
not significantly predicted by WMSA corrected for ICV,
however does not give any specific figure for this ana-
lysis [53]. The follow up paper found a significant nega-
tive relationship between gait velocity and WMSA at
baseline (p < 0.05) [52], however this is in contrast to the
baseline paper and only 14 of the original 28 subjects
consented for this study. Change in gait speed between
visit 1 and 2 did not predict WMSA volume (p = 0.07).
They also state they found a significant negative rela-
tionship between change in gait speed between visits
and CSF volume (r = 0.733, p < 0.005) and a positive rela-
tionship between change in gait speed and WM volume
(r = 0.558, p < 0.05) [52]. However both the quoted cor-
relations are positive.
Moscufo et al. recruited 99 subjects to a longitudinal
study about mobility, brain changes and cardiovascular
risk factors [50,51]. Gait speed was measured using time
to walk 2.5 metres as part of the Short Physical Perform-
ance Battery (SPPB). This is a considerably shorter dis-
tance than most other measures of gait speed used. The
authors supplied Spearman partial correlations betweenthe brain volumetric variables and gait speed, which
were not described in the paper. Greater WMH burden
(rho = −0.365, p = 0.0002) and CSF volumes (rho = −0.284,
p = 0.004) are associated with slower gait speed. White
matter was not found to significantly predict gait speed,
however larger GM volume did predict faster gait speed
(rho = 0.232, p = 0.020) [51].
An analysis was made in the baseline paper, to investi-
gate whether location of WMH affected gait speed [51].
They selected 10 regions of interest (ROI), which were
neural pathways involved in sensory input or motor re-
sponse and performed a Spearman’s correlation with a
corrected significance threshold of ≤0.005 (calculated
using the Bonferroni method to adjust for multiple com-
parisons). All 10 ROI were found to significantly correl-
ate with the walking speed score at p < 0.005 (rho values
between 0.279 and 0.426), except in the superior longitu-
dinal fasciculus (p = 0.035) [51].
The follow up paper in this study, performed after
2 years, found that total WMH burden was significantly
associated with usual walking speed at baseline but not
at follow-up, and maximum walking speed was not asso-
ciated with total WMH at baseline or follow up [50]. At
baseline, regional GM WMH burden in the splenium of
corpus callosum and anterior and superior corona
radiata, was significantly associated with both usual
and maximum walking speed (p < 0.05) and in addition
the body of the corpus callosum was also associated
with usual walking speed (p < 0.05). At follow-up,
WMH burden in the splenium was significantly associ-
ated with both walking measures (p < 0.05) and in the
body with maximum walking speed. Change in WMH
burden, either total or in any of the 7 regional areas,
over 2 years was not associated with a decline in usual
walking speed (p > 0.1). However decline in walking
speed was entered as a binary variable for this analysis
(i.e. decline or no decline in walking speed over 2 years),
which may have missed a relationship between greater
WMH burden and greater declines in walking speed.
Two papers carried out their studies at the Beth Israel
Deaconess Medical Centre. One paper looked at healthy
volunteers [49] and the other looked at stroke patients
in comparison to healthy volunteers [48]. It does not ex-
plicitly state the healthy volunteers are the same for each
study, but the exclusion criteria, time period and author
list would indicate this. The first study measured gait
speed over 12 minutes at normal walking speed. MR
brain images were analysed for WMH burden and brain
volumes corrected for ICV. They found that gait speed
was correlated to frontal WM volume (r 0.4, p = 0.003)
and frontal grey matter volume (r 0.3, p = 0.01) [49].
However total WMH burden was not associated with
gait speed. It is not exactly clear why they looked at
frontal brain volumes and gait speed and not other
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paper also measured gait speed over 12 minutes and
used MR brain images. In the non-stroke group, white
matter volume was found to predict gait speed (B 1.30,
p = 0.03) but not grey matter (p > 0.05). They comment
that greater brain atrophy is associated with slower gait
speed, but this is for the whole group, so includes stroke
patients.
The final study from Boston was by Manor et al. and
quoted results from the control group [47]. They found
no association between total GM volume or regional
GM volumes and walking speed over 75 metres (p >
0.005, Bonferroni adjusted). They were being compared
to subjects with diabetic peripheral neuropathy in this
study. No results for WM or CSF were reported in the
study.
Seven studies from the Cardiovascular Health Study
(CHS) met our criteria for inclusion. However three of
the studies did not contain any associations between the
variables of interest and the study authors did not supply
the raw data or correlations [55,62,63]. The first study
used gait speed measured over 15 feet, and MR brain
images were used to measure ventricular enlargement
(VE) and WMH both of which were recorded on a 10
point scale (0–9). Both greater ventricular enlargement
(p < 0.001) and greater WMH burden (p = 0.003) were
associated with slower baseline gait speed and greater
decline in gait speed over the 4 year follow up period
[57]. Indeed, after adjusting for baseline performance,
those with severe VE were found to have 2.5x the de-
cline in gait speed compared to those with minimal VE
at baseline. The model included adjustment for age, sex,
race and education.
The next study looked at a subset of the CHS who had
undergone two MR brain scans, separated by roughly
5 years, and a MMSE and had undergone assessment on
the GaitMat, a 4 metre long instrumented walking sur-
face [56]. THE MR brain scans were classified as
above, but given binary cutoffs for the analysis of
WMH grade ≥3 or <3 and VE >4 or <4 for some of the
analyses. Gait speed was correlated with WMH grade
(r = −0.18, p < 0.0001) and with WMH in the brain-
stem (r = −0.18, p < 0.01). Logistic regression was used
to analyse the relationship further and gait speed was
separated into quartiles. This showed that those in the
lowest two quartiles of gait speed (i.e. < 1.02 m/s) had
double the likelihood of having WMH graded 3 or
above (p = 0.03). VE graded >4 was not found to be
significantly predicted by gait speed, however VE graded
> 5 was significantly predicted by gait speed (OR= 2.91 for
1st vs. 4th quartile, OR 3.82 for 2nd vs 4th quartile) [56].
Longstreth et al. is mentioned in the above section on
grip strength and brain structure, as this was also stu-
died in this paper [64]. Gait speed was again measuredover 15 feet and WMH burden was scored 0–9 on MR
brains scans. Time to walk 15 feet was found to correlate
with WMH grade (partial correlation coefficient 0.153,
p < 0.001, adjusting for age, sex and presence of clinical
silent stroke on MR brain) [64]. The population in this
study and the study by Rosano et al. [57] overlap consid-
erably and only appear to differ in the time they were
still in the study and the particular inclusion and exclu-
sion criteria for that part of the study.
In a separate paper, Rosano et al. found that prefrontal
area volume significantly predicted time to walk in a
stepwise forward model (beta −0.15, p = 0.02) [54]. This
relationship was attenuated when adjustment was made
for DSST score, which is a measure of processing speed.
They conclude that smaller prefrontal area volume may
contribute to slower gait speed through slower informa-
tion processing.
The final two studies identified are both from the Ore-
gon Brain Aging Study (OBAS) [58,59]. OBAS I is a pro-
spective study commenced in 1989 of healthy older
adults age 65 years or older at the initial assessment, a
second arm was added in 2004, OBAS II, with less strin-
gent exclusion criteria and these subjects were 85 or
older at the start of the study. The first paper by
Marquis et al. (2002), looked at the correlation of timed
walk, measured at self-selected pace over 9 metres,
against brain volumes. Hippocampal volume was found
to negatively correlate with timed walk (partial r = −0.12),
however no significance value was given and it did not ex-
plicitly state what was adjusted for in the correlation [59].
The correlation between TBV and timed walk was <0.1.
The other OBAS paper, by Silbert et al. (2008), found that
a higher baseline total WMH volume was associated with
a greater increase in timed walk over follow up (R2 = 0.08,
p = 0.0052), the average follow up was 9.1 years [58]. They
then looked at whether location of WMH mattered and
found that whilst periventricular (PV) WMH volume was
associated with a greater change in timed walk over follow
up (R2 = 0.12, p = 0.0039), a higher subcortical WMH vol-
ume was not. These analyses were adjusted for age and
ICV. They next looked at change in WMH volume with
time and found that a higher rate of accumulation of PV
WMH was associated with a greater increase in timed
walk (R2 = 0.15, p = 0.0453). However there was no rela-
tionship described between subcortical or total WMH ac-
crual and change in timed walk. Further data from the
study was requested, which was kindly provided. Baseline
data from all subjects from OBAS I and II who had had a
MRI brain scan and a timed walk at baseline was used to
perform our analysis (n = 176).
GLMs were performed to investigate the relationship
between brain structures and gait speed, calculated in
metres per second for the analysis. In an unadjusted
model, gait speed was predicted by TBV, hippocampal
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for age, sex, ICV and height, TBV (t 3.61, p = 0.004, par-
tial eta squared 4.3%) and WMH (t −2.80, p = 0.006, par-
tial eta squared 4.4%) significantly predicted gait speed,
but hippocampal volume did not (p > 0.05).
Association of brain function and muscle structure
Fifteen papers were identified which looked at brain
function and muscle structure: DEXA was used in eleven
of the studies; BIA in two; and CT for thigh muscle CSA
and MRI for neck muscle CSA in the final two papers
(Table 4). Measures of brain function were the MMSE,
the Community Screening Instrument of Dementia (CSI-D),
Trail Making Test (TMT) A and B, digit span and a meas-
ure of global cognitive performance (using z scores from
multiple cognitive tests). The studies included the Kansas
Brain Aging Project [28-30] and the MHEM study [27], both
mentioned in the above section, and studies from Canada
[65], Chile [67], the Chinese University of Hong Kong
[69,71],Denmark [72], Italy [73], Lithuania [74], Taiwan
(the I-Lan Longitudinal Aging Study, ILAS) [75], and from
the USA, the Baltimore Longitudinal Study of Aging [76]
and the FITKids Study [77,78].
From the Kansas Brain Aging Project, Burns et al.
(2010) found a relationship between both MMSE (beta
0.11, p = 0.009) and global cognitive performance (beta
0.12, p = 0.007) and TLM, again grouping AD and con-
trol subjects together [29]. They state that in this rela-
tionship if the AD subjects are removed from the
analysis the results are attenuated, but do not show any
results for this. A GLM was performed on the data from
the non-demented group supplied to us by the study au-
thors, and we found that neither the global cognitive
performance score nor MMSE was predicted by TLM
adjusting for age and sex. Adjusting for height and edu-
cation did not affect this.
The MHEM study used 9 different cognitive tests,
which they reduced to two factors using principal com-
ponents analysis [27]. Total neck muscle CSA did not
significantly predict variance in either the memory factor
or the cognitive processing factor (p > 0.05), however,
it did predict 10% of the variance in the NART score
(t = −2.12, p < 0.05). The NART score is a measure of
childhood intelligence and the authors comment that
the finding is the opposite of what they hypothesized,
as they found that lower childhood intelligence is as-
sociated with larger neck muscle size in old age.
Berryman et al. supplied the baseline data from their
physical training intervention trial. Subjects had performed
a MMSE and modified Stroop test and underwent a DEXA
scan at baseline [65]. A GLM was performed which
showed no association between LBM and MMSE or the
Stroop naming, reading or inhibition tasks. However there
was an association between the Stroop flexibility task andLBM (t 2.126, p = 0.039, partial eta squared 9.3%), however
after adjusting for education and height the effect was at-
tenuated (p > 0.05). This effect was in the opposite direc-
tion than might be expected, i.e. bigger muscle mass is
associated with a worse score (the Stroop test is measured
in seconds to perform the task).
The two papers from Chile are a study by Bunout
et al. which includes baseline data for a randomized con-
trolled trial (RCT) investigating an exercise intervention
in the elderly [67] and a paper by Bites et al. which used
baseline trial data from several studies, including the
study by Bunout et al., held on their University database
[66]. The authors sent one data sheet for both studies as
there is a large amount of overlap between the studies
(overlap n = 203). A GLM was performed which showed
total LM (t 2.38, p = 0.018, partial eta squared 1.4%) and
leg LM (t 3.53, p < 0.001, partial eta squared 3.1%) were
both associated with MMSE score but arm LM is not.
After adjusting for height the relationship between TLM
and MMSE became non-significant and between leg LM
and MMSE is attenuated (t 2.09, p = 0.038, partial eta
squared 1.1%). Therefore it seems that leg LM is driving
the relationship between total LM and MMSE.
Four papers from the Chinese University of Hong
Kong were identified which used data from a large pro-
spective longitudinal study looking at bone mineral
density in older Chinese adults to assess the relationship
between physical and cognitive function [68-71]. They
used two measures of cognitive function; the MMSE and
the cognitive score from the Community Screening In-
strument for Dementia (CS-CSID). Only one of the pa-
pers included the associations between the cognitive
tests and muscle mass [69]. They found that in men, but
not in women, lower appendicular skeletal mass (SM) at
baseline predicted lower MMSE at follow up (for a
2.54 kg increase in appendicular SM, there would a
0.246 change improvement in MMSE, p < 0.001). How-
ever after adjustment for age, years of education and
baseline MMSE, the relationship became non-significant
(P > 0.05) [69]. The authors from this study kindly sup-
plied further analyses of their data upon our request.
They performed Spearman’s partial correlations,
adjusting for age and sex. There was no significant rela-
tionship between baseline CS-CSID and total LM or ap-
pendicular LM at baseline or 4 years. However baseline
MMSE predicted both baseline total LM (partial rho
0.058, p = 0.002) and appendicular LM (partial rho
0.061, p = 0.001) and 4 years follow up total LM (par-
tial rho 0.058, p = 0.002) and appendicular LM (partial
rho 0.054, p = 0.005). However, the effect size is small.
They also looked at the whether those with lower
MMSE at follow up had lower muscle mass at baseline or
follow up but found no significant associations (p > 0.05)
[69]. Unfortunately the study authors did not supply data
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change in muscle mass over the four year follow up which
would be very interesting in such a large study population.
Pedersen et al. investigated cognition and physical fit-
ness in normal controls, subjects with impaired glucose
tolerance and type 2 diabetes [72]. They supplied the
raw data for their control group to be analysed. Subjects
underwent DEXA for FFM and six cognitive tests (a cog-
nitive z score was computed as a marker of general cog-
nition). FFM did not predict the cognitive z score with
or without adjusting for BMI and childhood intelligence
(Danish Adult Reading Test, DART). The six individual
cognitive tests were then analysed. There was no associ-
ation between FFM and most of the individual cognitive
tests. Also, unadjusted there was no significant associ-
ation between the letter fluency test (using “s”) and
FFM (P > 0.05), however after adjustment for BMI and
DART, letter fluency was significantly associated with
FFM (t 2.34, p = 0.02, partial eta squared 7.7%). Letter
fluency is a test of executive function and this may in-
dicate that change in this type of cognition with age is
associated with FFM in older age. TMT-A test did signifi-
cantly predict FFM (t 3.08, p = 0.003, partial eta squared
12.3%), but after adjusting for BMI and DART the rela-
tionship became non-significant. The TMT-A test is a
measure of processing speed.
Magri et al. (2006) performed a cross-sectional study
looking at postmenopausal women and HRT, however
their study also contained a control group of young
healthy women which were used for our analyses after
the study authors kindly supplied their data [73]. A
GLM was performed with MMSE as the outcome/
dependent variable and FFM as the predictor/independ-
ent variable as measured by BIA. FFM did not signifi-
cantly predict MMSE after adjustment for age (p > 0.05)
[73]. Adjustments for BMI and educational level did not
further affect these results.
Lasaite et al. performed an observational case–control
study which looked at women with osteoporosis and
healthy controls [74]. The study data for the healthy
controls was supplied to us on request. The cognitive
measures were the TMT-A and B and a digit span test.
FFM was measured using BIA. A GLM was performed
on the available data. FFM did not predict TMT-A or B
adjusting for age +/− height (p > 0.05). There was a non-
significant trend with FFM predicting digit span adjust-
ing for age (t 1.96, p = 0.06, partial eta squared 13%),
however when adjusted for height too, the relationship
was attenuated (p = 0.37).
The I-Lan Longitudinal Aging Study is an ageing co-
hort study in Taiwan [75]. Within the study they per-
formed a t test comparing mean MMSE in those with a
normal relative appendicular skeletal mass (RASM =
ASM/height2) with those in the lowest 20% for RASM,and they found a significant difference in both men and
women. They also supplied the results of a linear regres-
sion on our request for further data, which showed that
RASM did not predict MMSE after adjusting for age
and sex (beta −0.003, p = 0.940). This may mean there is
a non-linear relationship between cognition and muscle
mass.
The Baltimore Longitudinal Aging Study is a large lon-
gitudinal cohort study, in which the subjects underwent
four cognitive tests and had a mid-femur CT for thigh
CSA [76]. No associations between the cognitive tests
and thigh CSA were included in the study, but the au-
thors sent the results of a MLR they had performed.
They found that none of the cognitive tests predicted
thigh CSA, adjusting for age and gender. After adjusting
for age, gender and height, the digit-span backward test
became significantly negatively associated with thigh
CSA (beta −1.55, p = 0.024), meaning those with bigger
thigh muscles perform better on the test (a higher score
is better in the digit span tests).
The final study which looked at cognition and muscle
structure is the FITKids study based in Illinois, USA
[77,78]. Two papers from this study were identified;
however there were no relevant associations in the pa-
pers and the study authors kindly provided us with the
raw data on which to perform an analysis. As the sub-
jects were all from the same study the authors provided
us with one dataset for the study. We performed a GLM
which found that TLM did not predict the Kaufman
Brief Intelligence Test, used to assess IQ.
Discussion
This systematic review looked at the evidence for
whether: a) brain structure is related to muscle struc-
ture, b) brain structure is related to muscle function and
c) brain function is related to muscle structure in
healthy humans over the life course.
Brain volumes and muscle mass
The relationship between brain structure and muscle
structure was first reviewed (see Table 6 for summary).
Three studies tested for an association between whole
brain volume and muscle mass; the three papers from
the Kansas Brain Aging Project are treated as one study
[26-30]. Two studies found a positive association be-
tween WBV and muscle mass [26,27] and one study
found no significant association [28-30]. However, this
study found a significant positive association between
WM volume and FFM but no association between GM
volume and FFM [28-30]. A different study looked at re-
gional GM volume and found four areas negatively asso-
ciated with FFM but found most areas to have no
association with FFM [31]. Two studies found no associ-
ation between hippocampal volume and muscle mass
Table 6 Number of studies of brain structure and muscle structure, direction of effect and number of subjects
Negative association (n) No association (n) Positive association (n) References
Whole brain size and muscle size - 1 (70) 2 (311) [26-30]
White matter volume and muscle size - - 1 (70) [28-31]
Grey matter volume and muscle size 1 (76)* 2 (146)* - [28-31]
Hippocampal volume and muscle size - 2 (121) - [27-30]
Cerebellar volume and muscle size - 1 (51) - [27]
Ventricular volume and muscle size - 1 (51) - [27]
*This study found negative associations between some areas of grey matter volume (the right temporal pole and bilateral vmPFC) and muscle size but found the
majority of GM areas had no association.
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cerebellar volume and muscle size and found no associ-
ation either [27]. Four of the studies were of older adults
and two were of younger adults, and it may be that the
relationship between brain and muscle structure varies
over the life course. Furthermore if there is a relation-
ship between whole brain volume and muscle size it
looks like it may be regional brain volume that drives
this relationship rather than total volume. The studies
are all cross-sectional and a large longitudinal study is
needed to explore these relationships further.
Brain structure and muscle function
Next evidence for an association between muscle func-
tion and brain structure was reviewed. Muscle function
was either grip strength (5 studies, see Table 7 for sum-
mary) or gait speed (13 studies, see Table 8 for sum-
mary) apart from in one paper where isometric knee
extensor strength (IKES) was used [60].Table 7 Number of studies of brain structure and grip streng
Negative association (n
Grip strength and whole brain volume -
Grip strength and WM volume -
Grip strength and GM volume -
Grip strength and caudate volume -
Grip strength and ventricular volume/brain
atrophy
2 (804)
Grip strength and WMH 1 (478)
Change in grip strength over f/u and whole
brain volume
-
Change in grip strength over f/u and WM
volume
-
Change in grip strength over f/u and GM
volume
-
Change in grip strength over f/u and
ventricular volume
-
Change in grip strength over f/u and
WMH volume
-
aAt wave 1 in this study there was no association and at wave 2 there was a positivBrain structure and grip strength
Only one study looked at the relationship between whole
brain, GM or WM volume and grip strength [61]. There
were no significant associations except for a positive re-
lationship between WM volume and grip strength at
wave 2 (age 73) [61]. This could mean that the relation-
ship between WM volume and grip strength only be-
comes important with age, once a volumetric threshold
is passed. Another study found no association between
caudate volume and grip strength [37]. However the
basal ganglia may be expected to play less of a role in
grip strength than in gait speed. Two studies found a
negative association with markers of brain atrophy and
grip strength [36,61], however one of these studies also
looked at change in grip strength over 3 years and found
no association with ventricular volume (a marker of
brain atrophy) [61]. This means that whilst cerebral atro-
phy and grip strength appear to be associated, decline
in grip strength does not predict cerebral atrophy. Ath, direction of effect and number of subjects
) No association (n) Positive association (n) References
1 (694) - [61]
1 (694)a 1 (694)a [61]
1 (694) - [61]
1 (41) - [37]
- - [36,61]
2 (4352) - [35,61,64]
1 (694) - [61]
1 (694) - [61]
1 (694) - [61]
1 (694) - [61]
1 (694) - [61]
e association [61].
Table 8 Number of studies of brain structure and gait speed, direction of effect and number of subjects
Negative association (n) No association (n) Positive association (n) References
Gait speed and whole brain volume - - 2 (885) [58,59,61]
Gait speed and WM volume - 2 (1587) 3 (813)b [42,48-50,61]
Gait speed and GM volume - 4 (2449)c 3 (367)b,d [43,47-50,54,61]
Gait speed and hippocampal volume - 1 (191) - [58,59]
Gait speed and cerebellar volume - 1 (111) - [38]
Gait speed and WMH volume 7 (7145)e 4 (278)e,f - [45,46,49,50,52,53,56-61,64]
Gait speed and CSF volume/ventricular
volume/brain atrophy
3 (3221)g 2 (1489)g - [50,56,57,60,61]
Gait speed and WMH progression
over f/u
- 1 (14) - [52]
Change in gait speed over f/u and whole
brain volume
- 1 (694) - [61]
Change in gait speed over f/u and
WM volume
- 2 (1622) - [42,61]
Change in gait speed over f/u and
GM volume
- 1 (694) - [61]
Change in gait speed over f/u and
CSF/ventricular volume
- 1 (694) 1 (2450) [57,61]
Change in gait speed over f/u and
WMH volume
- 1 (694) 2 (4152) [45,57,61]
Change in gait speed over f/u and
WM atrophy
- - 1 (225) [39]
Change in gait speed over f/u and
GM atrophy
- 1 (225) - [39]
Change in gait speed over f/u and
hippocampal atrophy
- - 1 (225) [39]
Change in gait speed over f/u and
WMH progression
- 1 (77) 1 (225) [39,50]
bone study only looked at frontal WM/GM volume not total WM volume [49].
cbasal ganglia volume was positively associated with gait speed in this study [43].
done study only looked at prefrontal area volume within GM [54].
ethis study found usual walking speed was negatively associated with WMH but that maximum walking speed was not [50].
fexcept brainstem WMH which were negatively associated with gait speed in this study [46].
gat wave 1 there was a negative association and at wave 2 there was no association in this study [61].
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explain this relationship further.
One study found an association between WMH and
grip strength [35]. They found that location of the
WMH is important, with some brain areas correlating
with grip strength and others not [35]. On looking at the
data separated by sex, this relationship persisted in men,
but not women, but the study authors think this is due
to a sex difference present in their study population,
with the men having higher volumes of WMH [32]. Two
larger studies found no association between WMH and
grip strength, however one of these studies used a visual
rating scale from 0–9 to measure WMH, which may lead
to differing results than using WMH volumes [61,64]. The
other study also looked at change in grip strength over
3 years and WMH volume at follow up and found no as-
sociation [61]. WMH are known to predict dementia andcerebrovascular disease but their relationship to physical
function is less well understood [110].
Brain structure and gait speed
Two studies found a positive association between WBV
and gait speed [58,59,61], whereas studies investigating
the relationship between WM and GM volume and gait
speed found less unanimous results. Three studies found
a positive association between WM volume and gait
speed [48,49,61] and two studies found no association
[42,50]. Four studies found no association between GM
volume and gait speed [43,47,48,61] but three studies
found a positive relationship [49,50,54]. There was no
evidence that hippocampal volume or cerebellar volume
were associated with gait speed [38,58,59]. It may be that
specific sub-regions of the white and grey matter are as-
sociated with gait speed, for example one paper found
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speed but no association with total GM and gait speed.
Further studies looking at regional brain areas will help
to clarify these relationships. Five studies looked at
markers of brain atrophy and gait speed; two found a
negative association (i.e. more atrophy associated with a
slower gait speed) [50,56,57] and one found no associ-
ation [60], with one finding an association at wave 1 but
not at wave 2 [61].
No association was found between change in gait
speed over follow up and whole brain, WM and GM vol-
ume (mean length of follow up in each study, 3 and
7 years) [42,61]. However one large study did find an as-
sociation between ventricular volume and change in gait
speed over follow up (mean 4 years) [57] but another
study found no association (mean follow up 3 years)
[61]. Only one study looked at the relationship between
change in gait speed and change in brain structure over
time (mean follow up 30.6 months) [39]. They found a
positive association between change in gait speed and
WM and hippocampal atrophy but no association with
GM atrophy. The well-established relationship between
cognitive decline and gait speed and cognitive decline
and brain atrophy could underpin the possible relation-
ship between brain atrophy and gait speed [4-8]. It is in-
teresting that the only study to look at both variables in
a longitudinal study found significant associations be-
tween brain structure and gait speed and further studies
like this are needed.
Eleven studies were found which looked at gait speed
and WMH, making it the most studied relationship in
our review. Seven of these studies found that greater
levels of WMH were associate with slower gait speed
[45,50,52,56-61,64], but four other smaller studies foundTable 9 Number of studies of cognition and muscle size, dire
Negative association
Muscle size and global cognitive score -
Muscle size and MMSE -
Muscle size and California Verbal Learning Test -
Muscle size and CSI-D -
Muscle size and digit span -
Muscle size and Kaufman Brief Intelligence Test -
Muscle size and modified Stroop test -
Muscle size and NART 1 (51)
Muscle size and TMT-a -
Muscle size and TMT-b -
hLeg LM was associated with muscle size but not total LM or arm LM in this study [
iIn an MLR there was no association between MMSE and FFM but when comparing
study found a significant difference [75].
jDigit span forwards unadjusted and adjusted was not associated with thigh muscle
muscle CSA in this study [76].no association [46,49,50,53]. Two of these studies found
that this is primarily due to the volume of PVH and not
subcortical WMH lesions [45,58] and two papers found
that volume of brainstem WMH was associated with gait
speed [46,56]. One small study (n = 14) found no associ-
ation between gait speed and WMH progression over
follow up (19–22 months) [52]. However, change in gait
speed was found to be associated with WMH volume in
two large studies [45,57] with another study showing no
association [61]. Two studies looked at change in both
variables; one found that greater decline in gait speed
was associated with greater WMH progression [39],
whereas the other found no association [50]. Further
studies looking not just at total WMH volume but their
rate of accumulation and location within the brain, and
their association with gait speed should help clarify this
area.
Cognitive function and muscle mass
Nine studies were found which looked at cognitive func-
tion and muscle structure. Table 9 shows the main re-
sults from these studies. Three studies looked at a
measure of global cognitive performance (a composite
score of several tests used in their study) and muscle size
and all 3 found no association [27,28,72]. The Kaufman
Brief Intelligence Test can also be used as a marker of
general cognition and it too found no association with
muscle size [77,78]. Seven studies looked at muscle size
and MMSE score, which is a useful screening tool for
dementia but is not a robust test of cognitive function.
Four of the studies found no association between MMSE
and muscle mass [28,65,73,75] and one found an asso-
ciation but with a very small effect size [68]. However
in one study which showed no association betweenction of effect and number of subjects
(n) No association (n) Positive association (n) References
3 (193) - [27,28,72]
5 (1434)h,i 2 (3459)h [28,65,66,68,73,75]
1 (786) - [76]
1 (3153) - [68]
2 (815)j - [74,76]
1 (139) - [77,78]
1 (48) - [65]
- - [27]
3 (887) - [72,74,76]
3 (887) - [72,74,76]
66].
subjects with normal RASM and those within the lowest 20% of RASM this
CSA, but adjusted backwards digit span was negatively associated with thigh
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mal RASM and those within the lowest 20% of RASM
this study found a significant difference in mean
MMSE [75]. Several of the included studies did not in-
clude those with cognitive impairment and it may be
that an association does exist between MMSE and
muscle size but in a non-linear relation, affecting the
frailer older adult more, but that it was not picked up
in these studies due to the method of analysis in a lin-
ear regression. Overall though in healthy individuals it
seems that no such association exists. The final study
found an association between leg LM and MMSE but
not between total or arm LM [66]. Sarcopenia is
known to affect leg and arm muscles differently which
perhaps explains this effect [111]. Another screening
tool for dementia, the cogscore part of the CSI-D, also
found no association with muscle mass [68]. It is well
established that gait speed and cognition are associated
in older age and these results appear to show that
muscle size is not a driving force behind this relation-
ship [4-6].
With regard to the individual cognitive tests (which
measure processing speed and executive function), there
were no significant associations [65,72,74,76], except for
the NART (a measure of childhood IQ, which showed a
negative association with neck muscle CSA [27]. The au-
thors comment that perhaps subjects with higher cogni-
tion are more likely to have sedentary jobs and therefore
more likely to lose their muscle mass over time. None of
the studies looking at cognition and muscle size con-
tained longitudinal associations therefore whilst these re-
sults appear to support no association between muscle
mass and cognition; it may be that longitudinal data
would show an association, whereby those that lose
more muscle with age have a sharper slope of decline in
their cognition also. Longitudinal studies will help to
elucidate these complex relationships further.
Limitations
In the review protocol the decision was made to write to
study authors for relevant associations or data that were
not given in the study but could be calculated using the
recorded variables. This expanded the number of articles
included in the review and the scope that they covered,
however this may have led to some bias in which articles
responded to the request and therefore what was re-
ported, as study authors who found an association may
have been more likely to reply. Of the 79 articles written
to 59 replied therefore 25% did not respond. However
the studies that did respond included both those which
showed a significant association and those that did not.
The associations which were sent to us and the associations
performed by us have not undergone peer review (e.g. for
variable selection when adjusting the models), however wehave included this information in our review and the statis-
tical technique used to remain as transparent as possible.
The studies included in the review used a wide variety
of techniques to record the variables of interest which
means it is difficult to compare them (e.g. in a meta-
analysis). Gait speed for example was recorded over
multiple lengths, using automated and manual tech-
niques and different levels of speed (i.e. maximum or
usual pace). The large differences in how gait speed was
measured combined with the fact that over longer dis-
tances it can become a test of cardiovascular fitness etc.
more than a test of muscle function, makes it difficult to
compare the results of these studies directly. Hopefully
more standardized testing will come about in the wake
of resources like the NIH toolbox which includes a pro-
forma for measuring gait speed [112].
When looking at the relationship between brain size
and muscle size or function it is important to make sure
that the size of the individual being studied is not acting
as a confounding factor (i.e. that large people have large
brains and large muscles). This meant that it was im-
portant to ensure that some measure of body size had
been adjusted for in each association (e.g. ICV, height,
BMI). In most of the studies we looked at this occurred
but in some it did not and this may lead to a false rela-
tionship being reported.
A relatively wide range of ethnicities are represented
in the study, however Caucasian subjects were by far the
most commonly studied and there were no studies in-
cluding those of Arabic or Indian ethnicity. Also most of
the studies used subjects in their sixties, seventies or
eighties, meaning the validity of our findings for other
age groups, particularly children and adolescents is
limited.
Finally, while a few of the studies included longitudinal
data, it would be very useful to have more studies look-
ing at the relationships over time as these may be able
to highlight potential modifiable factors.
Conclusions
An increasing body of research has now linked brain
function (cognition) and muscle function (e.g. gait speed)
[4-8], however less well studied is the role of muscle and
brain structure in this relationship. This systematic review
looks at the evidence for whether: brain structure is re-
lated to muscle structure; brain structure is related to
muscle function; and brain function is related to muscle
structure in healthy humans across the lifecourse.
The review found evidence of a positive association
between whole brain volume and total white matter vol-
ume with muscle size and evidence that some areas of
regional grey matter volume (right temporal pole and bi-
lateral vmPFC) are negatively associated with muscle
size [26-31].
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tween grip strength and whole brain volume, however
there was some evidence of a positive association be-
tween grip strength and WM volume. Markers of brain
ageing, that is brain atrophy and greater WMH accumu-
lation, were associated with grip strength [35,36,61]. Un-
like grip strength, there is evidence that gait speed is
positively associated with whole brain volume; this rela-
tionship may be driven by total WM volume or regional
GM volumes, specifically the hippocampus [58,59,61]. Like
grip strength, gait speed is also associated with markers of
brain aging; WMH accumulation, brain atrophy and WM
atrophy all show evidence of either a temporal association
with gait speed or change in gait speed with time, with
PVH and brainstem WMHs playing a particularly import-
ant role, but not subcortical WMH [45,57].
The evidence overwhelmingly points to no association
between cognition and muscle size, except in the case of
MMSE where it is mixed, but MMSE is more a screen-
ing tool for dementia than a true marker of cognitive
function [27,28,65,66,68,72,73,75]. Longitudinal studies
are now needed to explore these relationships over time,
which will allow a better understanding of the potential
causal relationships.
Appendix 1 Medline Search
1. brain/ or exp brain stem/ or exp cerebral ventricles/
or exp limbic system/ or exp mesencephalon/ or
exp prosencephalon/ or exp rhombencephalon/
2. (brain adj3 volume).tw.
3. white matter.tw.
4. mental processes/ or cognition/ or cognitive
reserve/ or comprehension/ or executive function/
or higher nervous activity/ or maze learning/ or exp
memory/ or thinking/ or decision making/ or
judgment/ or problem solving/
5. Intelligence/
6. exp aptitude tests/ or exp neuropsychological tests/
7. cognitive function.tw.
8. muscles/ or muscle, skeletal/ or abdominal
muscles/ or rectus abdominis/ or deltoid muscle/ or
neck muscles/ or pectoralis muscles/ or psoas
muscles/ or quadriceps muscle/ or rotator cuff/
9. Body Composition/
10. muscle cross sectional area.tw.
11. exp Muscular Atrophy/





17. 1 or 2 or 3
18. 4 or 5 or 6 or 719. 8 or 9 or 10 or 11
20. 12 or 13 or 14 or 15 or 16
21. 17 and 19
22. 17 and 20
23. 18 and 19
24. 21 or 22 or 23
25. limit 24 to humans
26. limit 25 to case reports
27. 25 not 26
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11-Hydroxysteroid Dehydrogenase Activity in
the Brain Does Not Contribute to Systemic
Interconversion of Cortisol and Cortisone in
Healthy Men
Alixe H.M. Kilgour, Scott Semple, Ian Marshall, Peter Andrews, Ruth Andrew,
and Brian R. Walker
MRC Centre for Cognitive Aging and Cognitive Epidemiology (A.H.M.K.), Geriatric Medicine Unit, and
Centre for Clinical Brain Sciences (S.S., I.M., P.A.), University of Edinburgh, Edinburgh, United Kingdom;
Clinical Research Imaging Centre (S.S.) and BHF Centre for Cardiovascular Science (S.S., R.A., B.R.W.),
Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Critical Care (P.A.),
Western General Hospital, NHS Lothian University Hospitals Division, Edinburgh EH4 2XU, United Kingdom
Context and Objective: 11-hydroxysteroid dehydrogenase type 1 (11HSD1) catalyses regener-
ation of cortisol in liver, adipose tissue, and skeletal muscle, making a substantial contribution to
circulating cortisol as demonstrated in humans by combining stable isotope tracer infusion with
arteriovenous sampling. In the brain, 11HSD1 is a potential therapeutic target implicated in
age-associated cognitive dysfunction. We aimed to quantify brain 11HSD1 activity, both to assess
its contribution to systemic cortisol/cortisone turnover and to develop a tool for measuring
11HSD1 in dementia and following administration of 11HSD1 inhibitors.
Design, Setting, and Participants: With ethical approval and informed consent, 8 healthy men
aged 38.1 years (sd 16.5) underwent an ECG-gated phase-contrast magnetic resonance scan to
quantify internal jugular vein blood flow and were infused with 1,2 [2H]2-cortisone and
9,11,12,12 [2H]4-cortisol for 3 h before samples were obtained from the internal jugular vein
and an arterialized hand vein. Steroids were quantified by liquid chromatography-tandem
mass spectrometry.
Main Outcome Measures and Results: Steady state tracer enrichments were achieved and systemic
indices of cortisol/cortisone interconversion were consistent with previous studies in healthy men.
However, there was no measurable release or production of cortisol, 9,12,12 [2H]3-cortisol or
cortisone into the internal jugular vein.
Conclusions: Although cerebral 11HSD1 reductase activity may be greater in cognitively impaired
patients, in healthy men any contribution of 11HSD1 in the brain to systemic cortisol/cortisone
turnover is negligible. The influence of 11HSD1 in the brain is likely confined to subregions,
notably the hippocampus. Alternative approaches are required to quantify pharmacodynamics
effects of 11HSD1 inhibitors in the human brain. (J Clin Endocrinol Metab 100: 483–489, 2015)
The 11-hydroxysteroid dehydrogenases (11HSDs)are intracellular enzymes that catalyze interconver-
sion of inactive cortisone and active cortisol; 11HSD
type 1 is a predominant reductase, regenerating cortisol
from cortisone, while 11HSD type 2 is an exclusive de-
hydrogenase, inactivating cortisol to cortisone. An exten-
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sive literature documents the role of 11HSDs in regulat-
ing intracellular glucocorticoid concentrations and hence
modulating tissue-specific activation of corticosteroid re-
ceptors (reviewed in 1, 2). 11HSD1 amplifies glucocor-
ticoid action in the liver, adipose tissue, inflammatory
cells, and vasculature, providing a therapeutic target for
inhibition in type 2 diabetes. 11HSD2 limits cortisol ac-
tion, and thereby facilitates aldosterone action in the distal
nephron and a few other sites, explaining the mineralo-
corticoid excess state which ensues when 11HSD2 is in-
hibited by licorice.
Both 11HSD isozymes also contribute to systemic
turnover of cortisol. Activity of the two isozymes has been
quantified in humans using stable isotope (deuterated)
glucocorticoid tracers (Figure 1). Production of cortisone
can be measured by the rate of dilution of 1,2-[2H]2-cor-
tisone (d2-cortisone) by cortisone, and is inhibited by
licorice (3). A more complex tracer is used to measure
regeneration of cortisol by 11HSD1: 9,11,12,12-[2H]4-
cortisol (d4-cortisol) is infused and production of cortisol
is measured by the rate of dilution of d4-cortisol by cor-
tisol (an index of net cortisol production from all sources,
including the adrenal gland) and by 9,12,12-[2H]3-corti-
sol (d3-cortisol, a specific measure of cortisol regeneration
by 11HSD1) (4). Using these tracers in combination
with selective venous catheterization and measurement of
blood flow has allowed quantification in humans of cor-
tisol-cortisone interconversion in splanchnic (3, 5, 6), sub-
cutaneous adipose (3, 7), and skeletal muscle (3) circula-
tions, and exclusion of significant 11HSD activity in the
myocardium (8). These studies reveal rapid shuttling be-
tween cortisol and cortisone such that in healthy men at
rest, remarkably, the magnitude of extra-adrenal regen-
eration of cortisol by 11HSD1 is greater than the mag-
nitude of adrenal cortisol secretion. They also suggest,
surprisingly, that 11HSD1 may catalyze both reductase
and dehydrogenase activity in vivo, resulting in “recy-
cling” between cortisol and cortisone (detected by dilution
of d2-cortisone by cortisone and by simultaneous dilution
ofd4-cortisolbyd3-cortisol) even in tissueswhere11HSD2
is not expressed (3).
11HSDs may also play key roles in the brain (9).
11HSD2 is expressed in the developing, but not the adult
brain (10). 11HSD1 is expressed more widely in the adult
brain, and notably in the prefrontal cortex, hippocampus,
and cerebellum, a distribution confirmed in humans (11).
Increased local regeneration of cortisol by 11HSD1 may
cause glucocorticoid-dependent neurotoxicity and hence
contribute to cognitive aging and dementia, while inhibi-
tion of 11HSD1 has been proposed as a therapeutic strat-
egy to treat age- and dementia-associated cognitive dys-
function. In mice, 11HSD1 levels in the hippocampus
and parietal cortex rise with age and correlate with im-
paired cognitive performance, while transgenic overex-
pression of 11HSD1 in the forebrain accelerates age-
associated cognitive decline (12). Conversely, 11HSD1
knockout mice are protected from age-related learning
impairment (13, 14). Moreover, selective 11HSD1 in-
hibitors, after either systemic or intracerebroventricular
administration, improve cognitive function in aged mice
(14). Indeed in humans, the nonselective 11HSD inhib-
itor carbenoxolone improved cognitive performance in
healthy elderly and diabetic men (11). However, a recent
phase II clinical trial of a selective 11HSD1 inhibitor,
ABT384, in patients with mild-to-moderate Alzheimer’s
disease was halted prematurely because of lack of efficacy
(15). It is uncertain whether this reflected selection of pa-
tients whose cognitive dysfunction is no longer responsive
to reducing cortisol action, or inadequate inhibition of brain
11HSD1 by ABT384.
Against this background, quantification of brain
11HSD1 activity in vivo in humans would be highly
desirable. Here, we aimed: (i) to determine whether, as a
major organ by mass, brain 11HSD1 contributes to cor-
tisol/cortisone turnover in vivo; (ii) to establish whether
11HSD1, as the only 11HSD isozyme expressed in an
Figure 1. Stable isotope tracers for measuring cortisol-cortisone
interconversion by 11-HSDs. 11-HSD2 is a unidirectional enzyme
catalyzing the dehydrogenase conversion of cortisol to cortisone.
11-HSD1 is a potentially reversible enzyme catalyzing
interconversion of cortisol and cortisone, predominantly in the
reductase (cortisone to cortisol) direction. The shaded boxes on left
and right represent the circulating pools of cortisol and cortisone,
respectively. Production of cortisone can be measured by infusing a
tracer, d2-cortisone, into the cortisone pool and measuring its dilution
by cortisone. Similarly, production of cortisol can be measured by
infusing a tracer, d4-cortisol, into the cortisol pool. When d4-cortisol is
metabolized by 11-HSD2, the deuterium in the 11 position is
removed, producing d3-cortisone; when this d3-cortisone is converted
back to cortisol by 11-HSD1 it is highly unlikely that a deuterium
rather than a proton will be reincorporated, so that d3-cortisol is
produced. Dilution of d4-cortisol with d3-cortisol therefore indicates
11-HSD1 reductase activity.
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adult brain (11), catalyzes only regeneration of cortisol or
also recycling between cortisol and cortisone; (iii) to pro-
vide a tool with which to quantify changes in human brain
11HSD1 activity with dementia, and to use as a phar-
macodynamics biomarker to quantify enzyme inhibition
during clinical development of selective 11HSD1 inhib-
itors for treating dementia. We therefore extended our
previous studies using arteriovenous sampling with stable
isotope tracer infusions in vivo to quantify 11HSD ac-
tivities in the human brain.
Materials and Methods
Participants
Participants were recruited through advertisements in the lo-
cal press and around the University campus. Participants were
healthy male volunteers between 18 and 70 years old. Exclusion
criteria were glucocorticoid medication (by any route of admin-
istration) within the past 3 months; diabetes mellitus, cerebro-
vascular disease or other significant chronic illness; history of
recent heavy alcohol or illegal drug use; current use of any im-
munosuppressive medication; abnormal screening liver, thyroid,
renal or coagulation function (ie, INR  1.5 or platelets  50 
109/L) or abnormal full blood count or random blood glucose;
research participant in the previous 3 months; any contraindi-
cation to magnetic resonance (MR) imaging. The study complied
with the Declaration of Helsinki; ethical approval was obtained
from the local Research Ethics Committee (Scotland A REC,
reference 12/SS/0079) and all participants gave written informed
consent.
Reagents
Reagents were obtained from Sigma, Steraloids, or VWR. 1,2
[2H]2-cortisone (d2-cortisone) and 9,11,12,12 [
2H]4-cortisol
(d4-cortisol) were from Cambridge Isotope Laboratories. Sol-
vents were high-performance liquid chromatography (HPLC)
grade from Fisher Scientific.
Clinical protocol
Screening tests were performed within the 2 weeks prior to the
procedure. On the day of the study, subjects attended the Clinical
Research Facility at around 0830 h. They were allowed to eat a
light breakfast at home, but were only allowed water after their
arrival at the research facility. They first underwent an ECG-
gated phase contrast MR neck scan, which lasted 20–30 min.
After this, a cannula was inserted into the left antecubital fossa
and blood was taken to measure baseline endogenous steroids
and their background isotopomers. At t  5 min a 0.7 mg
loading bolus of d4-cortisol was given intravenously (IV), fol-
lowed by an infusion at 0.35 mg/h (15.94 nmol/min) at t  0 min.
A cannula was inserted into a vein in the dorsum of the right hand
in a retrograde direction and when required the hand was placed
in a hot box at 60°C to arterialize the blood. Arterialization of
the blood was accepted if the oxygen saturation was 98%.
A jugular bulb cannula was inserted in the dominant internal
jugular vein (assessed by MR venography) under ultrasound
guidance. Placement was checked using a plain lateral C-spine
x-ray: the tip of the catheter was visualized to ensure it was above
the second cervical vertebra (16). The oxygen saturation of the
blood was checked to ensure it was 85%.
At t  145 min a 76.0 g bolus of d2-cortisone was admin-
istered IV, followed by an infusion at 105.3 g/h (4.88 nmol/min).
From t  180 min four sets of simultaneous blood samples were
taken from the arterialized and jugular bulb cannulae at 10 min
intervals (t  180, 190, 200, and 210 min) into Lithium heparin
and plasma separated and stored at 80°C until analysis.
Magnetic resonance scanning
The MR imaging was performed with participants in the su-
pine position on a 1.5 Tesla MR imaging unit (Signa HDxt, GE
Healthcare) at the Brain Research Imaging Centre (www.bric.
ed.ac.uk). An eight-channel neurovascular array coil was used. A
noncontrast MR angiogram of the carotids from the level of the
exterior auditory meatus down to the angle of the mandible was
performed, followed by an MR venogram over the same area
with a saturation band over the inferior aspect of the slices. The
MR venogram was used to select the level for the ECG-gated
phase-contrast MR scan by measuring a quarter of the way down
from the jugular bulb to where the facial vein enters the internal
jugular vein; axial images were taken perpendicular to the table.
This level was chosen to ensure blood flow was measured in the
vessel before any of the tributaries entered. The facial vein was
the first, and to avoid measuring flow dynamics in the bulb itself,
it may not be representative of the rest of the vessel, as there may
be some pooling of blood where it first enters the bulb. Sixteen
phase and magnitude images were taken at this level over one
cardiac cycle. The flip angle was 25°, bandwidth 15.63 kHz,
echo time (TE) 6 ms, repetition time (TR) 25 ms, and encoding
velocity (Venc) 100 cm/s. Data were checked at the point of ac-
quisition for any aliasing artifact. The field of view (FOV) was
25.6 cm  25.6 cm and slice thickness of 5 mm. These images
took approximately 8 min to acquire per patient, depending on
the heart rate.
The image analysis software Medis Q flow (Medis medical
imaging systems) was used to calculate jugular venous blood
flow in mL/min on the side which was cannulated. The outline of
the internal jugular vein was traced on each of the magnitude
images from the cardiac cycle and blood flow calculated using
data from the corresponding phase images. For completeness,
the blood flow for the opposite internal jugular vein and both
common carotid arteries were also measured.
Laboratory analysis
Steroids (cortisol, d4-cortisol, 9,12,12 [2H]3-cortisol (d3-
cortisol), cortisone and d2-cortisone) were quantified using
liquid chromatography-tandem mass spectrometry (LC-MS).
An internal standard solution [0.5 microg epicortisol (Steraloids),
0.25microg2,2,4,6,6,9,12,12[2H]8-cortisone(d8-cortisone,Santa
Cruz Biotechnology), and 0.25 microg 2,2,4,6,6,17A,21,21
[2H]8-corticosterone (d8-corticosterone, Cambridge Isotope
Laboratories) with 9 L methanol] was added to 1.5 mL of
plasma, before 15 mL of chloroform was added for extraction of
the steroids. The organic phase was then reduced to dryness
under oxygen free nitrogen at 60°C before being reconstituted in
the mobile phase [acetonitrile: water (35:65) with 0.1% formic
acid]. Samples were injected on to a Sunfire C18 column (150
mm  4.6 mm  5 m), with a column temperature of 10°C and
a mobile phase flow rate of 1.5 mL/min using an Acquity Ultra
Performance Liquid Chromatograph (Waters) coupled to a
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Qtrap 5500 mass spectrometer (AB Sciex). Ionization was
achieved in the positive electrospray mode. The following tran-
sitions (precursor3product mass-to-charge ratios) used were as
follows: cortisol (3633121), d2-cortisol (3653121), d3-corti-
sol (3663121), d4-cortisol (3673121), cortisone (361377),
d3-cortisone (3643164), and d2-cortisone (3633165). Steroid
concentrations and tracer/tracee ratios were calculated from cal-
ibration curves and corrected for background isotopomer en-
richments as described previously (17).
Data analysis and kinetic calculations
Whole-body rate of appearance (Ra) of cortisol, d3-cortisol,
and cortisone were calculated by dividing the rate of tracer in-
fusion by the relevant tracer/tracee ratio (d4-cortisol/cortisol,
d4-cortisol/d3-cortisol and d2-cortisone/cortisone, respectively)
(3, 4). Brain tissue production of cortisol was calculated using
data from arterial (A) and internal jugular vein (V) samples and
corrected for cerebral blood flow using Eq. (1). Brain tissue pro-
duction of d3-cortisol and cortisone were also calculated with
Eq. (1), substituting arterial concentrations of d3-cortisol or cor-
tisone and the relevant arterial and venous tracer:tracee ratios, as
appropriate (3). Net release or uptake of cortisol across the brain
was calculated using Eq. (2). Net release or uptake of d4-cortisol
or cortisone were also calculated with Eq. (2), substituting ar-
terial and venous concentrations of d4-cortisol and cortisone,
respectively.
Tissue cortisol production  (Blood flow  [cortisolA])
 d4-coristol: cortisolAd4-coristol: cortisolV(Blood flow  [cortisolA]) (1)
Net cortisol release  ([cortisolV][cortisolA])
 (Blood flow) (2)
Statistical analysis
There were no prior data for cortisol or cortisone production
or uptake across the brain on which to base a power calculation,
therefore we used previous data from a study on cortisol and
cortisone production in skeletal muscle in healthy men (3). We
calculated that in order to detect the same magnitude of differ-
ence from zero for net uptake or release across the brain of cor-
tisol, d3-cortisol or cortisone, with a similar variance to that in
skeletal muscle, would require sample sizes of 3, 5, and 7, re-
spectively (for alpha 0.05, power 80% in a two-tailed test). We
therefore considered a sample size of 8 to be reasonable.
Using SPSS, the student t-test was used to detect a difference
from zero in brain production of cortisol, d3-cortisol, and cor-
tisone. The small n in the study required the use of parametric
tests, despite being unable to fully check the assumptions (18).
However, on visual inspection there were no obvious outliers
and the data appeared to meet the assumptions of normality.
Results
Eight healthy men were recruited with a mean age of 38.1
years (sd 16.5) and mean BMI of 24.9 kg/m2 (sd 3.7). In 7
of the 8 subjects, the right internal jugular was found to be
dominant or co-dominant on the MR scan and was used
for cannulation and measurement of blood flow. In one
subject, the left internal jugular vein (IJV) was dominant
and was cannulated instead. Mean blood flow in the se-
lected left internal jugular vein for all subjects was 481
mL/min (sd 232).
Endogenous cortisol and cortisone concentrations in
both arterialized and jugular venous samples reduced
from baseline to 180 min of infusion, when the first set of
arteriovenous samples were obtained, which is consistent
with diurnal variation (Figure 2, A and D). In both arte-
rialized and jugular venous samples, concentrations of
cortisol and cortisone and tracer/tracee ratios were similar
at all four sampling time points between 180 and 210 min
of infusion, consistent with the steady state being achieved
(Figure 2).
Mean values in arterialized samples in the steady state
were used to calculate whole body rates of appearance of
cortisol, d3-cortisol, and cortisone (Table 1), all of which
were readily detectable, confirming technical success of
the tracer infusions. Mean steady state data from arteri-
alized and jugular venous samples were combined with
blood flow measurements to calculate net release (or up-
take) of cortisol and cortisone [Eq. (2)] and to estimate
cortisol, d3-cortisol, and cortisone production across the
brain [Eq. (1)] (Table 1). Surprisingly, d4-cortisol concen-
trations were higher in the jugular vein than arterialized
samples, so that there was a net release of d4-cortisol
across the brain in the steady state. No other indices of
brain steroid release/uptake or production were signifi-
cantly different from zero.
Discussion
We found no detectable interconversion of cortisol and
cortisone across the human brain in eight healthy male
volunteers, using deuterated glucocorticoid tracers and
arteriovenous sampling. Previous studies using this ap-
proach have detected interconversion of cortisol plus or
minus cortisone within liver, adipose tissue, and skeletal
muscle (3, 5–7). Systemic cortisol/cortisone turnover val-
ues were similar in the subjects reported here to those
observed in previous studies, so the approach was tech-
nically successful. The lack of statistically significant net
production or release of cortisol, d3-cortisol or cortisone
across the brain could not be attributed to variability in
blood flow, either methodological due to the magnetic
resonance method used, or biological due to asymmetry of
internal jugular blood flow. Since we did not observe ex-
pected gradients in relevant steroid concentrations from
arterialized to jugular venous blood, we sampled from the
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dominant jugular vein, and therefore from venous drain-
age of a substantial proportion of brain tissue. Any con-
tribution of 11HSD in the brain to whole body turnover
between cortisol and cortisone is, therefore, negligible. It
remains possible that, had we sampled from discreet brain
subregions, 11HSD activity might have been measur-
able, but this remains a speculation. The consequences of
brain 11HSD1 activity are likely to be confined to the
subregions in which the enzyme is highly expressed (11).
In the absence of arteriovenous gradients in cortisol
or cortisone concentrations, we did find a net release of
d4-cortisol across the brain. It is unclear why there was
release of tracer from the brain but it
may indicate overpriming and higher
circulating d4-cortisol levels earlier
in the infusion, with resulting rer-
elease from the brain during steady
state. However, this speculation can-
not be tested in the absence of earlier
samples.
One previous study has evaluated
in vivo 11HSD1 activity in the
brain, by measuring peripheral ve-
nous plasma and cerebrospinal fluid
(CSF) steroid concentrations during
d4-cortisol infusion (19). Unfortu-
nately, data were presented for only
two subjects without administra-
tion of a potent 11HSD1 inhibitor.
Strangely, these subjects did not ap-
pear to reach steady state of tracer
enrichment after 4 h of infusion and
tracer/tracee ratios in plasma were
not adjusted for d4-cortisol infusion
to calculate the rate of appearance of
cortisol and d3-cortisol and establish
if the results were comparable with
other published studies. CSF d3-
cortisol concentrations were shown
to be higher, relative to d4-cortisol,
than plasma d3-cortisol concentra-
tions, but only by comparing CSF
data with plasma obtained 60 min
earlier. This adjustment was applied
on the grounds of closer correlation
between plasma and CSF steroid
concentrations separated by 60 min
than those separated by shorter or
longer intervals, but again indicates
that steady state was not achieved in
CSF. The authors attributed the ap-
parent excess of d3-cortisol in CSF to
brain 11HSD1, partly on the basis
that it was abolished in a dose-dependent fashion by ad-
ministration of the 11HSD1 inhibitor ABT384. How-
ever,ABT384dramatically loweredplasmad3-cortisol con-
centrations, consistent with potent inhibition of systemic
11HSD1 activity. The associated fall in CSF d3-cortisol
concentrations, which fell below the limit of quantifica-
tion in most samples, can be explained by the dramatic fall
in plasma d3-cortisol without invoking any contribution
of brain 11HSD1. Against this background, it has not
been established whether activity of 11HSD1 in the
brain is sufficient in magnitude to affect CSF cortisol
concentrations.
Figure 2. Arterialized and jugular venous steroid concentrations and tracer/tracee ratios during
steady state stable isotope tracer infusion. Data are mean  SEM for n  8. (A) Cortisol
concentration; (B) cortisone concentration; (C) d4-cortisol/cortisol ratio; (D) d4-cortisol/d3-cortisol
ratio; (E) d2-cortisone/cortisone ratio. Statistical comparisons were made for the kinetic
parameters derived from these “raw” data (Table 1).
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We took a different approach to measuring steroids in
jugular venous blood and calculating arteriovenous dif-
ferences during steady state tracer infusion. With the mea-
surement of blood flow, this allows absolute quantifica-
tion of 11HSD activities for all tissue draining to the
cannulated internal jugular vein. 11HSD1 is known to be
expressed in specific neuronal subregions of the human
brain: hippocampus (in particular the dentate gyrus and
the cornu ammonis), prefrontal cortex, and the area of
highest expression, the granule cell layer of the cerebellum
(11). The venous drainage of the human brain is complex
and appears to display considerable interindividual dif-
ferences. Cerebellar venous blood drains to the superior
and inferior cerebellar veins and usually ultimately into
the internal jugular veins. However, posture affects cere-
brovenous drainage such that in the supine position the
internal jugular veins drain around 95% of blood flow
from the intracerebral structures, while in the erect posi-
tion this can drop to as little as 25%, with the remainder
draining through the vertebral venous plexus (20). Our
subjects were reclining at an angle of 45° for the arterio-
venous sampling, but the measure of internal jugular vein
blood flow was performed supine within a magnetic res-
onance imaging (MRI) machine. It could be that during
blood sampling more of the cerebellar venous drainage
was to the vertebral venous system rather than to the in-
ternal jugular veins, and that the brain 11HSD1 was
underestimated as a result. Moreover, the forebrain sub-
regions where 11HSD1 is expressed represent a minor-
ity, by mass, of forebrain tissue and hence any contribu-
tion of these subregions to the plasma steroid pool may be
diluted by blood from elsewhere. More selective venous
cannulation might therefore detect 11HSD1 activity,
which was not measurable here, but this is unlikely to be
feasible in healthy volunteers.
As there were no previous data on brain release or up-
take of cortisol or cortisone, sample size was calculated
using data from a previous study on skeletal muscle (3).
With the current novel results from the brain in hand, we
have performed new power calculations which show that
to demonstrate that the observed mean differences are sta-
tistically significantly different from zero for Ra cortisol,
Ra d3-cortisol, and net Ra cortisone, we would need sam-
ple sizes of 40, 57, and 4006, respectively (for alpha 0.05,
power 90% in a two-tailed test). We do not consider it
justified to undertake invasive studies in this large number
of subjects in order to more precisely quantify any small
amount of cortisol production in the brain, having shown
its mean magnitude to be negligible relative to other
tissues.
If 11HSD activity in the brain had been detectable
with the approach used here, this could have provided a
useful pharmacodynamic tool to quantify brain enzyme
inhibition by selective 11HSD1 inhibitors in develop-
ment for treatment of dementia (14, 19). As things stand,
neither this approach nor the CSF approach attempted by
Katz et al (19) appear well-suited for this purpose in
healthy volunteers. Given that 11HSD1 expression in-
creases with age in mice and is predictive of cognitive de-
cline (12), it remains possible that arteriovenous sampling
could be used to detect cortisol regeneration by 11HSD1
in the brains of patients with dementia or with risk factors
for cognitive decline (eg, diabetes, older age).
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